**Table of contents**

[S1: PRISMA Checklist1](#_3j2qqm3) **3**

[S2: Supplementary Methods](#_1y810tw) **7**

[S.2.1: Additional methods description](#_4i7ojhp) 7

[Table S1: Study- and Estimate-level Classification Decisions](#_2xcytpi) 8

[S2.2: Criteria for WHO Unity-alignment of sero-epidemiological investigations](#_1ci93xb) 10

[Table S2. Unity-aligned vs not unity-aligned sero-epidemiological studies](#_3whwml4) 12

[S2.3 SeroTracker inclusion and exclusion criteria](#_2bn6wsx) 13

[Table S3: Criteria for including evidence (must meet all the criteria to be included)](#_3as4poj) 14

[Table S4: Criteria for excluding evidence (if any met then exclude)](#_1pxezwc) 14

[S2.4: Search Strategy](#_49x2ik5) 15

[S2.5 Risk of Bias Tool Breakdown](#_2p2csry) 17

[S3 Supplementary analysis information](#_147n2zr) **21**

[S3.1 Estimate Prioritization](#_3o7alnk) 21

[S3.2 Additional analysis description](#_23ckvvd) 22

[S4 Supplementary Results](#_6pj4tzgagipb) **24**

[S4.1 Studies included for descriptive analysis, meta-analysis, and ascertainment estimation](#_1hmsyys) 24

[Table S5. Studies used in ascertainment analysis.](#_5kkua96hmmjm) 24

[Table S6. Additional studies used in meta-analysis and meta-regression.](#_asmi1tlhus) 62

[Table S7. Additional studies used in descriptive analysis.](#_bd30r4tia9zt) 105

[S4.2 Risk of Bias breakdown for all studies](#_jd1049mm7yz3) 175

[Table S8. Risk of Bias Assessment of Included Studies.](#_xp5iya) 175

[S4.3 Additional figures and results](#_2a997sx) 200

[Figure S2: Risk of Bias Assessment for Included Studies.](#_peji0q) 273

[Figure S3: Asymptomatic Prevalence in SEROPREV Protocol Studies by Age and Sex.](#_39e70oj) 274

[Table S9: Estimated seroprevalence over time by region (meta-analysis).](#_1ojhawc) 275

[Table S10: Estimated seroprevalence over time globally (population-weighted).](#_48j4tk5) 285

[Table S11: Meta-regression results and model comparison.](#_r1puekqz7q85) 289

[S5 References for all included studies](#_12tpdzr) **2**91

[S6 References cited in supplementary file](#_21yn6vd) **325**

# S1: PRISMA Checklist[1](https://www.zotero.org/google-docs/?C2FlmK)

| **Section and Topic** | **Item #** | **Checklist item** | **Location where item is reported** |
| --- | --- | --- | --- |
| **TITLE** | | |  |
| Title | 1 | Identify the report as a systematic review. | Pg.1: Title |
| **ABSTRACT** | | |  |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | Pg. 2 |
| **INTRODUCTION** | | |  |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Pg. 2-3 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Pg. 2-3 |
| **METHODS** | | |  |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Pg. 4-5; S2.1, S2.2, S2.3 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Pg. 4-5, S2.1 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | S2.4 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | Pg. 4-5, S2.1 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Pg. 4-5, S2.1 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | Pg. 5-6, S3.1, S3.2 |
| 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | Pg. 5-6, 7, Table S1, |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Pg.5, S2.1, S.2.5 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | Pg. 5- 7 |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | Pg. 5-7 |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Pg. 5-6, S2.1, S3.2, S3.1 |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Pg. 5-6, S.3.2 |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Pg. 6 |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | Pg. 5-6 |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | N/A |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Pg. 5, S2.1, S.2.5 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Pg. 6-7 |
| **RESULTS** | | |  |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Pg. 6-8. Fig 1 |
| 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | N/A |
| Study characteristics | 17 | Cite each included study and present its characteristics. | S.4.1, S5 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | S.4.2 |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | S.4.1 |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | S.5.1 |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Pg 6-9, S.4.3, Table S9-10 |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Pg 9, Fig 3 |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | N/A |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Pg. 8 |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | Pg 6-9, S.4.3 |
| **DISCUSSION** | | |  |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Pg 9-11 |
| 23b | Discuss any limitations of the evidence included in the review. | Pg 10 |
| 23c | Discuss any limitations of the review processes used. | Pg 10 |
| 23d | Discuss implications of the results for practice, policy, and future research. | Pg 9-11 |
| **OTHER INFORMATION** | | |  |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Pg. 4 |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Pg. 4 |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | N/A |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | Pg 2, 6 |
| Competing interests | 26 | Declare any competing interests of review authors. | Pg 11 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Pg. 4, S.2.1, S3.1, Pg 12 |

# S2: Supplementary Methods

## S.2.1: Additional methods description

**Search strategy, screening, extraction protocol**

The primary search strategy we used was developed in consultation with a health sciences librarian, searching Medline, EMBASE, Web of Science, and Europe PMC for preprints (Supplementary file S3.1). Our secondary search was a targeted Google news search for media preprints and institutional or governmental reports. We have study team members proficient in English, French, Portuguese, Spanish, and Cyrillic languages - articles in all other languages were translated using Google Translate where possible. We also invited submissions to our database through the open-access SeroTracker platform and recommendations from international experts, including literature compiled through the WHO Unity studies initiative. Lastly, we also contacted WHO UNITY study collaborators that had not yet made results available to the general public prior to our inclusion dates, to upload their aggregate results to the open access Zenodo research data repository. This will allow reproducibility of our analysis. We accepted Unity Initiative templates up to September 17th 2021 to leave time for follow-up if needed (see below for more details).

Preliminary screening was conducted using the SeroTracker screening criteria [2](https://www.zotero.org/google-docs/?M0ehE5) for seroprevalence studies and then further refined by the ‘Unity’ aligned criteria (below, and S2.3), using Covidence software. Studies were then uploaded to AirTable for extraction of summary-level estimates and study factors.

Notably, published studies meeting the inclusion criteria, or otherwise deemed “Unity Aligned” beyond the October 29th cutoff date for this analysis, are extracted and updated weekly on an interactive and open-access dashboard and data platform, SeroTracker.com/Unity. [3](https://www.zotero.org/google-docs/?BTqJns)

**Inclusion and exclusion criteria**

Included study designs comprise cross-sectional and cohort studies which had the objective to determine SARS-CoV-2 seroprevalence in human general populations. We defined ‘general population’ study sample populations as: Household and community samples, blood donors, residual sera, pregnant and parturient women, people residing in slum dwellings, and some patient populations in humanitarian settings where the patient population in question was extensive enough to be considered a proxy sample frame (evaluated on a case-by-case basis). Both random or non-random (i.e., convenience, sequential, quota) sampling methods were included. Where a robust sampling frame can be described that approximates to a wider population, convenience samples are included as UNITY studies, for example, national studies sampling blood donors. Sampling of specific or closed populations or participants recruited without a sampling frame are not included.

Studies had to use serological assays in line with the test performance specifications: threshold of at least 90% sensitivity and 97% specificity as reported by the manufacturer or reported by the study authors through an independent evaluation of the test used. We implemented an exception regarding the use of assays below this assay performance threshold for studies conducted in humanitarian settings. Studies employing dried blood spots as a specimen type must meet this threshold as determined through study author-conducted sensitivity and specificity validation using dried blood spots. Multiple testing strategies were included if the combined sensitivity and specificity met these validity thresholds, using standard formulas for parallel and serial testing. [4](https://www.zotero.org/google-docs/?H01eJd) Complex multiple testing strategies (3+ tests used) were reviewed on a case-by-case basis by two study members. To accommodate these limitations and ensure study inclusion equity, we included all assay types from HRP countries regardless of their reported sensitivity and specificity values, as long as the authors report an assay which has been independently validated from either an in-house evaluation or a WHO-approved head-to-head evaluation. [5–7](https://www.zotero.org/google-docs/?frb3yc) Finally, algorithms employing a commercial or author-designed binding assay followed by confirmatory testing by virus neutralization assay are included as they constitute the gold standard in serological evaluation. [8](https://www.zotero.org/google-docs/?AcZqGP)

### Table S1: Study- and Estimate-level Classification Decisions

| **Geographic scope** | **Definitions** |
| --- | --- |
| National | Research was conducted across multiple regions within a country |
| Sub-national | Research was conducted across multiple sub-regions or municipalities within the same state or province. |
| Local | Research was conducted in a single county, municipality, or neighborhood. |
| **Sample Frames** | **Definitions** |
| Household and community samples/samples from existing surveillance programs | Population based studies with community or house-hold based surveys derived from nonspecific members of the general population (including members selected from previously established population surveys) |
| Blood donors | Retention samples that have already been taken from banked blood derived from blood donation practices; or samples that are taken from individuals who have donated blood. |
| Residual sera | Samples that have already been taken in health care settings for a variety of reasons other than COVID serological testing; or general groups of non-COVID patients attending healthcare that do not solely belong to a specific patient population |
| Pregnant or parturient women | Samples that have already been taken from pregnant women during routine pregnancy trimester screening; or samples taken from or parturient women. |
| Persons living in slums | Samples taken from people residing in slum dwellings. |
| Representative patient population | Patient population groups where the health condition is common/endemic enough for it to constitute a meaningful sample of the general population (Malaria, HIV) |
| Multiple general populations | Samples that are composed of multiple distinct above-described populations with a single pooled seroprevalence estimate. |
| **Sampling method** | **Definitions** |
| Convenience | Non-probability sampling based on convenient sources of specimens. The sampling method should still have a clear and defined sample frame (i.e., advertisements in public spaces are not included) |
| Sequential | Non-probability sampling based on entire sampling performed within a self-determined time interval. The sampling method should still have a clear and defined sample frame, and is often drawn from convenience samples. |
| Stratified non-probability (Quota) | Non-probability sampling based on groupings of similar units. Groupings are then sampled in a non-randomized fashion, wherein nonresponders may be also ignored and replaced |
| Probability | Probability sampling based on randomized sampling methods wherein all individuals have an equal probability of being selected. |
| **Serological assays** | **Definitions** [**9**](https://www.zotero.org/google-docs/?Gwxuly) |
| Multiplex | Assay that simultaneously detects presence of antibodies against multiple viral antigens (i.e., spike, nucleocapsid, envelope). |
| Rapid diagnostic test | Point-of-care diagnostic platform that can be used and evaluated directly at the testing site. Typical features include short turnaround time (<15 minutes), low cost, easy interpretation of results (typically binary), and ease of use with minimal training. |
| ELISA | Enzyme linked immunosorbent assay: Wells coated with the viral antigen of interest. After the formation of immune complexes, an enzyme-linked secondary antibody followed by the enzyme’s substrate are added, which results in chemical modification of the substrate in the presence of immune complexes, which is measured colorimetrically through spectroscopy. The relative light absorption at a particular wavelength is directly proportional to the amount of labeled complexes present. |
| CLIA | Chemiluminescent immunoassay (includes chemiluminescent microparticle immunoassays [CMIA]): Stationary solid particles or wells coated with the viral antigen of interest. After the formation of immune complexes, substrate is added which results in generation of light, the intensity of which is directly proportional to the amount of labeled complexes present. |
| IFA | Immunofluorescence assay. Antibodies bind to the SARS-CoV-2 protein of interest. Fluorescent dyes are coupled to these immune complexes in order to visualize the protein of interest using microscopy or flow cytometry |
| LFIA | Lateral flow immunoassay: A liquid sample containing the analyte of interest moves without the assistance of external forces (capillary action) through various zones of polymeric strips. Antibodies of interest can bind to immobilized antigen of interest in various zones. A secondary reporter antibody (typically functionalized with gold nanoparticles) then binds to these immune complexes resulting in visual band formation for interpretation. |
| Neutralization assay | Heat treated, inactivated serum is added to cell culture (typically Vero E6 cells). Presence of neutralizing antibodies against SARS-CoV-2 is measured by the extent of binding inhibition in cell culture inoculated with the virus . Quantification is determined by the serum dilutions needed to prevent cytopathic effects in the cell monolayer. |

**Aggregate early data template procedures**

In addition to our screening and inclusion of published and publicly available literature, we invited investigators conducting SEROPREV protocol-aligned studies through the Unity Initiative to submit their early, standardized data (not yet posted publicly) to us for inclusion in this meta-analysis. Results were input into a formulated standard Excel template designed to match the same data extracted during routine published study extraction, and uploaded directly to R for analysis in tandem with other studies included in the meta-analysis. Templates were verified by two independent reviewers and we conducted follow-up to complete information with study investigators where needed. In instances where data from early reporting templates we had received were published prior to October 29th or a partial dataset was previously published of the same data, we ensured to de-duplicate this data for analysis. We evaluated cases of duplicated results on a case-by-case basis, prioritizing the author’s published version by default but made exceptions where data was more complete, robust, or up-to-date in the submitted templates. An open-access repository for these early results is available on Zenodo in order to ensure reproducibility of analysis and identification of source details to readers. [10](https://www.zotero.org/google-docs/?BoEmVZ) A blank version of the Excel template used is also available for reference. [11](https://www.zotero.org/google-docs/?wSxRhr) Once authors have published or preprinted their results, a link to the full source will be added to the Zenodo repository. Early results were screened and evaluated for risk of bias using the same criteria as studies captured through routine screening processes.

## S2.2: Criteria for WHO Unity-alignment of sero-epidemiological investigations

The primary aim of the Unity Studies is to contribute to global standardization of sero-epidemiological studies, which in turn will facilitate international comparison of data. The aim is to collect estimates at population level rather than in specific populations. To achieve this, the study protocol “[Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection](https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2)” contains criteria outlining methodological approaches related to study design, data collection and analysis. The following key criteria should be adhered to:

* **Study population:** General population, any age group. Age stratification is not required. For studies not providing age-stratification, authors will be requested to provide that data if available.
* **Study design**: A one-time cross-sectional; or repeat cross sectional study; or a longitudinal cohort study. There is no sample size requirement.
* **Geographic scope**: national, sub-national, or local (ideally representative of overall burden of infection)
* **Sampling**: Both random sampling or convenience sampling is acceptable
* ***Random Sampling***: Individuals can be approached to participate in investigations using a variety of probability sampling techniques.
* ***Convenience Sampling***: Where a robust sampling frame can be described that approximates to a wider population, convenience samples are included as UNITY studies. Thus, for example, individuals attending medical services (e.g. blood donors, pregnant mothers, primary care attendees, etc.) or residual sera taken from patients for other a variety of other investigations can be included. Sampling of specific (e.g. healthcare workers) or closed (e.g. residents of institutions such as boarding schools or prisons) populations or recruited without a sampling frame (e.g. through advertising or volunteers at a venue) are not included.
* There may be circumstances where a study makes use of a patient population for a prevalence disease (e.g. some HIV clinics) as a proxy for the general population, subject to evaluation by the Unity team for inclusion on a case-by-case basis
* **Recruitment**: Study participants can be recruited through existing studies (e.g. general health surveys, research population, or patient cohorts (non-COVID-19 patient cohorts, etc.) or by establishing new studies.
* **Inclusion criteria**: All individuals identified for recruitment into the investigation, irrespective of acute or prior COVID-19 infection. All attempts should be made to include participants over a range of ages.
* **Exclusion criteria**: Refusal to give informed consent, or contraindication to venipuncture.

Suspected or confirmed acute or prior COVID-19 infection should not be excluded, with an exception for excluding active COVID-19 cases (for research staff safety reasons or local isolation and public health protocols).

* **Serological testing method**: Serological testing may be carried out using any testing method (and may use multiple assays), whether enzyme linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), or rapid diagnostic test (RDT), **as long as they meet the specified sensitivity and specificity thresholds as per below.**
  + Test should be validated for the specimen type being used
  + Test must meet 90% sensitivity, 97% specificity or higher as reported by the manufacturer (or author-evaluated in-house test, if manufacturer data is not present)
* **An exception regarding the use of assays below a certain sensitivity and specificity can be made for studies conducted in** **humanitarian settings** (63 countries).
  + We will include all assay types from HRP countries regardless of their reported sensitivity and specificity, as long as the authors report an assay which has been independently validated from either an in-house evaluation or a WHO-approved head-to-head evaluation
* **Ethical clearance**: Availability of ethical approval/exception

Sero-epidemiological investigations that are conducted in line with the key criteria outlined above can be considered as **‘Unity-aligned’**.

While the criteria listed above are broad and inclusive, accounting for various circumstances and offering many possibilities for investigators to collect data, there are several methodological aspects that are **not acceptable** for ‘Unity-alignment’:

* There may be circumstances where probability sampling techniques cannot be used and therefore non-probability sampling can be justified. In this case it is pivotal to make sure that the sampling frame clearly corresponds to the study population. For example, while it is acceptable to approach a clearly defined number of individuals attending specific medical services within a pre-defined time frame, it is not acceptable to call for participants/volunteers where it is not possible to establish representativeness of the study population at large.
* Studies for which robust sampling frames that do not approximate to wider populations (e.g. through advertising or volunteers at a venue) or that sample specific (e.g. healthcare workers) or closed (e.g. residents of institutions such as boarding schools or prisons) populations.
* Use of serological assays below a certain sensitivity (90%) and specificity (97%) threshold, unless countries meet the HRP exception criteria explained above.
* Use of multiple assays with a non-overlapping algorithm (study uses two or more different tests for different subsets of samples)

### Table S2. Unity-aligned vs not unity-aligned sero-epidemiological studies

|  | **Unity-aligned** | **Not Unity-aligned** |
| --- | --- | --- |
| **Study population** | Age-stratified sample from general population | Populations with substantial comorbidities or elevated exposure to COVID-19 |
| **Potential output and analysis** | * Seroprevalence of antibodies to COVID-19   Cumulative incidence of infection/Infection attack rates   * Fraction of asymptomatic infection * (Case fatality ratio) | Any other outcomes |
| **Study design** | Population-based, age-stratified prospective study   * One-time cross-sectional investigation * Repeated cross-sectional investigation in the same geographic area (but not sampling the same individuals) * Longitudinal cohort investigation with serial sampling of the same individuals each time |  |
| **Geographic scope** | * National * Sub-national * Local |  |
| **Sampling** | * Random sampling * Convenience sampling | Absence of sampling framework that approximates to a wider population |
| **Recruitment** | * Through new studies * Through existing studies |  |
| **Inclusion criteria** | * General population * All individuals identified for recruitment into the investigation, irrespective of age and irrespective of acute or prior COVID-19 infection. * All attempts should be made to include participants over a range of ages. | High-risk group i.e. those with substantial comorbidities or elevated exposure (e.g. healthcare workers with immediate exposure to COVID-19 patients) |
| **Exclusion criteria** | * Suspected or confirmed acute or prior COVID-19 infection should **not** be excluded | * Exclusion of study participants with suspected or confirmed acute or prior COVID-19 infection |
| **Testing method** | * ELISA * IFA * CLIA/CMIA * Multiplex immunoassay * Other comprehensively validated test | * Use of serological assays below sensitivity/specificity threshold.   (**except in humanitarian settings** reporting assays that have been independently validated from either an in-house evaluation or a WHO-approved head-to-head evaluation) |
| **Ethical considerations** | * Ethical clearance (i.e. ethical approval or exemption) prior to study implementation * Informed consent | * No ethical clearance (including the absence of ethical exemption) * Absence of informed consent |

## S2.3 SeroTracker inclusion and exclusion criteria

### Table S3: Criteria for including evidence (must meet all the criteria to be included)

| **Characteristics** | **Criteria for inclusion** |
| --- | --- |
| Population | * Humans of any age   + If it’s a general population sample, it may include COVID-19 antigen positive persons and those with suspected disease. |
| Study design | * Sero-surveys – defined as the collection and testing of serum (or proxy such as oral fluid) specimens from a sample of a defined population over a specified period of time to estimate the prevalence of antibodies against SARS-CoV-2 as an indicator of immunity[12](https://www.zotero.org/google-docs/?broken=eRggyd) * Cross-sectional, repeated cross sectional, and cohort study designs, with serology measurements at single time points or repeated at multiple time points |
| \*Special design | * Include systematic reviews and meta-analysis of seroprevalence studies for the purpose of tracking evidence synthesis efforts |
| Sampling | * Any sampling method |
| Types of evidence | * Published or unpublished academic literature, grey literature (government or institutional reports), or media reports. Slide deck presentations were included if we could identify the person giving the presentation and the date of the presentation |
| Outcome measures | * Reports a seroprevalence estimate (proportion of the population with detectable antibodies) * Reports the number of participants enrolled in the study (denominator) * Reports study sampling end date/week * Reports the locations at which the study took places such that they could be categorized as neighbourhood, city, state/province/territory, or country |
| Languages | * Any |

### Table S4: Criteria for excluding evidence (if any met then exclude)

| **Characteristics** | **Criteria for exclusion** |
| --- | --- |
| Population | * Non-human (e.g., *in silico*, animal, *in vitro*) * The study only included individuals with suspected, active, or previously diagnosed with COVID-19 using PCR, antigen testing, clinical assessment, or self-assessment * The study only included individuals vaccinated against SARS-CoV2 |
| Study design | * Study designs other than cross-sectional or cohort design: case reports, case-control studies, evaluations of serological tests, study protocols, |
| Sampling | * N/A |
| Types of evidence | * Multimedia sources of data (audio clips, video clips) were excluded due to the feasibility of extracting. Slide deck presentations were excluded if we could not identify the person giving the presentation and the date of the presentation * Dashboards not associated with a defined serology study |
| Outcome measures | * Only reports incidence or prevalence of SARS-CoV-2 antigen (as opposed to antibody) * Does not report study sampling end date/week * Does not report the number of participants included in the study (sample denominator) * Does not report the location at which the study took place |
| Language | * N/A |

We defined a seroprevalence study as the collection and testing of serum, plasma, whole blood, dried blood specimens, or saliva from a sample of a defined population over a specified period of time to estimate the proportion of the population with antibodies against SARS-CoV-2. [12–14](https://www.zotero.org/google-docs/?0hRs3D)

If a study sampled people with confirmed or suspected SARS-CoV-2 for the reason of obtaining estimates that were representative of the general population then the study was included. We included studies examining seroprevalence among close contacts of patients with confirmed infection. Each cluster was considered one unit, and therefore, studies of one unit (i.e., one cluster around a patient) were considered case reports and excluded.

Multimedia sources of data (audio clips, video clips) were excluded due to the feasibility of extracting. However, slide deck presentations were included if we could identify the person giving the presentation, the date of the presentation, and the location where the presentation was given.

Systematic reviews and meta-analysis of seroprevalence studies were included for the purposes of tracking evidence synthesis efforts however, these data will not be quantitatively analysed.

Assay validation studies that test the effectiveness of the assay on a sample of the population irrespective of PCR diagnostics status were included.

Articles not in English or French were included if they could be extracted in full using machine translation. [15](https://www.zotero.org/google-docs/?0or5m5)

## S2.4: Search Strategy

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Dates: January 1, 2020 to October 29, 2021

Notes: Covid-19 search terms were adapted from Ovid Expert Searches

| **#** | **Search terms** |
| --- | --- |
| 1 | exp Coronavirus/ |
| 2 | exp Coronavirus Infections/ |
| 3 | (coronavirus\* or corona virus\* or OC43 or NL63 or 229E or HKU1 or HCoV\* or ncov\* or covid\* or sars-cov\* or sarscov\* or Sars-coronavirus\* or Severe Acute Respiratory Syndrome Coronavirus\*).tw,kf.[EB2] |
| 4 | or/1-3 |
| 5 | 4 not ((MERS or MERS-CoV or Middle East respiratory syndrome or camel\* or dromedar\* or equine or coronary or coronal or covidence\* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV).mp. or (animals/ not humans/)) |
| 6 | ((pneumonia or covid\* or coronavirus\* or corona virus\* or ncov\* or 2019-ncov or sars\* or virus).tw,kf. or exp pneumonia/) and Wuhan.tw,kf. |
| 7 | (2019-ncov\* or 2019nCov\* or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2\* or sars-cov-2\* or sarscov2\* or sarscov-2\* or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus\* or coronavirus 2 or coronavirus2\* or corona or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus\* or corona virus or Pandemi\*2)) or ((covid or covid19\* or covid-19) and pandemic\*2) or (coronavirus\* and pneumonia)).tw,kf. |
| 8 | COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os. |
| 9 | or/6-8 |
| 10 | 5 or 9 |
| 11 | immunoglobulins/ or antibodies/ or antibodies, blocking/ or exp antibodies, neutralizing/ or antibodies, viral/ or antigen-antibody complex/ or immune sera/ or exp immunoglobulin isotypes/ or immunoglobulin a/ or immunoglobulin d/ or immunoglobulin e/ or immunoglobulin g/ or immunoglobulin m/ |
| 12 | serologic tests/ or complement fixation tests/ or hemagglutination inhibition tests/ or neutralization tests/ |
| 13 | immunoassay/ or fluoroimmunoassay/ or exp immunoblotting/ or immunoenzyme techniques/ or exp enzyme-linked immunosorbent assay/ or exp enzyme-linked immunospot assay/ or immunosorbent techniques/ or serologic tests/ or complement fixation tests/ or hemagglutination inhibition tests/ or neutralization tests/ or Serology/di |
| 14 | (enzyme linked immunosorbent or enzyme-linked immunosorbent or ELISA or immunofluorescence or complement fixation or hemagglutination inhibition or immunoblot or western blot or neutrali\*).tw,kf. |
| 15 | (antibod\* or immunoglobulin\* or immune globulin\* or titer\* or isotype\* or IgG or IgM or IgA or neutrali\* or sera or serum or serolog\* or saliva).tw,kf. |
| 16 | or/11-14 |
| 17 | seroepidemiologic studies/ |
| 18 | incidence/ or prevalence/ |
| 19 | (seroconver\* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog\* or sero-epidemiolog\*).mp. |
| 20 | (inciden\* or prevalen\* or count\* or rate\*).mp. |
| 21 | (serosurvey or sero-survey or screen\* or diagnostic).mp. |
| 22 | (seroconver\* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog\* or sero-epidemiolog\* or inciden\* or prevalen\* or silent or asymptomatic or serosurvey or sero-survey).tw,kf. |
| 23 | or/17-21 |
| 24 | 10 and (16 and 23) |
| 25 | 10 and 15 |
| 26 | 10 and 22 |
| 27 | or/24-26 |
| 28 | limit 27 to yr="2020-Current" |
| 29 | remove duplicates from 28 |

## S2.5 Risk of Bias Tool Breakdown

To assess risk of bias, a decision rule assigned a rating of low, moderate, or high risk of bias to each study based on the specific combination of JBI checklist ratings for that study. [16](https://www.zotero.org/google-docs/?eq7QL0) This decision rule was developed based on guidance on estimating disease prevalence [17,18](https://www.zotero.org/google-docs/?KyNMAh) and was validated against assessments derived manually by two independent reviewers for 2,070 seroprevalence studies in the SeroTracker database, showing good agreement with manual review (intraclass correlation 0.77, 95% CI 0.74-0.80) in a recent preprint. [(*16*)](https://www.zotero.org/google-docs/?broken=2MTacp)

​

| **Item 1: Was the sample frame appropriate to address the target population?** | |
| --- | --- |
| Yes | Sample frame described and approximated the target population |
| No | Sample frame did not approximate the target population (e.g., blood donors do not represent general population, doctors do not represent all health care providers) |
| Exclude | Sample frame not described |
| \*Notes | The term “target population” should not be taken to infer every individual from everywhere or with similar disease or exposure characteristics. Instead, give consideration to specific population characteristics in the study, including age range, gender, morbidities, medications, and other potentially influential factors. For example, a sample frame may not be appropriate to address the target population if a certain group has been used (such as those working for one organisation, or one profession) and the results then inferred to the target population (i.e. working adults). A sample frame may be appropriate when it includes almost all the members of the target population (i.e. a census, or a complete list of participants or complete registry data). |

| **Item 2: Were study participants recruited in an appropriate way?** | |
| --- | --- |
| Yes | Probability sampling method (simple or stratified random) or entire sample (e.g., an entire town) was used |
| No | Non-probability sampling |
| Exclude | Sampling method not reported |

| **Item 3: Was the sample size adequate?** | |
| --- | --- |
| Yes | >599 |
| No | <599 |
| Exclude | Sample size not reported |
| \*Notes | To calculate the required sample size we used an assumed prevalence of 2.5%, which was the global average estimated by the WHO in April, 2020.1 Based on guidance by the Joanna Briggs Institute and published medical statistical recommendations we selected a precision value that was half the assumed prevalence (1.25%) [2,3]. We calculated a minimum sample size of 599 using these inputs:  Sample size calculation:  Where n = sample size;  Z = Z statistic for level of confidence (95%);  P = expected prevalence (2.5% WHO global estimate);  d = precision (1.25%)    In cases where the sample size calculation was provided and the required sample for 80% power was below our threshold (n<599) but was met by the study, this item was marked as yes. |

| **Item 4: Were the study subjects and setting described in detail?** | |
| --- | --- |
| Yes | Average age and distribution of gender/sex provided |
| No | Neither age or gender/sex is provided, or only one of age and gender/sex is provided |

| **Item 5: Was data analysis conducted with sufficient coverage of the identified sample?** | |
| --- | --- |
| Yes | The demographic characteristics (gender/sex, age, and ethnicity) of the sample are at least somewhat representative of the population in both the main and sub-group analyses |
| No | The demographic characteristics (gender/sex, age, and ethnicity) of the sample are not representative of the population in both the main and sub-group analyses |
| Unclear | Information is not provided about demographic characteristics of the sample (gender/sex, age, and ethnicity) |

| **Item 6: Were valid methods used for the identification of the condition?** | |
| --- | --- |
| Yes | * The serological test used met the WHO Unity Study Criteria for serological tests: sensitivity minimum 90%, specificity minimum 97% * Two test algorithms with combined sensitivity >=90% and combined specificity >=97%. Calculation varies based on whether parallel or series testing was utilized * Two test algorithms using a commercial or in-house binding assay with confirmatory testing using virus neutralization assay irrespective of combined sensitivity/specificity * Multiple testing algorithms employing three or more tests using robust strategies and well performing tests including:   + Parallel testing with two tests followed by a third confirmatory test for discordant results. ⅔ positive is defined as true positive   + Series testing with 3 tests (⅔ positive for true seropositive)   + Parallel testing with 3 tests (At least one positive tests and no negative tests) |
| No | * The serological test used did not meet the WHO Unity Study Criteria for serological tests: sensitivity minimum 90%, specificity minimum 97% * The combined sensitivity and specificity for the two test algorithm is below the threshold * Complex multiple test algorithms without a rational or robust strategy |
| Exclude | Test sensitivity and specificity not reported |

| **Item 7: Was the condition measured in a standard, reliable way for all participants?** | |
| --- | --- |
| Yes | The same serology test was used for all participants |
| No | Different serology tests were used for participants |
| Unclear | No details were provided about which participants received which serology tests |

| **Item 8: Was there appropriate statistical analysis?** | |
| --- | --- |
| Yes | Does all of the following: corrects for test characteristics, corrects for population characteristics or the sample is somewhat representative of the population (probability sampling), and provides the information necessary to determine the numerator, denominator, prevalence estimate, and confidence interval. |
| No | Does not correct for population characteristics and the sample is not likely representative of the population (non-probability sampling), does not correct for test or provide the information necessary to correct for test characteristics, or does not provide the information necessary to determine the numerator, denominator, prevalence estimate, and confidence interval. |

| **Item 9: Was the response rate adequate, and if not, was the low response rate managed appropriately?** | |
| --- | --- |
| Yes | Response rate > 60% or the demographics of the sample were a reasonable match to those of the target population [5] |
| No | Response rate < 60% and the demographics of the sample were not a reasonable match to those of the target population |
| Unclear | Response rate not provided and it was unclear if the demographics of the sample differed from the target population |
| N/A | Response rate not applicable (e.g., blood donors, residual sera) |

| **Item 10: Overall risk of bias** | |
| --- | --- |
| Low | The estimates are very likely correct for the target population. To obtain a low risk of bias classification, all criteria must be met or departures from the criteria must be minimal and unlikely to impact on the validity and reliability of the prevalence estimate. These include sample sizes that are just below the threshold when all other criteria are met, reporting only some of characteristics of the sample, test characteristics below the threshold but corrections for the test performance, and response rates that are just below the threshold in the context of probability based sampling of an appropriate sampling frame with population weighted seroprevalence estimates. |
| Moderate | The estimates are likely correct for the target population. To obtain a moderate risk of bias classification, most criteria must be met and departures from the criteria are likely to have only a small impact on the validity and reliability of the prevalence estimates. |
| High | The estimates are not likely correct for the target population. To obtain a high risk of bias, many criteria must not be met or departures from criteria are likely to have a major impact on the validity and reliability of the prevalence estimates. |
| Unclear | There was insufficient information to assess the risk of bias. |

# S3 Supplementary analysis information

## S3.1 Estimate Prioritization

Where multiple summary estimates were available or multiple estimates available for one subgroup, we prioritized estimates based on estimate adjustment (population adjustment, test adjustment), antibody isotypes measured (Total Ab, IgG, IgM, other), test type used (Neutralization, CLIA, ELISA, LFIA, other), and antibody targets measured (Multiple Ab targets, Spike, Nucleocapsid).

When multiple estimate adjustments were available, we prioritized as follows:

1. Test unadjusted and Population adjusted
2. Both unadjusted
3. Both adjusted
4. Test adjusted and Population unadjusted

When multiple isotypes were available, we prioritized as follows:

1. Total antibodies
2. IgG OR other antibodies
3. IgG only
4. IgM OR other antibodies
5. IgG AND other antibodies
6. IgM only
7. IgM AND other antibodies
8. Other

When multiple test types were available (i.e. from use of different tests), we prioritized as follows:

1. Neutralization
2. CLIA
3. ELISA
4. LFIA
5. Other

When multiple antibody targets were available (i.e. from use of different tests), we prioritized as follows:

1. Multiple antibody targets
2. Anti - Spike
3. Anti - Nucleocapsid

If the above defined prioritization criteria led to estimates left on equal terms, we further introduced test sensitivity and specificity (highest sensitivity and specificity) prioritization criteria. If multiple estimates were present (e.g. an extraction only contained equivalent subgroup data), we further pooled estimate information to generate a single summary estimate.

**The Python code used for our automated estimate prioritization is available on GitHub:** https://github.com/serotracker/iit-backend/blob/8059e9b905395de997f28a1a2dff5def795276ad/app/utils/estimate\_prioritization/estimate\_prioritization.py

## S3.2 Additional analysis description

We drew confirmed case data from the WHO COVID-19 dashboard matched to nine days before the study mid-date to account for time from infection to seroconversion. We used data from Our World in Data dashboard to pull vaccination data, timed fourteen days before the study’s mid date. [19](https://www.zotero.org/google-docs/?4NpGBL) We also calculated the average global public health and social measures (PHSM) stringency index value on a scale from 1 to 10 in the country of the study between the date of the 100th reported case and 14 days before the study mid date. The PHSM data was taken from a global dataset created in collaboration between the London School of Hygiene and Tropical Medicine (LSHTM) and WHO, which aggregates six indicators including masks, international travel, gatherings, schools, workplaces and businesses, and movement into one overall stringency index. [20](https://www.zotero.org/google-docs/?ajtkfh) Finally, we defined the transmission phase in the country of the study using the seven-day rolling average of daily confirmed cases from the WHO dashboard. We smoothed the case series using smoothing splines and identified the peaks of the series using local maxima. We then classified the study mid date as before the peak of 1st SARS-CoV-2 wave, after the peak of 1st SARS-CoV-2 wave, or after the peak of 2nd SARS-CoV-2 wave in the country of the study.

We produced estimates of seroprevalence over time by first meta-analyzing studies by country in 12-week rolling windows. For each month starting January 1, 2020, we first identified the sub-national and national studies in each region within a 12-week moving window centred on that week. If there was a single study in the window, we specified seroprevalence to be equal to that study’s estimate. If there were multiple studies in the window, we pooled the studies using a random intercept logistic regression model (rma.glmm from R package metafor) to calculate a pooled seroprevalence for that week. We then advanced the 12-week window to the next week and repeated the process.

We computed global estimates as the population-weighted average of the regional estimates, carrying forward the latest regional estimates to July 2021 to represent all regions. The global estimates were calculated as

,

Where weights are weights for each region, normalized to sum to 1, and are the seroprevalence proportions in each region computed via random-effects meta-analysis (‘metaprop’). The standard error of the global estimates was calculated using the laws of variance as

where are the standard errors of the seroprevalence proportions in each region computed via metaprop on the logit scale. The confidence intervals of the global estimates were calculated using the normal distribution as

To capture the trend in seroprevalence in each WHO region and globally, we took the weighted point estimates and fitted a flexible, smooth function of time using non-parametric regression. To anchor the trend line in the early pandemic period before the first serosurveys were conducted, we specified seroprevalence to be less than 0.1 percent before the 500th confirmed case of COVID-19 in each region.

We repeated the previous step using only national studies and used the results to compute the ratio between regional and global seroprevalence and the corresponding cumulative incidence of confirmed SARS-CoV-2 cases. This analysis measured to what extent confirmed SARS-CoV-2 cases underestimated seroprevalence, as reported by the WHO’s case definition. [21](https://www.zotero.org/google-docs/?tb8SE8)

To produce estimates of ascertainment, we adjusted 2021 seroprevalence data for antibody target and vaccination to generate estimates of seroprevalence attributable to infection. In countries administering only vaccines using Spike (S) protein antigens (e.g., mRNA, viral vector), we calculated the ascertainment ratio from January to April 2021 using only studies that detected anti-nucleocapsid (N) seroprevalence, as a proxy for infection-induced seroprevalence. In countries administering inactivated vaccines that may generate both anti-S and anti-N responses (e.g., Sinopharm, Bharat Biotech), (CITE) we adjusted the reported seroprevalence for studies between January and April 2021 using the formula

,

Where is observed seroprevalence, is the vaccination rate in adults, and is a proxy for infection-induced seroprevalence. [22](https://www.zotero.org/google-docs/?tpgh0D)

To examine study and geographic factors affecting seroprevalence estimates, we constructed a Poisson generalized linear mixed-effects model with log link function using the glmer function from the lme4 package in R. [23](https://www.zotero.org/google-docs/?arlJB5) Categorical covariates in the meta-regression, coded as indicator variables, included country WHO region (reference: Americas), country World Bank income class (reference: High income), study geographic scope (reference: national), study sample frame (reference: household and community samples), and transmission phase in the country of the study at the time of the study (reference: before peak of 1st wave). Continuous covariates included cumulative incidence of reported cases per hundred in the country of the study and LSHTM global index tracking PHSM in the country of the study. The PHSM index scale ranged from 0 (least stringent) to 10 (most stringent).

We performed model comparison using all possible models that could be constructed by dropping a single *a priori* specified predictor, i.e., using predictors where there were predictors in total. We also compared the Poisson model to a logistic generalized linear mixed-effects model. We selected the model with the lowest Akaike Information Criterion (AIC) as the preferred model.

# 

# 

# S4 Supplementary Results

## S4.1 Studies included for descriptive analysis, meta-analysis, and ascertainment estimation

### Table S5. Studies used in ascertainment analysis.

#### *Africa region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cameroon - HRP** | Tiffany Harris (ICAP at Columbia University)1 | 2020-10-20 - 2020-12-16 | National | Moderate | 9,332 | Multiple groups | All | Convenience | Household and community samples | 10.5% (95% CI 9.1-12%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.957, 1 | Complex test algorithm: Manual calculation |
| **Ethiopia - HRP** | Tadesse (Federal Ministry of Health)2 | 2020-06-24 - 2020-07-08 | National | Low | 16,932 | Multiple groups | All | Probability | Household and community samples | 1.9% (95% CI 1.7-2.1%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Kenya - HRP** | Uyoga (KEMRI-Wellcome Trust Research Programme)3 | 2021-01-03 - 2021-03-15 | National | Moderate | 3,018 | Multiple groups | All | Convenience | Blood donors | 45.3% | NA - IgG - Author designed (ELISA) -Spike | 0.927, 0.99 | Validated by independent authors/third party/non-developers |
| **Kenya - HRP** | Adetifa (KEMRI-Wellcome Trust Research Programme)4 | 2020-08-20 - 2020-09-30 | National | Moderate | 3,723 | Adults (18-64 years) | All | Sequential | Blood donors | 9.1% | NA - IgG - Author designed (ELISA) -Spike | 0.927, 0.99 | Validated by independent authors/third party/non-developers |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-07-01 - 2021-07-31 | National | Low | 288 | Multiple groups | All | Probability | Blood donors | 70.1% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-06-01 - 2021-06-30 | National | Low | 319 | Multiple groups | All | Probability | Blood donors | 61.8% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-05-01 - 2021-05-31 | National | Low | 298 | Multiple groups | All | Probability | Blood donors | 63.6% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-04-01 - 2021-04-30 | National | Low | 296 | Multiple groups | All | Probability | Blood donors | 64.7% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-03-01 - 2021-03-31 | National | Low | 298 | Multiple groups | All | Probability | Blood donors | 53.1% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-02-01 - 2021-02-28 | National | Low | 365 | Multiple groups | All | Probability | Blood donors | 53.1% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2021-01-01 - 2021-01-31 | National | Low | 303 | Multiple groups | All | Probability | Blood donors | 26.7% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-12-01 - 2020-12-31 | National | Low | 263 | Multiple groups | All | Probability | Blood donors | 11% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-11-01 - 2020-11-30 | National | Low | 365 | Multiple groups | All | Probability | Blood donors | 10.5% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Matthews Kagoli/Joe Theu (Public Health Institute of Malawi(PHIM) MOH)6 | 2020-10-14 - 2020-12-08 | National | Low | 4,261 | Multiple groups | All | Probability | Household and community samples | 7.8% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-10-01 - 2020-10-31 | National | Low | 324 | Multiple groups | All | Probability | Blood donors | 21.1% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-09-01 - 2020-09-30 | National | Low | 309 | Multiple groups | All | Probability | Blood donors | 13% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-08-01 - 2020-08-31 | National | Low | 192 | Multiple groups | All | Probability | Blood donors | 9.9% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-07-01 - 2020-07-31 | National | Low | 204 | Multiple groups | All | Probability | Blood donors | 8.2% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-06-01 - 2020-06-30 | National | Low | 242 | Multiple groups | All | Probability | Blood donors | 1.4% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-05-01 - 2020-05-31 | National | Low | 194 | Multiple groups | All | Probability | Blood donors | 1.1% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-04-01 - 2020-04-30 | National | Low | 205 | Multiple groups | All | Probability | Blood donors | 0.5% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-01-01 - 2020-01-31 | National | Low | 227 | Multiple groups | All | Probability | Blood donors | 0% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-02-01 - 2020-02-29 | National | Low | 194 | Multiple groups | All | Probability | Blood donors | 0.3% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)5 | 2020-03-01 - 2020-03-31 | National | Low | 199 | Multiple groups | All | Probability | Blood donors | 0.5% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Omega diagnostics - IgG - COVID-19 IgG ELISA | 0.928, 1 | Complex test algorithm: Manual calculation |
| **Senegal** | Talla (Institut Pasteur de Dakar)7 | 2020-10-25 - 2020-11-26 | National | Low | 1,422 | Multiple groups | All | Probability | Household and community samples | 27.9% (95% CI 25.6-30.3%) | Omega diagnostics - IgG - COVID-19 IgG ELISA, ID.Vet - IgG - ID Screen, Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | N/A | Complex test algorithm: Manual review |
| **Sierra Leone - HRP** | Barrie (Harvard Medical School)8 | 2021-03-01 - 2021-03-31 | National | Low | 1,893 | Multiple groups | All | Probability | Household and community samples | 2.8% (95% CI 2.1-3.6%) | Hangzhou Biotest Biotech Co., Ltd - IgG, IgM - RightSign COVID-19 IgG/IgM Rapid Test Cassette | 0.914, 1 | Validated by manufacturer |
| **South Africa** | Wolter (National Health Laboratory Service)9 | 2021-04-01 - 2021-04-15 | National | Moderate | 1,849 | Multiple groups | All | Probability | Household and community samples | 47.2% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.9701 | Complex test algorithm: Manual calculation |
| **South Africa** | Vermeulen (South African National Blood Service)10 | 2021-01-15 - 2021-05-15 | National | Moderate | 16,762 | Multiple groups | All | Sequential | Blood donors | 47.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Uganda - HRP** | Dr. Henry Kyobe Bosa (Ministry of Health/ UPDF)11 | 2021-03-14 - 2021-03-28 | National | Moderate | 7,029 | Multiple groups | All | Probability | Household and community samples | 15.6% (95% CI 14.7-16.4%) | Hangzhou Biotest Biotech Co., Ltd - IgG, IgM - RightSign COVID-19 IgG/IgM Rapid Test Cassette | 0.914, 1 | Validated by manufacturer |
| **Zambia - HRP** | Mulenga (Zambia Ministry of Health)12 | 2020-07-04 - 2020-07-27 | National | Low | 2,704 | Multiple groups | All | Probability | Household and community samples | 2.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Zambia - HRP** | Hines (US Centers for Disease Control and Prevention)13 | 2020-07-02 - 2020-07-31 | National | Moderate | 1,657 | Multiple groups | All | Convenience | Residual sera | 5.3% (95% CI 4.3-6.5%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |

#### *Americas region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Brazil - HRP** | Barros (Universidade Federal de Pelotas)14 | 2020-05-14 - 2020-06-23 | National | Moderate | 89,362 | Multiple groups | All | Probability | Household and community samples | 2.3% (95% CI 2.2-2.4%) | Guangzhou Wondfo Biotech Co.， Ltd - IgG, IgM, IgA - Wondfo SARS-CoV-2 Antibody Test | 0.864, 0.996 | Validated by manufacturer |
| **Dominican Republic - HRP** | Ramirez (Universidad Iberoamericana)15 | 2020-04-15 - 2020-06-15 | National | Moderate | 12,897 | Multiple groups | All | Probability | Household and community samples | 5.5% (95% CI 5.1-5.9%) | GenBody Inc. - IgG, IgM - GenBody COVID-19 IgM/IgG | 0.893, 0.959 | Validated by manufacturer |
| **Honduras** | Nunez (Colegio Médico)16 | 2020-06-16 - 2020-06-23 | National | Moderate | 792 | Multiple groups | All | Probability | Household and community samples | 6.2% (95% CI 4.6-8.1%) | NA - - Not reported/ Unable to specify | 0.934, 0.977 | Validated by manufacturers |
| **Mexico - HRP** | Canto-Osorio (Instituto Nacional de Salud Públic)17 | 2020-08-15 - 2020-11-15 | National | Low | 944 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 18.7% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Mexico - HRP** | Canto-Osorio (Instituto Nacional de Salud Públic)17 | 2020-08-15 - 2020-11-15 | National | Low | 858 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 26.7% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services )18 | 2021-09-14 - 2021-09-24 | National | Moderate | 9,363 | Multiple groups | All | Sequential | Blood donors | 4.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services )19 | 2021-08-15 - 2021-08-26 | National | Moderate | 9,109 | Multiple groups | All | Sequential | Blood donors | 4.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services )20 | 2021-07-14 - 2021-07-23 | National | Moderate | 8,457 | Multiple groups | All | Sequential | Blood donors | 4.1% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)21 | 2021-06-14 - 2021-06-29 | National | Moderate | 16,884 | Multiple groups | All | Sequential | Blood donors | 4.5% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)22 | 2021-05-08 - 2021-06-04 | National | Moderate | 17,001 | Multiple groups | All | Sequential | Blood donors | 4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)23 | 2021-04-13 - 2021-04-30 | National | Moderate | 16,931 | Multiple groups | All | Sequential | Blood donors | 3.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)24 | 2021-02-27 - 2021-03-13 | National | Moderate | 16,873 | Multiple groups | All | Sequential | Blood donors | 3.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)25 | 2021-01-01 - 2021-01-27 | National | Moderate | 33,400 | Multiple groups | All | Sequential | Blood donors | 3.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)26 | 2020-12-10 - 2020-12-23 | National | Moderate | 16,961 | Multiple groups | All | Sequential | Blood donors | 1.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)26 | 2020-11-07 - 2020-11-25 | National | Moderate | 17,049 | Multiple groups | All | Sequential | Blood donors | 1.5% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Canada** | Canadian Blood Services (Canadian Blood Services)26 | 2020-10-12 - 2020-10-31 | National | Moderate | 16,811 | Multiple groups | All | Sequential | Blood donors | 0.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Canada** | Saeed (Canadian Blood Services)27 | 2020-05-09 - 2020-07-21 | National | Moderate | 74,642 | Multiple groups | All | Probability | Blood donors | 0.7% (95% CI 0.7-0.8%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Chile - HRP** | Vial (Universidad del Desarrollo)28 | 2020-09-25 - 2020-11-25 | National | Low | 2,493 | Multiple groups | All | Probability | Household and community samples | 10.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown), Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | N/A | Complex test algorithm: Manual review |
| **United States of America** | Jones (Vitalant Research Institute)29 | 2021-05-01 - 2021-05-31 | National | Moderate | 135,174 | Multiple groups | All | Probability | Blood donors | 20.2% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **United States of America** | Jones (Vitalant Research Institute)29 | 2021-04-01 - 2021-04-30 | National | Moderate | 134,763 | Multiple groups | All | Probability | Blood donors | 20.7% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **United States of America** | Jones (Vitalant Research Institute)29 | 2021-03-01 - 2021-03-31 | National | Moderate | 135,161 | Multiple groups | All | Probability | Blood donors | 19.8% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **United States of America** | Jones (Vitalant Research Institute)29 | 2021-02-01 - 2021-02-28 | National | Moderate | 134,995 | Multiple groups | All | Probability | Blood donors | 18.4% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **United States of America** | Jones (Vitalant Research Institute)29 | 2021-01-01 - 2021-01-31 | National | Moderate | 135,592 | Multiple groups | All | Probability | Blood donors | 15.9% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **United States of America** | Sullivan (Emory University)30 | 2020-11-01 - 2020-12-08 | National | Low | 2,241 | Multiple groups | All | Probability | Household and community samples | 7.2% | Bio-rad - IgG, IgM, IgA - Platelia SARS-CoV-2 Total Ab assay | 0.993, 0.98 | Validated by manufacturer |
| **United States of America** | Anand (Stanford University)31 | 2020-07-01 - 2020-07-31 | National | Low | 28,503 | Multiple groups | All | Probability | Residual sera | 9.3% | Siemens - IgG, IgM, IgA - ADVIA Centaur Immunoassay System | 1, 0.998 | Validated by manufacturers |

#### *Eastern Mediterranean region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Iran (Islamic Republic of) - HRP** | Khalagi (Tehran University of Medical Sciences)32 | 2020-08-03 - 2020-10-31 | National | Low | 11,256 | Multiple groups | All | Probability | Household and community samples | 11.8% | Pishtaz Diagnostics Iran - IgG - ELISA kit Pishtaz Teb Diagnostics | 0.941, 0.983 | Validated by manufacturer |
| **Iran (Islamic Republic of) - HRP** | Poustchi (Tehran University of Medical Sciences)33 | 2020-04-17 - 2020-06-02 | National | Low | 3,530 | Multiple groups | All | Probability | Household and community samples | 12.9% | Pishtaz Diagnostics Iran - IgG - ELISA kit Pishtaz Teb Diagnostics | 0.941, 0.983 | Validated by manufacturer |
| **Jordan - HRP** | Bellizzi (World Health Organization)34 | 2020-12-27 - 2021-01-06 | National | Moderate | 5,044 | Multiple groups | All | Probability | Household and community samples | 34.2% (95% CI 32.9-35.5%) | Beijing Wantai Biological - IgM - Wantai SARS-CoV-2 IgM ELISA | 0.868, 1 | Validated by manufacturer |
| **Jordan - HRP** | Bellizzi (World Health Organization)34 | 2020-10-01 - 2020-10-31 | National | Moderate | 5,470 | Multiple groups | All | Probability | Household and community samples | 7% (95% CI 6.3-7.7%) | Beijing Wantai Biological - IgM - Wantai SARS-CoV-2 IgM ELISA | 0.868, 1 | Validated by manufacturer |
| **Jordan - HRP** | Bellizzi (World Health Organization)34 | 2020-08-01 - 2020-08-31 | National | Moderate | 4,704 | Multiple groups | All | Probability | Household and community samples | 0.3% (95% CI 0.2-0.5%) | Beijing Wantai Biological - IgM - Wantai SARS-CoV-2 IgM ELISA | 0.868, 1 | Validated by manufacturer |
| **Lebanon - HRP** | Dr Alissar Rady (WHO)[@] | 2021-02-15 - 2021-03-22 | National | Low | 1,252 | Multiple groups | All | Probability | Household and community samples | 39.2% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Lebanon - HRP** | Dr Alissar Rady (WHO)[@] | 2021-02-15 - 2021-03-22 | National | Moderate | 755 | Multiple groups | All | Probability | Household and community samples | 46.7% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **occupied Palestinian territory, including east Jerusalem - HRP** | Sharif E. Qaddomi (PNIPH)[@] | 2020-12-01 - 2020-12-31 | National | Moderate | 6,154 | Multiple groups | All | Probability | Household and community samples | 39.7% (95% CI 38.5-40.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **Oman** | Al-Abri (Ministry of Health (Oman))35 | 2020-11-08 - 2020-11-19 | National | Moderate | 4,064 | Multiple groups | All | Probability | Household and community samples | 22% (95% CI 20.7-23.3%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Oman** | Al-Abri (Ministry of Health (Oman))35 | 2020-09-13 - 2020-09-24 | National | Moderate | 4,780 | Multiple groups | All | Probability | Household and community samples | 16.4% (95% CI 15.4-17.5%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Oman** | Al-Abri (Ministry of Health (Oman))35 | 2020-08-16 - 2020-08-27 | National | Moderate | 4,403 | Multiple groups | All | Probability | Household and community samples | 9.7% (95% CI 8.8-10.6%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Oman** | Al-Abri (Ministry of Health (Oman))35 | 2020-07-12 - 2020-07-23 | National | Moderate | 4,210 | Multiple groups | All | Probability | Household and community samples | 5.5% (95% CI 4.8-6.2%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Pakistan - HRP** | Haq (Riphah International University )36 | 2020-07-15 - 2020-07-31 | National | Moderate | 15,390 | Multiple groups | All | Probability | Household and community samples | 42.4% (95% CI 41.6-43.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Qatar** | Coyle (Cornell University)37 | 2020-05-12 - 2020-09-09 | National | Moderate | 112,941 | Multiple groups | All | Sequential | Residual sera | 13.3% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |

#### *Europe region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Belarus** | Popova (St. Petersburg Pasteur Institute)38 | 2021-05-14 - 2021-05-19 | National | Moderate | 12,926 | Multiple groups | All | Probability | Household and community samples | 36.3% (95% CI 35.5-37.1%) | NA - IgG - Author designed (ELISA) - Nucleocapsid |  |  |
| **Bosnia and Herzegovina** | Dejan Bokonjic (Faculty of Medicine Foca Faculty of Medicine Banja Luka Public Health Institute of Republic of Srpska )39 | 2020-11-04 - 2020-12-16 | National | Moderate | 1,855 | Multiple groups | All | Probability | Household and community samples | 40.3% (95% CI 38-42.5%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Kazakhstan** | Manar Smangul (Ministry of Health of the Republic of Kazakhstan)40 | 2020-10-24 - 2021-01-11 | National | Moderate | 6,891 | Multiple groups | All | Probability | Household and community samples | 57% (95% CI 55.8-58.2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Kyrgyzstan** | Popova (Saint Petersburg Pasteur Institute)41 | 2021-06-28 - 2021-07-03 | National | Moderate | 9,471 | Multiple groups | All | Probability | Household and community samples | 47.5% (95% CI 46.5-48.5%) | NA - - Author designed (ELISA) - Nucleocapsid |  |  |
| **Kyrgyzstan** | Nurmatov Zuridin, Kuchuk Tatyana (Scientific Production Association “Preventive medicine”)42 | 2020-07-04 - 2020-08-12 | National | Moderate | 4,540 | Multiple groups | All | Convenience | Household and community samples | 32.5% (95% CI 31.1-33.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Republic of Moldova** | Alexei Ceban Stela Gheorghita, WHO CO (National Agency for Public Health)43 | 2020-11-17 - 2021-01-15 | National | Moderate | 5,656 | Multiple groups | All | Probability | Residual sera | 48.4% (95% CI 47.1-49.7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Uzbekistan** | Rakhimov (Research Institute of Virology)44 | 2020-08-27 - 2020-09-11 | National | Moderate | 86,879 | Multiple groups | All | Convenience | Residual sera | 23.1% (95% CI 22.8-23.4%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Andorra** | Cebrecos (ISGlobal)45 | 2020-05-04 - 2020-05-28 | National | Moderate | 72,964 | Multiple groups | All | Probability | Household and community samples | 11% (95% CI 10.8-11.2%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-10-12 - 2020-10-17 | National | Low | 2,966 | Multiple groups | All | Probability | Residual sera | 4.2% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-09-07 - 2020-09-12 | National | Low | 3,047 | Multiple groups | All | Probability | Residual sera | 3.3% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-06-29 - 2020-07-04 | National | Low | 3,023 | Multiple groups | All | Probability | Residual sera | 3.7% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-06-08 - 2020-06-13 | National | Low | 2,960 | Multiple groups | All | Probability | Residual sera | 4.7% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-05-18 - 2020-05-25 | National | Low | 3,242 | Multiple groups | All | Probability | Residual sera | 6.2% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-04-20 - 2020-04-26 | National | Low | 3,397 | Multiple groups | All | Probability | Residual sera | 5.2% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Belgium** | Herzog (University of Antwerp)46 | 2020-03-30 - 2020-04-05 | National | Low | 3,910 | Multiple groups | All | Probability | Residual sera | 1.8% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Denmark** | Fogh (Copenhagen University Hospital)47 | 2021-01-08 - 2021-01-31 | National | Moderate | 22,677 | Multiple groups | All | Probability | Blood donors | 5.8% (95% CI 5.5-6.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark** | Espenhain (Statens Serum Institut)48 | 2020-12-01 - 2020-12-31 | National | Low | 4,044 | Multiple groups | All | Probability | Household and community samples | 4.1% (95% CI 3.5-4.8%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark** | Espenhain (Statens Serum Institut)48 | 2020-10-01 - 2020-11-30 | National | Low | 9,654 | Multiple groups | All | Probability | Household and community samples | 2.2% (95% CI 1.9-2.5%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark** | Fogh (Copenhagen University Hospital)49 | 2020-10-02 - 2020-10-11 | National | Moderate | 318,552 | Multiple groups | All | Probability | Household and community samples | 0.8% (95% CI 0.8-0.8%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **Denmark** | Espenhain (Statens Serum Institut)48 | 2020-08-15 - 2020-09-30 | National | Low | 11,478 | Multiple groups | All | Probability | Household and community samples | 2.1% (95% CI 1.8-2.4%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark** | Pedersen (Copenhagen University Hospital Rigshospitalet)50 | 2020-06-02 - 2020-06-19 | National | Low | 1,200 | Seniors (65+ years) | All | Probability | Blood donors | 1.8% (95% CI 1.2-2.8%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark** | Espenhain (Statens Serum Institut)48 | 2020-05-05 - 2020-05-15 | National | Low | 2,512 | Multiple groups | All | Probability | Household and community samples | 1.2% (95% CI 0.8-1.7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark** | Erikstrup (Copenhagen University Hospital)51 | 2020-04-06 - 2020-05-03 | National | Moderate | 20,640 | Adults (18-64 years) | All | Probability | Blood donors | 2% (95% CI 1.8-2.2%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-01-31 - 2021-02-06 | National | Moderate | 110 | Adults (18-64 years) | All | Probability | Household and community samples | 2.7% (95% CI 0.6-7.8%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-01-24 - 2021-01-30 | National | Moderate | 30 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-11.6%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-01-17 - 2021-01-23 | National | Moderate | 5 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-52.2%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-01-10 - 2021-01-16 | National | Moderate | 6 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-45.9%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-01-03 - 2021-01-09 | National | Moderate | 12 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-26.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-12-27 - 2021-01-02 | National | Moderate | 26 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-13.2%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-12-20 - 2020-12-26 | National | Moderate | 65 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-5.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-12-13 - 2020-12-19 | National | Moderate | 115 | Adults (18-64 years) | All | Probability | Household and community samples | 0.9% (95% CI 0-4.7%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-12-06 - 2020-12-12 | National | Moderate | 106 | Adults (18-64 years) | All | Probability | Household and community samples | 0.9% (95% CI 0-5.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-11-29 - 2020-12-05 | National | Moderate | 80 | Adults (18-64 years) | All | Probability | Household and community samples | 2.5% (95% CI 0.3-8.7%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-11-22 - 2020-11-28 | National | Moderate | 85 | Adults (18-64 years) | All | Probability | Household and community samples | 3.5% (95% CI 0.7-10%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-11-15 - 2020-11-21 | National | Moderate | 64 | Adults (18-64 years) | All | Probability | Household and community samples | 3.1% (95% CI 0.4-10.8%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-11-08 - 2020-11-14 | National | Moderate | 52 | Adults (18-64 years) | All | Probability | Household and community samples | 1.9% (95% CI 0-10.3%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-11-01 - 2020-11-07 | National | Moderate | 55 | Adults (18-64 years) | All | Probability | Household and community samples | 5.4% (95% CI 1.1-15.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-10-25 - 2020-10-31 | National | Moderate | 56 | Adults (18-64 years) | All | Probability | Household and community samples | 1.8% (95% CI 0-9.6%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-10-18 - 2020-10-24 | National | Moderate | 55 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-6.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-10-11 - 2020-10-17 | National | Moderate | 59 | Adults (18-64 years) | All | Probability | Household and community samples | 1.7% (95% CI 0-9.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-10-04 - 2020-10-10 | National | Moderate | 51 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-7%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-09-27 - 2020-10-03 | National | Moderate | 60 | Adults (18-64 years) | All | Probability | Household and community samples | 1.7% (95% CI 0-8.9%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-04-19 - 2020-04-25 | National | Moderate | 674 | Adults (18-64 years) | All | Probability | Household and community samples | 0.3% (95% CI 0-1.1%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **France** | Vu (Santé publique France)53 | 2020-05-11 - 2020-05-17 | National | Low | 3,592 | Multiple groups | All | Probability | Residual sera | 5% (95% CI 4.3-5.7%) | NA - - Author designed (Neutralization Assay), NA - IgG - Author designed (ELISA) -Spike, NA - IgG - Author designed (ELISA) - Nucleocapsid | N/A | Complex test algorithm: Manual review |
| **France** | Vu (Santé publique France)53 | 2020-04-06 - 2020-04-12 | National | Low | 3,595 | Multiple groups | All | Probability | Residual sera | 4.3% (95% CI 3.7-5.1%) | NA - - Author designed (Neutralization Assay), NA - IgG - Author designed (ELISA) -Spike, NA - IgG - Author designed (ELISA) - Nucleocapsid | N/A | Complex test algorithm: Manual review |
| **France** | Vu (Santé publique France)53 | 2020-03-09 - 2020-03-15 | National | Low | 3,834 | Multiple groups | All | Probability | Residual sera | 0.7% (95% CI 0.5-1%) | NA - - Author designed (Neutralization Assay), NA - IgG - Author designed (ELISA) -Spike, NA - IgG - Author designed (ELISA) - Nucleocapsid | N/A | Complex test algorithm: Manual review |
| **Germany** | Fuest (ifo Institute)54 | 2020-10-26 - 2020-11-18 | National | Moderate | 9,929 | Multiple groups | All | Convenience | Household and community samples | 1.1% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Germany** | Gornyk (Helmholtz Centre for Infection Research)55 | 2020-07-15 - 2020-12-15 | National | Moderate | 13,405 | Multiple groups | All | Probability | Household and community samples | 2% (95% CI 1.8-2.3%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Hungary** | Merkely (Semmelweis University)56 | 2020-05-01 - 2020-05-16 | National | Low | 10,474 | Multiple groups | All | Probability | Household and community samples | 0.7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Israel** | Indenbaum (Tel Aviv University)57 | 2020-01-01 - 2021-03-31 | National | Moderate | 2,765 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 5.6% (95% CI 4.8-6.6%) | NA - - Author designed (ELISA) -Spike, NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Israel** | Reicher (Ministry of Health)58 | 2020-06-28 - 2020-09-14 | National | Moderate | 54,357 | Multiple groups | All | Convenience | Household and community samples | 4.6% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Italy** | Instituto Nazionale di Statistica (Italian Ministry of Health)59 | 2020-05-25 - 2020-07-15 | National | Moderate | 64,660 | Multiple groups | All | Stratified non-probability | Household and community samples | 2.5% (95% CI 2.4-2.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Jersey** | Statistics Jersey (Statistics Jersey)60 | 2020-06-21 - 2020-06-27 | National | Low | 1,386 | Multiple groups | All | Probability | Household and community samples | 4.2% | CTK Biotech, Inc. - IgG, IgM - OnSite COVID-19 IgG/IgM Rapid Test | 0.969, 0.994 | Validated by manufacturer |
| **Lithuania** | Smigelskas ( Lithuanian University of Health Sciences)61 | 2020-08-10 - 2020-09-10 | National | Moderate | 3,089 | Multiple groups | All | Probability | Household and community samples | 1.9% (95% CI 1.4-2.4%) | AMEDA Labordiagnostik GmbH - IgG, IgM - AMP Rapid Test SARS-CoV-2 IgG/IgM | 1, 0.975 | Validated by manufacturer |
| **Luxembourg** | Snoeck (Luxembourg Institute of Health)62 | 2020-04-15 - 2020-05-05 | National | Low | 1,820 | Multiple groups | All | Probability | Household and community samples | 2.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Norway** | Tunheim (Norwegian Institute of Public Health)63 | 2020-12-27 - 2021-02-13 | National | Moderate | 1,912 | Multiple groups | All | Convenience | Residual sera | 3.2% (95% CI 2.4-4.1%) | NA - - Author designed (type unknown) | 0.96, 0.998 | Validated by independent authors/third party/non-developers |
| **Portugal** | Kislaya ( Instituto Nacional de Saúde Doutor Ricardo Jorge)64 | 2020-05-21 - 2020-07-08 | National | Moderate | 2,301 | Multiple groups | All | Stratified non-probability | Residual sera | 2.9% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG), Beijing Wantai Biological - IgM - Wantai SARS-CoV-2 IgM ELISA | 0.9868, 1 | Complex test algorithm: Manual calculation |
| **Slovenia** | Poljak (University of Ljubljana)65 | 2020-10-17 - 2020-11-10 | National | Low | 1,211 | Multiple groups | All | Probability | Household and community samples | 4.3% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N), Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **Slovenia** | Poljak (University of Ljubljana)65 | 2020-04-20 - 2020-05-01 | National | Low | 1,316 | Multiple groups | All | Probability | Household and community samples | 3.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **Spain** | Olmeda ( Instituto de Salud Carlos III)66 | 2020-11-16 - 2020-11-29 | National | Moderate | 5,827 | Multiple groups | All | Probability | Household and community samples | 4.9% (95% CI 4.4-5.5%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Spain** | Prados (IVIRMA Global Headquarters)67 | 2020-04-27 - 2020-06-26 | National | Moderate | 6,140 | Adults (18-64 years) | All | Convenience | Residual sera | 0.7% (95% CI 0.5-0.9%) | Epitope Diagnostics, Inc. - IgM - EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit | 1, 1 | Validated by manufacturer |
| **Sweden** | Swedish Public Health Agency (Swedish Public Health Agency)68 | 2021-09-20 - 2021-10-03 | National | Moderate | 2,959 | Multiple groups | All | Convenience | Residual sera | 75.6% | Sci LifeLab / KTH - - Not available | 0.989, 0.994 | Validated by independent authors/third party/non-developers |
| **Sweden** | Swedish Public Health Agency (Swedish Public Health Agency)69 | 2021-05-24 - 2021-06-04 | National | Moderate | 3,949 | Multiple groups | All | Stratified non-probability | Residual sera | 52.2% | Sci LifeLab / KTH - - Not available | 0.989, 0.994 | Validated by independent authors/third party/non-developers |
| **Sweden** | Swedish Public Health Agency (The Swedish Public Health Agency (Folkhälsomyndigheten))70 | 2020-11-23 - 2020-12-04 | National | Moderate | 3,183 | Multiple groups | All | Convenience | Blood donors | 7% | Sci LifeLab / KTH - - Not available | 0.994, 0.989 | Validated by manufacturers |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2021-09-01 - 2021-10-31 | National | Moderate | 600 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 33.5% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)72 | 2021-09-06 - 2021-10-10 | National | Moderate | 3,023 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 18.1% (95% CI 16.7-19.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2021-07-01 - 2021-08-31 | National | Moderate | 685 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 22.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)73 | 2021-06-28 - 2021-08-01 | National | Moderate | 2,990 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 12.7% (95% CI 11.5-14%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)74 | 2021-05-24 - 2021-06-27 | National | Moderate | 3,052 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 11.2% (95% CI 10.1-12.3%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2021-05-01 - 2021-06-30 | National | Moderate | 1,187 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 21.8% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)75 | 2021-04-19 - 2021-05-23 | National | Moderate | 3,333 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 10% (95% CI 9-11.1%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)76 | 2021-03-15 - 2021-04-18 | National | Moderate | 3,326 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 11.4% (95% CI 10.3-12.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2021-03-01 - 2021-04-30 | National | Moderate | 930 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 25.7% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Aldridge (University College London)77 | 2021-02-01 - 2021-05-03 | National | Moderate | 10,330 | Multiple groups | All | Convenience | Household and community samples | 8.2% (95% CI 7.7-8.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Beale (University College London)78 | 2021-02-01 - 2021-04-28 | National | Moderate | 3,761 | Adults (18-64 years) | All | Convenience | Household and community samples | 11.6% (95% CI 10.6-12.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Whitaker (Public Health England)79 | 2021-02-22 - 2021-03-21 | National | Moderate | 7,717 | Multiple groups | All | Convenience | Blood donors | 14.5% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)80 | 2021-02-08 - 2021-03-14 | National | Moderate | 3,355 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 8.9% (95% CI 7.9-9.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2021-01-01 - 2021-02-28 | National | Moderate | 970 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 20.7% (95% CI 18.2-23.4%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)81 | 2021-01-04 - 2021-02-07 | National | Moderate | 2,497 | Multiple groups | All | Sequential | Blood donors | 12.1% (95% CI 10.9-13.5%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)81 | 2021-01-04 - 2021-02-07 | National | Moderate | 3,478 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 6.9% (95% CI 6.1-7.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)82 | 2020-11-30 - 2021-01-03 | National | Moderate | 2,499 | Multiple groups | All | Sequential | Blood donors | 4.2% (95% CI 3.5-5.1%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)82 | 2020-11-30 - 2021-01-03 | National | Moderate | 3,052 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 5.3% (95% CI 4.6-6.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2020-11-01 - 2020-12-31 | National | Moderate | 711 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 13.2% (95% CI 10.8-15.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **The United Kingdom** | Ladhani (Public Health England)83 | 2020-11-17 - 2020-11-30 | National | Moderate | 1,216 | Multiple groups | All | Probability | Household and community samples | 10.4% (95% CI 8.7-12.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)84 | 2020-10-26 - 2020-11-29 | National | Moderate | 2,499 | Multiple groups | All | Sequential | Blood donors | 4.2% (95% CI 3.4-5%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-08-19 - 2020-09-13 | National | Low | 7,888 | Multiple groups | All | Probability | Blood donors | 6.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-08-13 - 2020-09-06 | National | Low | 7,899 | Multiple groups | All | Probability | Blood donors | 5.5% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-06-22 - 2020-07-20 | National | Low | 9,220 | Multiple groups | All | Probability | Blood donors | 6.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-06-01 - 2020-08-02 | National | Low | 2,062 | Children and Youth (0-17 years) | All | Probability | Residual sera | 2.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-06-01 - 2020-08-02 | National | Moderate | 285 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 4.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-06-08 - 2020-07-06 | National | Low | 11,385 | Multiple groups | All | Probability | Blood donors | 7.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-07-01 - 2020-08-14 | National | Low | 2,153 | Seniors (65+ years) | All | Probability | Residual sera | 3.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-05-13 - 2020-06-07 | National | Low | 7,777 | Adults (18-64 years) | All | Probability | Blood donors | 8.2% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-05-01 - 2020-05-31 | National | Moderate | 1,061 | Children and Youth (0-17 years) | All | Probability | Residual sera | 7.8% (95% CI 6.3-9.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-03-16 - 2020-06-30 | National | Low | 6,000 | Seniors (65+ years) | All | Probability | Residual sera | 3.9% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-04-01 - 2020-04-30 | National | Moderate | 647 | Children and Youth (0-17 years) | All | Probability | Residual sera | 6.6% (95% CI 4.9-8.8%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-04-01 - 2020-04-30 | National | Moderate | 201 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 4.5% (95% CI 2.1-8.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-02-01 - 2020-03-31 | National | Moderate | 106 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 1.4% (95% CI 0-5.1%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |

#### *South-East Asia region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Bangladesh - HRP** | Firdausi Qadri (International Centre for Diarrhoeal Disease Research )[@] | 2021-09-21 - 2021-10-09 | National | Low | 721 | Multiple groups | All | Probability | Household and community samples | 60% (95% CI 56.4-63.7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Bangladesh - HRP** | Firdausi Qadri (International Centre for Diarrhoeal Disease Research )[@] | 2021-03-27 - 2021-06-13 | National | Low | 2,307 | Multiple groups | All | Probability | Household and community samples | 62% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **India** | Murhekar (Indian Council of Medical Research)86 | 2020-12-18 - 2021-01-06 | National | Low | 28,598 | Multiple groups | All | Probability | Household and community samples | 24.6% | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India** | Murhekar (The Indian Council of Medical Research (ICMR))86 | 2020-08-18 - 2020-09-20 | National | Low | 29,082 | Multiple groups | All | Probability | Household and community samples | 7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Indonesia** | Dr. dr. Tri Yunis Miko Wahyono, M.Sc (University of Indonesia)87 | 2020-12-15 - 2021-03-03 | National | Moderate | 10,161 | Multiple groups | All | Probability | Household and community samples | 20.5% (95% CI 19.7-21.3%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Nepal** | Government of Nepal (Government of Nepal)88 | 2020-10-09 - 2020-10-22 | National | Low | 3,040 | Multiple groups | All | Probability | Household and community samples | 14.4% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Thailand** | Sutthichai Nakphook, MD (Ministry of Public Health)89 | 2020-12-18 - 2021-02-02 | National | Moderate | 1,200 | Multiple groups | All | Probability | Household and community samples | 0.4% (95% CI 0.1-1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |

#### *Western Pacific region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Australia** | Coatsworth (Australian National University)90 | 2020-06-02 - 2020-07-17 | National | Moderate | 2,991 | Multiple groups | All | Sequential | Residual sera | 0.2% (95% CI 0.1-0.4%) | NA - - Author designed (ELISA) - MULTIPLEXED | 1, 0.989 | Validated by independent authors/third party/non-developers |
| **China** | Li (Chinese Center for Disease Control and Prevention)91 | 2020-04-10 - 2020-04-18 | National | Moderate | 34,857 | Multiple groups | All | Probability | Household and community samples | 1.2% (95% CI 1.1-1.4%) | Guangzhou Wondfo Biotech Co., Ltd - IgG, IgM - Finecare SARS-CoV-2 Antibody test, Innovita Biological Technology Co. Ltd - IgG - 2019-nCoV IgG Rapid Test, Bioscience Diagnostics - IgG, IgM - Magnetic Chemiluminescence Enzyme Immunoassay Kit, NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Malaysia** | Chong Zhuo Lin (Institute for Public Health)92 | 2020-08-07 - 2020-10-06 | National | Moderate | 5,131 | Multiple groups | All | Probability | Household and community samples | 0.6% (95% CI 0.4-0.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;GenScript - IgG, IgM - cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit | 0.907, 1 | Complex test algorithm: Manual calculation |
| **Mongolia** | Battogtokh Chimeddorj (Mongolian National University of Medical Sciences (MNUMS))93 | 2021-01-18 - 2021-03-15 | National | Moderate | 4,530 | Multiple groups | All | Convenience | Household and community samples | 1.6% (95% CI 1.3-2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Kantaro Biosciences, LLC - IgG - COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit | 0.955, 1 | Complex test algorithm: Manual calculation |
| **Mongolia** | Battogtokh Chimeddorj (Mongolian National University of Medical Sciences (MNUMS))93 | 2020-10-18 - 2020-12-05 | National | Moderate | 5,000 | Multiple groups | All | Convenience | Household and community samples | 1.4% (95% CI 1.1-1.8%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Kantaro Biosciences, LLC - IgG - COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit | 0.955, 1 | Complex test algorithm: Manual calculation |
| **Papua New Guinea** | Moses Laman (Papua New Guinea Institute of Medical Research)94 | 2020-05-01 - 2020-06-30 | National | Moderate | 12,177 | Multiple groups | All | Convenience | Household and community samples | 2.6% (95% CI 2.4-2.9%) | Hanghzhou AllTest Biotech Co., Ltd - IgG, IgM - 2019-nCoV IgG/IgM Rapid Test Cassette | 1, 0.962 | Validated by manufacturer |
| **Republic of Korea** | Nah (Korea Association of Health Promotion)95 | 2020-09-24 - 2020-12-09 | National | Moderate | 4,085 | Multiple groups | All | Probability | Residual sera | 0.4% (95% CI 0.2-0.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |

### Table S6. Additional studies used in meta-analysis and meta-regression.

#### *Africa region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Democratic Republic of the Congo - HRP (All the 35 health districts of Kinshasa)** | Makiala Mandanda Sheila (Institut National de Recherche Biomédicale)96 | 2021-03-06 - 2021-03-14 | Subnational | Moderate | 2,476 | Multiple groups | All | Probability | Household and community samples | 72.1% (95% CI 70.3-73.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Ethiopia - HRP (Harari,Oromia)** | Assefa (The London School of Hygiene & Tropical Medicine)97 | 2020-04-01 - 2021-03-31 | Subnational | Moderate | 1,447 | Adults (18-64 years) | Female | Probability | Pregnant or parturient women | 5.7% (95% CI 4.5-7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)98 | 2021-12-12 - 2021-12-19 | National | Moderate | 1,027 | Multiple groups | All | Probability | Household and community samples | 86.7% (95% CI 84.4-88.7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)98 | 2021-07-01 - 2021-07-29 | National | Moderate | 2,275 | Multiple groups | All | Probability | Household and community samples | 66.9% (95% CI 64.9-68.8%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)98 | 2021-05-03 - 2021-06-30 | National | Moderate | 2,234 | Multiple groups | All | Probability | Household and community samples | 65.9% (95% CI 63.9-67.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)98 | 2021-02-13 - 2021-02-23 | National | Moderate | 401 | Multiple groups | All | Probability | Household and community samples | 29.4% (95% CI 25-34.2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Nigeria - HRP** | Olatunji Kolawole (Ministerial Expert Advisory Committee on COVID-19- Health Sector Response)99 | 2021-06-29 - 2021-08-31 | National | Moderate | 4,904 | Multiple groups | All | Probability | Residual sera | 78.9% (95% CI 77.7-80%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Nigeria - HRP (Anambra State)** | Okpala (Anambra State Ministry of Health)100 | 2020-12-08 - 2020-12-15 | Subnational | Moderate | 3,142 | Multiple groups | All | Probability | Household and community samples | 17.6% (95% CI 16.3-18.9%) | Hangzhou Realy Tech Co., Ltd - IgG, IgM - Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test | 0.967, 0.937 | Validated by manufacturer |
| **Nigeria - HRP (Enugu State)** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (University of Maryland, Baltimore)101 | 2020-09-21 - 2020-10-27 | Subnational | Low | 2,147 | Multiple groups | All | Probability | Household and community samples | 25.2% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;EUROIMMUN AG - IgG - SARS-CoV-2-NCP-IgG ELISA;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay | N/A | Complex test algorithm: Manual review |
| **Nigeria - HRP (Gombe State)** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (University of Maryland, Baltimore)101 | 2020-09-21 - 2020-10-27 | Subnational | Low | 3,432 | Multiple groups | All | Probability | Household and community samples | 9.3% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;EUROIMMUN AG - IgG - SARS-CoV-2-NCP-IgG ELISA;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay | N/A | Complex test algorithm: Manual review |
| **Nigeria - HRP (Nasarawa State)** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (University of Maryland, Baltimore)101 | 2020-09-21 - 2020-10-27 | Subnational | Low | 2,657 | Multiple groups | All | Probability | Household and community samples | 18% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;EUROIMMUN AG - IgG - SARS-CoV-2-NCP-IgG ELISA;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay | N/A | Complex test algorithm: Manual review |
| **Nigeria - HRP (Lagos State)** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (Nigeria Institute for Medical Research)101 | 2020-09-21 - 2020-10-27 | Subnational | Low | 2,393 | Multiple groups | All | Probability | Household and community samples | 23.2% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;EUROIMMUN AG - IgG - SARS-CoV-2-NCP-IgG ELISA;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay;Luminex Corp - IgG - Multiplexed Particle Flow Cytometry Assay | N/A | Complex test algorithm: Manual review |
| **Nigeria - HRP (Niger State)** | Majiya (Ibrahim Badamasi Babangida University)102 | 2020-06-26 - 2020-06-30 | Subnational | Moderate | 185 | Multiple groups | All | Probability | Household and community samples | 25.4% (95% CI 19.3-32.3%) | Cambridge Network - IgG, IgM - COVID-19 IgG and IgM Rapid Test | 1, 1 | Validated by independent authors/third party/non-developers |
| **South Africa (Gauteng)** | George (National Health Laboratory Service)103 | 2020-10-01 - 2020-10-31 | Subnational | Moderate | 1,664 | Multiple groups | All | Convenience | Residual sera | 28.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |

#### *Americas region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Brazil - HRP (Rio Grande do Sul)** | Barros (Universidade Federal de Pelotas)104 | 2021-04-09 - 2021-04-11 | Subnational | Moderate | 4,499 | Multiple groups | All | Probability | Household and community samples | 18.2% (95% CI 17-19.3%) | NA - IgG - Author designed (ELISA) -Spike | 0.95, 0.986 | Validated by developers |
| **Brazil - HRP (Rio Grande do Sul)** | Barros (Universidade Federal de Pelotas)104 | 2021-02-05 - 2021-02-07 | Subnational | Moderate | 4,501 | Multiple groups | All | Probability | Household and community samples | 10% (95% CI 9.1-10.9%) | NA - IgG - Author designed (ELISA) -Spike | 0.95, 0.986 | Validated by developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2021-02-02 - 2021-02-04 | Subnational | Moderate | 1,742 | Multiple groups | All | Probability | Household and community samples | 16% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2021-01-19 - 2021-01-21 | Subnational | Moderate | 1,795 | Multiple groups | All | Probability | Household and community samples | 13.9% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2021-01-05 - 2021-01-07 | Subnational | Moderate | 1,908 | Multiple groups | All | Probability | Household and community samples | 14.1% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Maranhão)** | Silva (Universidade Federal do Maranhao)106 | 2020-10-19 - 2020-10-30 | Subnational | Low | 4,563 | Multiple groups | All | Probability | Household and community samples | 38.1% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Brazil - HRP (Vale do Rio Pardo)** | Schneider (Universidade de Santa Cruz do Sul)107 | 2020-10-04 - 2020-10-17 | Subnational | Moderate | 1,063 | Multiple groups | All | Probability | Household and community samples | 3.4% | Beijing Lepu Medical Technology - IgG, IgM - Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) | 0.989, 0.976 | Validated by manufacturer |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-09-22 - 2020-09-24 | Subnational | Moderate | 2,012 | Multiple groups | All | Probability | Household and community samples | 13.6% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-09-08 - 2020-09-10 | Subnational | Moderate | 2,125 | Multiple groups | All | Probability | Household and community samples | 11.9% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Rio Grande do Sul)** | Hallal (Universidade Federal de Pelotas )108 | 2020-09-04 - 2020-09-06 | Subnational | Moderate | 4,500 | Multiple groups | All | Probability | Household and community samples | 1.6% | Guangzhou Wondfo Biotech Co.， Ltd - IgG, IgM, IgA - Wondfo SARS-CoV-2 Antibody Test | 0.864, 0.996 | Validated by manufacturer |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-08-25 - 2020-08-27 | Subnational | Moderate | 2,225 | Multiple groups | All | Probability | Household and community samples | 13.9% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-08-11 - 2020-08-13 | Subnational | Moderate | 2,447 | Multiple groups | All | Probability | Household and community samples | 11% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-07-28 - 2020-07-30 | Subnational | Moderate | 2,529 | Multiple groups | All | Probability | Household and community samples | 10.9% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-07-13 - 2020-07-16 | Subnational | Moderate | 2,323 | Multiple groups | All | Probability | Household and community samples | 11.1% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-06-29 - 2020-07-02 | Subnational | Moderate | 2,481 | Multiple groups | All | Probability | Household and community samples | 9.7% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Greater São Paulo)** | Albuquerque (Secretaria Municipal de Saude de Sao Paulo)105 | 2020-06-10 - 2020-06-17 | Subnational | Moderate | 2,645 | Multiple groups | All | Probability | Household and community samples | 9.5% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.848, 0.99 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Espirito Santo)** | Maciel (Laboratorio de Epidemiologia)109 | 2020-05-10 - 2020-06-21 | Subnational | Moderate | 1,693 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 6.1% (95% CI 5-7.3%) | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.864, 0.996 | Validated by independent authors/third party/non-developers |
| **Colombia - HRP (Department of La Guajira,Department of Cesar)** | Concha (Medical Mission Institute)110 | 2021-03-28 - 2021-04-26 | Subnational | Moderate | 452 | Multiple groups | All | Convenience | Household and community samples | 27.7% (95% CI 23.6-32%) | PharmACT - IgG, IgM - BELTEST-IT COV-2 Rapid Test | 0.982, 0.997 | Validated by manufacturer |
| **Colombia - HRP (Cordoba Department)** | Garay (Colombia-Universidad de Cordoba)111 | 2020-07-15 - 2020-11-15 | Subnational | Moderate | 2,564 | Multiple groups | All | Stratified non-probability | Household and community samples | 40.8% (95% CI 38.9-42.7%) | Eurofins Ingenasa - IgG, IgM, IgA - INgezim COVID 19 DR | 0.983, 0.992 | Validated by manufacturer |
| **Colombia - HRP (Cordoba)** | Guzma (Universidad de Cordoba)112 | 2020-03-15 - 2020-10-02 | Subnational | Moderate | 2,447 | Multiple groups | All | Probability | Household and community samples | 40.8% (95% CI 38.8-42.8%) | Eurofins Ingenasa - IgG, IgM, IgA - INgezim COVID 19 DR | 0.983, 0.992 | Validated by manufacturer |
| **Peru - HRP (Cusco Region)** | Huamani (Universidad Andina del Cusco)113 | 2020-09-12 - 2020-09-27 | Subnational | Moderate | 1,924 | Multiple groups | All | Probability | Household and community samples | 33.1% (95% CI 31-35.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Canada (Québec)** | Hema-Quebec (Héma-Québec)114 | 2021-01-25 - 2021-04-22 | Subnational | Moderate | 7,924 | Multiple groups | All | Sequential | Blood donors | 14.7% | NA - - Author designed (ELISA) -Spike | 0.989, 0.985 | Validated by developers |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2021-01-11 - 2021-01-14 | Subnational | Moderate | 11,049 | Multiple groups | All | Sequential | Residual sera | 3.6% (95% CI 3.3-4%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-12-07 - 2020-12-10 | Subnational | Moderate | 12,076 | Multiple groups | All | Sequential | Residual sera | 2% (95% CI 1.8-2.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-11-09 - 2020-11-13 | Subnational | Moderate | 11,471 | Multiple groups | All | Sequential | Residual sera | 1.2% (95% CI 1-1.4%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-10-01 - 2020-10-30 | Subnational | Moderate | 7,107 | Multiple groups | All | Convenience | Residual sera | 1.2% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-10-05 - 2020-10-09 | Subnational | Moderate | 13,490 | Multiple groups | All | Sequential | Residual sera | 0.9% (95% CI 0.7-1%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-09-03 - 2020-09-30 | Subnational | Moderate | 4,901 | Multiple groups | All | Convenience | Residual sera | 0.7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-09-07 - 2020-09-11 | Subnational | Moderate | 12,006 | Multiple groups | All | Sequential | Residual sera | 1% (95% CI 0.8-1.1%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-08-01 - 2020-08-31 | Subnational | Moderate | 6,789 | Multiple groups | All | Convenience | Residual sera | 1.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-08-04 - 2020-08-11 | Subnational | Moderate | 12,284 | Multiple groups | All | Sequential | Residual sera | 0.7% (95% CI 0.6-0.9%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-07-04 - 2020-07-31 | Subnational | Moderate | 7,001 | Multiple groups | All | Convenience | Residual sera | 1.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-07-06 - 2020-07-10 | Subnational | Moderate | 13,175 | Multiple groups | All | Sequential | Residual sera | 0.5% (95% CI 0.4-0.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-06-05 - 2020-06-30 | Subnational | Moderate | 7,014 | Multiple groups | All | Convenience | Residual sera | 1.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (Alberta)** | Charlton (Alberta Precision Laboratories)115 | 2020-06-01 - 2020-06-05 | Subnational | Moderate | 8,442 | Multiple groups | All | Sequential | Residual sera | 0.9% (95% CI 0.7-1.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-05-26 - 2020-05-31 | Subnational | Moderate | 1,061 | Multiple groups | All | Convenience | Residual sera | 1.5% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (British Columbia)** | Skowronski (British Columbia Centre for Disease Control)117 | 2020-05-15 - 2020-05-27 | Subnational | Moderate | 870 | Multiple groups | All | Probability | Residual sera | 0.8% (95% CI 0.3-1.5%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | N/A | Complex test algorithm: Manual review |
| **Canada (Ontario)** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)116 | 2020-03-27 - 2020-04-30 | Subnational | Moderate | 827 | Multiple groups | All | Convenience | Residual sera | 0.5% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 0.904, 1 | Complex test algorithm: Manual calculation |
| **Canada (British Columbia)** | Skowronski (British Columbia Centre for Disease Control)117 | 2020-03-05 - 2020-03-13 | Subnational | Moderate | 870 | Multiple groups | All | Probability | Residual sera | 0.8% (95% CI 0.3-1.5%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **Chile - HRP (Cities: Santiago (34 municipalities), Coquimbo-La serena (2 Municipalities) and Talca (1 Municipality))** | Ximena Aguilera (Universidad del Desarrollo, Centro de Epidemiología y Políticas de Salud)118 | 2021-10-05 - 2021-11-25 | Subnational | NA | 2,198 | Multiple groups | All | Probability | Household and community samples | 97.3% (95% CI 96.6-98%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **United States of America (California)** | Mehrotra (California Department of Public Health)119 | 2021-04-20 - 2021-08-01 | Subnational | Low | 7,483 | Multiple groups | All | Probability | Household and community samples | 89% (95% CI 88.3-89.7%) | Enable Biosciences - IgG, IgM, IgA - Enable’s ADAP SARS-CoV-2 total antibody assay | 1, 1 | Validated by manufacturer |
| **United States of America (California)** | Mehrotra (California Department of Public Health)119 | 2021-04-20 - 2021-06-16 | Subnational | Low | 1,375 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 42% (95% CI 39.3-44.6%) | Enable Biosciences - IgG, IgM, IgA - Enable’s ADAP SARS-CoV-2 total antibody assay | 1, 1 | Validated by manufacturer |
| **United States of America (Arkansas)** | Boehme (University of Arkansas for Medical Sciences)120 | 2021-04-05 - 2021-04-28 | Subnational | Moderate | 590 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 25.8% (95% CI 22.3-29.5%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 0.946, 1 | Validated by developers |
| **United States of America (California)** | Wong (University of California)121 | 2021-02-15 - 2021-04-15 | Subnational | Moderate | 4,641 | Multiple groups | All | Convenience | Household and community samples | 31.3% (95% CI 30-32.6%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, NA - - Author designed (ELISA) -Spike | N/A | Complex test algorithm: Manual review |
| **United States of America (Arkansas)** | Kennedy (University of Arkansas for Medical Sciences)122 | 2020-11-07 - 2020-12-19 | Subnational | Moderate | 2,405 | Multiple groups | All | Convenience | Residual sera | 7.4% | Beckman Coulter - IgG - Access SARS-CoV-2 IgG Antibody Test, NA - - Author designed (ELISA) - Unknown | N/A | Complex test algorithm: Manual review |
| **United States of America (Arkansas)** | Boehme (University of Arkansas for Medical Sciences)120 | 2020-11-07 - 2020-12-17 | Subnational | Moderate | 600 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 13.2% (95% CI 10.6-16.1%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 0.946, 1 | Validated by developers |
| **United States of America (California)** | Pressman (Sutter Health)123 | 2020-10-01 - 2020-12-31 | Subnational | Moderate | 4,500 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 8.1% (95% CI 7.3-8.9%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T) | 0.985, 0.998 | Validated by manufacturer |
| **United States of America (California)** | Wong (University of California)121 | 2020-10-15 - 2020-12-15 | Subnational | Moderate | 5,308 | Multiple groups | All | Convenience | Household and community samples | 0.6% (95% CI 0.4-0.8%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (Arkansas)** | Kennedy (University of Arkansas for Medical Sciences)122 | 2020-09-12 - 2020-10-24 | Subnational | Moderate | 2,098 | Multiple groups | All | Convenience | Residual sera | 4.1% | Beckman Coulter - IgG - Access SARS-CoV-2 IgG Antibody Test, NA - - Author designed (ELISA) - Unknown | N/A | Complex test algorithm: Manual review |
| **United States of America (Arkansas)** | Boehme (University of Arkansas for Medical Sciences)120 | 2020-09-08 - 2020-10-17 | Subnational | Moderate | 594 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 16.2% (95% CI 13.3-19.4%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 0.946, 1 | Validated by developers |
| **United States of America (Virginia)** | Levorson (Inova Health System)124 | 2020-07-31 - 2020-10-13 | Subnational | Moderate | 1,038 | Children and Youth (0-17 years) | All | Convenience | Multiple general populations | 8.5% (95% CI 6.9-10.3%) | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 1, 1 | Validated by manufacturer |
| **United States of America (North Carolina)** | Lopez (University of North Carolina)125 | 2020-08-09 - 2020-10-03 | Subnational | Moderate | 2,633 | Multiple groups | All | Convenience | Residual sera | 10.8% (95% CI 9.6-12%) | NA - IgG - Author designed (ELISA) -Spike | 0.98, 1 | Validated by developers |
| **United States of America (Arkansas)** | Kennedy (University of Arkansas for Medical Sciences)122 | 2020-08-15 - 2020-09-05 | Subnational | Moderate | 1,301 | Multiple groups | All | Convenience | Residual sera | 2.6% | Beckman Coulter - IgG - Access SARS-CoV-2 IgG Antibody Test, NA - - Author designed (ELISA) - Unknown | N/A | Complex test algorithm: Manual review |
| **United States of America (California)** | Wong (University of California)121 | 2020-07-15 - 2020-09-15 | Subnational | Moderate | 4,670 | Multiple groups | All | Convenience | Household and community samples | 0.6% (95% CI 0.4-0.9%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (California)** | Adams (University of California, Berkeley)126 | 2020-07-04 - 2020-09-01 | Subnational | Moderate | 4,760 | Multiple groups | All | Stratified non-probability | Household and community samples | 1% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (Colorado)** | Kugeler (Centers for Disease Control and Prevention)127 | 2020-07-22 - 2020-08-08 | Subnational | Moderate | 1,598 | Multiple groups | All | Convenience | Residual sera | 6.8% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (Colorado)** | Kugeler (Centers for Disease Control and Prevention)127 | 2020-07-22 - 2020-08-08 | Subnational | Moderate | 381 | Multiple groups | All | Probability | Household and community samples | 8% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (North Carolina)** | Lopez (University of North Carolina)125 | 2020-06-14 - 2020-08-08 | Subnational | Moderate | 3,528 | Multiple groups | All | Convenience | Residual sera | 10.5% (95% CI 9.5-11.5%) | NA - IgG - Author designed (ELISA) -Spike | 0.98, 1 | Validated by developers |
| **United States of America (Virginia)** | McQuade (University of Virginia )128 | 2020-06-01 - 2020-08-14 | Subnational | Moderate | 4,675 | Multiple groups | All | Convenience | Residual sera | 2.2% (95% CI 1.8-2.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (Arkansas)** | Boehme (University of Arkansas for Medical Sciences)120 | 2020-06-06 - 2020-08-10 | Subnational | Moderate | 300 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 9.7% (95% CI 6.6-13.6%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 0.946, 1 | Validated by developers |
| **United States of America (Connecticut)** | Mahajan (Yale School of Medicine)129 | 2020-06-23 - 2020-07-22 | Subnational | Moderate | 148 | Multiple groups | All | Probability | Household and community samples | 6.4% | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 1, 1 | Validated by manufacturer |
| **United States of America (Connecticut)** | Mahajan (Yale School of Medicine)129 | 2020-06-23 - 2020-07-22 | Subnational | Moderate | 171 | Multiple groups | All | Probability | Household and community samples | 19.9% | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 1, 1 | Validated by manufacturer |
| **United States of America (New York)** | Cohen (Donald and Barbara Zucker School of Medicine)130 | 2020-05-27 - 2020-07-24 | Subnational | Moderate | 1,671 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 16.1% (95% CI 14.4-17.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United States of America (Connecticut)** | Mahajan (Yale School of Medicine)129 | 2020-06-04 - 2020-06-23 | Subnational | Moderate | 567 | Multiple groups | All | Probability | Household and community samples | 4% | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 1, 1 | Validated by manufacturer |
| **United States of America (Connecticut)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 8,929 | Multiple groups | All | Probability | Residual sera | 5.7% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Florida)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 7,787 | Multiple groups | All | Probability | Residual sera | 4.8% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Louisiana)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 2,849 | Multiple groups | All | Probability | Residual sera | 7.7% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Minnesota)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 7,944 | Multiple groups | All | Probability | Residual sera | 4.9% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Missouri)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 9,356 | Multiple groups | All | Probability | Residual sera | 2.5% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Utah)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 8,769 | Multiple groups | All | Probability | Residual sera | 2.7% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Washington)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Subnational | Low | 7,544 | Multiple groups | All | Probability | Residual sera | 2% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Utah)** | Samore (University of Utah)132 | 2020-05-04 - 2020-06-30 | Subnational | Low | 8,108 | Multiple groups | All | Probability | Household and community samples | 1.1% (95% CI 0.9-1.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (Oregon)** | Sutton (Oregon Health Authority)133 | 2020-05-11 - 2020-06-15 | Subnational | Moderate | 897 | Multiple groups | All | Probability | Residual sera | 1% (95% CI 0.4-1.7%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (North Carolina)** | Lopez (University of North Carolina)125 | 2020-04-19 - 2020-06-13 | Subnational | Moderate | 3,463 | Multiple groups | All | Convenience | Residual sera | 5.3% (95% CI 4.6-6.1%) | NA - IgG - Author designed (ELISA) -Spike | 0.98, 1 | Validated by developers |
| **United States of America (Rhode Island)** | Chan (Brown University)134 | 2020-05-05 - 2020-05-22 | Subnational | Low | 1,032 | Multiple groups | All | Probability | Household and community samples | 2.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (Indiana)** | Menachemi (Indiana University Fairbanks School of Public Health)135 | 2020-04-25 - 2020-04-29 | Subnational | Low | 3,518 | Multiple groups | All | Probability | Household and community samples | 1.1% | NA - IgG - Author designed (ELISA) -Unknown | 1, 0.996 | Validated by developers |
| **United States of America (Arkansas)** | Boehme (University of Arkansas for Medical Sciences)120 | 2020-04-02 - 2020-05-06 | Subnational | Moderate | 316 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 7.9% (95% CI 4.9-11.1%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 0.946, 1 | Validated by developers |

#### *Eastern Mediterranean region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Iran (Islamic Republic of) - HRP (Guilan)** | Shakiba (Tehran University of Medical Sciences)136 | 2020-04-11 - 2020-04-19 | Subnational | Moderate | 528 | Multiple groups | All | Probability | Household and community samples | 22.1% | VivaChek Biotech (Hangzhou) Co., Ltd - IgG, IgM - VivaDiag COVID-19 IgM/IgG Rapid Test | 0.971, 1 | Validated by manufacturer |
| **Iran (Islamic Republic of) - HRP (Mazandaran)** | Mousavi (Mazandaran University of Medical Sciences)137 | 2020-03-15 - 2020-05-15 | Subnational | Low | 1,588 | Multiple groups | All | Probability | Household and community samples | 17.3% | Pishtaz Diagnostics Iran - IgG - ELISA kit Pishtaz Teb Diagnostics | 0.941, 0.983 | Validated by manufacturer |
| **occupied Palestinian territory, including east Jerusalem - HRP (West Bank)** | Maraqa (An-Najah National University)138 | 2020-11-01 - 2020-12-31 | Subnational | Moderate | 1,269 | Multiple groups | All | Probability | Residual sera | 24% (95% CI 21.6-26.4%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United Arab Emirates (Emirate of Abu Dhabi)** | Alsuwaidi (Abu Dhabi Public Health Center)139 | 2020-07-19 - 2020-08-14 | Subnational | Moderate | 8,831 | Multiple groups | All | Probability | Household and community samples | 11.3% (95% CI 10.6-12%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 0.974, 0.9999 | Complex test algorithm: Manual calculation |

#### *Europe region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Bosnia and Herzegovina (District Sarajevo)** | Sanjin Musa (Institute for Public Health of the Federation of Bosnia and Herzegovina)140 | 2020-11-02 - 2020-12-07 | Subnational | Moderate | 1,015 | Multiple groups | All | Probability | Blood donors | 19.1% (95% CI 16.6-21.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG;Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.984, 1 | Complex test algorithm: Manual calculation |
| **Georgia (4 Districts:4 highly touristic districts of Georgia (Borjomi, Martvili, Khelvachauri and Kobuleti))** | Khatuna Zakhashvili (National Center for Disease Control and Public Health)141 | 2020-12-01 - 2020-12-14 | Subnational | Moderate | 1,219 | Multiple groups | All | Probability | Household and community samples | 44.1% (95% CI 41.2-46.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Georgia (4 Districts:4 highly touristic districts of Georgia (Borjomi, Martvili, Khelvachauri and Kobuleti))** | Khatuna Zakhashvili (National Center for Disease Control and Public Health)141 | 2020-08-01 - 2020-08-14 | Subnational | Moderate | 1,218 | Multiple groups | All | Probability | Household and community samples | 0.5% (95% CI 0.2-1.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Denmark (Capital Region and Region Zealand)** | Rytter (Slagelse Sygehus)142 | 2020-06-22 - 2020-07-03 | Subnational | Moderate | 750 | Adults (18-64 years) | All | Probability | Blood donors | 2% (95% CI 1.1-3.3%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **Denmark (Capital Region of Denmark)** | Iversen (University of Copenhagen)143 | 2020-04-15 - 2020-04-22 | Subnational | Moderate | 4,672 | Adults (18-64 years) | All | Sequential | Blood donors | 3% (95% CI 2.6-3.6%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **Faroe Islands (Faroe Islands)** | Petersen (University of the Faroe Islands)144 | 2020-04-27 - 2020-05-01 | Subnational | Moderate | 1,075 | Adults (18-64 years) | All | Probability | Household and community samples | 0.6% (95% CI 0.2-1.2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-08-29 - 2021-09-04 | National | Moderate | 1 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-97.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-08-22 - 2021-08-28 | National | Moderate | 8 | Adults (18-64 years) | All | Probability | Household and community samples | 75% (95% CI 34.9-96.8%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-08-15 - 2021-08-21 | National | Moderate | 7 | Adults (18-64 years) | All | Probability | Household and community samples | 85.7% (95% CI 29-96.3%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-08-08 - 2021-08-14 | National | Moderate | 25 | Adults (18-64 years) | All | Probability | Household and community samples | 84% (95% CI 63.9-95.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-08-01 - 2021-08-07 | National | Moderate | 42 | Adults (18-64 years) | All | Probability | Household and community samples | 92.9% (95% CI 80.5-98.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-07-25 - 2021-07-31 | National | Moderate | 11 | Adults (18-64 years) | All | Probability | Household and community samples | 81.8% (95% CI 48.2-97.7%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-07-18 - 2021-07-24 | National | Moderate | 2 | Adults (18-64 years) | All | Probability | Household and community samples | 100% (95% CI 15.8-100%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-07-11 - 2021-07-17 | National | Moderate | 2 | Adults (18-64 years) | All | Probability | Household and community samples | 100% (95% CI 15.8-100%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-07-04 - 2021-07-10 | National | Moderate | 12 | Adults (18-64 years) | All | Probability | Household and community samples | 58.3% (95% CI 21.1-78.9%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-06-27 - 2021-07-03 | National | Moderate | 48 | Adults (18-64 years) | All | Probability | Household and community samples | 68.8% (95% CI 53.7-81.3%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-06-20 - 2021-06-26 | National | Moderate | 44 | Adults (18-64 years) | All | Probability | Household and community samples | 72.7% (95% CI 57.2-85%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-06-13 - 2021-06-19 | National | Moderate | 47 | Adults (18-64 years) | All | Probability | Household and community samples | 57.5% (95% CI 42.2-71.7%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-06-06 - 2021-06-12 | National | Moderate | 68 | Adults (18-64 years) | All | Probability | Household and community samples | 60.3% (95% CI 46.2-70.6%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-05-30 - 2021-06-05 | National | Moderate | 39 | Adults (18-64 years) | All | Probability | Household and community samples | 48.7% (95% CI 32.4-65.2%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-05-23 - 2021-05-29 | National | Moderate | 93 | Adults (18-64 years) | All | Probability | Household and community samples | 49.5% (95% CI 37.9-59%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-05-16 - 2021-05-22 | National | Moderate | 86 | Adults (18-64 years) | All | Probability | Household and community samples | 44.2% (95% CI 33.5-55.3%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-05-09 - 2021-05-15 | National | Moderate | 52 | Adults (18-64 years) | All | Probability | Household and community samples | 26.9% (95% CI 14-38.9%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-05-02 - 2021-05-08 | National | Moderate | 74 | Adults (18-64 years) | All | Probability | Household and community samples | 28.4% (95% CI 18.5-40.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-04-25 - 2021-05-01 | National | Moderate | 109 | Adults (18-64 years) | All | Probability | Household and community samples | 22.9% (95% CI 15.4-32%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-04-18 - 2021-04-24 | National | Moderate | 102 | Adults (18-64 years) | All | Probability | Household and community samples | 18.6% (95% CI 11.6-27.6%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-04-11 - 2021-04-17 | National | Moderate | 29 | Adults (18-64 years) | All | Probability | Household and community samples | 13.8% (95% CI 2.2-27.4%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-04-04 - 2021-04-10 | National | Moderate | 59 | Adults (18-64 years) | All | Probability | Household and community samples | 6.8% (95% CI 1.9-16.5%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-03-28 - 2021-04-03 | National | Moderate | 60 | Adults (18-64 years) | All | Probability | Household and community samples | 8.3% (95% CI 1.8-16.2%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-03-21 - 2021-03-27 | National | Moderate | 73 | Adults (18-64 years) | All | Probability | Household and community samples | 10.6% (95% CI 3.9-18.8%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-03-14 - 2021-03-20 | National | Moderate | 104 | Adults (18-64 years) | All | Probability | Household and community samples | 6.7% (95% CI 2.1-12.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-03-07 - 2021-03-13 | National | Moderate | 64 | Adults (18-64 years) | All | Probability | Household and community samples | 3.1% (95% CI 0-8.4%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-02-28 - 2021-03-06 | National | Moderate | 132 | Adults (18-64 years) | All | Probability | Household and community samples | 2.3% (95% CI 0.2-5.4%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-02-21 - 2021-02-27 | National | Moderate | 123 | Adults (18-64 years) | All | Probability | Household and community samples | 6.5% (95% CI 2.3-11.4%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-02-14 - 2021-02-20 | National | Moderate | 69 | Adults (18-64 years) | All | Probability | Household and community samples | 7.2% (95% CI 2.4-16.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2021-02-07 - 2021-02-13 | National | Moderate | 111 | Adults (18-64 years) | All | Probability | Household and community samples | 5.4% (95% CI 2-11.4%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **France (Corsica)** | Capai (Université de Corse)145 | 2021-02-01 - 2021-02-12 | Subnational | Moderate | 1,254 | Multiple groups | All | Convenience | Residual sera | 8.5% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Germany (Bavaria)** | Laub (University of Regensburg)146 | 2020-05-22 - 2020-07-22 | Subnational | Moderate | 2,832 | Children and Youth (0-17 years) | All | Probability | Multiple general populations | 4.8% (95% CI 4-5.6%) | NA - IgG - Author designed (ELISA) -Spike, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N), NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Germany (Hesse,Lower Saxony,North Rhine-Westphalia)** | Fischer (Heart and Diabetes Center NRW)147 | 2020-03-09 - 2020-06-03 | Subnational | Moderate | 3,186 | Multiple groups | All | Sequential | Residual sera | 0.9% (95% CI 0.6-1.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG), DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | N/A | Complex test algorithm: Manual review |
| **Holy See** | Ralli (Università Cattolica del Sacro Cuore)148 | 2021-01-01 - 2021-01-04 | National | Moderate | 17 | Multiple groups | All | Convenience | Household and community samples | 5.9% | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T) | 0.985, 0.998 | Validated by manufacturer |
| **Italy (Campania (Southern Italy))** | Calo (University of Campania)149 | 2020-06-01 - 2020-06-10 | Subnational | Moderate | 143 | Multiple groups | All | Sequential | Blood donors | 2.8% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Italy (Trento)** | Stefanelli (Azienda Provinciale per i Servizi Sanitari)150 | 2020-05-05 - 2020-05-15 | Subnational | Moderate | 6,075 | Multiple groups | All | Convenience | Household and community samples | 23.1% (95% CI 22-24.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Portugal** | Castro (Los Alamos National Laboratory)151 | 2021-03-01 - 2021-03-17 | National | Low | 2,435 | Multiple groups | All | Probability | Household and community samples | 17.3% | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T) | 0.985, 0.998 | Validated by manufacturer |
| **Spain (Catalonia)** | Karachaliou (Barcelona Institute For Global Health)152 | 2020-06-30 - 2020-11-15 | Subnational | Moderate | 4,740 | Multiple groups | All | Convenience | Household and community samples | 15.3% | NA - - Author designed (Multiplex) | 0.9578, 1 | Validated by independent authors/third party/non-developers |
| **Spain (Cantabria)** | Iruzubieta (University of Cantabria)153 | 2020-04-27 - 2020-05-29 | Subnational | Moderate | 1,022 | Multiple groups | All | Probability | Household and community samples | 3.1% (95% CI 2.1-4.3%) | Hangzhou Clongene Biotech Co., Ltd - IgG, IgM - Lungene 2019-nCoV IgG/IgM Rapid Test | 0.911, 0.965 | Validated by manufacturer |
| **Switzerland (Canton of Fribourg)** | May (Université de Fribourg)154 | 2020-11-30 - 2021-02-05 | Subnational | Moderate | 449 | Multiple groups | All | Probability | Household and community samples | 19% | NA - - Author designed (Luminex) | 0.966, 0.997 | Validated by developers |
| **Switzerland (Canton of Fribourg)** | Anker (Université de Fribourg)155 | 2020-07-08 - 2020-10-14 | Subnational | Moderate | 418 | Multiple groups | All | Probability | Household and community samples | 8% | NA - - Author designed (Luminex) | 0.966, 0.997 | Validated by developers |
| **Switzerland (Canton of Geneva)** | Richard (Geneva University Hospitals)156 | 2020-06-01 - 2020-06-30 | Subnational | Low | 3,407 | Multiple groups | All | Probability | Household and community samples | 6.3% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Switzerland (Vaud)** | Fenwick (Lausanne University Hospital and University of Lausanne)157 | 2020-05-04 - 2020-06-27 | Subnational | Moderate | 311 | Multiple groups | All | Probability | Household and community samples | 3.9% (95% CI 2-6.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Switzerland (Geneva)** | Bi (Johns Hopkins Bloomberg School of Public Health)158 | 2020-04-03 - 2020-06-30 | Subnational | Moderate | 4,534 | Multiple groups | All | Convenience | Household and community samples | 6.6% (95% CI 5.8-7.3%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)159 | 2021-10-11 - 2021-11-14 | National | Moderate | 2,496 | Multiple groups | All | Sequential | Blood donors | 94.4% (95% CI 93.4-95.2%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)159 | 2021-10-11 - 2021-11-14 | National | Low | 2,882 | Multiple groups | All | Probability | Residual sera | 78.1% (95% CI 76.6-79.6%) | NA - - Not reported/ Unable to specify | 0.973, 0.996 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)72 | 2021-09-06 - 2021-10-10 | National | Moderate | 2,494 | Multiple groups | All | Sequential | Blood donors | 95.3% (95% CI 94.4-96.1%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)72 | 2021-09-06 - 2021-10-10 | National | Low | 3,132 | Multiple groups | All | Probability | Residual sera | 74.3% (95% CI 72.8-75.9%) | NA - - Not reported/ Unable to specify | 0.973, 0.996 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)73 | 2021-06-28 - 2021-08-01 | National | Moderate | 2,493 | Multiple groups | All | Sequential | Blood donors | 94.2% (95% CI 93.2-95.1%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)73 | 2021-06-28 - 2021-08-01 | National | Low | 3,427 | Multiple groups | All | Probability | Residual sera | 69.4% (95% CI 67.8-70.9%) | NA - - Not reported/ Unable to specify | 0.973, 0.996 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)74 | 2021-05-24 - 2021-06-27 | National | Moderate | 2,494 | Multiple groups | All | Sequential | Blood donors | 76.8% (95% CI 75-78.4%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)74 | 2021-05-24 - 2021-06-27 | National | Low | 3,554 | Multiple groups | All | Probability | Residual sera | 59.3% (95% CI 57.6-60.9%) | NA - - Not reported/ Unable to specify | 0.973, 0.996 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)75 | 2021-04-19 - 2021-05-23 | National | Moderate | 2,494 | Multiple groups | All | Sequential | Blood donors | 58.8% (95% CI 56.8-60.7%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)75 | 2021-05-03 - 2021-05-09 | National | Low | 713 | Multiple groups | All | Probability | Residual sera | 47.5% | NA - - Not reported/ Unable to specify | 0.973, 0.996 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)76 | 2021-04-12 - 2021-04-18 | National | Low | 708 | Multiple groups | All | Probability | Residual sera | 42.8% (95% CI 39.1-46.5%) | NA - - Not reported/ Unable to specify | 0.973, 0.996 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)76 | 2021-03-15 - 2021-04-18 | National | Moderate | 2,493 | Multiple groups | All | Sequential | Blood donors | 39.7% (95% CI 37.7-41.6%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)80 | 2021-02-08 - 2021-03-14 | National | Moderate | 2,492 | Multiple groups | All | Sequential | Blood donors | 22.1% (95% CI 20.5-23.8%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (England)** | Office for National Statistics (Office For National Statistics)160 | 2021-02-04 - 2021-03-03 | Subnational | Low | 34,623 | Multiple groups | All | Probability | Household and community samples | 34.6% | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Northern Ireland)** | Office for National Statistics (Office For National Statistics)160 | 2021-02-04 - 2021-03-03 | Subnational | Low | 632 | Multiple groups | All | Probability | Household and community samples | 31.2% | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Scotland)** | Office for National Statistics (Office For National Statistics)160 | 2021-02-04 - 2021-03-03 | Subnational | Low | 2,737 | Multiple groups | All | Probability | Household and community samples | 22.3% | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Wales)** | Office for National Statistics (Office For National Statistics)160 | 2021-02-04 - 2021-03-03 | Subnational | Low | 1,224 | Multiple groups | All | Probability | Household and community samples | 30.5% | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-12-18 - 2021-01-14 | Subnational | Moderate | 24,150 | Multiple groups | All | Probability | Household and community samples | 15.3% (95% CI 14.8-15.8%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Northern Ireland)** | Office for National Statistics (Office of National Statistics)161 | 2020-12-18 - 2021-01-14 | Subnational | Moderate | 313 | Multiple groups | All | Probability | Household and community samples | 12% (95% CI 8.5-15.9%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Scotland)** | Office for National Statistics (Office of National Statistics)161 | 2020-12-18 - 2021-01-14 | Subnational | Moderate | 1,832 | Multiple groups | All | Probability | Household and community samples | 10.7% (95% CI 9.3-12.2%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Wales)** | Office for National Statistics (Office of National Statistics)161 | 2020-12-18 - 2021-01-14 | Subnational | Moderate | 732 | Multiple groups | All | Probability | Household and community samples | 11.5% (95% CI 9.3-14%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-11-20 - 2020-12-17 | Subnational | Moderate | 21,684 | Multiple groups | All | Probability | Household and community samples | 10.1% (95% CI 9.7-10.5%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Northern Ireland)** | Office for National Statistics (Office of National Statistics)161 | 2020-11-20 - 2020-12-17 | Subnational | Moderate | 248 | Multiple groups | All | Probability | Household and community samples | 3.7% (95% CI 1.7-6.8%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Scotland)** | Office for National Statistics (Office of National Statistics)161 | 2020-11-20 - 2020-12-17 | Subnational | Moderate | 1,034 | Multiple groups | All | Probability | Household and community samples | 5.9% (95% CI 4.5-7.5%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Wales)** | Office for National Statistics (Office of National Statistics)161 | 2020-11-20 - 2020-12-17 | Subnational | Moderate | 631 | Multiple groups | All | Probability | Household and community samples | 7.2% (95% CI 5.2-9.4%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Scotland)** | Office for National Statistics (Office of National Statistics)161 | 2020-10-23 - 2020-11-19 | Subnational | Moderate | 397 | Multiple groups | All | Probability | Household and community samples | 7.8% (95% CI 5.2-10.6%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Northern Ireland)** | Office for National Statistics (Office of National Statistics)161 | 2020-10-23 - 2020-11-19 | Subnational | Moderate | 333 | Multiple groups | All | Probability | Household and community samples | 3.5% (95% CI 1.7-5.8%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Wales)** | Office for National Statistics (Office of National Statistics)161 | 2020-10-23 - 2020-11-19 | Subnational | Moderate | 497 | Multiple groups | All | Probability | Household and community samples | 6.1% (95% CI 4.1-8.5%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-10-23 - 2020-11-19 | Subnational | Moderate | 15,834 | Multiple groups | All | Probability | Household and community samples | 8.7% (95% CI 8.3-9.1%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-09-25 - 2020-10-22 | Subnational | Moderate | 15,687 | Multiple groups | All | Probability | Household and community samples | 6.9% (95% CI 6.5-7.3%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Northern Ireland)** | Office for National Statistics (Office of National Statistics)161 | 2020-09-25 - 2020-10-22 | Subnational | Moderate | 249 | Multiple groups | All | Probability | Household and community samples | 2.8% (95% CI 0.9-5.2%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Scotland)** | Office for National Statistics (Office of National Statistics)161 | 2020-09-25 - 2020-10-22 | Subnational | Moderate | 383 | Multiple groups | All | Probability | Household and community samples | 6.8% (95% CI 4.5-9.8%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Wales)** | Office for National Statistics (Office of National Statistics)161 | 2020-09-25 - 2020-10-22 | Subnational | Moderate | 473 | Multiple groups | All | Probability | Household and community samples | 4.7% (95% CI 2.9-7%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Wales)** | Office for National Statistics (Office of National Statistics)161 | 2020-08-28 - 2020-09-24 | Subnational | Moderate | 236 | Multiple groups | All | Probability | Household and community samples | 4.7% (95% CI 2.3-8.2%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-08-28 - 2020-09-24 | Subnational | Moderate | 8,742 | Multiple groups | All | Probability | Household and community samples | 5.8% (95% CI 5.3-6.3%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-07-31 - 2020-08-27 | Subnational | Moderate | 6,189 | Multiple groups | All | Probability | Household and community samples | 5.6% (95% CI 5-6.2%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-06-05 - 2020-07-02 | Subnational | Moderate | 2,392 | Multiple groups | All | Probability | Household and community samples | 4.2% (95% CI 3.4-5%) | NA - - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-07-03 - 2020-07-30 | Subnational | Moderate | 3,236 | Multiple groups | All | Probability | Household and community samples | 6.5% (95% CI 5.7-7.4%) | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Office for National Statistics (Office of National Statistics)161 | 2020-05-08 - 2020-06-04 | Subnational | Low | 1,575 | Multiple groups | All | Probability | Household and community samples | 6.3% | NA - IgG - Author designed (ELISA) -Spike | 0.99, 0.991 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-04-24 - 2020-04-26 | Subnational | Low | 865 | Adults (18-64 years) | All | Probability | Blood donors | 5% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-04-23 - 2020-04-24 | Subnational | Low | 1,043 | Adults (18-64 years) | All | Probability | Blood donors | 7.3% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-04-15 - 2020-04-20 | Subnational | Low | 936 | Adults (18-64 years) | All | Probability | Blood donors | 6.2% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (Scotland)** | Thompson (University of Oxford)162 | 2020-03-17 - 2020-05-18 | Subnational | Moderate | 3,500 | Adults (18-64 years) | All | Probability | Blood donors | 3.2% (95% CI 2.6-3.8%) | NA - - Author designed (Neutralization Assay) | 0.94, 1 | Validated by developers |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-04-14 - 2020-04-16 | Subnational | Low | 1,017 | Adults (18-64 years) | All | Probability | Blood donors | 4.6% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-04-09 - 2020-04-13 | Subnational | Low | 1,085 | Adults (18-64 years) | All | Probability | Blood donors | 11.1% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-04-02 - 2020-04-03 | Subnational | Low | 916 | Adults (18-64 years) | All | Probability | Blood donors | 2.4% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (England)** | Public Health England (Public Health England)85 | 2020-03-26 - 2020-03-27 | Subnational | Low | 757 | Adults (18-64 years) | All | Probability | Blood donors | 2.6% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |

#### *South-East Asia region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **India (Kerala)** | Government of Kerala (Government of Kerala Department of Health)163 | 2021-09-01 - 2021-09-30 | Subnational | Moderate | 1,459 | Children and Youth (0-17 years) | All | Probability | Household and community samples | 40.2% (95% CI 37.6-42.7%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India (Kerala)** | Government of Kerala (Government of Kerala Department of Health)163 | 2021-09-01 - 2021-09-30 | Subnational | Moderate | 1,476 | Multiple groups | All | Probability | Household and community samples | 87.7% (95% CI 85.9-89.3%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India (Kerala)** | Government of Kerala (Government of Kerala Department of Health)163 | 2021-09-01 - 2021-09-30 | Subnational | Moderate | 4,429 | Multiple groups | All | Probability | Household and community samples | 82.6% (95% CI 81.4-83.7%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India (Kerala)** | Government of Kerala (Government of Kerala Department of Health)163 | 2021-09-01 - 2021-09-30 | Subnational | Moderate | 1,706 | Multiple groups | All | Probability | Persons living in slums | 85.3% (95% CI 83.5-86.9%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India (Kerala)** | Government of Kerala (Government of Kerala Department of Health)163 | 2021-09-01 - 2021-09-30 | Subnational | Moderate | 1,521 | Multiple groups | All | Probability | Household and community samples | 78.2% (95% CI 76-80.2%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India (Kerala)** | Government of Kerala (Government of Kerala Department of Health)163 | 2021-08-15 - 2021-09-15 | Subnational | Moderate | 2,274 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 65.4% (95% CI 63.4-67.3%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.9999, 0.998 | Complex test algorithm: Manual calculation |
| **India (1. National Capital Region (New Delhi & Faridabad) 2.Gorakhpur, Uttar Pradesh 3. Bhubaneshwar, Odisha 4. Pondicherry 5.Agartala, Tripura)** | Dr Puneet Misra (All India Institute of Medical Sciences, New Delhi)164 | 2021-03-15 - 2021-06-17 | Subnational | Moderate | 5,123 | Multiple groups | All | Probability | Household and community samples | 64.4% (95% CI 63.1-65.7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **India (Delhi)** | Sharma (Maulana Azad Medical College)165 | 2021-01-11 - 2021-01-22 | Subnational | Low | 27,436 | Multiple groups | All | Probability | Household and community samples | 50.5% | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 1, 1 | Validated by manufacturer |
| **India (Kashmir)** | Khan (Government Medical College Srinagar)166 | 2020-10-17 - 2020-11-04 | Subnational | Low | 6,230 | Multiple groups | All | Probability | Household and community samples | 36.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (NCT Delhi)** | Sharma (Government of National Capital Territory of Delhi)167 | 2020-10-15 - 2020-10-21 | Subnational | Low | 14,905 | Multiple groups | All | Probability | Household and community samples | 25.2% | Calbiotech Inc. - IgG - ErbaLisa COVID-19 IgG ELISA Kit | 0.983, 0.981 | Validated by manufacturer |
| **India (Puducherry)** | Kar (Jawaharlal Institute)168 | 2020-10-12 - 2020-10-16 | Subnational | Moderate | 900 | Multiple groups | All | Probability | Household and community samples | 34.5% (95% CI 31.3-37.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (Puducherry)** | Kar (Jawaharlal Institute)168 | 2020-09-10 - 2020-09-16 | Subnational | Moderate | 898 | Multiple groups | All | Probability | Household and community samples | 20.7% (95% CI 18-23.4%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (Uttar Pradesh)** | Namasivayam (Government of Uttar Pradesh)169 | 2020-09-04 - 2020-09-10 | Subnational | Low | 16,012 | Multiple groups | All | Probability | Household and community samples | 22.1% | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **India (NCT Delhi)** | Sharma (Government of National Capital Territory of Delhi)167 | 2020-09-01 - 2020-09-07 | Subnational | Low | 16,953 | Multiple groups | All | Probability | Household and community samples | 24.6% | Calbiotech Inc. - IgG - ErbaLisa COVID-19 IgG ELISA Kit | 0.983, 0.981 | Validated by manufacturer |
| **India (Puducherry)** | Kar (Jawaharlal Institute)168 | 2020-08-11 - 2020-08-16 | Subnational | Moderate | 869 | Multiple groups | All | Probability | Household and community samples | 4.9% (95% CI 3.5-6.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (NCT Delhi)** | Sharma (Government of National Capital Territory of Delhi)167 | 2020-08-01 - 2020-08-07 | Subnational | Low | 14,779 | Multiple groups | All | Probability | Household and community samples | 28.8% | J. Mitra & Co. Pvt., Ltd - IgG - COVID Kawach IgG Microlisa | 0.921, 0.977 | Validated by developers |
| **India (West Bengal)** | Satpati (Medical College Kolkata)170 | 2020-07-26 - 2020-08-08 | Subnational | Moderate | 458 | Multiple groups | All | Probability | Household and community samples | 4.2% (95% CI 2.5-6.4%) | Calbiotech Inc. - IgG - ErbaLisa COVID-19 IgG ELISA Kit | 0.983, 0.981 | Validated by manufacturer |
| **India (Srinagar)** | Khan (Government Medical College Srinagar)171 | 2020-07-01 - 2020-07-15 | Subnational | Moderate | 2,906 | Multiple groups | All | Convenience | Residual sera | 3.6% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (NCT Delhi)** | Ministry of Health and Family Welfare (Indian Center for Disease Control)172 | 2020-06-27 - 2020-07-10 | Subnational | Moderate | 21,387 | Multiple groups | All | Probability | Household and community samples | 23.5% (95% CI 22.9-24.1%) | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **Indonesia (East Java)** | Megasari (Kobe University)173 | 2020-06-15 - 2020-12-15 | Subnational | Moderate | 1,819 | Multiple groups | All | Convenience | Household and community samples | 11.4% (95% CI 10-12.9%) | Nanjing Vazyme Medical Technology Co., Ltd - IgG, IgM - 2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit | 0.967, 0.688 | Validated by manufacturer |

#### *Western Pacific region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **China (Wuhan)** | He (Chinese Academy of Medical Sciences & Peking Union Medical College)174 | 2020-04-14 - 2020-04-15 | Subnational | Low | 9,542 | Multiple groups | All | Probability | Household and community samples | 6.9% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Japan (Hiroshima Prefecture)** | Prefecture of Hiroshima (Hiroshima University )175 | 2020-10-15 - 2020-11-15 | Subnational | Moderate | 2,396 | Multiple groups | All | Probability | Household and community samples | 0.2% (95% CI 0.1-0.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Malaysia (Selangor)** | Sam (University of Malaya)176 | 2020-12-15 - 2021-04-15 | Subnational | Moderate | 653 | Multiple groups | All | Convenience | Residual sera | 4.1% (95% CI 2.6-5.8%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |

### Table S7. Additional studies used in descriptive analysis.

#### *Africa region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Angola - HRP (Luanda)** | Sebastiao (Instituto Nacional de Investigação em Saúde)177 | 2020-09-01 - 2020-09-30 | Local | High | 55 | Adults (18-64 years) | All | Convenience | Blood donors | 20% | Biomerieux - IgG, IgM, IgA - VIDAS Multiparametric immunoassay system for medium throughput | 1, 1 | Validated by manufacturer |
| **Burkina Faso - HRP (Ouagadougou & Bobo-Dioulasso)** | Dr Isidore Traore (National Institute of Public Health)178 | 2021-04-03 - 2021-04-16 | Local | Moderate | 5,240 | Multiple groups | All | Probability | Household and community samples | 67.8% (95% CI 66.5-69.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Cameroon - HRP (Yaoundé)** | Nwosu (Hopital Central de Yaounde)179 | 2020-10-14 - 2020-11-26 | Local | Low | 971 | Multiple groups | All | Probability | Household and community samples | 31.3% | Abbott Laboratories - IgG, IgM - Panbio COVID-19 IgG/IgM rapid test device | 0.978, 0.928 | Validated by manufacturer |
| **Central African Republic - HRP (Bangui, the capital of the Central African Republic)** | Alexandre Manirakiza (Institut Pasteur of Bangui)180 | 2021-07-12 - 2021-08-20 | Local | Moderate | 799 | Multiple groups | All | Probability | Household and community samples | 75.5% (95% CI 72.3-78.4%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Democratic Republic of the Congo - HRP (Kinshasa)** | Nkuba (Institut National de Recherche Biomédicale)181 | 2020-10-22 - 2020-11-08 | Local | Low | 1,080 | Multiple groups | All | Probability | Household and community samples | 16.6% | NA - - Author designed (Luminex) | 1, 0.997 | Validated by developers |
| **Ethiopia - HRP (Addis Ababa)** | Gudina (University of Munich)182 | 2021-04-08 - 2021-04-10 | Local | High | 176 | Multiple groups | All | Convenience | Household and community samples | 72.7% (95% CI 64.9-78.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Gudina (University of Munich)182 | 2021-04-01 - 2021-04-03 | Local | High | 188 | Multiple groups | All | Convenience | Household and community samples | 54.8% (95% CI 47.4-62%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Gudina (University of Munich)182 | 2021-02-04 - 2021-03-16 | Local | High | 100 | Multiple groups | All | Convenience | Household and community samples | 31% (95% CI 22.1-41%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Gudina (University of Munich)182 | 2021-02-02 - 2021-03-15 | Local | High | 166 | Multiple groups | All | Convenience | Household and community samples | 45.2% (95% CI 37.5-53.1%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Gudina (University of Munich)182 | 2021-02-11 - 2021-02-26 | Local | High | 151 | Multiple groups | All | Convenience | Household and community samples | 58.2% (95% CI 49.3-65.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Gudina (University of Munich)182 | 2021-02-01 - 2021-03-07 | Local | High | 149 | Multiple groups | All | Convenience | Household and community samples | 45.7% (95% CI 37.5-54%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Gudina (University of Munich)182 | 2021-01-21 - 2021-02-25 | Local | High | 133 | Multiple groups | All | Convenience | Household and community samples | 26.3% (95% CI 18.4-33.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Gudina (University of Munich)182 | 2021-01-02 - 2021-02-04 | Local | High | 191 | Multiple groups | All | Convenience | Household and community samples | 40.8% (95% CI 33.3-47.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Gudina (University of Munich)182 | 2021-01-02 - 2021-01-22 | Local | High | 218 | Multiple groups | All | Convenience | Household and community samples | 54.2% (95% CI 47.3-60.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Gudina (University of Munich)182 | 2020-12-05 - 2021-02-04 | Local | High | 224 | Multiple groups | All | Convenience | Household and community samples | 39.7% (95% CI 32.8-46%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Gudina (University of Munich)182 | 2020-12-01 - 2021-02-01 | Local | High | 297 | Multiple groups | All | Convenience | Household and community samples | 32.3% (95% CI 26.7-37.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Gudina (University of Munich)182 | 2020-12-03 - 2021-01-27 | Local | High | 238 | Multiple groups | All | Convenience | Household and community samples | 18% (95% CI 13-23.1%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Abdella (Ethiopian Public Health Institute)183 | 2020-07-22 - 2020-09-02 | Local | Low | 956 | Multiple groups | All | Probability | Household and community samples | 4.7% (95% CI 3.5-6.2%) | Core Technology Co. Ltd - IgG, IgM - Coretests COVID-19 IgM/IgG Ab Test | 0.939, 0.981 | Validated by manufacturer |
| **Ethiopia - HRP (Jimma)** | Abdella (Ethiopian Public Health Institute)183 | 2020-07-22 - 2020-09-02 | Local | Low | 900 | Multiple groups | All | Probability | Household and community samples | 1.2% (95% CI 0.5-2%) | Core Technology Co. Ltd - IgG, IgM - Coretests COVID-19 IgM/IgG Ab Test | 0.939, 0.981 | Validated by manufacturer |
| **Ethiopia - HRP (Dire Dawa city)** | Shaweno (Jimma University Institute of Health)184 | 2020-06-15 - 2020-07-30 | Local | Moderate | 684 | Multiple groups | All | Probability | Household and community samples | 3.2% (95% CI 1.9-4.7%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Ethiopia - HRP (Addis Ababa)** | Kempen (Kuwait University)185 | 2020-05-18 - 2020-05-21 | Local | High | 99 | Multiple groups | All | Convenience | Residual sera | 3% (95% CI 0.2-7.1%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Gabon (Libreville)** | Nzoghe (Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant)186 | 2020-07-15 - 2020-10-15 | Local | High | 1,495 | Multiple groups | All | Convenience | Residual sera | 36.2% (95% CI 33.7-38.7%) | Biomerieux - IgG, IgM, IgA - VIDAS Multiparametric immunoassay system for medium throughput, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Complex test algorithm: Manual calculation |
| **Kenya - HRP** | Nyagwange (KEMRI-Wellcome Trust Research Programme)187 | 2021-08-01 - 2021-08-31 | National | High | 176 | Adults (18-64 years) | All | Convenience | Blood donors | 83% (95% CI 76.6-88.2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Kenya - HRP (NA)** | Munywoki (Kenya Medical Research Institute)188 | 2020-11-27 - 2020-12-05 | Local | Moderate | 511 | Multiple groups | All | Probability | Household and community samples | 43.3% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Kenya - HRP (Kilifi)** | Lucinde (KEMRI-Wellcome Trust)189 | 2020-11-01 - 2020-11-24 | Local | High | 154 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 10.4% (95% CI 6.1-16.3%) | NA - IgG - Author designed (ELISA) -Spike | 0.927, 0.99 | Validated by independent authors/third party/non-developers |
| **Kenya - HRP (Nairobi City County)** | Ngere (Washington State University)190 | 2020-11-02 - 2020-11-23 | Local | Low | 1,164 | Multiple groups | All | Probability | Household and community samples | 32.7% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Kenya - HRP (Kilifi)** | Lucinde (KEMRI-Wellcome Trust)189 | 2020-10-01 - 2020-10-31 | Local | High | 183 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 1.6% (95% CI 0.1-3.9%) | NA - IgG - Author designed (ELISA) -Spike | 0.927, 0.99 | Validated by independent authors/third party/non-developers |
| **Kenya - HRP (Kilifi)** | Lucinde (KEMRI-Wellcome Trust)189 | 2020-09-18 - 2020-09-30 | Local | High | 82 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 0% (95% CI 0-4.4%) | NA - IgG - Author designed (ELISA) -Spike | 0.927, 0.99 | Validated by independent authors/third party/non-developers |
| **Kenya - HRP (Nairobi)** | Lucinde (KEMRI-Wellcome Trust)189 | 2020-07-30 - 2020-08-25 | Local | High | 196 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 46.4% (95% CI 39.3-53.7%) | NA - IgG - Author designed (ELISA) -Spike | 0.927, 0.99 | Validated by independent authors/third party/non-developers |
| **Kenya - HRP** | Nyagwange (KEMRI-Wellcome Trust Research Programme)187 | 2020-05-01 - 2020-05-31 | National | High | 176 | Adults (18-64 years) | All | Convenience | Blood donors | 2.3% (95% CI 0.4-4.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Kenya - HRP (Western Region)** | Crowell (Walter Reed Army Institute of Research)191 | 2020-01-01 - 2020-03-19 | Subnational | High | 582 | Adults (18-64 years) | All | Convenience | Residual sera | 3.3% (95% CI 2-5.1%) | Bio-rad - IgG, IgM, IgA - Platelia SARS-CoV-2 Total Ab assay | 0.993, 0.98 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2021-05-01 - 2021-05-26 | Local | High | 500 | Adults (18-64 years) | All | Sequential | Blood donors | 64.8% (95% CI 60.4-69%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2021-04-01 - 2021-04-30 | Local | High | 493 | Adults (18-64 years) | All | Sequential | Blood donors | 58.4% (95% CI 53.7-62.6%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2021-03-01 - 2021-03-31 | Local | High | 497 | Adults (18-64 years) | All | Sequential | Blood donors | 49.9% (95% CI 45.4-54.4%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2021-02-01 - 2021-02-28 | Local | High | 319 | Adults (18-64 years) | All | Sequential | Blood donors | 50.5% (95% CI 44.8-56.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2021-01-01 - 2021-01-31 | Local | High | 389 | Adults (18-64 years) | All | Sequential | Blood donors | 44.7% (95% CI 39.5-49.6%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2020-12-01 - 2020-12-31 | Local | High | 177 | Adults (18-64 years) | All | Sequential | Blood donors | 22% (95% CI 15.7-28.3%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-11-01 - 2020-11-30 | Local | High | 502 | Adults (18-64 years) | All | Convenience | Blood donors | 31.3% (95% CI 27.2-35.5%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Fianarantsoa)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-11-01 - 2020-11-30 | Local | High | 172 | Adults (18-64 years) | All | Convenience | Blood donors | 12.8% (95% CI 8.2-18.7%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Mahajanga)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-11-01 - 2020-11-30 | Local | High | 30 | Adults (18-64 years) | All | Convenience | Blood donors | 16.7% (95% CI 5.6-34.7%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toamasina)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-11-01 - 2020-11-30 | Local | High | 282 | Adults (18-64 years) | All | Convenience | Blood donors | 18.4% (95% CI 13.8-23.1%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toliara)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-11-01 - 2020-11-30 | Local | High | 199 | Adults (18-64 years) | All | Convenience | Blood donors | 18.1% (95% CI 13-24.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2020-11-01 - 2020-11-30 | Local | High | 503 | Adults (18-64 years) | All | Sequential | Blood donors | 31.2% (95% CI 27-35.3%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-10-01 - 2020-10-31 | Local | High | 502 | Adults (18-64 years) | All | Convenience | Blood donors | 36% (95% CI 31.7-40.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Fianarantsoa)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-10-01 - 2020-10-31 | Local | High | 152 | Adults (18-64 years) | All | Convenience | Blood donors | 15.1% (95% CI 9.3-21.1%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Mahajanga)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-10-01 - 2020-10-31 | Local | High | 26 | Adults (18-64 years) | All | Convenience | Blood donors | 26.9% (95% CI 9-43.6%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toamasina)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-10-01 - 2020-10-31 | Local | High | 199 | Adults (18-64 years) | All | Convenience | Blood donors | 26.1% (95% CI 19.7-32.3%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toliara)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-10-01 - 2020-10-31 | Local | High | 139 | Adults (18-64 years) | All | Convenience | Blood donors | 22.3% (95% CI 15.1-29.4%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Razafimahatratra (Institut Pasteur de Madagascar)192 | 2020-10-01 - 2020-10-31 | Local | High | 497 | Adults (18-64 years) | All | Sequential | Blood donors | 35.8% (95% CI 31.4-40%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-09-01 - 2020-09-30 | Local | High | 481 | Adults (18-64 years) | All | Convenience | Blood donors | 38.5% (95% CI 34.1-43%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Fianarantsoa)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-09-01 - 2020-09-30 | Local | High | 173 | Adults (18-64 years) | All | Convenience | Blood donors | 18.5% (95% CI 13-25.1%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Mahajanga)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-09-01 - 2020-09-30 | Local | High | 53 | Adults (18-64 years) | All | Convenience | Blood donors | 37.7% (95% CI 23.1-50.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toamasina)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-09-01 - 2020-09-30 | Local | High | 213 | Adults (18-64 years) | All | Convenience | Blood donors | 29.1% (95% CI 22.7-35.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toliara)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-09-01 - 2020-09-30 | Local | High | 185 | Adults (18-64 years) | All | Convenience | Blood donors | 20.5% (95% CI 14.5-26.5%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Fianarantsoa)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-08-01 - 2020-08-31 | Local | High | 120 | Adults (18-64 years) | All | Convenience | Blood donors | 9.2% (95% CI 4.7-15.8%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Mahajanga)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-08-01 - 2020-08-31 | Local | High | 107 | Adults (18-64 years) | All | Convenience | Blood donors | 35.5% (95% CI 25.6-44.4%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toamasina)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-08-01 - 2020-08-31 | Local | High | 227 | Adults (18-64 years) | All | Convenience | Blood donors | 40.1% (95% CI 33.7-46.8%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toliara)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-08-01 - 2020-08-31 | Local | High | 167 | Adults (18-64 years) | All | Convenience | Blood donors | 7.2% (95% CI 3.8-12.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-08-01 - 2020-08-30 | Local | High | 432 | Adults (18-64 years) | All | Convenience | Blood donors | 35.2% (95% CI 30.7-39.9%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-07-01 - 2020-07-31 | Local | High | 428 | Adults (18-64 years) | All | Convenience | Blood donors | 29% (95% CI 24.7-33.5%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Mahajanga)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-07-01 - 2020-07-31 | Local | High | 98 | Adults (18-64 years) | All | Convenience | Blood donors | 1% (95% CI 0-3.7%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toamasina)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-07-01 - 2020-07-31 | Local | High | 182 | Adults (18-64 years) | All | Convenience | Blood donors | 43.4% (95% CI 35.6-50.4%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toliara)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-07-01 - 2020-07-31 | Local | High | 147 | Adults (18-64 years) | All | Convenience | Blood donors | 0.7% (95% CI 0-3.7%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Fianarantsoa)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-07-01 - 2020-07-30 | Local | High | 142 | Adults (18-64 years) | All | Convenience | Blood donors | 0% (95% CI 0-2.6%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-06-01 - 2020-06-30 | Local | High | 308 | Adults (18-64 years) | All | Convenience | Blood donors | 3.3% (95% CI 1.6-5.9%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Fianarantsoa)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-06-01 - 2020-06-30 | Local | High | 129 | Adults (18-64 years) | All | Convenience | Blood donors | 0.8% (95% CI 0-4.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Mahajanga)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-06-01 - 2020-06-30 | Local | High | 50 | Adults (18-64 years) | All | Convenience | Blood donors | 0% (95% CI 0-7.1%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toamasina)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-06-01 - 2020-06-30 | Local | High | 82 | Adults (18-64 years) | All | Convenience | Blood donors | 39% (95% CI 27.3-49.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Toliara)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-06-01 - 2020-06-30 | Local | High | 87 | Adults (18-64 years) | All | Convenience | Blood donors | 1.2% (95% CI 0-6.2%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-05-01 - 2020-05-31 | Local | High | 598 | Adults (18-64 years) | All | Convenience | Blood donors | 0.2% (95% CI 0-0.9%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-04-01 - 2020-04-30 | Local | High | 157 | Adults (18-64 years) | All | Convenience | Blood donors | 0% (95% CI 0-2.3%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Madagascar (Antananarivo)** | Schoenhals (Institut Pasteur de Madagascar)193 | 2020-03-01 - 2020-03-30 | Local | High | 496 | Adults (18-64 years) | All | Convenience | Blood donors | 0.8% (95% CI 0.1-1.8%) | ID.Vet - IgG - ID Screen | 0.952, 0.998 | Validated by manufacturer |
| **Mali - HRP (Bancoumana,Doneguebougou,Sotuba)** | Sagara (University of Sciences )194 | 2020-12-14 - 2021-01-29 | Local | Moderate | 2,353 | Multiple groups | All | Convenience | Household and community samples | 30.8% (95% CI 28.9-32.7%) | NA - IgG - Author designed (ELISA) -Spike | 0.739, 0.994 | Validated by developers |
| **Mali - HRP (Bancoumana,Doneguebougou,Sotuba)** | Sagara (University of Sciences)194 | 2020-07-28 - 2020-10-16 | Local | Moderate | 2,659 | Multiple groups | All | Convenience | Household and community samples | 6.5% (95% CI 5.6-7.5%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 0.739, 0.994 | Validated by developers |
| **Mozambique - HRP (Massinga)** | Mahomed (Republica de Mocambique Ministerio da Saude)195 | 2020-11-26 - 2020-12-03 | Local | Moderate | 1,577 | Multiple groups | All | Probability | Household and community samples | 7.4% (95% CI 6.1-8.8%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Mozambique - HRP (Maxixe)** | Mahomed (Republica de Mocambique Ministerio da Saude)195 | 2020-11-07 - 2020-11-21 | Local | Moderate | 3,974 | Multiple groups | All | Probability | Household and community samples | 5.5% (95% CI 4.8-6.2%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Mozambique - HRP (Chimoio)** | Mahumane (Republica de Mocambique Ministerio da Saude)196 | 2020-11-02 - 2020-11-17 | Local | Moderate | 9,756 | Multiple groups | All | Probability | Household and community samples | 1.4% (95% CI 1.2-1.6%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Mozambique - HRP (Lichinga)** | Langa (Republica de Mocambique Ministerio da Saude)197 | 2020-09-28 - 2020-10-09 | Local | Moderate | 1,635 | Multiple groups | All | Probability | Household and community samples | 0.3% (95% CI 0.1-0.6%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Mozambique - HRP (Tete)** | Mahomed (Republica de Mocambique Ministerio da Saude)198 | 2020-08-31 - 2020-10-12 | Local | Moderate | 1,946 | Multiple groups | All | Probability | Household and community samples | 0.7% (95% CI 0.4-1.1%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Mozambique - HRP (Pemba)** | Arnaldo (República de Moçambique Ministério da Saúde)199 | 2020-07-06 - 2020-07-13 | Local | Moderate | 1,360 | Multiple groups | All | Probability | Household and community samples | 2.5% (95% CI 1.7-3.5%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Mozambique - HRP (Nampula)** | Gudo (Republica de Mocambique Ministerio da Saude)200 | 2020-06-17 - 2020-06-30 | Local | Moderate | 1,769 | Multiple groups | All | Probability | Household and community samples | 5% (95% CI 4-6.1%) | SD Biosensor - IgG, IgM - Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit | 0.991, 0.951 | Validated by manufacturer |
| **Nigeria - HRP (Enugu,Abuja)** | Ifeorah (Molecular Pathology Institute)201 | 2020-08-01 - 2020-08-31 | Local | High | 113 | Adults (18-64 years) | All | Convenience | Blood donors | 42% (95% CI 32.4-51.2%) | NovaTec Immundiagnostics GmbH - IgG - NovaLisa® SARS-CoV-2 IgG | 1, 0.98 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-09-13 - 2021-09-25 | Local | Moderate | 541 | Multiple groups | All | Probability | Household and community samples | 60.1% (95% CI 55.8-64.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-09-13 - 2021-09-25 | Local | Moderate | 487 | Multiple groups | All | Probability | Household and community samples | 69.6% (95% CI 65.1-73.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-07-19 - 2021-08-05 | Local | Moderate | 572 | Multiple groups | All | Probability | Household and community samples | 38.5% (95% CI 34.5-42.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-07-19 - 2021-08-05 | Local | Moderate | 494 | Multiple groups | All | Probability | Household and community samples | 55.3% (95% CI 50.8-59.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-05-20 - 2021-06-09 | Local | Moderate | 573 | Multiple groups | All | Probability | Household and community samples | 25.8% (95% CI 22.3-29.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-05-20 - 2021-06-09 | Local | Moderate | 499 | Multiple groups | All | Probability | Household and community samples | 48.9% (95% CI 44.4-53.4%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Hillbrow Community Healthcare Centre and Esselen Street Clinic, Region F, City of Johannesburg, Gauteng, South Africa)** | Lee Fairlie (Wits Reproductive Health and HIV Institute)203 | 2021-03-17 - 2021-06-09 | Local | High | 500 | Multiple groups | All | Convenience | Pregnant or parturient women | 64% (95% CI 59.6-68.2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA;Roche Diagnostics, Basel, Switzerland - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 | 1, 0.97 | Complex test algorithm: Manual calculation |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-03-22 - 2021-04-11 | Local | Moderate | 586 | Multiple groups | All | Probability | Household and community samples | 25.3% (95% CI 21.8-29%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-03-22 - 2021-04-11 | Local | Moderate | 505 | Multiple groups | All | Probability | Household and community samples | 40.4% (95% CI 36.1-44.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-01-25 - 2021-02-21 | Local | Moderate | 586 | Multiple groups | All | Probability | Household and community samples | 21.5% (95% CI 18.1-24.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2021-01-25 - 2021-02-21 | Local | Moderate | 509 | Multiple groups | All | Probability | Household and community samples | 35.4% (95% CI 31-39.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2020-11-23 - 2020-12-12 | Local | Moderate | 566 | Multiple groups | All | Probability | Household and community samples | 7.1% (95% CI 5.1-9.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2020-11-23 - 2020-12-12 | Local | Moderate | 523 | Multiple groups | All | Probability | Household and community samples | 27% (95% CI 23.2-31%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2020-09-21 - 2020-10-10 | Local | Moderate | 490 | Multiple groups | All | Probability | Household and community samples | 4.9% (95% CI 3.2-7.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2020-09-21 - 2020-10-10 | Local | Moderate | 498 | Multiple groups | All | Probability | Household and community samples | 21.7% (95% CI 18.1-25.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Agincourt)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2020-07-20 - 2020-09-17 | Local | Moderate | 439 | Multiple groups | All | Probability | Household and community samples | 1.1% (95% CI 0.4-2.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Klerksdorp)** | Jackie Kleynhans (National Institute for Communicable Diseases)202 | 2020-07-20 - 2020-09-17 | Local | Moderate | 501 | Multiple groups | All | Probability | Household and community samples | 14.4% (95% CI 11.4-17.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Africa (Cape Town)** | Hsiao ( University of Cape Town)204 | 2020-06-15 - 2020-08-07 | Local | High | 2,791 | Adults (18-64 years) | All | Sequential | Residual sera | 40.2% (95% CI 38.3-42%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **South Sudan - HRP (Juba)** | Wiens (World Health Organization)205 | 2020-08-10 - 2020-09-11 | Local | Low | 2,214 | Multiple groups | All | Probability | Household and community samples | 22.3% (95% CI 20.5-24.1%) | NA - IgG - Author designed (ELISA) -Spike | 0.655, 1 | Validated by developers |
| **Zimbabwe - HRP (Harare)** | Fryatt (Biomedical Research and Training Institute)206 | 2021-02-10 - 2021-04-17 | Local | Moderate | 1,530 | Multiple groups | All | Probability | Household and community samples | 53% (95% CI 50.4-55.5%) | NA - - Author designed (type unknown) | 0.992, 0.9865 | Validated by developers |
| **Zimbabwe - HRP (Harare)** | Fryatt (Biomedical Research and Training Institute)206 | 2020-11-20 - 2020-12-20 | Local | Moderate | 620 | Multiple groups | All | Probability | Household and community samples | 19% (95% CI 15.9-22.2%) | NA - - Author designed (type unknown) | 0.992, 0.9865 | Validated by developers |

#### *Americas region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Argentina - HRP (Quilmes)** | Munoz (Ministerio de Salud de la Provincia de Buenos Aires)207 | 2020-07-15 - 2020-07-16 | Local | High | 284 | Multiple groups | All | Stratified non-probability | Household and community samples | 14.8% (95% CI 10.9-19.5%) | COVIDAR - IgG - SEROKIT-ELISA COVIDAR IgG | 0.95, 1 | Validated by manufacturers |
| **Argentina - HRP (Buenos Aires)** | Figar (Ministry of Health of the City of Buenos Aires)208 | 2020-06-10 - 2020-06-26 | Local | Low | 873 | Multiple groups | All | Probability | Persons living in slums | 53.4% | CONICET - IgG, IgM - COVIDAR IgM and IgG ELISA | 0.9, 1 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (São Paulo)** | Tess (Inteligência em Pesquisa e Consultoria)209 | 2021-04-22 - 2021-05-01 | Local | Moderate | 1,187 | Multiple groups | All | Probability | Household and community samples | 41.6% (95% CI 38.7-44.4%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 0.99, 1 | Complex test algorithm: Manual calculation |
| **Brazil - HRP (São Paulo)** | City of Sao Paulo (City of São Paulo)210 | 2021-02-16 - 2021-02-18 | Local | Moderate | 1,793 | Multiple groups | All | Probability | Household and community samples | 25% (95% CI 23-27.1%) | Guangzhou Wondfo Biotech Co., Ltd - IgG, IgM - Finecare SARS-CoV-2 Antibody test, EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9872, 0.991 | Complex test algorithm: Manual calculation |
| **Brazil - HRP (Belém)** | Silva (Universidade Federal do Pará)211 | 2020-09-15 - 2021-01-15 | Local | Moderate | 101 | Multiple groups | All | Probability | Household and community samples | 83.2% (95% CI 74.4-89.9%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Brazil - HRP (São Paulo)** | Miraglia (Hospital Israelita Albert Einstein)212 | 2020-09-15 - 2020-12-15 | Local | Moderate | 272 | Multiple groups | All | Probability | Household and community samples | 45.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Pontes (Instituto Nacional de Pesquisas da Amazônia)213 | 2020-10-10 - 2020-11-14 | Local | High | 280 | Multiple groups | All | Sequential | Household and community samples | 64.6% (95% CI 58.4-69.9%) | EUROIMMUN AG - IgA - Anti-SARS-CoV-2 ELISA (IgA), EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9969, 0.983 | Complex test algorithm: Manual calculation |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-10-12 - 2020-10-24 | Local | Moderate | 877 | Multiple groups | All | Sequential | Blood donors | 19.5% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-10-10 - 2020-10-17 | Local | Moderate | 882 | Multiple groups | All | Sequential | Blood donors | 43.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-09-07 - 2020-09-29 | Local | Moderate | 933 | Multiple groups | All | Sequential | Blood donors | 16.7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-09-05 - 2020-09-14 | Local | Moderate | 868 | Multiple groups | All | Sequential | Blood donors | 45.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-08-10 - 2020-08-29 | Local | Moderate | 906 | Multiple groups | All | Sequential | Blood donors | 17.2% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-08-08 - 2020-08-19 | Local | Moderate | 881 | Multiple groups | All | Sequential | Blood donors | 44% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Rio de Janeiro)** | Lugon (Oswaldo Cruz Foundation)215 | 2020-05-18 - 2020-09-24 | Local | High | 515 | Multiple groups | All | Convenience | Multiple general populations | 29.3% (95% CI 25.2-33.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-07-13 - 2020-07-25 | Local | Moderate | 879 | Multiple groups | All | Sequential | Blood donors | 12.8% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Oliveira (Universidade de São Paulo)216 | 2020-06-30 - 2020-08-04 | Local | High | 439 | Multiple groups | All | Convenience | Residual sera | 13.9% (95% CI 10.8-17.5%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 0.974, 0.9999 | Complex test algorithm: Manual calculation |
| **Brazil - HRP (Betim)** | Silva ( Escola de Saúde Pública de Betim)217 | 2020-07-13 - 2020-07-15 | Local | Moderate | 1,080 | Multiple groups | All | Probability | Household and community samples | 2.6% (95% CI 1.7-3.6%) | Guangzhou Wondfo Biotech Co., Ltd - IgG, IgM - Finecare SARS-CoV-2 Antibody test | 0.872, 0.991 | Validated by manufacturer |
| **Brazil - HRP (Joinville)** | Diegoli (City Hall of Joinville)218 | 2020-06-15 - 2020-08-07 | Local | Moderate | 4,403 | Multiple groups | All | Probability | Household and community samples | 4.8% | Celer Technologies Inc. - IgG, IgM - One Step COVID-19 Test | 0.8643, 0.9957 | Validated by independent authors/third party/non-developers |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-07-06 - 2020-07-15 | Local | Moderate | 1,147 | Multiple groups | All | Sequential | Blood donors | 46.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Rio de Janeiro)** | Santos (Oswaldo Cruz Foundation)219 | 2020-01-07 - 2021-01-11 | Local | High | 31 | Adults (18-64 years) | Female | Unclear | Pregnant or parturient women | 19.4% (95% CI 5.5-33.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Brazil - HRP (Carmópolis)** | Bernardes-Souza (Federal University of Ouro Preto)220 | 2020-06-27 - 2020-06-28 | Local | Moderate | 400 | Multiple groups | All | Probability | Household and community samples | 1.8% (95% CI 0.7-3.6%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Brazil - HRP (Betim)** | Silva ( Escola de Saúde Pública de Betim)217 | 2020-06-23 - 2020-06-25 | Local | Moderate | 1,080 | Multiple groups | All | Probability | Household and community samples | 0.7% (95% CI 0.3-1.5%) | Guangzhou Wondfo Biotech Co., Ltd - IgG, IgM - Finecare SARS-CoV-2 Antibody test | 0.872, 0.991 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-06-08 - 2020-06-20 | Local | Moderate | 880 | Multiple groups | All | Sequential | Blood donors | 15% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Ribeirão Preto (RP))** | Martinez (Universidade de São Paulo)221 | 2020-06-11 - 2020-06-14 | Local | Moderate | 646 | Multiple groups | All | Probability | Household and community samples | 2.8% (95% CI 1.7-4.4%) | Guangzhou Wondfo Biotech Co.， Ltd - IgG, IgM, IgA - Wondfo SARS-CoV-2 Antibody Test | 0.864, 0.996 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-06-05 - 2020-06-15 | Local | Moderate | 911 | Multiple groups | All | Sequential | Blood donors | 52.7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Betim)** | Silva ( Escola de Saúde Pública de Betim)217 | 2020-06-03 - 2020-06-05 | Local | Moderate | 1,079 | Multiple groups | All | Probability | Household and community samples | 0.3% (95% CI 0.1-0.8%) | Guangzhou Wondfo Biotech Co., Ltd - IgG, IgM - Finecare SARS-CoV-2 Antibody test | 0.872, 0.991 | Validated by manufacturer |
| **Brazil - HRP (Nepomuceno)** | Bernardes-Souza (Federal University of Ouro Preto)220 | 2020-05-30 - 2020-05-31 | Local | Moderate | 400 | Multiple groups | All | Probability | Household and community samples | 0.5% (95% CI 0.1-1.8%) | Qingdao Hightop Biotech Co., Ltd - IgG, IgM - Hightop COVID-19 IgM/IgG Ab Rapid Test Kit | 0.942, 0.939 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-05-08 - 2020-05-21 | Local | Moderate | 826 | Multiple groups | All | Sequential | Blood donors | 7.5% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-05-05 - 2020-05-14 | Local | Moderate | 901 | Multiple groups | All | Sequential | Blood donors | 42.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP** | Tess (Universidade de Sao Paulo)222 | 2020-05-04 - 2020-05-12 | Subnational | High | 463 | Multiple groups | All | Stratified non-probability | Multiple general populations | 6% | Snibe Co., Ltd (Shenzhen New Industries Biomedical Engineering Co., Ltd) - IgG, IgM - MAGLUMI 2019-nCoV IgM/IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.9821 | Complex test algorithm: Manual calculation |
| **Brazil - HRP (Ribeirão Preto (RP))** | Martinez (Universidade de São Paulo)221 | 2020-05-01 - 2020-05-03 | Local | Moderate | 709 | Multiple groups | All | Probability | Household and community samples | 1.3% (95% CI 0.6-2.4%) | Guangzhou Wondfo Biotech Co.， Ltd - IgG, IgM, IgA - Wondfo SARS-CoV-2 Antibody Test | 0.864, 0.996 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-04-08 - 2020-04-30 | Local | Moderate | 900 | Multiple groups | All | Sequential | Blood donors | 6.8% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-04-06 - 2020-04-17 | Local | Moderate | 829 | Multiple groups | All | Sequential | Blood donors | 7.7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-03-09 - 2020-03-21 | Local | Moderate | 2,454 | Multiple groups | All | Sequential | Blood donors | 5.8% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-03-06 - 2020-03-12 | Local | Moderate | 832 | Multiple groups | All | Sequential | Blood donors | 2.6% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Manaus)** | Buss (Universidade de Sao Paulo)214 | 2020-02-07 - 2020-02-13 | Local | Moderate | 821 | Multiple groups | All | Sequential | Blood donors | 3.6% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Brazil - HRP (Sao Paulo)** | Buss (Universidade de Sao Paulo)214 | 2020-02-08 - 2020-02-29 | Local | Moderate | 799 | Multiple groups | All | Sequential | Blood donors | 4.2% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Colombia - HRP (Mitú)** | Serrano-Coll (Universidad de Córdoba)223 | 2020-12-01 - 2020-12-31 | Local | High | 589 | Multiple groups | All | Unclear | Household and community samples | 57.6% (95% CI 53.4-61.6%) | Eurofins Ingenasa - IgG, IgM, IgA - INgezim COVID 19 DR | 0.983, 0.992 | Validated by manufacturer |
| **Colombia - HRP (Monteria)** | Mattar (Universidad de Córdoba)224 | 2020-08-04 - 2020-09-01 | Local | Low | 1,368 | Multiple groups | All | Probability | Household and community samples | 55.3% | Eurofins Ingenasa - IgG, IgM, IgA - INgezim COVID 19 DR | 0.983, 0.992 | Validated by manufacturer |
| **Ecuador - HRP (Atahualpa)** | Brutto (Universidad Espíritu Santo)225 | 2020-05-01 - 2021-04-30 | Local | High | 673 | Adults (18-64 years) | All | Convenience | Household and community samples | 63.7% (95% CI 59.8-67.2%) | Biohit Health Care Ltd - IgG, IgM - BIOHIT SARS-CoV-2 antibody test | 0.975, 1 | Validated by independent authors/third party/non-developers |
| **Ecuador - HRP (Canton of Cuenca)** | Paez (University of Antwerp)226 | 2020-08-11 - 2020-11-01 | Local | Moderate | 2,457 | Multiple groups | All | Probability | Household and community samples | 13.2% (95% CI 11.9-14.6%) | SD Biosensor - IgG, IgM - Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit | 0.991, 0.951 | Validated by manufacturer |
| **French Guiana** | Flamand (Institut Pasteur )227 | 2020-07-15 - 2020-07-23 | National | High | 480 | Multiple groups | All | Sequential | Residual sera | 15.4% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Jamaica (Kingston)** | Chisolm (University of the West Indies)228 | 2020-11-01 - 2020-11-30 | Local | High | 77 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 24% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Mexico - HRP** | Munoz-Medina (Instituto de Salud para el Bienestar)229 | 2020-12-01 - 2020-12-31 | National | High | 5,359 | Multiple groups | All | Stratified non-probability | Residual sera | 30.6% | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG, GenScript - IgG, IgM - cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit | 0.9136, 0.9999 | Complex test algorithm: Manual calculation |
| **Mexico - HRP (Veracruz City)** | Remes-Troche (Universidad Veracruzana)230 | 2020-06-01 - 2020-07-31 | Local | High | 2,174 | Multiple groups | All | Sequential | Residual sera | 29.5% (95% CI 27.6-31.5%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Mexico - HRP (Nuevo Leon)** | a (Autonomous University of Nuevo Leon)231 | 2020-01-01 - 2020-12-15 | Subnational | High | 2,068 | Adults (18-64 years) | All | Sequential | Blood donors | 4.8% (95% CI 3.9-5.7%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Peru - HRP (La Riconanda)** | Champigneulle (Grenoble Alpes University)232 | 2020-10-11 - 2020-10-18 | Local | High | 159 | Multiple groups | All | Sequential | Household and community samples | 48.4% (95% CI 39.8-55.9%) | AAZ LMB - IgG, IgM - COVID-PRESTO® | 1, 1 | Validated by independent authors/third party/non-developers |
| **Peru - HRP (Iquitos)** | Alvarez-Antonio (Universidad de Ingeniería y Tecnología)233 | 2020-08-13 - 2020-08-18 | Local | Low | 621 | Multiple groups | All | Probability | Household and community samples | 68% (95% CI 64.1-71.6%) | Zhejiang Orient Gene Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test | 0.972, 1 | Validated by manufacturer |
| **Peru - HRP (Iquitos)** | Alvarez-Antonio (Universidad de Ingeniería y Tecnología)233 | 2020-07-13 - 2020-07-18 | Local | Low | 716 | Multiple groups | All | Probability | Household and community samples | 73.7% (95% CI 70.2-76.8%) | Zhejiang Orient Gene Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test | 0.972, 1 | Validated by manufacturer |
| **Peru - HRP (Lima metropolitan area)** | Vega (Peruvian Ministry of Health)234 | 2020-06-28 - 2020-07-09 | Local | Low | 3,212 | Multiple groups | All | Probability | Household and community samples | 21.4% | SD Biosensor - IgG, IgM - Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit | 0.991, 0.951 | Validated by manufacturer |
| **Peru - HRP (Lima)** | Rios (National Maternal Perinatal Institut)235 | 2020-04-15 - 2020-05-15 | Local | Moderate | 2,419 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 7% (95% CI 6-8.1%) | NA - - Not reported/ Unable to specify | 0.976, 0.988 | Validated by manufacturers |
| **Canada (Edmonton)** | Manny (University of Alberta)236 | 2020-08-14 - 2020-10-23 | Local | High | 565 | Children and Youth (0-17 years) | All | Convenience | Household and community samples | 1.6% (95% CI 0.7-3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Canada (Québec)** | Lewin (Héma-Québec)237 | 2020-05-25 - 2020-07-09 | Subnational | High | 7,691 | Adults (18-64 years) | All | Convenience | Blood donors | 2.2% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.989, 0.985 | Validated by developers |
| **Panama - HRP (Colon,Panama City)** | Villarreal (Instituto de Investigaciones Científicas y Servicios de Alta Tecnología)238 | 2020-04-30 - 2020-07-07 | Local | High | 255 | Multiple groups | All | Convenience | Blood donors | 13.3% (95% CI 9.1-17.7%) | NA - IgG, IgM - Author designed (ELISA) - Nucleocapsid | 0.8701, 0.9889 | Validated by developers |
| **United States of America (Texas)** | Messiah (University of Texas at Houston)239 | 2021-01-01 - 2021-06-01 | Subnational | High | 503 | Children and Youth (0-17 years) | All | Convenience | Household and community samples | 38.7% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United States of America (Pittsburgh)** | Xu (University of Pittsburgh)240 | 2021-02-01 - 2021-02-05 | Local | High | 194 | Multiple groups | All | Sequential | Residual sera | 16.5% (95% CI 11.1-21.9%) | NA - - Author designed (Neutralization Assay), NA - IgG - Author designed (ELISA) - Nucleocapsid | N/A | Complex test algorithm: Manual review |
| **United States of America (St Louis)** | Smith (Washington University School of Medicine)241 | 2020-12-24 - 2021-01-21 | Local | High | 1,001 | Multiple groups | All | Convenience | Residual sera | 20.7% (95% CI 18.2-23.3%) | NA - IgG - Author designed (ELISA) -Spike | 0.982, 0.987 | Validated by developers |
| **United States of America** | Dodd (American Red Cross)242 | 2020-06-15 - 2021-06-25 | National | High | 1,567,446 | Multiple groups | All | Convenience | Blood donors | 60.1% (95% CI 60-60.1%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America** | Stout (Clinical Reference Laboratory Inc.)243 | 2020-12-01 - 2020-12-06 | National | High | 14,605 | Multiple groups | All | Convenience | Residual sera | 10.4% (95% CI 9.9-10.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United States of America** | Dodd (American Red Cross)244 | 2020-11-29 - 2020-11-30 | National | High | 13,268 | Multiple groups | All | Sequential | Blood donors | 9.7% | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (St Louis)** | Smith (Washington University School of Medicine)241 | 2020-10-27 - 2020-11-30 | Local | High | 1,013 | Multiple groups | All | Convenience | Residual sera | 11.7% (95% CI 9.7-13.8%) | NA - IgG - Author designed (ELISA) -Spike | 0.982, 0.987 | Validated by developers |
| **United States of America (NA)** | Staszewski (North Shore University Hospital)245 | 2020-10-15 - 2020-11-15 | Local | High | 149 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 14.1% (95% CI 8.9-20.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **United States of America (Centre County)** | Arnold (Pennsylvania State University)246 | 2020-08-07 - 2020-12-20 | Local | High | 345 | Adults (18-64 years) | All | Convenience | Household and community samples | 8.2% (95% CI 5.5-11.5%) | NA - IgG - Author designed (ELISA) -Spike | 0.933, 0.99 | Validated by independent authors/third party/non-developers |
| **United States of America (New Mexico)** | Bonelli (Dia Sorin Inc)247 | 2020-09-01 - 2020-09-30 | Subnational | High | 1,931 | Multiple groups | All | Sequential | Residual sera | 2% (95% CI 1.4-2.7%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG, Beckman Coulter - IgG - Access SARS-CoV-2 IgG Antibody Test | 1, 0.983 | Complex test algorithm: Manual calculation |
| **United States of America** | Stout (Clinical Reference Laboratory Inc)248 | 2020-09-01 - 2020-09-30 | National | High | 61,910 | Multiple groups | All | Sequential | Household and community samples | 6.6% (95% CI 6.4-6.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United States of America (Houston)** | Symanski (Houston Health Department)249 | 2020-09-01 - 2020-09-19 | Local | Low | 685 | Multiple groups | All | Probability | Household and community samples | 11.5% | Bio-rad - IgG, IgM, IgA - Platelia SARS-CoV-2 Total Ab assay, NA - IgG - Author designed (ELISA) -Spike | N/A | Complex test algorithm: Manual review |
| **United States of America (Washington D.C)** | Bahar (Children’s National Hospital)250 | 2020-07-07 - 2020-10-29 | Local | High | 385 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 9.9% (95% CI 6.9-13%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **United States of America (Denver)** | Jia (University of Colorado)251 | 2020-07-08 - 2020-10-23 | Local | High | 102 | Adults (18-64 years) | All | Convenience | Household and community samples | 3.9% (95% CI 0.6-8.4%) | NA - - Author designed (CLIA) | 1, 0.999 | Validated by independent authors/third party/non-developers |
| **United States of America (Denver)** | Jia (University of Colorado)251 | 2020-07-08 - 2020-10-23 | Local | High | 562 | Children and Youth (0-17 years) | All | Convenience | Household and community samples | 2.8% (95% CI 1.5-4.4%) | NA - - Author designed (CLIA) | 1, 0.999 | Validated by independent authors/third party/non-developers |
| **United States of America (Washington DC)** | Sherman (Government of the District of Columbia)252 | 2020-07-27 - 2020-08-21 | Local | High | 671 | Multiple groups | All | Convenience | Household and community samples | 7.6% (95% CI 5.6-9.7%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **United States of America (New York City)** | Parrott (New York City Department of Health and Mental Hygiene)253 | 2020-06-01 - 2020-10-09 | Local | Low | 1,074 | Multiple groups | All | Probability | Household and community samples | 24.3% | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **United States of America (St Louis)** | Smith (Washington University School of Medicine)241 | 2020-07-22 - 2020-08-16 | Local | High | 1,052 | Multiple groups | All | Convenience | Residual sera | 5.9% (95% CI 4.5-7.4%) | NA - IgG - Author designed (ELISA) -Spike | 0.982, 0.987 | Validated by developers |
| **United States of America (Orange County)** | Bruckner (University of California Irvine)254 | 2020-07-10 - 2020-08-16 | Local | Low | 2,979 | Multiple groups | All | Probability | Household and community samples | 11.5% | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 0.94, 1 | Validated by independent authors/third party/non-developers |
| **United States of America (Baton Rouge)** | Feehan (Louisiana State University)255 | 2020-07-15 - 2020-07-31 | Local | Low | 2,138 | Multiple groups | All | Probability | Household and community samples | 3.6% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (Fullerton)** | Yamaki (St. Jude Medical Center)256 | 2020-07-15 - 2020-07-27 | Local | High | 865 | Multiple groups | All | Sequential | Residual sera | 9.4% (95% CI 7.5-11.5%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (Belle Glade,Delray Beach,West Palm Beach,Lantana)** | Gonik (Wayne State University School of Medicine)257 | 2020-06-29 - 2020-08-05 | Local | Moderate | 618 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 26.4% (95% CI 22.9-30%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (New York City)** | Molenaar ( Icahn School of Medicine)258 | 2020-04-20 - 2020-09-22 | Local | High | 708 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 16.4% (95% CI 13.7-19.3%) | NA - - Author designed (ELISA) -Spike | 0.95, 1 | Validated by developers |
| **United States of America (New York City)** | Stadlbauer (Icahn School of Medicine at Mount Sinai)259 | 2020-06-29 - 2020-07-05 | Local | High | 182 | Multiple groups | All | Sequential | Residual sera | 23.1% | NA - IgG - Author designed (ELISA) -Spike | 0.95, 1 | Validated by developers |
| **United States of America (New York City)** | Stadlbauer (Icahn School of Medicine at Mount Sinai)259 | 2020-06-29 - 2020-07-05 | Local | High | 311 | Multiple groups | All | Sequential | Residual sera | 22.2% | NA - IgG - Author designed (ELISA) -Spike | 0.95, 1 | Validated by developers |
| **United States of America** | Robertson (City University of New York)260 | 2020-05-15 - 2020-08-15 | National | High | 4,459 | Multiple groups | All | Convenience | Household and community samples | 6.8% (95% CI 6.1-7.6%) | Bio-rad - IgG, IgM, IgA - Platelia SARS-CoV-2 Total Ab assay | 0.993, 0.98 | Validated by manufacturer |
| **United States of America (New York City)** | Kamath (Serimmune)261 | 2020-06-24 - 2020-07-07 | Local | High | 69 | Multiple groups | All | Sequential | Blood donors | 11.6% | Serimmune - IgG, IgM, IgA - Serum Epitope Repertoire Analysis (SERA) | 0.91, 0.993 | Validated by manufacturers |
| **United States of America (Long Island)** | Morozova (Stony Brook University)262 | 2020-03-25 - 2020-09-18 | Local | High | 1,042 | Multiple groups | All | Convenience | Household and community samples | 21% (95% CI 18.5-23.5%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (New York City)** | Molenaar (Icahn School of Medicine at Mount Sinai)263 | 2020-04-20 - 2020-08-15 | Local | Moderate | 696 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 15% (95% CI 12.4-17.8%) | NA - IgG - Author designed (ELISA) -Spike | 0.95, 1 | Validated by independent authors/third party/non-developers |
| **United States of America (San Francisco Bay Area)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Local | Low | 4,980 | Multiple groups | All | Probability | Residual sera | 1.9% | NA - IgG - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (New York City)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Local | Low | 7,746 | Multiple groups | All | Probability | Residual sera | 17.2% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (Philadelphia)** | Lim (Centers for Disease and Control )131 | 2020-03-23 - 2020-08-14 | Local | Low | 8,657 | Multiple groups | All | Probability | Residual sera | 4.3% | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (North Carolina)** | Barzin (University of North Carolina Chapel Hill)264 | 2020-06-01 - 2020-06-04 | Subnational | High | 1,449 | Adults (18-64 years) | All | Convenience | Residual sera | 0% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (New York)** | Reifer (Sherman Abrams Laboratory )265 | 2020-05-15 - 2020-06-15 | Local | High | 28,523 | Multiple groups | All | Convenience | Residual sera | 44% (95% CI 43.4-44.6%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **United States of America (NA)** | Staszewski (North Shore University Hospital)245 | 2020-05-15 - 2020-06-15 | Local | High | 149 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 16.1% (95% CI 10-22.3%) | Gold Standard Diagnostic - IgG - SARS-CoV-2 IgG ELISA Assay | 1, 1 | Validated by manufacturer |
| **United States of America** | Stout (Clinical Reference Laboratory Inc.)243 | 2020-05-12 - 2020-06-15 | National | High | 50,072 | Multiple groups | All | Convenience | Residual sera | 3% (95% CI 2.9-3.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United States of America (Jefferson, Orleans)** | Feehan (Oschner Clinic Foundation)266 | 2020-05-09 - 2020-05-15 | Local | Low | 2,640 | Adults (18-64 years) | All | Probability | Household and community samples | 6.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (San Francisco)** | Routledge (University of California San Francisco)267 | 2020-03-28 - 2020-06-26 | Local | Moderate | 4,735 | Multiple groups | All | Stratified non-probability | Residual sera | 4.1% (95% CI 3.6-4.7%) | NA - - Author designed (Luminex), NA - IgG - Author designed (ELISA) -Unknown | N/A | Complex test algorithm: Manual review |
| **United States of America (Philadelphia)** | Flannery (University of Pennsylvania)268 | 2020-04-04 - 2020-06-03 | Local | Moderate | 1,293 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 6.2% (95% CI 4.9-7.6%) | NA - IgG, IgM - Author designed (ELISA) -Spike | 1, 0.989 | Validated by independent authors/third party/non-developers |
| **United States of America (St Louis)** | Smith (Washington University School of Medicine)269 | 2020-04-27 - 2020-05-12 | Local | High | 503 | Multiple groups | All | Sequential | Residual sera | 4.2% (95% CI 2.4-6.1%) | NA - IgG - Author designed (ELISA) -Spike | 0.982, 0.987 | Validated by independent authors/third party/non-developers |
| **United States of America (Rhode Island)** | Nesbitt (Lindsley F Kimball Research Institute)270 | 2020-04-27 - 2020-05-11 | Subnational | High | 1,996 | Multiple groups | All | Sequential | Blood donors | 0.7% (95% CI 0.3-1.1%) | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG | 1, 1 | Validated by manufacturer |
| **United States of America (DeKalb, Fulton)** | Biggs (CDC COVID-19 Response Team)271 | 2020-04-28 - 2020-05-03 | Local | Low | 696 | Multiple groups | All | Probability | Household and community samples | 2.7% (95% CI 1.5-4.1%) | Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Validated by manufacturer |
| **United States of America (Atlanta)** | Bajema (Centers for Disease Control and Prevention)272 | 2020-04-27 - 2020-05-01 | Local | High | 1,343 | Multiple groups | All | Convenience | Residual sera | 4.2% (95% CI 3.2-5.4%) | NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | 0.96, 0.993 | Validated by developers |
| **United States of America (San Francisco)** | Chamie (University of California, San Francisco)273 | 2020-04-25 - 2020-04-28 | Local | High | 3,861 | Multiple groups | All | Convenience | Household and community samples | 3.1% (95% CI 2.6-3.7%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **United States of America (St Louis)** | Smith (Washington University School of Medicine)269 | 2020-04-14 - 2020-05-08 | Local | High | 555 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 2.7% (95% CI 1.4-4.2%) | NA - IgG - Author designed (ELISA) -Spike | 0.982, 0.987 | Validated by independent authors/third party/non-developers |
| **United States of America (Baltimore)** | Laeyendecker (Johns Hopkins University )274 | 2020-03-16 - 2020-05-31 | Local | High | 3,255 | Multiple groups | All | Sequential | Residual sera | 3.5% (95% CI 2.9-4.2%) | Hangzhou Biotest Biotech Co., Ltd - IgG, IgM - RightSign COVID-19 IgG/IgM Rapid Test Cassette, EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9914, 1 | Complex test algorithm: Manual calculation |
| **United States of America (Los Angeles County)** | Sood (Stanford University School of Medicine)275 | 2020-04-10 - 2020-04-14 | Local | Low | 863 | Multiple groups | All | Probability | Household and community samples | 4.3% | Premier Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test Cassette | 1, 1 | Validated by manufacturer |
| **United States of America (Seattle)** | Rathe (University of Washington)276 | 2020-03-26 - 2020-04-15 | Local | High | 100 | Multiple groups | All | Probability | Household and community samples | 4% (95% CI 1.1-9.9%) | NA - - Author designed (Neutralization Assay), Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, NA - IgG, IgM, IgA - Author designed (ELISA) -Spike | N/A | Complex test algorithm: Manual review |
| **United States of America (Santa Clara County)** | Bendavid (Stanford University School of Medicine)277 | 2020-04-03 - 2020-04-04 | Local | High | 3,328 | Multiple groups | All | Stratified non-probability | Household and community samples | 1.5% (95% CI 1.1-1.9%) | Premier Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test Cassette | 1, 1 | Validated by manufacturer |
| **United States of America (Seattle)** | Dingens (Fred Hutchinson Cancer Research Center)278 | 2020-03-03 - 2020-04-24 | Local | High | 1,076 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 0.9% (95% CI 0.4-1.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, NA - IgG - Author designed (ELISA) -Spike | N/A | Complex test algorithm: Manual review |
| **United States of America (San Francisco)** | Ng (University of California, San Francisco)279 | 2020-03-01 - 2020-03-31 | Local | High | 1,000 | Multiple groups | All | Sequential | Blood donors | 0.1% (95% CI 0-0.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG, NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |

#### *Eastern Mediterranean region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Egypt - HRP (Cairo)** | Abdelmaksoud (Ain-Shams University)280 | 2020-09-06 - 2020-10-31 | Local | High | 100 | Adults (18-64 years) | All | Probability | Blood donors | 38% (95% CI 28.5-48.3%) | AMEDA Labordiagnostik GmbH - IgG, IgM - AMP Rapid Test SARS-CoV-2 IgG/IgM | 1, 0.975 | Validated by manufacturer |
| **Egypt - HRP (Cairo)** | Girgis (Ain-Shams University)281 | 2020-05-05 - 2020-10-31 | Local | High | 2,927 | Multiple groups | All | Sequential | Residual sera | 30% (95% CI 28.3-31.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Iran (Islamic Republic of) - HRP (Zahedan)** | Mohammadi (Tehran University of Medical Sciences)282 | 2020-07-01 - 2020-07-31 | Local | High | 134 | Adults (18-64 years) | Male | Probability | Household and community samples | 4.8% (95% CI 1.7-9.5%) | Pishtaz Diagnostics Iran - IgG - ELISA kit Pishtaz Teb Diagnostics | 0.941, 0.983 | Validated by manufacturer |
| **Iraq - HRP (Duhok)** | Hussein (University of Duhok)283 | 2021-01-10 - 2021-01-30 | Local | Moderate | 743 | Multiple groups | All | Probability | Household and community samples | 62.6% (95% CI 58.9-65.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Jordan - HRP** | Sughayer (King Hussein Cancer Center)284 | 2021-06-01 - 2021-06-30 | National | High | 536 | Adults (18-64 years) | All | Sequential | Blood donors | 74.4% (95% CI 70.3-77.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **Jordan - HRP** | Sughayer (King Hussein Cancer Center)285 | 2021-01-28 - 2021-02-05 | National | High | 292 | Adults (18-64 years) | All | Sequential | Blood donors | 27.4% (95% CI 22.4-32.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Jordan - HRP** | Sughayer (King Hussein Cancer Center)285 | 2020-09-01 - 2020-09-15 | National | High | 348 | Adults (18-64 years) | All | Sequential | Blood donors | 0% (95% CI 0-1.1%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Jordan - HRP** | Sughayer (King Hussein Cancer Center)285 | 2020-01-15 - 2020-06-15 | National | High | 736 | Adults (18-64 years) | All | Sequential | Blood donors | 0% (95% CI 0-0.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **occupied Palestinian territory, including east Jerusalem - HRP (West Bank)** | Qutob (Arab American University )286 | 2020-06-15 - 2020-06-30 | Local | Low | 1,355 | Multiple groups | All | Probability | Household and community samples | 0% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **occupied Palestinian territory, including east Jerusalem - HRP (West Bank)** | Qutob (Arab American University )286 | 2020-05-01 - 2020-07-09 | Local | High | 1,136 | Multiple groups | All | Convenience | Residual sera | 0.3% (95% CI 0.1-0.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Pakistan - HRP (District East)** | Nisar (Aga Khan University)287 | 2020-08-17 - 2020-08-22 | Local | Moderate | 500 | Multiple groups | All | Probability | Household and community samples | 24% (95% CI 20.3-28%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Pakistan - HRP (District Malir)** | Nisar (Aga Khan University)287 | 2020-08-17 - 2020-08-22 | Local | Moderate | 501 | Multiple groups | All | Probability | Household and community samples | 16% (95% CI 12.9-19.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Pakistan - HRP (NA)** | Ansari (Liaquat University)288 | 2020-06-15 - 2020-08-15 | Local | High | 728 | Multiple groups | All | Convenience | Residual sera | 10.8% (95% CI 8.6-13.2%) | NA - - Not reported/ Unable to specify | 1, 0.998 | Validated by manufacturers |
| **Pakistan - HRP (District East)** | Nisar (Aga Khan University)287 | 2020-06-25 - 2020-07-11 | Local | Moderate | 500 | Multiple groups | All | Probability | Household and community samples | 20% (95% CI 16.6-23.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Pakistan - HRP (District Malir)** | Nisar (Aga Khan University)287 | 2020-06-25 - 2020-07-11 | Local | Moderate | 504 | Multiple groups | All | Probability | Household and community samples | 12.7% (95% CI 9.9-15.9%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Pakistan - HRP (District East)** | Nisar (Aga Khan University)287 | 2020-04-15 - 2020-04-25 | Local | Moderate | 500 | Multiple groups | All | Probability | Household and community samples | 0.4% (95% CI 0-1.4%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Pakistan - HRP (District Malir)** | Nisar (Aga Khan University)287 | 2020-04-15 - 2020-04-25 | Local | Moderate | 500 | Multiple groups | All | Probability | Household and community samples | 0% (95% CI 0-0.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Saudi Arabia (Riyadh)** | Alosaimi (King Saud University)289 | 2020-11-22 - 2020-12-17 | Local | High | 515 | Multiple groups | All | Convenience | Blood donors | 12.2% (95% CI 9.4-15.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Saudi Arabia (NA)** | Almudarra (Saudi Ministry of Health)290 | 2020-08-01 - 2020-08-31 | Local | Moderate | 5,629 | Multiple groups | All | Probability | Household and community samples | 50.2% (95% CI 48.9-51.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **United Arab Emirates (Dubai)** | Raouf (Dubai Health Authority)291 | 2020-08-15 - 2020-12-15 | Local | Moderate | 1,418 | Adults (18-64 years) | All | Probability | Blood donors | 13.5% (95% CI 11.7-15.4%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |

#### *Europe region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Albania (Tirana)** | Sulcebe (University of Medicine and University Hospital Center of Tirana)292 | 2020-12-21 - 2020-12-28 | Local | Moderate | 815 | Adults (18-64 years) | All | Probability | Household and community samples | 48.2% (95% CI 44.6-51.6%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Albania (Tirana)** | Sulcebe (University of Medicine and University Hospital Center of Tirana)292 | 2020-06-27 - 2020-07-03 | Local | High | 266 | Adults (18-64 years) | All | Probability | Household and community samples | 7.5% (95% CI 4.4-10.9%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Bosnia and Herzegovina (Sarajevo)** | Asic (International Burch University)293 | 2020-04-21 - 2020-07-17 | Local | High | 1,121 | Multiple groups | All | Convenience | Residual sera | 4.3% (95% CI 3.1-5.5%) | Dynamiker Biotechnology (Tianjin) Co., Ltd - IgG, IgM - 2019-nCoV IgG/IgM Rapid Test | 0.957, 0.991 | Validated by manufacturer |
| **Bosnia and Herzegovina (Sarajevo)** | Asic (International Burch University)293 | 2020-04-15 - 2020-05-15 | Local | High | 1,720 | Multiple groups | All | Convenience | Residual sera | 3.4% (95% CI 2.6-4.3%) | Artron Laboratories Inc. - IgG, IgM - One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test | 0.972, 0.978 | Validated by manufacturer |
| **Bulgaria (Varna)** | Tsaneva-Damyanova (Medical Diagnostic Laboratory “STATUS” )294 | 2020-03-26 - 2020-04-20 | Local | High | 586 | Multiple groups | All | Convenience | Residual sera | 4.8% (95% CI 3.2-6.8%) | Zhejiang Orient Gene Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test | 0.972, 1 | Validated by manufacturer |
| **North Macedonia (Skopje)** | Bojadjieva ( Institute for Transfusion Medicine)295 | 2020-11-15 - 2021-03-15 | Local | High | 9,773 | Multiple groups | All | Sequential | Blood donors | 25% (95% CI 24.1-25.9%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Russian Federation (Saint Petersburg)** | Barchuk (Smorodinova Research Institute of Influenza)296 | 2020-10-12 - 2020-12-06 | Local | Low | 1,322 | Multiple groups | All | Probability | Household and community samples | 21% | Genetico - IgG, IgM, IgA - CoronaPass total antibodies test | 0.911, 0.9 | Validated by manufacturer |
| **Russian Federation (Saint Petersburg)** | Barchuk (Smorodinova Research Institute of Influenza)296 | 2020-07-20 - 2020-08-08 | Local | Moderate | 474 | Multiple groups | All | Probability | Household and community samples | 12.2% | Genetico - IgG, IgM, IgA - CoronaPass total antibodies test | 0.911, 0.9 | Validated by manufacturer |
| **Russian Federation (Saint Petersburg)** | Barchuk (European University at St. Petersburg )297 | 2020-05-27 - 2020-06-26 | Local | Low | 990 | Multiple groups | All | Probability | Household and community samples | 7.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Turkey - HRP (Ankara)** | Celik (Etlik Zübeyde Hanim Women’s Health Care, Training, and Research Hospital)298 | 2020-06-01 - 2020-07-31 | Local | High | 230 | Adults (18-64 years) | All | Sequential | Pregnant or parturient women | 0% (95% CI 0-1.6%) | Assure Tech. (Hangzhou) Co., Ltd - IgG, IgM - COVID-19 IgG/IgM Rapid Test Device | 1, 0.988 | Validated by manufacturer |
| **Turkey - HRP (Ankara)** | Celik (Etlik Zübeyde Hanim Women’s Health Care, Training, and Research Hospital)298 | 2020-06-01 - 2020-07-31 | Local | High | 205 | Adults (18-64 years) | All | Sequential | Pregnant or parturient women | 2.9% (95% CI 1.1-6.3%) | Assure Tech. (Hangzhou) Co., Ltd - IgG, IgM - COVID-19 IgG/IgM Rapid Test Device | 1, 0.988 | Validated by manufacturer |
| **Austria (Vienna)** | Riesenhuber (Universitätsklinik für Innere Medizin II )299 | 2021-02-08 - 2021-02-22 | Local | High | 3,082 | Multiple groups | All | Sequential | Residual sera | 9.3% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Austria (Weißenkirchen in der Wachau)** | Rebholz (Danube Private University)300 | 2021-02-13 - 2021-02-13 | Local | High | 552 | Multiple groups | All | Convenience | Household and community samples | 25% (95% CI 21.4-28.8%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Austria** | Weidner ( University Hospital of Salzburg)301 | 2020-11-05 - 2020-12-04 | National | High | 3,311 | Multiple groups | All | Convenience | Blood donors | 5.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Austria (Ischgl)** | Lehmann ( Medical University of Innsbruck)302 | 2020-04-21 - 2020-04-27 | Local | High | 451 | Multiple groups | All | Probability | Household and community samples | 43.7% (95% CI 39-48.4%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, EUROIMMUN AG - IgA - Anti-SARS-CoV-2 ELISA (IgA), EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG), NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Belgium (Ghent)** | Heireman (Ghent University Hospital)303 | 2020-01-15 - 2020-11-15 | Local | High | 265 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 1.5% (95% CI 0.2-3.3%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG), Epitope Diagnostics, Inc. - IgG - EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit | 0.9984, 0.998 | Complex test algorithm: Manual calculation |
| **Belgium (Antwerp, Ghent)** | Dam (Antwerp University Hospital)304 | 2020-03-24 - 2020-05-31 | Local | High | 90 | Multiple groups | All | Sequential | Residual sera | 5.6% (95% CI 1.8-12.5%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Croatia** | Vilibic-Cavlek (Croatian Institute of Public Health)305 | 2020-12-15 - 2021-02-15 | National | High | 1,436 | Multiple groups | All | Convenience | Multiple general populations | 25.1% (95% CI 22.8-27.4%) | Vircell S.L. - IgG - COVID-19 ELISA IgG, NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Croatia** | Vilibic-Cavlek (Croatian Institute of Public Health)305 | 2020-05-15 - 2020-07-15 | National | High | 1,088 | Multiple groups | All | Convenience | Multiple general populations | 2.2% (95% CI 1.3-3.2%) | Vircell S.L. - IgG - COVID-19 ELISA IgG, NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Croatia (Zagreb)** | Krleza (Children’s Hospital Zagreb)306 | 2020-05-13 - 2020-05-29 | Local | High | 240 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 2.9% (95% CI 0.9-5.4%) | Vircell S.L. - IgG - COVID-19 ELISA IgG, Vircell S.L. - IgM, IgA - COVID-19 ELISA IgM/IgA, NA - - Author designed (Neutralization Assay) | N/A | Complex test algorithm: Manual review |
| **Czechia (Prague)** | Bloomfield (Charles University and Thomayer’s Hospital)307 | 2020-07-03 - 2020-08-19 | Local | High | 200 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 0% (95% CI 0-1.8%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Denmark (Capital Region and Region Zealand)** | Rytter (Slagelse Sygehus)142 | 2020-06-22 - 2020-07-03 | Subnational | High | 1,033 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 1.6% (95% CI 0.9-2.5%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **Denmark (Eastern Central Denmark Region)** | Jespersen (Aarhus University Hospital)308 | 2020-06-17 - 2020-06-30 | Subnational | High | 180 | Adults (18-64 years) | All | Convenience | Blood donors | 0.6% (95% CI 0-3.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Denmark (Western Central Denmark Region)** | Jespersen (Aarhus University Hospital)308 | 2020-06-17 - 2020-06-30 | Subnational | High | 180 | Adults (18-64 years) | All | Convenience | Blood donors | 1.2% (95% CI 0.1-4%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Denmark** | Pedersen (Copenhagen University Hospital Rigshospitalet)50 | 2020-06-01 - 2020-06-26 | National | High | 1,110 | Adults (18-64 years) | All | Sequential | Blood donors | 3% (95% CI 2.1-4.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Denmark (Copenhagen)** | Egerup (Copenhagen University Hospital Hvidovre)309 | 2020-04-04 - 2020-07-03 | Local | Moderate | 1,313 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 2.1% (95% CI 1.4-3%) | Shenzhen Yhlo Biotech Co. Ltd - IgG, IgM - iFlash-SARS-CoV-2 IgM/IgG | 0.94, 0.993 | Validated by independent authors/third party/non-developers |
| **Estonia** | Soeorg (University of Tartu)310 | 2021-02-08 - 2021-03-25 | National | High | 2,517 | Multiple groups | All | Stratified non-probability | Residual sera | 20.1% (95% CI 18.5-21.7%) | Abbott Laboratories - IgG - SARS-CoV-2 IgG II Quant | 0.994, 0.996 | Validated by manufacturer |
| **Estonia** | Veerus (University of Tartu)311 | 2020-05-04 - 2020-06-10 | National | High | 433 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 0.5% (95% CI 0-1.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-09-20 - 2020-09-26 | National | High | 56 | Adults (18-64 years) | All | Probability | Household and community samples | 1.8% (95% CI 0-9.6%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-09-13 - 2020-09-19 | National | High | 48 | Adults (18-64 years) | All | Probability | Household and community samples | 2.1% (95% CI 0-7.4%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-09-06 - 2020-09-12 | National | High | 54 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-6.6%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-08-30 - 2020-09-05 | National | High | 63 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-5.7%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-08-23 - 2020-08-29 | National | High | 48 | Adults (18-64 years) | All | Probability | Household and community samples | 2.1% (95% CI 0-7.4%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-08-16 - 2020-08-22 | National | High | 63 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-5.7%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-08-09 - 2020-08-15 | National | High | 64 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-5.6%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-08-02 - 2020-08-08 | National | High | 49 | Adults (18-64 years) | All | Probability | Household and community samples | 2% (95% CI 0-7.3%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-07-26 - 2020-08-01 | National | High | 75 | Adults (18-64 years) | All | Probability | Household and community samples | 1.3% (95% CI 0-4.8%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-07-19 - 2020-07-25 | National | High | 9 | Adults (18-64 years) | All | Probability | Household and community samples | 11.1% (95% CI 0-33.6%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-07-12 - 2020-07-18 | National | High | 7 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-41%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-07-05 - 2020-07-11 | National | High | 51 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-7%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-06-28 - 2020-07-04 | National | High | 85 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-4.2%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-06-21 - 2020-06-27 | National | High | 32 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-10.9%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-06-14 - 2020-06-20 | National | High | 78 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-4.6%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-06-07 - 2020-06-13 | National | High | 174 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-2.1%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-05-31 - 2020-06-06 | National | High | 214 | Adults (18-64 years) | All | Probability | Household and community samples | 0.5% (95% CI 0-2.6%) | NA - - Author designed (Neutralization Assay), NA - - Author designed (Multiplex) | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-05-24 - 2020-05-30 | National | High | 178 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-2.1%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-05-17 - 2020-05-23 | National | High | 210 | Adults (18-64 years) | All | Probability | Household and community samples | 0.5% (95% CI 0-2.6%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-05-10 - 2020-05-16 | National | High | 401 | Adults (18-64 years) | All | Probability | Household and community samples | 0.2% (95% CI 0-1.4%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-05-03 - 2020-05-09 | National | High | 514 | Adults (18-64 years) | All | Probability | Household and community samples | 0% (95% CI 0-0.7%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-04-26 - 2020-05-02 | National | High | 426 | Adults (18-64 years) | All | Probability | Household and community samples | 0.5% (95% CI 0.1-1.7%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)52 | 2020-04-12 - 2020-04-18 | National | High | 362 | Adults (18-64 years) | All | Probability | Household and community samples | 0.3% (95% CI 0-1.5%) | NA - - Author designed (Neutralization Assay), NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | N/A | Complex test algorithm: Manual review |
| **France** | Carrat (Unité des Virus Émergents)312 | 2020-09-01 - 2020-09-30 | National | High | 5,770 | Multiple groups | All | Convenience | Household and community samples | 3.9% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **France (Perpignan)** | Beaumont (Perpignan Hospital Center)313 | 2020-06-29 - 2020-07-17 | Local | Moderate | 700 | Multiple groups | All | Probability | Household and community samples | 35.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **France (Nancy)** | Petit (Université de Lorraine)314 | 2020-06-26 - 2020-07-04 | Local | Moderate | 2,006 | Multiple groups | All | Convenience | Household and community samples | 2.1% (95% CI 1.5-2.8%) | Bio-rad - IgG, IgM, IgA - Platelia SARS-CoV-2 Total Ab assay, Biosynex - IgG, IgM - Biosynex COVID-19 BSS assay, EUROIMMUN AG - IgA - Anti-SARS-CoV-2 ELISA (IgA) | N/A | Complex test algorithm: Manual review |
| **France** | Woudenberg (Institut Pasteur)315 | 2020-05-01 - 2020-08-15 | National | High | 1,306 | Multiple groups | All | Convenience | Residual sera | 8.5% | NA - - Author designed (Luminex) | N/A | Complex test algorithm: Manual review |
| **France (Paris)** | Tsatsarisa (Université Paris-Saclay)316 | 2020-04-29 - 2020-06-26 | Local | High | 529 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 4.7% (95% CI 2.9-6.7%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **France (Paris)** | Mattern (Paris Saclay University)317 | 2020-05-04 - 2020-05-31 | Local | High | 249 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 8% (95% CI 4.7-11.7%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **France (Corsica)** | Capai (Université de Corse)318 | 2020-04-16 - 2020-06-15 | Subnational | High | 1,973 | Multiple groups | All | Sequential | Residual sera | 5.5% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **France (Paris)** | Cohen (Centre Hospitalier Intercommunal de Créteil)319 | 2020-04-14 - 2020-05-12 | Local | High | 605 | Children and Youth (0-17 years) | All | Sequential | Residual sera | 10.7% (95% CI 8.2-13.3%) | Biosynex - IgG, IgM - Biosynex COVID-19 BSS assay | 0.975, 1 | Validated by manufacturer |
| **Germany (Munich)** | Radon (German Research Center for Environmental Health)320 | 2020-11-02 - 2021-01-31 | Local | Low | 4,433 | Multiple groups | All | Probability | Household and community samples | 3.1% (95% CI 2.6-3.6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Germany (Berlin-Mitte)** | Robert Koch Institut (Robert Koch Institut)321 | 2020-11-17 - 2020-12-05 | Local | Low | 2,287 | Multiple groups | All | Probability | Household and community samples | 2.4% | EUROIMMUN AG - IgG - SARS-CoV-2-NCP-IgG ELISA, NA - - Author designed (Neutralization Assay) | 0.946, 0.999 | Validated by manufacturer |
| **Germany (Ruhr)** | Brinkmann (Ruhr University Bochum)322 | 2020-06-15 - 2021-02-15 | Subnational | High | 2,145 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 2.6% (95% CI 1.9-3.3%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Germany (Straubing)** | Robert Koch Institute (Robert Koch Institute)323 | 2020-09-08 - 2020-09-26 | Local | Low | 2,361 | Multiple groups | All | Probability | Household and community samples | 1.8% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG), NA - - Author designed (Neutralization Assay) | 0, 0 | Multiple tests with diff validations or values derived from each type |
| **Germany (Würzburg)** | Eichner (Universität Würzburg)324 | 2020-06-01 - 2020-10-31 | Local | Moderate | 3,034 | Multiple groups | All | Stratified non-probability | Household and community samples | 1.1% (95% CI 0.7-1.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Germany (Bavaria)** | Hippich ( German Research Center for Environmental Health)325 | 2020-07-01 - 2020-07-31 | Subnational | High | 2,746 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 0.9% | NA - - Author designed (CLIA) | 0.973, 1 | Validated by independent authors/third party/non-developers |
| **Germany (Tirschenreuth)** | Wagner (Friedrich-Alexander University)326 | 2020-06-28 - 2020-07-10 | Local | Moderate | 4,201 | Multiple groups | All | Probability | Household and community samples | 8.6% (95% CI 7.8-9.5%) | Shenzhen Yhlo Biotech Co. Ltd - IgG, IgM - iFlash-SARS-CoV-2 IgM/IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N), NA - IgG - Author designed (ELISA) -Spike | N/A | Complex test algorithm: Manual review |
| **Germany (Kupferzell)** | Hovener (Robert Koch Institute)327 | 2020-05-20 - 2020-06-09 | Local | Moderate | 2,203 | Multiple groups | All | Probability | Household and community samples | 11.3% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Germany (Bonn)** | Aziz (University of Bonn)328 | 2020-04-24 - 2020-06-30 | Local | High | 4,755 | Multiple groups | All | Convenience | Household and community samples | 1% (95% CI 0.7-1.3%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Germany (Munich)** | Pritsch (University Hospital LMU Munich)329 | 2020-04-05 - 2020-06-12 | Local | Low | 5,313 | Multiple groups | All | Probability | Household and community samples | 1.9% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Germany (Southwest)** | Runkel (University Medical Center of The Johannes Gutenberg-University Mainz)330 | 2020-03-15 - 2020-06-15 | Subnational | High | 3,880 | Multiple groups | All | Convenience | Blood donors | 0.9% (95% CI 0.6-1.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Germany (Jena)** | Zollkau (Universitätsklinikum Jena)331 | 2020-04-06 - 2020-05-13 | Local | High | 180 | Multiple groups | Female | Sequential | Pregnant or parturient women | 0.6% (95% CI 0-3.1%) | Epitope Diagnostics, Inc. - IgG - EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit | 0.984, 0.998 | Validated by manufacturer |
| **Germany (Regensberg)** | Hausler (Hospital St Hedwig of the Order of St John)332 | 2020-04-09 - 2020-04-30 | Local | High | 151 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 2% (95% CI 0.4-5.7%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG), EUROIMMUN AG - IgA - Anti-SARS-CoV-2 ELISA (IgA) | 0.9969, 0.983 | Complex test algorithm: Manual calculation |
| **Germany (Gangelt)** | Streeck (University of Bonn)333 | 2020-03-31 - 2020-04-06 | Local | Moderate | 919 | Multiple groups | All | Probability | Household and community samples | 13.6% (95% CI 11.3-15.9%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Greece (Athens)** | Maltezou (University of Athens)334 | 2021-06-01 - 2021-06-22 | Local | High | 901 | Multiple groups | All | Convenience | Residual sera | 55.7% (95% CI 52.3-58.9%) | Abbott Laboratories - IgG - SARS-CoV-2 IgG II Quant | 0.994, 0.996 | Validated by manufacturer |
| **Greece (Athens)** | Maltezou (University of Athens)334 | 2021-03-01 - 2021-03-22 | Local | High | 764 | Multiple groups | All | Convenience | Residual sera | 11.6% (95% CI 9.3-14%) | Abbott Laboratories - IgG - SARS-CoV-2 IgG II Quant | 0.994, 0.996 | Validated by manufacturer |
| **Greece** | Bogogiannidou (University of Thessaly)335 | 2020-04-01 - 2020-04-30 | National | High | 4,511 | Multiple groups | All | Convenience | Residual sera | 0.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Iceland** | Gudbjartsson (deCODE Genetics)336 | 2020-04-27 - 2020-06-12 | National | High | 23,452 | Multiple groups | All | Convenience | Household and community samples | 0.3% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S), Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.911, 0 | Validated by manufacturers |
| **Ireland (Dublin)** | Heavey (Health Protection Surveillance Centre)337 | 2020-06-22 - 2020-07-16 | Local | Low | 913 | Multiple groups | All | Probability | Household and community samples | 3.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.9573, 1 | Complex test algorithm: Manual calculation |
| **Ireland (Sligo)** | Heavey (Health Protection Surveillance Centre)337 | 2020-06-22 - 2020-07-16 | Local | Low | 820 | Multiple groups | All | Probability | Household and community samples | 0.6% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.9573, 1 | Complex test algorithm: Manual calculation |
| **Israel (Jerusalem)** | Breuer (Shaare Zedek Medical Center)338 | 2020-10-18 - 2021-01-12 | Local | Moderate | 1,138 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 10% (95% CI 8.3-11.8%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.9643, 1 | Complex test algorithm: Manual calculation |
| **Israel (Modiin)** | Gozlan (Israel Ministry of Health)339 | 2020-09-01 - 2020-09-30 | Local | High | 283 | Multiple groups | All | Convenience | Household and community samples | 16.6% (95% CI 12.5-21.5%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG, NA - IgG - Author designed (ELISA) -Spike | N/A | Complex test algorithm: Manual review |
| **Italy (Foggia)** | Antonucci (University Hospital “Ospedali Riuniti” Foggia)340 | 2021-03-01 - 2021-03-15 | Local | Moderate | 484 | Multiple groups | All | Convenience | Blood donors | 18.8% | Ortho Clinical Diagnostics Inc. - IgG - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG, Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total | 1, 1 | Complex test algorithm: Manual calculation |
| **Italy (Benevento)** | Polvere (Università degli Studi del Sannio)341 | 2020-09-01 - 2020-09-30 | Local | Moderate | 1,383 | Seniors (65+ years) | All | Convenience | Household and community samples | 4.7% (95% CI 3.6-6%) | Beijing Lepu Medical Technology - IgG, IgM - Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) | 0.989, 0.976 | Validated by manufacturer |
| **Italy (Santa Cristina,and Selva,the main municipalities),Gardena Valley ( Ortisei)** | Melotti (Hospital of Bolzano)342 | 2020-05-26 - 2020-06-08 | Local | Low | 2,106 | Multiple groups | All | Probability | Household and community samples | 26.2% (95% CI 24.3-28%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Italy (Castiglione D’Adda)** | Pagani (University of Milan)343 | 2020-05-18 - 2020-06-07 | Local | Moderate | 4,143 | Multiple groups | All | Probability | Household and community samples | 22.2% (95% CI 20.9-23.5%) | PRIMA Lab S.A. - IgG, IgM - PRIMA COVID-19 IgG/IgM Rapid Test | 0.92, 0.98 | Validated by manufacturer |
| **Italy (Ariano Irpino)** | Cerino (The Zoo-Prophylactic Institute of Southern Italy)344 | 2020-05-16 - 2020-05-19 | Local | Moderate | 13,218 | Multiple groups | All | Convenience | Household and community samples | 5.6% (95% CI 5.2-6%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Italy (Foggia)** | Fiore (University of Foggia)345 | 2020-05-01 - 2020-05-31 | Local | Moderate | 904 | Adults (18-64 years) | All | Convenience | Blood donors | 1% (95% CI 0.4-1.7%) | Snibe Co., Ltd (Shenzhen New Industries Biomedical Engineering Co., Ltd) - IgG, IgM - MAGLUMI 2019-nCoV IgM/IgG | 0.94, 0.987 | Validated by manufacturer |
| **Italy (Vo)** | Dorigatti (University of Padova)346 | 2020-05-01 - 2020-05-31 | Local | Moderate | 2,602 | Multiple groups | All | Probability | Household and community samples | 6.2% (95% CI 5.3-7.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N), DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | N/A | Complex test algorithm: Manual review |
| **Italy (Lodi)** | Cassaniti (IRCCS Policlinico)347 | 2020-03-18 - 2020-06-24 | Local | High | 1,922 | Multiple groups | All | Convenience | Blood donors | 19.7% (95% CI 17.9-21.5%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Italy (Verona)** | Guerriero (Instituto di Ricovero e Cura A Caratterre)348 | 2020-04-25 - 2020-05-08 | Local | Moderate | 1,515 | Multiple groups | All | Probability | Household and community samples | 2.7% (95% CI 1.9-3.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Italy (Lodi)** | Baracco (A.S.S.T.Lodi)349 | 2020-04-23 - 2020-05-05 | Local | Moderate | 1,792 | Multiple groups | All | Probability | Household and community samples | 29.8% (95% CI 27.7-32%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **Italy (Prato)** | Cavaliere (Santo Stefano Hospital)350 | 2020-04-04 - 2020-05-16 | Local | High | 134 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 4.5% (95% CI 1.7-9.5%) | ACRO Biotech Inc - IgG, IgM - Acro Biotech COVID-19 IgM/IgG Rapid POC test | 0.977, 0.99 | Validated by manufacturer |
| **Italy (Villa Caldari)** | Cito (Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale )351 | 2020-04-18 - 2020-04-19 | Local | Moderate | 667 | Multiple groups | All | Probability | Household and community samples | 10.9% (95% CI 8.5-13.4%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Italy (Milan)** | Valenti ( Fondazione IRCCS Ca’ Granda Ospedale Maggiore )352 | 2020-03-30 - 2020-04-08 | Local | High | 60 | Adults (18-64 years) | All | Convenience | Blood donors | 6.7% | PRIMA Lab S.A. - IgG, IgM - PRIMA COVID-19 IgG/IgM Rapid Test | 0.92, 0.98 | Validated by manufacturer |
| **Italy (Arezzo)** | Pancrazzi (Ospedale San Donato)353 | 2020-03-17 - 2020-03-21 | Local | High | 516 | Adults (18-64 years) | All | Sequential | Residual sera | 13% (95% CI 10.2-16.2%) | ACRO Biotech Inc - IgG, IgM - Acro Biotech COVID-19 IgM/IgG Rapid POC test | 0.977, 0.99 | Validated by manufacturer |
| **Netherlands (Amsterdam)** | Coyer (Public Health Service of Amsterdam)354 | 2020-06-24 - 2020-10-09 | Local | Moderate | 2,483 | Multiple groups | All | Probability | Household and community samples | 9.1% (95% CI 8-10.3%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Netherlands (Amsterdam)** | Keuning (University of Amsterdam)355 | 2020-04-12 - 2020-10-02 | Local | High | 487 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 3.3% (95% CI 1.9-5.3%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Netherlands** | Slot (Amsterdam UMC)356 | 2020-04-01 - 2020-04-15 | National | High | 7,361 | Multiple groups | All | Sequential | Blood donors | 3.4% (95% CI 3-3.8%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai Rapid Test for Total Antibody to SARS-CoV-2 | 0.947, 0.989 | Validated by manufacturer |
| **Poland (Gliwice and Sosnowiec,Katowice)** | Zejda (Slaski Uniwersytet Medyczny)357 | 2020-10-15 - 2020-11-15 | Local | Moderate | 1,167 | Multiple groups | All | Probability | Household and community samples | 11.4% (95% CI 9.6-13.4%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Romania (Timis County)** | Olariu (Victor Babes University of Medicine and Pharmacy)358 | 2020-07-08 - 2020-09-01 | Local | Moderate | 2,115 | Adults (18-64 years) | All | Sequential | Blood donors | 1.5% (95% CI 1-2.1%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Spain (Madrid)** | Soriano (UNIR Health Sciences School and Medical Centre)359 | 2020-09-15 - 2020-12-24 | Local | High | 601 | Multiple groups | All | Sequential | Residual sera | 7.7% (95% CI 5.7-10.1%) | PCL Inc - IgG, IgM - PCL COVID19 IgG/IgM Rapid Gold | 0.967, 1 | Validated by manufacturer |
| **Spain (Catalonia)** | Karachaliou (Barcelona Institute For Global Health)152 | 2020-06-30 - 2020-11-15 | Subnational | High | 260 | Children and Youth (0-17 years) | All | Convenience | Household and community samples | 11.5% (95% CI 7.6-15.6%) | NA - - Author designed (Multiplex) | 0.9578, 1 | Validated by independent authors/third party/non-developers |
| **Spain (Catalonia)** | Kogevinas (Barcelona Institute for Global Health)360 | 2020-05-17 - 2020-11-15 | Subnational | High | 4,103 | Adults (18-64 years) | All | Convenience | Household and community samples | 18.1% (95% CI 16.9-19.3%) | NA - - Author designed (Luminex) | 0.9578, 1 | Validated by developers |
| **Spain (Madrid)** | Vinuela (University Hospital Gregorio Marañón)361 | 2020-05-06 - 2020-05-21 | Local | High | 100 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 13% (95% CI 7.1-21.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **Spain (Madrid)** | Soriano (UNIR Health Sciences School and Medical Centre)359 | 2020-03-15 - 2020-06-30 | Local | High | 968 | Multiple groups | All | Sequential | Residual sera | 12.6% (95% CI 10.5-14.7%) | PCL Inc - IgG, IgM - PCL COVID19 IgG/IgM Rapid Gold | 0.967, 1 | Validated by manufacturer |
| **Spain (Barcelona)** | Crovetto (Universitat de Barcelona)362 | 2020-03-15 - 2020-05-31 | Local | High | 2,225 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 14.1% (95% CI 12.6-15.6%) | Vircell S.L. - IgG - COVID-19 ELISA IgG, Ortho Clinical Diagnostics Inc. - IgG, IgM, IgA - VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total, NA - - Author designed (Luminex) | N/A | Complex test algorithm: Manual review |
| **Spain (Madrid)** | Alenda (Centro de Transfusión de la Comunidad de Madrid)363 | 2020-03-15 - 2020-03-22 | Local | High | 89 | Multiple groups | All | Sequential | Blood donors | 0% | Quotient - IgG, IgM - MosaiQ COVID-19 Antibody Microarray | 1, 0.998 | Validated by manufacturer |
| **Sweden (Stockholm)** | Lundkvist (Uppsala University )364 | 2020-06-17 - 2020-06-18 | Local | High | 123 | Adults (18-64 years) | All | Probability | Household and community samples | 4.1% (95% CI 1.3-9.2%) | Zhejiang Orient Gene Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test | 0.972, 1 | Validated by manufacturer |
| **Sweden (Stockholm)** | Lundkvist (Uppsala University )364 | 2020-06-17 - 2020-06-18 | Local | High | 90 | Adults (18-64 years) | All | Probability | Household and community samples | 30% (95% CI 20.8-40.6%) | Zhejiang Orient Gene Biotech - IgG, IgM - COVID-19 IgG/IgM Rapid Test | 0.972, 1 | Validated by manufacturer |
| **Switzerland (Geneva)** | Stringhini (Geneva University Hospital )365 | 2021-06-01 - 2021-07-07 | Local | Moderate | 3,355 | Multiple groups | All | Probability | Household and community samples | 27% (95% CI 25.5-28.5%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 0.988, 1 | Complex test algorithm: Manual calculation |
| **Switzerland (Southern Switzerland)** | Giuliano (Università della Svizzera Italiana)366 | 2020-07-15 - 2020-12-15 | Subnational | High | 301 | Adults (18-64 years) | All | Sequential | Household and community samples | 3.3% (95% CI 1.4-5.6%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Switzerland (Zurich)** | Emmenegger (University of Zurich)367 | 2020-07-01 - 2020-07-15 | Local | High | 1,067 | Adults (18-64 years) | All | Sequential | Blood donors | 0.7% (95% CI 0.3-1.3%) | NA - - Author designed (ELISA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Switzerland (Zurich)** | Ulyte (University of Zurich)368 | 2020-06-16 - 2020-07-09 | Local | Low | 857 | Adults (18-64 years) | All | Probability | Household and community samples | 3.6% | NA - - Author designed (Luminex) | 0.983, 0.984 | Validated by developers |
| **Switzerland (Geneva)** | Baggio (Geneva University Hospitals)369 | 2020-06-01 - 2020-06-30 | Local | Moderate | 1,167 | Multiple groups | All | Convenience | Residual sera | 5.9% (95% CI 4.6-7.3%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Switzerland (Zurich)** | Emmenegger (University of Zurich)367 | 2020-05-15 - 2020-07-15 | Local | High | 12,831 | Adults (18-64 years) | All | Sequential | Residual sera | 0.9% (95% CI 0.7-1.1%) | NA - - Author designed (ELISA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Switzerland (Val Mesolcina)** | Milani (Università della Svizzera Italiana)370 | 2020-05-15 - 2020-05-31 | Local | High | 423 | Multiple groups | All | Convenience | Household and community samples | 2.6% (95% CI 1.1-4.3%) | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **Switzerland (Zurich)** | Emmenegger (University of Zurich)367 | 2020-04-01 - 2020-04-30 | Local | High | 1,469 | Adults (18-64 years) | All | Sequential | Blood donors | 1.2% (95% CI 0.7-1.8%) | NA - - Author designed (ELISA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Switzerland (Zurich)** | Emmenegger (University of Zurich)367 | 2020-04-01 - 2020-04-30 | Local | High | 4,275 | Adults (18-64 years) | All | Sequential | Residual sera | 1.4% (95% CI 1.1-1.8%) | NA - - Author designed (ELISA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **Switzerland (Zurich)** | Emmenegger (University of Zurich)367 | 2020-03-15 - 2020-03-31 | Local | High | 3,806 | Adults (18-64 years) | All | Sequential | Residual sera | 0.3% (95% CI 0.1-0.5%) | NA - - Author designed (ELISA) - MULTIPLEXED | 1, 1 | Validated by developers |
| **The United Kingdom** | Public Health Scotland (Public Health Scotland)159 | 2021-10-11 - 2021-11-14 | National | High | 2,890 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 86.2% (95% CI 84.8-87.4%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **The United Kingdom (Avon)** | Major-Smith (University of Bristol)371 | 2021-05-01 - 2021-06-28 | Local | High | 66 | Adults (18-64 years) | All | Convenience | Household and community samples | 36.4% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **The United Kingdom (Avon)** | Major-Smith (University of Bristol)371 | 2021-04-08 - 2021-06-28 | Local | High | 2,555 | Adults (18-64 years) | All | Convenience | Household and community samples | 96.4% (95% CI 95.6-97.1%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **The United Kingdom (London)** | Gaskell (London School of Hygiene & Tropical Medicine)372 | 2020-10-19 - 2020-12-07 | Local | Moderate | 1,242 | Multiple groups | All | Probability | Household and community samples | 64.3% (95% CI 61.5-66.9%) | NA - - Not reported/ Unable to specify | 0.962, 0.974 | Validated by independent authors/third party/non-developers |
| **The United Kingdom** | Oeser (UK Health Security Agency (UKHSA, formerly PHE))71 | 2020-09-01 - 2020-10-31 | National | High | 119 | Children and Youth (0-17 years) | All | Convenience | Residual sera | 6.7% (95% CI 2.4-11.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (S) | 0.988, 1 | Validated by manufacturer |
| **The United Kingdom (Blackpool)** | Oakey (NHS Foundation Trust )373 | 2020-08-01 - 2020-08-31 | Local | High | 225 | Multiple groups | All | Convenience | Residual sera | 5.3% (95% CI 2.5-8.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **The United Kingdom (Scotland)** | Abo-Leyah (University of Dundee)374 | 2020-05-28 - 2020-09-02 | Subnational | High | 231 | Multiple groups | All | Sequential | Residual sera | 4.8% (95% CI 2.4-8.4%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T) | 0.985, 0.998 | Validated by manufacturer |
| **The United Kingdom (South East England)** | Wells (King’s College London)375 | 2020-04-27 - 2020-06-02 | Subnational | High | 431 | Multiple groups | All | Convenience | Household and community samples | 12% (95% CI 8.9-15.3%) | NA - - Author designed (ELISA) - MULTIPLEXED | 0.9, 1 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Oxford)** | Lumley (University of Oxford)376 | 2020-04-14 - 2020-06-15 | Local | Moderate | 1,000 | Adults (18-64 years) | Female | Sequential | Pregnant or parturient women | 5.3% (95% CI 4-6.9%) | NA - IgG - Author designed (ELISA) -Spike | 0.991, 0.99 | Validated by independent authors/third party/non-developers |
| **The United Kingdom (Dublin)** | Glennon (University College Dublin)377 | 2020-05-04 - 2020-05-15 | Local | High | 598 | Adults (18-64 years) | Female | Convenience | Pregnant or parturient women | 1.7% (95% CI 0.7-2.8%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 0.99, 1 | Complex test algorithm: Manual calculation |
| **The United Kingdom (London)** | Amirthalingam (Public Health England)378 | 2020-05-01 - 2020-05-03 | Local | Moderate | 974 | Multiple groups | All | Convenience | Blood donors | 13% | EUROIMMUN AG - IgG - Anti-SARS-CoV-2 ELISA (IgG) | 0.9, 1 | Validated by manufacturer |
| **The United Kingdom (Leicester)** | Bird (University of Leicester)379 | 2020-03-16 - 2020-06-03 | Local | Moderate | 1,779 | Multiple groups | All | Probability | Household and community samples | 11.3% (95% CI 9.9-12.9%) | DiaSorin SpA - IgG - Liaison SARS-CoV-2 S1/S2 IgG | 0.974, 0.985 | Validated by manufacturer |
| **The United Kingdom (Greater Glasgow area)** | Hughes (University of Glasgow)380 | 2020-03-16 - 2020-05-24 | Local | Low | 6,635 | Multiple groups | All | Probability | Residual sera | 7.8% (95% CI 7.2-8.5%) | NA - IgG - Author designed (ELISA) -Spike | 0.9531, 0.972 | Validated by developers |
| **The United Kingdom** | Public Health England (Public Health England)85 | 2020-02-01 - 2020-03-31 | National | High | 443 | Children and Youth (0-17 years) | All | Probability | Residual sera | 4.9% (95% CI 3-7.2%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |

#### *South-East Asia region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Bangladesh - HRP (Chattogram)** | Bhuiyan (Johns Hopkins Bloomberg School of Public Health)381 | 2021-03-27 - 2021-04-13 | Local | Low | 664 | Multiple groups | All | Probability | Household and community samples | 59.2% (95% CI 55.3-63%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Bangladesh - HRP (FDMN populations in Cox’s Bazar Rohiyanga camps)** | Prof. Dr. Tahmina Shirin (IEDCR)382 | 2020-12-01 - 2020-12-30 | Local | Moderate | 3,446 | Multiple groups | All | Probability | Household and community samples | 58% | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **India (Hyderabad)** | Laxmaiah (CSIR-CentreForCellularAndMolecularBiology)383 | 2021-01-08 - 2021-01-24 | Local | Moderate | 9,363 | Multiple groups | All | Probability | Household and community samples | 54.2% (95% CI 53.2-55.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (South Andaman)** | Kumar (Andaman and Nicobar Islands Institute of Medical Sciences)384 | 2020-12-15 - 2021-02-15 | Local | Moderate | 2,400 | Multiple groups | All | Probability | Household and community samples | 39.3% (95% CI 37.3-41.2%) | Erba Manneim - IgG - ErbaLisa® COVID-19 IgG semi quantitative kit | 0.991, 0.993 | Validated by manufacturer |
| **India (Jabalpur)** | Ramaswamy (National Centre for Disease Control)385 | 2020-12-11 - 2020-12-21 | Local | Low | 9,279 | Multiple groups | All | Probability | Household and community samples | 28.7% | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **India (Cuttack)** | Mahapatra (Sriram Chandra Bhanja Medical College and Hospital)386 | 2020-11-01 - 2021-01-31 | Local | High | 1,032 | Adults (18-64 years) | All | Convenience | Blood donors | 35.9% (95% CI 32.8-38.8%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Vellore District)** | Isaac (University of Edinburgh)387 | 2020-11-06 - 2020-11-20 | Local | Moderate | 200 | Multiple groups | All | Probability | Household and community samples | 22% (95% CI 16.5-28.4%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.993 | Complex test algorithm: Manual calculation |
| **India (Ahmedabad)** | Prakash (Municipal Medical College)388 | 2020-10-15 - 2020-10-31 | Local | Moderate | 17,009 | Multiple groups | All | Convenience | Household and community samples | 24.2% (95% CI 23.6-24.8%) | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **India (Srinagar)** | Ayub (Government Medical College Srinagar)389 | 2020-10-17 - 2020-10-20 | Local | Moderate | 2,418 | Multiple groups | All | Probability | Household and community samples | 40.6% (95% CI 38.6-42.6%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Pimpri-Chinchwad)** | Banerjee (Dr. D. Y. Patil Medical College, Hospital and Research Centre)390 | 2020-10-07 - 2020-10-17 | Local | Moderate | 5,000 | Multiple groups | All | Probability | Household and community samples | 34% (95% CI 32.7-35.4%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Chennai)** | Kumar (National Institute of Epidemiology)391 | 2020-10-08 - 2020-10-15 | Local | Low | 6,366 | Multiple groups | All | Probability | Household and community samples | 30.4% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Bhubaneswar)** | Kshatri (Indian Council of Medical Research)392 | 2020-09-01 - 2020-09-30 | Local | Low | 1,403 | Multiple groups | All | Probability | Household and community samples | 49% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (Ahmedabad)** | Prakash (AMC MET Medical College)393 | 2020-08-15 - 2020-08-31 | Local | Moderate | 10,310 | Multiple groups | All | Probability | Household and community samples | 23.2% (95% CI 22.4-24.1%) | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **India (Mumbai)** | Seetharam (NITI-Aayog)394 | 2020-08-16 - 2020-08-29 | Local | Low | 2,176 | Multiple groups | All | Probability | Household and community samples | 17.5% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Mumbai)** | Seetharam (NITI-Aayog)394 | 2020-08-16 - 2020-08-29 | Local | Low | 3,024 | Multiple groups | All | Probability | Persons living in slums | 44.9% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Indore)** | Sakalle (National Centre for Disease Control)395 | 2020-08-11 - 2020-08-23 | Local | Low | 7,103 | Multiple groups | All | Probability | Household and community samples | 7.7% (95% CI 7.1-8.4%) | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **India (Berhampur)** | Kshatri (ICMR-Regional Medical Research Centre)396 | 2020-08-01 - 2020-08-31 | Local | Low | 1,375 | Multiple groups | All | Probability | Household and community samples | 31.1% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (Bhubaneswar)** | Kshatri (ICMR-Regional Medical Research Centre)396 | 2020-08-01 - 2020-08-31 | Local | Low | 1,319 | Multiple groups | All | Probability | Household and community samples | 5.2% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (Rourkela)** | Kshatri (ICMR-Regional Medical Research Centre)396 | 2020-08-01 - 2020-08-31 | Local | Low | 1,452 | Multiple groups | All | Probability | Household and community samples | 24.6% | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **India (Malegaon)** | Saple (The Municipality of Malegaon )397 | 2020-07-25 - 2020-08-20 | Local | High | 336 | Multiple groups | All | Stratified non-probability | Household and community samples | 40% (95% CI 34.6-45.3%) | NA - - Not reported/ Unable to specify | 0.93, 1 | Validated by independent authors/third party/non-developers |
| **India (Vellore District)** | Isaac (University of Edinburgh)387 | 2020-07-06 - 2020-08-20 | Local | Moderate | 501 | Multiple groups | All | Probability | Household and community samples | 2.2% (95% CI 1.1-3.9%) | Siemens - IgG, IgM, IgA - Atellica® IM SARS-CoV-2 Total (COV2T), Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.993 | Complex test algorithm: Manual calculation |
| **India (Chennai)** | Selvaraju (National Institute of Epidemiology)398 | 2020-07-01 - 2020-07-31 | Local | Low | 12,405 | Multiple groups | All | Probability | Household and community samples | 18.7% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Mumbai)** | Malani (Tata Institute for Fundamental Research)399 | 2020-06-29 - 2020-07-19 | Local | Low | 2,702 | Multiple groups | All | Probability | Household and community samples | 16% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Mumbai)** | Malani (Tata Institute for Fundamental Research)399 | 2020-06-29 - 2020-07-19 | Local | Low | 4,202 | Multiple groups | All | Probability | Persons living in slums | 54.1% | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Ahmedabad)** | Prakash ( Municipal Medical College )400 | 2020-06-16 - 2020-07-07 | Local | Moderate | 29,891 | Multiple groups | All | Convenience | Residual sera | 17.6% (95% CI 17.2-18%) | Zydus Diagnostics - IgG - Covid Kavach™ Anti-SARS CoV-2 IgG Antibody Detection ELISA | 0.987, 1 | Validated by manufacturer |
| **India (NA)** | Pandey (All India Institute of Medical Sciences )401 | 2020-04-15 - 2020-07-15 | Local | High | 1,191 | Adults (18-64 years) | All | Convenience | Blood donors | 9.5% (95% CI 7.9-11.3%) | Abbott Laboratories - IgG - Abbott Architect SARS-CoV-2 IgG | 0.99, 1 | Validated by manufacturer |
| **India (Karnataka)** | Chandrasingh (Bangalore Baptist Hospital)402 | 2020-05-15 - 2020-06-15 | Subnational | High | 210 | Multiple groups | All | Unclear | Blood donors | 0% (95% CI 0-1.7%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |

#### *Western Pacific region*

| **Country (Location)** | **Author (Organization)** | **Sampling Dates (YMD)** | **Geographic scope** | **Overall risk of bias** | **Sample size** | **Age** | **Sex** | **Sampling method** | **Sample frame** | **Seroprevalence (95% CI)** | **Test Manufacturers - Isotypes - Names** | **Test Sens, Spec** | **Sens, Spec Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Australia (Sydney, Melbourne, Brisbane, Adelaide, Perth)** | Kristine Macartney, Nicholas Wood, Archana Koirala (Australian National Centre for Immunisation Research and Surveillance)[@] | 2020-11-01 - 2021-03-13 | Subnational | High | 1,678 | Multiple groups | All | Convenience | Residual sera | 0.4% (95% CI 0.2-0.9%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Australia (Melbourne)** | Dorothy Machalek (The Kirby Institue at the University of New South Wales and Australian National Centre for Immunisation Research and Surveillance)403 | 2020-11-23 - 2020-12-17 | Local | High | 4,799 | Multiple groups | All | Convenience | Blood donors | 1.6% (95% CI 1.3-2%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **Australia (Sydney)** | Gidding (Children’s Hospital at Westmead)404 | 2020-05-04 - 2020-05-23 | Local | Moderate | 560 | Adults (18-64 years) | Female | Probability | Pregnant or parturient women | 1% (95% CI 0.3-2.1%) | NA - IgG, IgM - Author designed (IFA) - MULTIPLEXED | 0.907, 0.993 | Validated by independent authors/third party/non-developers |
| **Australia (Sydney)** | Gidding (Children’s Hospital at Westmead)404 | 2020-04-20 - 2020-05-22 | Local | Moderate | 3,231 | Multiple groups | All | Probability | Residual sera | 0.6% (95% CI 0.4-0.9%) | NA - - Author designed (IFA) - Unknown | 0.907, 0.993 | Validated by independent authors/third party/non-developers |
| **China (Taipei)** | Ho (Taipei Veterans General Hospital)405 | 2020-07-06 - 2020-07-08 | Local | Moderate | 4,988 | Multiple groups | All | Sequential | Residual sera | 0.1% | Academia Sinica - IgG, IgM - Academia Sinica ELISA assay, Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 1 | Complex test algorithm: Manual calculation |
| **China (Wuhan)** | He (Renmin Hospital of Wuhan University)406 | 2020-05-15 - 2020-05-29 | Local | Moderate | 4,454 | Multiple groups | All | Convenience | Household and community samples | 2.9% (95% CI 2.4-3.4%) | Zhuhai Livzon Diagnostics Inc - IgG, IgM - 2019-nCoV IgG/IgM Antibody Detection Kit | 0.906, 0.992 | Validated by manufacturer |
| **China (Shenzen)** | Zhang (Shenzhen Center for Disease Control and Prevention)407 | 2020-04-17 - 2020-04-23 | Local | High | 350 | Multiple groups | All | Convenience | Household and community samples | 0.3% (95% CI 0-1.6%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **China (Shenzen)** | Zhang (Shenzhen Center for Disease Control and Prevention)407 | 2020-04-17 - 2020-04-23 | Local | High | 50 | Multiple groups | All | Convenience | Household and community samples | 0% (95% CI 0-7.1%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **China (Guangzhou)** | Xu (Institute of Blood Transfusion)408 | 2020-03-23 - 2020-04-02 | Local | Moderate | 2,199 | Adults (18-64 years) | All | Probability | Blood donors | 0.3% (95% CI 0.1-0.7%) | Beijing Wantai Biological - IgG, IgM, IgA - Wantai SARS-CoV-2 Total Ab ELISA | 0.967, 0.975 | Validated by manufacturer |
| **China (Liaoning)** | Zhang (Shengjing Hospital of China Medical University)409 | 2020-01-21 - 2020-02-16 | Subnational | High | 225 | Multiple groups | All | Convenience | Residual sera | 0.4% (95% CI 0-1.6%) | Shenzhen Yhlo Biotech Co. Ltd - IgG, IgM - iFlash-SARS-CoV-2 IgM/IgG | 1, 0.9956 | Validated by independent authors/third party/non-developers |
| **Japan (Yamagata)** | Morikane (Yamagata University)410 | 2020-06-01 - 2020-06-04 | Local | High | 1,009 | Multiple groups | All | Sequential | Residual sera | 0.5% (95% CI 0.2-1.2%) | Roche Diagnostics - IgG, IgM, IgA - Elecsys® Anti‐SARS‐CoV‐2 (N) | 1, 0.995 | Validated by manufacturer |
| **Republic of Korea** | Lee (Korea Disease Control and Prevention Agency)411 | 2020-08-14 - 2020-10-31 | National | High | 1,379 | Multiple groups | All | Convenience | Residual sera | 0.2% (95% CI 0-0.6%) | NA - - Author designed (Neutralization Assay) | 0.933, 0.971 | Validated by independent authors/third party/non-developers |
| **Republic of Korea** | Lee (Korea Disease Control and Prevention Agency)411 | 2020-06-10 - 2020-08-13 | National | High | 1,440 | Multiple groups | All | Convenience | Residual sera | 0.1% (95% CI 0-0.4%) | NA - - Author designed (Neutralization Assay) | 0.933, 0.971 | Validated by independent authors/third party/non-developers |
| **Republic of Korea (Chungbuk Province)** | Jeong (Chungbuk National University)412 | 2020-05-01 - 2020-07-17 | Local | Low | 3,981 | Multiple groups | All | Probability | Residual sera | 0.8% (95% CI 0.6-1.2%) | NA - - Author designed (IFA) - Unknown | 0.995, 1 | NA |
| **Republic of Korea (Daegu)** | Jeong (Chungbuk National University)412 | 2020-05-01 - 2020-07-17 | Local | Low | 3,268 | Multiple groups | All | Probability | Residual sera | 1.2% (95% CI 0.9-1.7%) | NA - - Author designed (IFA) - Unknown | 0.995, 1 | Validated by developers |
| **Republic of Korea** | Lee (Korea Disease Control and Prevention Agency)411 | 2020-04-21 - 2020-06-16 | National | High | 1,500 | Multiple groups | All | Convenience | Residual sera | 0% (95% CI 0-0.2%) | NA - - Author designed (Neutralization Assay) | 0.933, 0.971 | Validated by independent authors/third party/non-developers |
| **Singapore** | Clapham (National University of Singapore)413 | 2020-11-15 - 2020-12-15 | National | High | 937 | Multiple groups | All | Convenience | Household and community samples | 0.2% (95% CI 0-0.6%) | GenScript - IgG, IgM - cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit | 0.938, 0.994 | Validated by manufacturer |

## 

#### 

## S4.2 Risk of Bias breakdown for all studies

### Table S8. Risk of bias breakdown for all studies.

#### *Africa region*

| **Country** | **Author (Organization)** | **Item 1: Appropriate sample frame** | **Item 2: Probability sampling method** | **Item 3: Adequate sample size** | **Item 4: Subjects & setting described** | **Item 5: Good coverage of sample** | **Item 6: Sens>=90%, Spec>=97%** | **Item 7: Same test for all subjects** | **Item 8: Appropriate statistical analysis** | **Item 9: Adequate response rate** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Burkina Faso** | Dr Isidore Traore (National Institute of Public Health)1 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Cameroon** | Kene Nwosu (Hopital Central de Yaounde)2 | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Low |
| **Cameroon** | Tiffany Harris (ICAP at Columbia University)3 | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **Central African Republic** | Alexandre Manirakiza (Institut Pasteur of Bangui)4 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Democratic Republic of the Congo** | Antoine N Nkuba (Institut National de Recherche Biomédicale)5 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Low |
| **Democratic Republic of the Congo** | Makiala Mandanda Sheila (Institut National de Recherche Biomédicale)6 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Ethiopia** | Nega Assefa (The London School of Hygiene & Tropical Medicine)7 | No | Yes | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Esayas Gudina (University of Munich)8 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ethiopia** | Enyew Birru Tadesse (Federal Ministry of Health)9 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Low |
| **Ethiopia** | Tamrat Shaweno (Jimma University Institute of Health)10 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Ethiopia** | Saro Abdella (Ethiopian Public Health Institute)11 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Low |
| **Ethiopia** | Saro Abdella (Ethiopian Public Health Institute)11 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Low |
| **Ethiopia** | John Kempen (Kuwait University)12 | No | No | No | Yes | No | Yes | Yes | No | Unclear | High |
| **Gabon** | Amandine Mveang Nzoghe (Centre Hospitalier Universitaire (CHU) ‐ Mère‐ Enfant)13 | No | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)14 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)14 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)14 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Ghana** | Irene Owusu Donkor (Noguchi Memorial Institute for Medical Rsearch)14 | NA | NA | NA | NA | NA | NA | NA | NA | NA | Moderate |
| **Kenya** | James Nyagwange (KEMRI-Wellcome Trust Research Programme)15 | No | No | No | No | No | Yes | Yes | No | N/A | High |
| **Kenya** | James Nyagwange (KEMRI-Wellcome Trust Research Programme)15 | No | No | No | No | No | Yes | Yes | No | N/A | High |
| **Kenya** | Isaac Ngere (Washington State University)16 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Kenya** | Sophie Uyoga (KEMRI-Wellcome Trust Research Programme)17 | No | No | Yes | Yes | No | Unclear | Yes | Yes | N/A | Moderate |
| **Kenya** | Trevor Crowell (Walter Reed Army Institute of Research)18 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Kenya** | Patrick Munywoki (Kenya Medical Research Institute)19 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **Kenya** | Ifedayo M. O. Adetifa (KEMRI-Wellcome Trust Research Programme)20 | Yes | No | Yes | Yes | No | Unclear | Yes | Yes | N/A | Moderate |
| **Kenya** | R Lucinde (KEMRI-Wellcome Trust)21 | No | No | No | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Kenya** | R Lucinde (KEMRI-Wellcome Trust)21 | No | No | No | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Kenya** | R Lucinde (KEMRI-Wellcome Trust)21 | No | No | No | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Kenya** | R Lucinde (KEMRI-Wellcome Trust)21 | No | No | No | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Solohery Razafimahatratra (Institut Pasteur de Madagascar)22 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Madagascar** | Matthieu Schoenhals (Institut Pasteur de Madagascar)23 | No | No | No | No | No | Yes | Yes | Yes | Unclear | High |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Kondwani Jambo (Malawi-Liverpool-Wellcome Trust Clinical Research programme, Liverpool School of Tropical Medicine)24 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | N/A | Low |
| **Malawi** | Matthews Kagoli/Joe Theu (Public Health Institute of Malawi(PHIM) MOH)25 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Mali** | Issaka Sagara (University of Sciences )26 | Yes | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Moderate |
| **Mali** | Issaka Sagara (University of Sciences)26 | Yes | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Moderate |
| **Mozambique** | Paulo Arnaldo (República de Moçambique Ministério da Saúde)27 | Yes | Yes | Yes | Yes | Yes | No | Yes | No | No | Moderate |
| **Mozambique** | Mussagy Mahomed (Republica de Mocambique Ministerio da Saude)28 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | Unclear | Moderate |
| **Mozambique** | Mussagy Mahomed (Republica de Mocambique Ministerio da Saude)28 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | Unclear | Moderate |
| **Mozambique** | Arlete Mahumane (Republica de Mocambique Ministerio da Saude)29 | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Unclear | Moderate |
| **Mozambique** | Jeronimo Langa (Republica de Mocambique Ministerio da Saude)30 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | Unclear | Moderate |
| **Mozambique** | Mussagy Mahomed (Republica de Mocambique Ministerio da Saude)31 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | Unclear | Moderate |
| **Mozambique** | Eduardo Samo Gudo (Republica de Mocambique Ministerio da Saude)32 | Yes | Yes | Yes | No | Unclear | No | Yes | No | Unclear | Moderate |
| **Nigeria** | OgoChukwu Vincent Okpala (Anambra State Ministry of Health)33 | Yes | Yes | Yes | Yes | No | No | Yes | No | N/A | Moderate |
| **Nigeria** | Ijeoma Ifeorah (Molecular Pathology Institute)34 | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Nigeria** | Hussaini Majiya (Ibrahim Badamasi Babangida University)35 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Nigeria** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (University of Maryland, Baltimore)36 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Nigeria** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (University of Maryland, Baltimore)36 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Nigeria** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (University of Maryland, Baltimore)36 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Nigeria** | Kristen A. Stafford (UMB); Laura Steinhardt (CDC); Elsie Ilori (NCDC); Rosemary Audu (NIMR) (Nigeria Institute for Medical Research)36 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Nigeria** | Olatunji Kolawole (Ministerial Expert Advisory Committee on COVID-19- Health Sector Response)37 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Senegal** | Cheikh Talla (Institut Pasteur de Dakar)38 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **Sierra Leone** | Mohamed Bailor Barrie (Harvard Medical School)39 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear | Low |
| **South Africa** | Nicole Wolter (National Health Laboratory Service)40 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Moderate |
| **South Africa** | Jaya George (National Health Laboratory Service)41 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **South Africa** | Marion Vermeulen (South African National Blood Service)42 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **South Africa** | Marvin Hsiao ( University of Cape Town)43 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | High |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Jackie Kleynhans (National Institute for Communicable Diseases)44 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **South Africa** | Lee Fairlie (Wits Reproductive Health and HIV Institute)45 | No | No | Yes | Yes | Unclear | Yes | Yes | No | No | High |
| **South Sudan** | Kirsten E Wiens (World Health Organization)46 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **Uganda** | Dr. Henry Kyobe Bosa (Ministry of Health/ UPDF)47 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Zambia** | Jonas Z Hines (US Centers for Disease Control and Prevention)48 | Yes | No | Yes | No | No | Yes | Yes | No | Unclear | Moderate |
| **Zambia** | Lloyd B Mulenga (Zambia Ministry of Health)49 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Zimbabwe** | Arun Fryatt (Biomedical Research and Training Institute)50 | No | Yes | Yes | Yes | Yes | Unclear | Yes | No | Yes | Moderate |
| **Zimbabwe** | Arun Fryatt (Biomedical Research and Training Institute)50 | No | Yes | Yes | Yes | Yes | Unclear | Yes | No | Yes | Moderate |

#### *Americas region*

| **Country** | **Author (Organization)** | **Item 1: Appropriate sample frame** | **Item 2: Probability sampling method** | **Item 3: Adequate sample size** | **Item 4: Subjects & setting described** | **Item 5: Good coverage of sample** | **Item 6: Sens>=90%, Spec>=97%** | **Item 7: Same test for all subjects** | **Item 8: Appropriate statistical analysis** | **Item 9: Adequate response rate** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Argentina** | Silvana Figar (Ministry of Health of the City of Buenos Aires)51 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Low |
| **Argentina** | Laura Munoz (Ministerio de Salud de la Provincia de Buenos Aires)52 | Yes | No | No | Yes | Yes | Unclear | Yes | No | Yes | High |
| **Brazil** | Aluisio Barros (Universidade Federal de Pelotas)53 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No | Unclear | Moderate |
| **Brazil** | Aluisio Barros (Universidade Federal de Pelotas)53 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No | Unclear | Moderate |
| **Brazil** | Ana Schneider (Universidade de Santa Cruz do Sul)54 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | N/A | Moderate |
| **Brazil** | Ana Silva ( Escola de Saúde Pública de Betim)55 | Yes | Yes | Yes | Yes | No | No | Yes | No | Yes | Moderate |
| **Brazil** | Ana Silva ( Escola de Saúde Pública de Betim)55 | Yes | Yes | Yes | Yes | No | No | Yes | No | Yes | Moderate |
| **Brazil** | Ana Silva ( Escola de Saúde Pública de Betim)55 | Yes | Yes | Yes | Yes | No | No | Yes | No | Yes | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | No | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | José Olimpio Moura de Albuquerque (Secretaria Municipal de Saude de Sao Paulo)56 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No | No | Moderate |
| **Brazil** | Alanna Calheiros Santos (Oswaldo Cruz Foundation)57 | Unclear | Unclear | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Brazil** | Ethel Leonor Noia Maciel (Laboratorio de Epidemiologia)58 | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Brazil** | Hilton Pereira da Silva (Universidade Federal do Pará)59 | Yes | Yes | No | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Brazil** | Gemilson Soares Pontes (Instituto Nacional de Pesquisas da Amazônia)60 | No | No | No | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Brazil** | Breno Bernardes-Souza (Federal University of Ouro Preto)61 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | N/A | Moderate |
| **Brazil** | Breno Bernardes-Souza (Federal University of Ouro Preto)61 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | N/A | Moderate |
| **Brazil** | Beatriz Tess (Universidade de Sao Paulo)62 | Yes | No | No | Yes | No | Yes | Yes | No | Unclear | High |
| **Brazil** | Joao Luiz Miraglia (Hospital Israelita Albert Einstein)63 | Yes | Yes | No | Yes | Unclear | Yes | Yes | Yes | Yes | Moderate |
| **Brazil** | Edson Zangiacomi Martinez (Universidade de São Paulo)64 | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Unclear | Moderate |
| **Brazil** | Edson Zangiacomi Martinez (Universidade de São Paulo)64 | Yes | Yes | Yes | No | Yes | No | Yes | No | Unclear | Moderate |
| **Brazil** | Pamella Lugon (Oswaldo Cruz Foundation)65 | Yes | No | No | No | Unclear | Yes | Yes | No | Yes | High |
| **Brazil** | Pedro C. Hallal (Universidade Federal de Pelotas )66 | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Yes | Moderate |
| **Brazil** | Fernando C Barros (Universidade Federal de Pelotas)67 | Yes | Yes | Yes | No | Yes | No | Yes | No | Unclear | Moderate |
| **Brazil** | Beatriz Tess (Inteligência em Pesquisa e Consultoria)68 | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **Brazil** | City of Sao Paulo (City of São Paulo)69 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Brazil** | Henrique Diegoli (City Hall of Joinville)70 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | No | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Lewis Buss (Universidade de Sao Paulo)71 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Brazil** | Luanda Mara da Silva Oliveira (Universidade de São Paulo)72 | No | No | Yes | Yes | No | Yes | Yes | No | Unclear | High |
| **Brazil** | Antonio da Silva (Universidade Federal do Maranhao)73 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Canada** | Canadian Blood Services (Canadian Blood Services )74 | No | No | Yes | Yes | No | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services )75 | No | No | Yes | Yes | No | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services )76 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)77 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Canada** | Carmen Charlton (Alberta Precision Laboratories)78 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)79 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)80 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Hema-Quebec (Héma-Québec)81 | No | No | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)82 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Antoine Lewin (Héma-Québec)83 | No | No | Yes | No | No | Unclear | Yes | Yes | Unclear | High |
| **Canada** | Canadian Blood Services (Canadian Blood Services)84 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)85 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **Canada** | Sahar Saeed (Canadian Blood Services)86 | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)85 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **Canada** | Canadian Blood Services (Canadian Blood Services)85 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **Canada** | Emilie Manny (University of Alberta)87 | Yes | No | No | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Canada** | Danuta Skowronski (British Columbia Centre for Disease Control)88 | No | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Canada** | Danuta Skowronski (British Columbia Centre for Disease Control)88 | No | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Canada** | Shelly Bolotin, Vanessa Tran (Public Health Ontario)89 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Chile** | Pablo Vial (Universidad del Desarrollo)90 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Low |
| **Chile** | Ximena Aguilera (Universidad del Desarrollo, Centro de Epidemiología y Políticas de Salud)91 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| **Colombia** | Hector Serrano-Coll (Universidad de Córdoba)92 | Unclear | Unclear | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Colombia** | Gustavo Concha (Medical Mission Institute)93 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Colombia** | Evelin Garay (Colombia-Universidad de Cordoba)94 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Colombia** | Nelson Alvis Guzma (Universidad de Cordoba)95 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Colombia** | Salim Mattar (Universidad de Córdoba)96 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | Unclear | Low |
| **Dominican Republic** | Robert Paulino Ramirez (Universidad Iberoamericana)97 | No | Yes | Yes | Yes | Unclear | No | Yes | No | Unclear | Moderate |
| **Ecuador** | Oscar Del Brutto (Universidad Espíritu Santo)98 | No | No | Yes | Yes | Yes | Unclear | Yes | No | Yes | High |
| **Ecuador** | David Acurio Paez (University of Antwerp)99 | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Unclear | Moderate |
| **French Guiana** | Claude Flamand (Institut Pasteur )100 | No | No | No | Yes | Yes | Yes | Yes | Yes | Unclear | High |
| **Honduras** | Mario Rene Mejia Nunez (Colegio Médico)101 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | No | Unclear | Moderate |
| **Jamaica** | TeAnne Chisolm (University of the West Indies)102 | Yes | No | No | No | Unclear | Yes | Yes | No | N/A | High |
| **Mexico** | Francisco Canto-Osorio (Instituto Nacional de Salud Públic)103 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | No | Low |
| **Mexico** | Francisco Canto-Osorio (Instituto Nacional de Salud Públic)103 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | No | Low |
| **Mexico** | Natalia Martinez-Acu a (Autonomous University of Nuevo Leon)104 | No | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Mexico** | Jose Munoz-Medina (Instituto de Salud para el Bienestar)105 | No | No | Yes | No | Yes | Yes | Yes | No | N/A | High |
| **Mexico** | Jose Maria Remes-Troche (Universidad Veracruzana)106 | Unclear | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Panama** | Alcibiades Villarreal (Instituto de Investigaciones Científicas y Servicios de Alta Tecnología)107 | No | No | No | Yes | No | Unclear | Yes | No | N/A | High |
| **Peru** | Charles Huamani (Universidad Andina del Cusco)108 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Peru** | Benoit Champigneulle (Grenoble Alpes University)109 | Yes | No | No | Yes | Unclear | Unclear | Yes | No | Unclear | High |
| **Peru** | Mary F Reyes Vega (Peruvian Ministry of Health)110 | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Low |
| **Peru** | Carlos Alvarez-Antonio (Universidad de Ingeniería y Tecnología)111 | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Low |
| **Peru** | Carlos Alvarez-Antonio (Universidad de Ingeniería y Tecnología)111 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | Unclear | Low |
| **Peru** | Enrique Guevara Rios (National Maternal Perinatal Institut)112 | Yes | No | Yes | No | Unclear | Unclear | Yes | No | Yes | Moderate |
| **United States of America** | Megha Mehrotra (California Department of Public Health)113 | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Low |
| **United States of America** | Megha Mehrotra (California Department of Public Health)113 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Low |
| **United States of America** | Alice Pressman (Sutter Health)114 | Yes | No | Yes | No | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Cameron Adams (University of California, Berkeley)115 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | Yes | Moderate |
| **United States of America** | Marcus Wong (University of California)116 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **United States of America** | Marcus Wong (University of California)116 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **United States of America** | Marcus Wong (University of California)116 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **United States of America** | Nina Molenaar ( Icahn School of Medicine)117 | No | No | Yes | No | Yes | Unclear | Yes | No | Unclear | High |
| **United States of America** | Charles Gonik (Wayne State University School of Medicine)118 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **United States of America** | Kiersten Kugeler (Centers for Disease Control and Prevention)119 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **United States of America** | Kiersten Kugeler (Centers for Disease Control and Prevention)119 | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **United States of America** | Rebecca Levorson (Inova Health System)120 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **United States of America** | Roger Dodd (American Red Cross)121 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | High |
| **United States of America** | Cara Staszewski (North Shore University Hospital)122 | Yes | No | No | No | No | Yes | Yes | No | N/A | High |
| **United States of America** | Cara Staszewski (North Shore University Hospital)122 | Yes | No | No | No | No | Yes | Yes | No | N/A | High |
| **United States of America** | McKaylee Robertson (City University of New York)123 | No | No | Yes | No | No | Yes | Yes | No | Yes | High |
| **United States of America** | Jefferson Jones (Vitalant Research Institute)124 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Jefferson Jones (Vitalant Research Institute)124 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Jefferson Jones (Vitalant Research Institute)124 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Jefferson Jones (Vitalant Research Institute)124 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Jefferson Jones (Vitalant Research Institute)124 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Matthew Samore (University of Utah)125 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Low |
| **United States of America** | Daniel Nesbitt (Lindsley F Kimball Research Institute)126 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | High |
| **United States of America** | Karl William Boehme (University of Arkansas for Medical Sciences)127 | Yes | No | No | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Karl William Boehme (University of Arkansas for Medical Sciences)127 | Yes | No | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Karl William Boehme (University of Arkansas for Medical Sciences)127 | Yes | No | No | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Karl William Boehme (University of Arkansas for Medical Sciences)127 | Yes | No | No | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Karl William Boehme (University of Arkansas for Medical Sciences)127 | Yes | No | No | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Brittany K. Smith (Washington University School of Medicine)128 | No | No | Yes | Yes | Yes | Unclear | Yes | No | N/A | High |
| **United States of America** | Brittany K. Smith (Washington University School of Medicine)128 | No | No | Yes | Yes | Yes | Unclear | Yes | No | N/A | High |
| **United States of America** | Brittany K. Smith (Washington University School of Medicine)128 | No | No | Yes | Yes | Yes | Unclear | Yes | No | N/A | High |
| **United States of America** | Roger Dodd (American Red Cross)129 | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | High |
| **United States of America** | Olga Morozova (Stony Brook University)130 | No | No | Yes | Yes | No | Yes | Yes | Yes | No | High |
| **United States of America** | Joshua Kennedy (University of Arkansas for Medical Sciences)131 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Joshua Kennedy (University of Arkansas for Medical Sciences)131 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Joshua Kennedy (University of Arkansas for Medical Sciences)131 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **United States of America** | Patrick Sean Sullivan (Emory University)132 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Low |
| **United States of America** | Sarah Messiah (University of Texas at Houston)133 | No | No | No | Yes | Unclear | Yes | Yes | Yes | N/A | High |
| **United States of America** | Isobel Routledge (University of California San Francisco)134 | No | No | Yes | Yes | No | Yes | Yes | Yes | N/A | Moderate |
| **United States of America** | Lingqing Xu (University of Pittsburgh)135 | No | No | No | Yes | No | Yes | Yes | No | N/A | High |
| **United States of America** | Jannae Parrott (New York City Department of Health and Mental Hygiene)136 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear | Low |
| **United States of America** | Oliver Laeyendecker (Johns Hopkins University )137 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | High |
| **United States of America** | Elaine Symanski (Houston Health Department)138 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Low |
| **United States of America** | Cesar Lopez (University of North Carolina)139 | No | No | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Cesar Lopez (University of North Carolina)139 | No | No | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Cesar Lopez (University of North Carolina)139 | No | No | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **United States of America** | Robert Stout (Clinical Reference Laboratory Inc)140 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | High |
| **United States of America** | Fabrizio Bonelli (Dia Sorin Inc)141 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Callum Arnold (Pennsylvania State University)143 | Yes | No | No | Yes | Unclear | Unclear | Yes | No | No | High |
| **United States of America** | Travis Lim (Centers for Disease and Control )142 | No | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Xiaofan Jia (University of Colorado)144 | Yes | No | No | No | Yes | Unclear | Yes | No | Unclear | High |
| **United States of America** | Xiaofan Jia (University of Colorado)144 | Yes | No | No | No | Yes | Unclear | Yes | No | Unclear | High |
| **United States of America** | Eran Bendavid (Stanford University School of Medicine)145 | No | No | Yes | Yes | No | Yes | Yes | Yes | Unclear | High |
| **United States of America** | Adrienne Sherman (Government of the District of Columbia)146 | No | No | Yes | Yes | No | Yes | Yes | No | No | High |
| **United States of America** | Philip A Chan (Brown University)147 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Low |
| **United States of America** | Elizabeth T Rogawski McQuade (University of Virginia )148 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United States of America** | Tim Bruckner (University of California Irvine)149 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Unclear | Low |
| **United States of America** | Brittany Smith (Washington University School of Medicine)150 | No | No | No | Yes | Unclear | Unclear | Yes | No | Unclear | High |
| **United States of America** | Brittany Smith (Washington University School of Medicine)150 | No | No | No | Yes | Unclear | Unclear | Yes | No | Unclear | High |
| **United States of America** | Nina Molenaar (Icahn School of Medicine at Mount Sinai)151 | Yes | No | Yes | No | Yes | Unclear | Yes | No | Yes | Moderate |
| **United States of America** | Burak Bahar (Children’s National Hospital)152 | No | No | No | Yes | Yes | Yes | Yes | No | N/A | High |
| **United States of America** | Robert Stout (Clinical Reference Laboratory Inc.)153 | No | No | Yes | No | No | Yes | Yes | No | No | High |
| **United States of America** | Robert Stout (Clinical Reference Laboratory Inc.)153 | No | No | Yes | No | No | Yes | Yes | No | No | High |
| **United States of America** | Jennifer Rathe (University of Washington)154 | Unclear | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **United States of America** | Kristina Bajema (Centers for Disease Control and Prevention)155 | No | No | Yes | Yes | Yes | Unclear | Yes | Yes | Unclear | High |
| **United States of America** | Jason Yamaki (St. Jude Medical Center)156 | No | No | Yes | Yes | No | Yes | Yes | No | Unclear | High |
| **United States of America** | Daniel Stadlbauer (Icahn School of Medicine at Mount Sinai)157 | No | No | Yes | Yes | No | Unclear | Yes | No | Unclear | High |
| **United States of America** | Daniel Stadlbauer (Icahn School of Medicine at Mount Sinai)157 | No | No | Yes | Yes | Yes | Unclear | Yes | No | Unclear | High |
| **United States of America** | Shiwani Mahajan (Yale School of Medicine)158 | Yes | Yes | No | Yes | No | Yes | Yes | Yes | No | Moderate |
| **United States of America** | Shiwani Mahajan (Yale School of Medicine)158 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **United States of America** | Shiwani Mahajan (Yale School of Medicine)158 | Yes | Yes | No | Yes | No | Yes | Yes | Yes | No | Moderate |
| **United States of America** | Amy K Feehan (Louisiana State University)159 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **United States of America** | Kathy Kamath (Serimmune)160 | No | No | Yes | Yes | Yes | Unclear | Yes | No | Unclear | High |
| **United States of America** | Amir Barzin (University of North Carolina Chapel Hill)161 | No | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **United States of America** | Shuchi Anand (Stanford University)162 | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Low |
| **United States of America** | Lylach Haizler Cohen (Donald and Barbara Zucker School of Medicine)163 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **United States of America** | Dianna Ng (University of California, San Francisco)164 | No | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **United States of America** | Adam S Dingens (Fred Hutchinson Cancer Research Center)165 | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | High |
| **United States of America** | Gabriel Chamie (University of California, San Francisco)166 | No | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **United States of America** | Melissa Sutton (Oregon Health Authority)167 | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **United States of America** | Amy K Feehan (Oschner Clinic Foundation)168 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **United States of America** | Dustin Flannery (University of Pennsylvania)169 | Yes | No | Yes | No | Yes | Unclear | Yes | No | Yes | Moderate |
| **United States of America** | Holly Biggs (CDC COVID-19 Response Team)170 | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United States of America** | Josh Reifer (Sherman Abrams Laboratory )171 | Unclear | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **United States of America** | Neeraj Sood (Stanford University School of Medicine)172 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Low |
| **United States of America** | Nir Menachemi (Indiana University Fairbanks School of Public Health)173 | Yes | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Low |

#### *Eastern Mediterranean region*

| **Country** | **Author (Organization)** | **Item 1: Appropriate sample frame** | **Item 2: Probability sampling method** | **Item 3: Adequate sample size** | **Item 4: Subjects & setting described** | **Item 5: Good coverage of sample** | **Item 6: Sens>=90%, Spec>=97%** | **Item 7: Same test for all subjects** | **Item 8: Appropriate statistical analysis** | **Item 9: Adequate response rate** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Egypt** | Sahar Abdelmaksoud (Ain-Shams University)174 | No | Yes | No | No | No | Yes | Yes | No | N/A | High |
| **Egypt** | Samia Girgis (Ain-Shams University)175 | No | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Iran (Islamic Republic of)** | Kazem Khalagi (Tehran University of Medical Sciences)176 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Low |
| **Iran (Islamic Republic of)** | Seyed Abbas Mousavi (Mazandaran University of Medical Sciences)177 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Low |
| **Iran (Islamic Republic of)** | Maryam Shakiba (Tehran University of Medical Sciences)178 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Moderate |
| **Iran (Islamic Republic of)** | Hossein Poustchi (Tehran University of Medical Sciences)179 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Iran (Islamic Republic of)** | Zahra Mohammadi (Tehran University of Medical Sciences)180 | Unclear | Yes | No | No | No | Yes | Yes | No | Unclear | High |
| **Iraq** | Nawfal Hussein (University of Duhok)181 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Jordan** | Maher Sughayer (King Hussein Cancer Center)182 | No | No | No | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Jordan** | Saverio Bellizzi (World Health Organization)183 | Yes | Yes | Yes | No | Unclear | No | Yes | No | Yes | Moderate |
| **Jordan** | Saverio Bellizzi (World Health Organization)183 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | Yes | Moderate |
| **Jordan** | Saverio Bellizzi (World Health Organization)183 | Yes | Yes | Yes | Yes | Unclear | No | Yes | No | Yes | Moderate |
| **Jordan** | Maher Sughayer (King Hussein Cancer Center)184 | No | No | No | Yes | No | Yes | Yes | No | N/A | High |
| **Jordan** | Maher Sughayer (King Hussein Cancer Center)184 | No | No | No | No | No | Yes | Yes | No | N/A | High |
| **Jordan** | Maher Sughayer (King Hussein Cancer Center)184 | No | No | Yes | No | No | Yes | Yes | No | N/A | High |
| **Lebanon** | Dr Alissar Rady (WHO)[@] | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Lebanon** | Dr Alissar Rady (WHO)[@] | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No | Moderate |
| **occupied Palestinian territory - including east Jerusalem** | Beesan Maraqa (An-Najah National University)185 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **occupied Palestinian territory - including east Jerusalem** | Nouar Qutob (Arab American University )186 | No | No | Yes | Yes | Yes | Yes | Yes | No | N/A | High |
| **occupied Palestinian territory - including east Jerusalem** | Nouar Qutob (Arab American University )186 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Low |
| **occupied Palestinian territory, including east Jerusalem** | Sharif E. Qaddomi (PNIPH)[@] | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Oman** | Seif Al-Abri (Ministry of Health (Oman))187 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Oman** | Seif Al-Abri (Ministry of Health (Oman))187 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Oman** | Seif Al-Abri (Ministry of Health (Oman))187 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Oman** | Seif Al-Abri (Ministry of Health (Oman))187 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Pakistan** | Mohsina Haq (Riphah International University )188 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **Pakistan** | Muhammed Imran Nisar (Aga Khan University)189 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Pakistan** | Muhammed Imran Nisar (Aga Khan University)189 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Pakistan** | Muhammed Imran Nisar (Aga Khan University)189 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Pakistan** | Muhammed Imran Nisar (Aga Khan University)189 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Pakistan** | Muhammed Imran Nisar (Aga Khan University)189 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Pakistan** | Muhammed Imran Nisar (Aga Khan University)189 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Unclear | Moderate |
| **Pakistan** | Sheeba Ansari (Liaquat University)190 | No | No | Yes | Yes | No | Unclear | Yes | No | Unclear | High |
| **Qatar** | Peter Coyle (Cornell University)191 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Saudi Arabia** | Sami Almudarra (Saudi Ministry of Health)192 | No | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Saudi Arabia** | Mohammed Alosaimi (King Saud University)193 | No | No | No | Yes | No | Yes | Yes | No | Unclear | High |
| **United Arab Emirates** | May Raouf (Dubai Health Authority)194 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **United Arab Emirates** | Ahmed R Alsuwaidi (Abu Dhabi Public Health Center)195 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |

#### *Europe region*

| **Country** | **Author (Organization)** | **Item 1: Appropriate sample frame** | **Item 2: Probability sampling method** | **Item 3: Adequate sample size** | **Item 4: Subjects & setting described** | **Item 5: Good coverage of sample** | **Item 6: Sens>=90%, Spec>=97%** | **Item 7: Same test for all subjects** | **Item 8: Appropriate statistical analysis** | **Item 9: Adequate response rate** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Albania** | Genc Sulcebe (University of Medicine and University Hospital Center of Tirana)196 | No | Yes | No | Yes | Unclear | Yes | Yes | No | Yes | High |
| **Albania** | Genc Sulcebe (University of Medicine and University Hospital Center of Tirana)196 | No | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Andorra** | Cristina Royo Cebrecos (ISGlobal)197 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Austria** | Heike Rebholz (Danube Private University)198 | Yes | No | No | Yes | Unclear | Yes | Yes | No | Yes | High |
| **Austria** | Lisa Weidner ( University Hospital of Salzburg)199 | No | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Austria** | M. Riesenhuber (Universitätsklinik für Innere Medizin II )200 | Unclear | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **Austria** | Jens Lehmann ( Medical University of Innsbruck)201 | Yes | Yes | No | Yes | Unclear | Yes | Yes | No | No | High |
| **Belgium** | Laura Heireman (Ghent University Hospital)202 | No | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Sereina Herzog (University of Antwerp)203 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **Belgium** | Peter van Dam (Antwerp University Hospital)204 | No | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Bosnia and Herzegovina** | Adna Asic (International Burch University)205 | No | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **Bosnia and Herzegovina** | Adna Asic (International Burch University)205 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **Bosnia and Herzegovina** | Sanjin Musa (Institute for Public Health of the Federation of Bosnia and Herzegovina)206 | No | Yes | Yes | Yes | No | Yes | Yes | No | NA | Moderate |
| **Bosnia and Herzegovina** | Dejan Bokonjic (Faculty of Medicine Foca Faculty of Medicine Banja Luka Public Health Institute of Republic of Srpska )207 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Bulgaria** | Denitsa Tsaneva-Damyanova (Medical Diagnostic Laboratory “STATUS” )208 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Croatia** | Tatjana Vilibic-Cavlek (Croatian Institute of Public Health)209 | Unclear | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Croatia** | Tatjana Vilibic-Cavlek (Croatian Institute of Public Health)209 | Unclear | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Croatia** | Jasna Lenicek Krleza (Children’s Hospital Zagreb)210 | No | No | No | Yes | Unclear | Yes | Yes | No | Yes | High |
| **Czechia** | Marketa Bloomfield (Charles University and Thomayer’s Hospital)211 | No | No | No | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Denmark** | Laura Espenhain (Statens Serum Institut)212 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | No | Low |
| **Denmark** | Laura Espenhain (Statens Serum Institut)212 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | No | Low |
| **Denmark** | Laura Espenhain (Statens Serum Institut)212 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | No | Low |
| **Denmark** | Laura Espenhain (Statens Serum Institut)212 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | No | Low |
| **Denmark** | Kamille Fogh (Copenhagen University Hospital)213 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Moderate |
| **Denmark** | Kamille Fogh (Copenhagen University Hospital)214 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Denmark** | Maren J H Rytter (Slagelse Sygehus)215 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | High |
| **Denmark** | Maren J H Rytter (Slagelse Sygehus)215 | No | Yes | Yes | No | No | Yes | Yes | No | N/A | Moderate |
| **Denmark** | Pia Egerup (Copenhagen University Hospital Hvidovre)216 | Yes | No | Yes | No | Unclear | Unclear | Yes | No | Yes | Moderate |
| **Denmark** | Ole Birger Pedersen (Copenhagen University Hospital Rigshospitalet)217 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Low |
| **Denmark** | Ole Birger Pedersen (Copenhagen University Hospital Rigshospitalet)217 | No | No | Yes | No | Unclear | Yes | Yes | Yes | Unclear | High |
| **Denmark** | Senne Jespersen (Aarhus University Hospital)218 | No | No | No | No | Unclear | Yes | Yes | No | N/A | High |
| **Denmark** | Senne Jespersen (Aarhus University Hospital)218 | No | No | No | No | Unclear | Yes | Yes | No | N/A | High |
| **Denmark** | Kasper Iversen (University of Copenhagen)219 | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes | Moderate |
| **Denmark** | Christian Erikstrup (Copenhagen University Hospital)220 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Estonia** | Hiie Soeorg (University of Tartu)221 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **Estonia** | Piret Veerus (University of Tartu)222 | Yes | No | No | No | Yes | Yes | Yes | No | Unclear | High |
| **Faroe Islands** | Maria Skaalum Petersen (University of the Faroe Islands)223 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Finland** | Finnish institute for health and welfare (Finnish Institute for Health and Welfare)224 | Yes | Yes | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **France** | Fabrice Carrat (Unité des Virus Émergents)225 | No | No | Yes | Yes | No | Yes | Yes | No | Unclear | High |
| **France** | Adeline Beaumont (Perpignan Hospital Center)226 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | Unclear | Moderate |
| **France** | Lisandru Capai (Université de Corse)227 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **France** | Tom Woudenberg (Institut Pasteur)228 | No | No | Yes | No | No | Yes | Yes | No | N/A | High |
| **France** | Anne Petit (Université de Lorraine)229 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | No | Moderate |
| **France** | Stephane Le Vu (Santé publique France)230 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **France** | Stephane Le Vu (Santé publique France)230 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **France** | Stephane Le Vu (Santé publique France)230 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **France** | Vassilis Tsatsarisa (Université Paris-Saclay)231 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **France** | Robert Cohen (Centre Hospitalier Intercommunal de Créteil)232 | No | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **France** | Lisandru Capai (Université de Corse)233 | No | No | Yes | Yes | No | Yes | Yes | No | Unclear | High |
| **France** | Jeremie Mattern (Paris Saclay University)234 | No | No | No | No | Unclear | Yes | Yes | No | Yes | High |
| **Georgia** | Khatuna Zakhashvili (National Center for Disease Control and Public Health)235 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Georgia** | Khatuna Zakhashvili (National Center for Disease Control and Public Health)235 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Germany** | Folke Brinkmann (Ruhr University Bochum)236 | No | No | Yes | No | Yes | Yes | Yes | No | N/A | High |
| **Germany** | Felizitas Eichner (Universität Würzburg)237 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Germany** | Otto Laub (University of Regensburg)238 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Germany** | Katja Radon (German Research Center for Environmental Health)239 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Germany** | Daniela Gornyk (Helmholtz Centre for Infection Research)240 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Moderate |
| **Germany** | N Ahmad Aziz (University of Bonn)241 | No | No | Yes | No | Unclear | Yes | Yes | No | Yes | High |
| **Germany** | Ralf Wagner (Friedrich-Alexander University)242 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Germany** | Michael Pritsch (University Hospital LMU Munich)243 | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Low |
| **Germany** | Sebastian Hausler (Hospital St Hedwig of the Order of St John)244 | No | No | No | No | Yes | Yes | Yes | No | N/A | High |
| **Germany** | Robert Koch Institut (Robert Koch Institut)245 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | Yes | Low |
| **Germany** | Markus Hippich ( German Research Center for Environmental Health)246 | No | No | Yes | Yes | Yes | Unclear | Yes | No | N/A | High |
| **Germany** | Robert Koch Institute (Robert Koch Institute)247 | Yes | Yes | Yes | No | Unclear | Yes | Yes | Yes | Yes | Low |
| **Germany** | Clemens Fuest (ifo Institute)248 | Yes | No | Yes | No | Unclear | Yes | Yes | Yes | Unclear | Moderate |
| **Germany** | Claudia Santos Hovener (Robert Koch Institute)249 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Germany** | Hendrik Streeck (University of Bonn)250 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Unclear | Moderate |
| **Germany** | Stefan Runkel (University Medical Center of The Johannes Gutenberg-University Mainz)251 | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Germany** | Janine Zollkau (Universitätsklinikum Jena)252 | No | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Germany** | Bastian Fischer (Heart and Diabetes Center NRW)253 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **Greece** | Helena Maltezou (University of Athens)254 | No | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Greece** | Helena Maltezou (University of Athens)254 | No | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Greece** | Zacharoula Bogogiannidou (University of Thessaly)255 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | High |
| **Hungary** | Bela Merkely (Semmelweis University)256 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Low |
| **Iceland** | Daniel Gudbjartsson (deCODE Genetics)257 | No | No | Yes | No | Yes | Yes | Yes | No | Unclear | High |
| **Ireland** | Laura Heavey (Health Protection Surveillance Centre)258 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Low |
| **Ireland** | Laura Heavey (Health Protection Surveillance Centre)258 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Low |
| **Israel** | Victoria Indenbaum (Tel Aviv University)259 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Israel** | Adin Breuer (Shaare Zedek Medical Center)260 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Israel** | Yael Gozlan (Israel Ministry of Health)261 | No | No | No | Yes | Yes | Yes | Yes | No | No | High |
| **Israel** | Shay Reicher (Ministry of Health)262 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Italy** | Francescopaolo Antonucci (University Hospital “Ospedali Riuniti” Foggia)263 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Italy** | Federica Calo (University of Campania)264 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **Italy** | Ilaria Dorigatti (University of Padova)265 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **Italy** | Roberto Melotti (Hospital of Bolzano)266 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Italy** | Immacolata Polvere (Università degli Studi del Sannio)267 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Italy** | Irene Cassaniti (IRCCS Policlinico)268 | No | No | Yes | No | Unclear | Yes | Yes | No | Unclear | High |
| **Italy** | Gabriele Pagani (University of Milan)269 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Italy** | Luca Valenti ( Fondazione IRCCS Ca’ Granda Ospedale Maggiore )270 | No | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Italy** | Pellegrino Cerino (The Zoo-Prophylactic Institute of Southern Italy)271 | Yes | No | Yes | Yes | No | Yes | Yes | No | Yes | Moderate |
| **Italy** | Massimo Guerriero (Instituto di Ricovero e Cura A Caratterre)272 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Italy** | Paola Stefanelli (Azienda Provinciale per i Servizi Sanitari)273 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Italy** | Francesa Cito (Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale )274 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Yes | Moderate |
| **Italy** | Jose Ramon Fiore (University of Foggia)275 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Italy** | Instituto Nazionale di Statistica (Italian Ministry of Health)276 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Italy** | Anna Cavaliere (Santo Stefano Hospital)277 | Yes | No | No | No | Unclear | Yes | Yes | No | Yes | High |
| **Italy** | Alessandro Baracco (A.S.S.T.Lodi)278 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Italy** | Alessandro Pancrazzi (Ospedale San Donato)279 | Yes | No | No | Yes | No | Yes | Yes | No | Unclear | High |
| **Jersey** | Statistics Jersey (Statistics Jersey)280 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Kazakhstan** | Manar Smangul (Ministry of Health of the Republic of Kazakhstan)281 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Kyrgyzstan** | Nurmatov Zuridin, Kuchuk Tatyana (Scientific Production Association “Preventive medicine”)282 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Lithuania** | Kastytis Smigelskas ( Lithuanian University of Health Sciences)283 | No | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Luxembourg** | Chantal Snoeck (Luxembourg Institute of Health)284 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Low |
| **Netherlands** | Maya Keuning (University of Amsterdam)285 | No | No | No | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Netherlands** | Liza Coyer (Public Health Service of Amsterdam)286 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Moderate |
| **Netherlands** | Ed Slot (Amsterdam UMC)287 | No | No | Yes | Yes | Yes | Yes | Yes | No | Yes | High |
| **North Macedonia** | Tatjana Makarovska Bojadjieva ( Institute for Transfusion Medicine)288 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **Norway** | Gro Tunheim (Norwegian Institute of Public Health)289 | Yes | No | Yes | Yes | Unclear | Unclear | Yes | Yes | N/A | Moderate |
| **Poland** | Jan Zejda (Slaski Uniwersytet Medyczny)290 | Yes | Yes | Yes | Yes | No | Yes | Yes | No | No | Moderate |
| **Portugal** | Luisa Canto e Castro (Los Alamos National Laboratory)291 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **Portugal** | Irina Kislaya ( Instituto Nacional de Saúde Doutor Ricardo Jorge)292 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **Republic of Moldova** | Alexei Ceban Stela Gheorghita, WHO CO (National Agency for Public Health)293 | No | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Moderate |
| **Romania** | Tudor Rares Olariu (Victor Babes University of Medicine and Pharmacy)294 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Russian Federation** | Anton Barchuk (Smorodinova Research Institute of Influenza)295 | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Low |
| **Russian Federation** | Anton Barchuk (Smorodinova Research Institute of Influenza)295 | Yes | Yes | No | Yes | Yes | No | Yes | Yes | No | Moderate |
| **Russian Federation** | Anton Barchuk (European University at St. Petersburg )296 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear | Low |
| **Slovenia** | Mario Poljak (University of Ljubljana)297 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | No | Low |
| **Slovenia** | Mario Poljak (University of Ljubljana)297 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No | Low |
| **Spain** | Manolis Kogevinas (Barcelona Institute for Global Health)298 | No | No | Yes | Yes | No | Unclear | Yes | No | Yes | High |
| **Spain** | Marianna Karachaliou (Barcelona Institute For Global Health)299 | Yes | No | Yes | No | Unclear | Unclear | Yes | Yes | No | Moderate |
| **Spain** | Marianna Karachaliou (Barcelona Institute For Global Health)299 | Yes | No | No | No | No | Unclear | Yes | No | Unclear | High |
| **Spain** | R. Alenda (Centro de Transfusión de la Comunidad de Madrid)300 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **Spain** | Paula Iruzubieta (University of Cantabria)301 | Yes | Yes | Yes | Yes | Yes | No | Yes | No | Yes | Moderate |
| **Spain** | Francesca Crovetto (Universitat de Barcelona)302 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **Spain** | Mayte Perez Olmeda ( Instituto de Salud Carlos III)303 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **Spain** | Vicente Soriano (UNIR Health Sciences School and Medical Centre)304 | No | No | Yes | No | Yes | Yes | Yes | No | Unclear | High |
| **Spain** | Vicente Soriano (UNIR Health Sciences School and Medical Centre)304 | No | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |
| **Spain** | Nicolas Prados (IVIRMA Global Headquarters)305 | Yes | No | Yes | No | No | Yes | Yes | No | Unclear | Moderate |
| **Spain** | Maria Vinuela (University Hospital Gregorio Marañón)306 | Yes | No | No | No | Yes | Yes | Yes | No | Yes | High |
| **Sweden** | Swedish Public Health Agency (Swedish Public Health Agency)307 | Yes | No | Yes | No | Unclear | Unclear | Yes | Yes | N/A | Moderate |
| **Sweden** | Swedish Public Health Agency (Swedish Public Health Agency)308 | Yes | No | Yes | No | Yes | Unclear | Yes | Yes | N/A | Moderate |
| **Sweden** | Swedish Public Health Agency (The Swedish Public Health Agency (Folkhälsomyndigheten))309 | No | No | Yes | No | Unclear | Unclear | Yes | Yes | N/A | Moderate |
| **Sweden** | Ake Lundkvist (Uppsala University )310 | Yes | Yes | No | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Sweden** | Ake Lundkvist (Uppsala University )310 | Yes | Yes | No | Yes | Unclear | Yes | Yes | No | Unclear | High |
| **Switzerland** | Aude Richard (Geneva University Hospitals)311 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Low |
| **Switzerland** | Silvia Stringhini (Geneva University Hospital )312 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Moderate |
| **Switzerland** | Agne Ulyte (University of Zurich)313 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **Switzerland** | Stephanie Baggio (Geneva University Hospitals)314 | Yes | No | Yes | Yes | No | Yes | Yes | No | Yes | Moderate |
| **Switzerland** | Emna El May (Université de Fribourg)315 | Yes | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Moderate |
| **Switzerland** | Gregorio Milani (Università della Svizzera Italiana)316 | Unclear | No | No | Yes | Unclear | Yes | Yes | No | Yes | High |
| **Switzerland** | Elena Giuliano (Università della Svizzera Italiana)317 | Yes | No | No | No | Yes | Yes | Yes | No | No | High |
| **Switzerland** | Qifang Bi (Johns Hopkins Bloomberg School of Public Health)318 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Switzerland** | Daniela Anker (Université de Fribourg)319 | Yes | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Moderate |
| **Switzerland** | Craig Fenwick (Lausanne University Hospital and University of Lausanne)320 | Yes | Yes | No | No | No | Unclear | Yes | No | Unclear | Moderate |
| **Switzerland** | Marc Emmenegger (University of Zurich)321 | No | No | Yes | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Switzerland** | Marc Emmenegger (University of Zurich)321 | No | No | Yes | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Switzerland** | Marc Emmenegger (University of Zurich)321 | No | No | Yes | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Switzerland** | Marc Emmenegger (University of Zurich)321 | No | No | Yes | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Switzerland** | Marc Emmenegger (University of Zurich)321 | No | No | Yes | No | Unclear | Unclear | Yes | No | Unclear | High |
| **Turkey** | Ozge Yucel Celik (Etlik Zübeyde Hanim Women’s Health Care, Training, and Research Hospital)322 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **Turkey** | Ozge Yucel Celik (Etlik Zübeyde Hanim Women’s Health Care, Training, and Research Hospital)322 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)323 | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)323 | No | No | Yes | No | Yes | Yes | Yes | No | N/A | High |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)323 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | No | No | Unclear | Yes | Yes | Yes | N/A | High |
| **United Kingdom of Great Britain and Northern Ireland** | Clarissa Oeser (UK Health Security Agency (UKHSA, formerly PHE))324 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)325 | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)325 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)325 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Daniel Major-Smith (University of Bristol)326 | No | No | Yes | No | No | Yes | Yes | No | Yes | High |
| **United Kingdom of Great Britain and Northern Ireland** | Daniel Major-Smith (University of Bristol)326 | No | No | Yes | No | No | Yes | Yes | No | Yes | High |
| **United Kingdom of Great Britain and Northern Ireland** | Kate Glennon (University College Dublin)327 | Yes | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)328 | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)328 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)328 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)329 | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)329 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)329 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Katherine Gaskell (London School of Hygiene & Tropical Medicine)330 | No | Yes | Yes | Yes | Yes | Unclear | Yes | No | Yes | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Paul William Bird (University of Leicester)331 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)332 | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)332 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)332 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Hani Abo-Leyah (University of Dundee)333 | No | No | No | No | Yes | Yes | Yes | No | N/A | High |
| **United Kingdom of Great Britain and Northern Ireland** | Gayatri Amirthalingam (Public Health England)334 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Robert W Aldridge (University College London)335 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Sarah Beale (University College London)336 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)337 | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)337 | No | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)337 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Heather J Whitaker (Public Health England)338 | Yes | No | Yes | No | Unclear | Yes | Yes | Yes | Yes | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Jane Oakey (NHS Foundation Trust )339 | No | No | No | Yes | Yes | Yes | Yes | No | N/A | High |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)340 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)340 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office For National Statistics)341 | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office For National Statistics)341 | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office For National Statistics)341 | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office For National Statistics)341 | Yes | Yes | Yes | Yes | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)342 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)342 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)343 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)343 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Shamez Ladhani (Public Health England)345 | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Ellen C Hughes (University of Glasgow)346 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health Scotland (Public Health Scotland)347 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Craig P Thompson (University of Oxford)348 | No | Yes | Yes | Yes | Yes | Unclear | Yes | No | N/A | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Sheila F Lumley (University of Oxford)349 | Yes | No | Yes | No | Unclear | Unclear | Yes | No | Yes | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Philippa M Wells (King’s College London)350 | No | No | No | Yes | Unclear | Unclear | Yes | No | No | High |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | No | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | Yes | Yes | No | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | Yes | Yes | No | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | No | No | Yes | Yes | Yes | No | Unclear | High |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | No | Unclear | Moderate |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Public Health England (Public Health England)351 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Unclear | Low |
| **United Kingdom of Great Britain and Northern Ireland** | Office for National Statistics (Office of National Statistics)344 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **Uzbekistan** | R A Rakhimov (Research Institute of Virology)352 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |

#### *South-East Asia region*

| **Country** | **Author (Organization)** | **Item 1: Appropriate sample frame** | **Item 2: Probability sampling method** | **Item 3: Adequate sample size** | **Item 4: Subjects & setting described** | **Item 5: Good coverage of sample** | **Item 6: Sens>=90%, Spec>=97%** | **Item 7: Same test for all subjects** | **Item 8: Appropriate statistical analysis** | **Item 9: Adequate response rate** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Bangladesh** | Taufiqur Rahman Bhuiyan (Johns Hopkins Bloomberg School of Public Health)353 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Bangladesh** | Firdausi Qadri (International Centre for Diarrhoeal Disease Research )[@] | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| **Bangladesh** | Firdausi Qadri (International Centre for Diarrhoeal Disease Research )[@] | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| **Bangladesh** | Prof. Dr. Tahmina Shirin (IEDCR)354 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No | Moderate |
| **India** | Deepak Kumar (Andaman and Nicobar Islands Institute of Medical Sciences)355 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **India** | Sindhulina Chandrasingh (Bangalore Baptist Hospital)356 | No | Unclear | No | No | Unclear | Yes | Yes | No | N/A | High |
| **India** | Vasanthakumar Namasivayam (Government of Uttar Pradesh)357 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Low |
| **India** | Smita Mahapatra (Sriram Chandra Bhanja Medical College and Hospital)358 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | High |
| **India** | Government of Kerala (Government of Kerala Department of Health)359 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Government of Kerala (Government of Kerala Department of Health)359 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Government of Kerala (Government of Kerala Department of Health)359 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Government of Kerala (Government of Kerala Department of Health)359 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Government of Kerala (Government of Kerala Department of Health)359 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Government of Kerala (Government of Kerala Department of Health)359 | Yes | No | Yes | No | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Muhammad Khan (Government Medical College Srinagar)360 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Amitav Banerjee (Dr. D. Y. Patil Medical College, Hospital and Research Centre)361 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | Yes | Moderate |
| **India** | Muthusamy Kumar (National Institute of Epidemiology)362 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Nandini Sharma (Maulana Azad Medical College)363 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Nandini Sharma (Government of National Capital Territory of Delhi)364 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **India** | Nandini Sharma (Government of National Capital Territory of Delhi)364 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **India** | Nandini Sharma (Government of National Capital Territory of Delhi)364 | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | N/A | Low |
| **India** | Avula Laxmaiah (CSIR-CentreForCellularAndMolecularBiology)365 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Om Prakash (AMC MET Medical College)366 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **India** | Manoj V Murhekar (Indian Council of Medical Research)367 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Jaya Singh Kshatri (ICMR-Regional Medical Research Centre)368 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **India** | Jaya Singh Kshatri (ICMR-Regional Medical Research Centre)368 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **India** | Jaya Singh Kshatri (ICMR-Regional Medical Research Centre)368 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
| **India** | Om Prakash (Municipal Medical College)369 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **India** | Jaya Singh Kshatri (Indian Council of Medical Research)370 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Pallavi Saple (The Municipality of Malegaon )371 | Yes | No | No | Yes | Unclear | Unclear | Yes | No | Unclear | High |
| **India** | Salil Sakalle (National Centre for Disease Control)372 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear | Low |
| **India** | Taha Ayub (Government Medical College Srinagar)373 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **India** | Rita Isaac (University of Edinburgh)374 | Yes | Yes | No | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **India** | Rita Isaac (University of Edinburgh)374 | Yes | Yes | No | Yes | Yes | Yes | Yes | No | N/A | Moderate |
| **India** | Hem Chandra Pandey (All India Institute of Medical Sciences )375 | No | No | Yes | Yes | No | Yes | Yes | No | N/A | High |
| **India** | Sudarshan Ramaswamy (National Centre for Disease Control)376 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | N/A | Low |
| **India** | Manoj V Murhekar (The Indian Council of Medical Research (ICMR))367 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Sriram Selvaraju (National Institute of Epidemiology)377 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Sitanshu Sekhar Kar (Jawaharlal Institute)378 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **India** | Sitanshu Sekhar Kar (Jawaharlal Institute)378 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **India** | Sitanshu Sekhar Kar (Jawaharlal Institute)378 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **India** | Om Prakash ( Municipal Medical College )379 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **India** | Anup Malani (Tata Institute for Fundamental Research)380 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Low |
| **India** | Anup Malani (Tata Institute for Fundamental Research)380 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Low |
| **India** | S Muhammad Salim Khan (Government Medical College Srinagar)381 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Moderate |
| **India** | Parthasarathi Satpati (Medical College Kolkata)382 | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **India** | Ullas Kolthur Seetharam (NITI-Aayog)383 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Ullas Kolthur Seetharam (NITI-Aayog)383 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **India** | Ministry of Health and Family Welfare (Indian Center for Disease Control)384 | Yes | Yes | Yes | No | No | Yes | Yes | No | Unclear | Moderate |
| **India** | Dr Puneet Misra (All India Institute of Medical Sciences, New Delhi)385 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | No | Moderate |
| **Indonesia** | Ni Luh Ayu Megasari (Kobe University)386 | Yes | No | Yes | Yes | Unclear | No | Yes | No | Unclear | Moderate |
| **Indonesia** | Dr. dr. Tri Yunis Miko Wahyono, M.Sc (University of Indonesia)387 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **Nepal** | Government of Nepal (Government of Nepal)388 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **Thailand** | Sutthichai Nakphook, MD (Ministry of Public Health)389 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |


#### *Western Pacific region*

| **Country** | **Author (Organization)** | **Item 1: Appropriate sample frame** | **Item 2: Probability sampling method** | **Item 3: Adequate sample size** | **Item 4: Subjects & setting described** | **Item 5: Good coverage of sample** | **Item 6: Sens>=90%, Spec>=97%** | **Item 7: Same test for all subjects** | **Item 8: Appropriate statistical analysis** | **Item 9: Adequate response rate** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Australia** | Heather F Gidding (Children’s Hospital at Westmead)390 | No | Yes | Yes | Yes | Yes | Unclear | Yes | No | N/A | Moderate |
| **Australia** | Heather F Gidding (Children’s Hospital at Westmead)390 | Yes | Yes | No | No | Yes | Unclear | Yes | No | N/A | Moderate |
| **Australia** | Nicholas Coatsworth (Australian National University)391 | Yes | No | Yes | No | Yes | Unclear | Yes | No | Yes | Moderate |
| **Australia** | Dorothy Machalek (The Kirby Institue at the University of New South Wales and Australian National Centre for Immunisation Research and Surveillance)392 | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | High |
| **Australia** | Kristine Macartney, Nicholas Wood, Archana Koirala (Australian National Centre for Immunisation Research and Surveillance)[@] | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | High |
| **China** | Zhenyu He (Chinese Academy of Medical Sciences & Peking Union Medical College)393 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Low |
| **China** | Zhongjie Li (Chinese Center for Disease Control and Prevention)394 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Moderate |
| **China** | Zhen Zhang (Shenzhen Center for Disease Control and Prevention)395 | No | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **China** | Zhen Zhang (Shenzhen Center for Disease Control and Prevention)395 | No | No | No | No | Unclear | Yes | Yes | No | Unclear | High |
| **China** | Lu He (Renmin Hospital of Wuhan University)396 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **China** | Hsiang-Ling Ho (Taipei Veterans General Hospital)397 | No | No | Yes | Yes | Unclear | Yes | Yes | No | N/A | Moderate |
| **China** | Ru Xu (Institute of Blood Transfusion)398 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **China** | Jin Zhang (Shengjing Hospital of China Medical University)399 | Yes | No | No | Yes | Yes | Unclear | Yes | No | Unclear | High |
| **Japan** | Prefecture of Hiroshima (Hiroshima University )400 | Yes | Yes | Yes | No | Unclear | Yes | Yes | No | No | Moderate |
| **Japan** | Keita Morikane (Yamagata University)401 | No | No | Yes | No | Unclear | Yes | Yes | No | N/A | High |
| **Malaysia** | I-Ching Sam (University of Malaya)402 | No | No | Yes | No | Unclear | Yes | Yes | Yes | N/A | Moderate |
| **Malaysia** | Chong Zhuo Lin (Institute for Public Health)403 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Mongolia** | Battogtokh Chimeddorj (Mongolian National University of Medical Sciences (MNUMS))404 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Mongolia** | Battogtokh Chimeddorj (Mongolian National University of Medical Sciences (MNUMS))404 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | Moderate |
| **Papua New Guinea** | Moses Laman (Papua New Guinea Institute of Medical Research)405 | Yes | No | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Republic of Korea** | Kwangmin Lee (Korea Disease Control and Prevention Agency)406 | No | No | Yes | No | Unclear | Unclear | Yes | No | N/A | High |
| **Republic of Korea** | Kwangmin Lee (Korea Disease Control and Prevention Agency)406 | No | No | Yes | No | Unclear | Unclear | Yes | No | N/A | High |
| **Republic of Korea** | Kwangmin Lee (Korea Disease Control and Prevention Agency)406 | No | No | Yes | No | Unclear | Unclear | Yes | No | N/A | High |
| **Republic of Korea** | Hye Won Jeong (Chungbuk National University)407 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **Republic of Korea** | Hye Won Jeong (Chungbuk National University)407 | Yes | Yes | Yes | No | Unclear | Unclear | Yes | Yes | Unclear | Low |
| **Republic of Korea** | Eun Hee Nah (Korea Association of Health Promotion)408 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear | Moderate |
| **Singapore** | Hannah E Clapham (National University of Singapore)409 | Unclear | No | Yes | Yes | Yes | Yes | Yes | No | Unclear | High |


#### 

#### 

## S4.3 Additional figures and results



### Figure S2: Risk of Bias Assessment for Included Studies.



### Figure S3: Asymptomatic Prevalence in SEROPREV Protocol Studies by Age and Sex.

The inner horizontal line and edges of the box indicate the median and interquartile range of the reported percentage of seropositives with no symptoms, while the whiskers extend from the box to the largest value no further than 1.5 times the interquartile range and indicate the spread of the data. Each point represents an individual SEROPREV protocol seroprevalence study.

### 

### Table S9. Estimated seroprevalence over time by region (meta-analysis).

95% confidence intervals are Clopper-Pearson intervals. See also S3.2.

| **WHO region** | **Population (millions)** | **Month** | **N** | **Effect size** | **95% CI** | **I2** |
| --- | --- | --- | --- | --- | --- | --- |
| **Africa** | 1118.8 | Jan 2020 | 2 | 0.0000 | [3e-04-0.0167] | 0.0000 |
| **Africa** | 1118.8 | Feb 2020 | 3 | 0.0000 | [8e-04-0.0128] | 0.0000 |
| **Africa** | 1118.8 | Mar 2020 | 3 | 0.0000 | [0.0016-0.0154] | 0.0000 |
| **Africa** | 1118.8 | Apr 2020 | 3 | 0.0067 | [0.0025-0.0177] | 0.0000 |
| **Africa** | 1118.8 | May 2020 | 4 | 0.0155 | [0.0054-0.0435] | 0.8250 |
| **Africa** | 1118.8 | May 2020 | 7 | 0.0301 | [0.0179-0.05] | 0.9672 |
| **Africa** | 1118.8 | Jun 2020 | 7 | 0.0392 | [0.0235-0.0647] | 0.9875 |
| **Africa** | 1118.8 | Jul 2020 | 9 | 0.0590 | [0.0311-0.1092] | 0.9951 |
| **Africa** | 1118.8 | Aug 2020 | 14 | 0.1150 | [0.0779-0.1667] | 0.9917 |
| **Africa** | 1118.8 | Sep 2020 | 12 | 0.1661 | [0.1222-0.2218] | 0.9887 |
| **Africa** | 1118.8 | Oct 2020 | 15 | 0.1505 | [0.1147-0.1951] | 0.9912 |
| **Africa** | 1118.8 | Nov 2020 | 14 | 0.1670 | [0.1311-0.2104] | 0.9884 |
| **Africa** | 1118.8 | Dec 2020 | 10 | 0.1779 | [0.1207-0.2545] | 0.9906 |
| **Africa** | 1118.8 | Jan 2021 | 10 | 0.2988 | [0.213-0.4015] | 0.9878 |
| **Africa** | 1118.8 | Feb 2021 | 12 | 0.3646 | [0.2356-0.5165] | 0.9967 |
| **Africa** | 1118.8 | Mar 2021 | 12 | 0.3957 | [0.2566-0.5541] | 0.9968 |
| **Africa** | 1118.8 | Apr 2021 | 9 | 0.4074 | [0.2246-0.6201] | 0.9976 |
| **Africa** | 1118.8 | May 2021 | 6 | 0.5199 | [0.3561-0.6796] | 0.9978 |
| **Africa** | 1118.8 | May 2021 | 5 | 0.6614 | [0.6487-0.6739] | 0.3697 |
| **Africa** | 1118.8 | Jun 2021 | 6 | 0.6839 | [0.6321-0.7315] | 0.9765 |
| **Africa** | 1118.8 | Jul 2021 | 4 | 0.7007 | [0.6318-0.7615] | 0.9796 |
| **Americas: High income** | 401.1 | Mar 2020 | 3 | 0.0000 | [0.0034-0.0619] | 0.9589 |
| **Americas: High income** | 401.1 | Apr 2020 | 7 | 0.0175 | [0.0082-0.037] | 0.9605 |
| **Americas: High income** | 401.1 | May 2020 | 20 | 0.0218 | [0.0151-0.0313] | 0.9913 |
| **Americas: High income** | 401.1 | May 2020 | 28 | 0.0301 | [0.0205-0.0438] | 0.9952 |
| **Americas: High income** | 401.1 | Jun 2020 | 29 | 0.0274 | [0.0184-0.0405] | 0.9955 |
| **Americas: High income** | 401.1 | Jul 2020 | 22 | 0.0310 | [0.0187-0.0509] | 0.9965 |
| **Americas: High income** | 401.1 | Aug 2020 | 18 | 0.0274 | [0.0163-0.0456] | 0.9943 |
| **Americas: High income** | 401.1 | Sep 2020 | 16 | 0.0272 | [0.0158-0.0465] | 0.9929 |
| **Americas: High income** | 401.1 | Oct 2020 | 18 | 0.0312 | [0.0184-0.0522] | 0.9934 |
| **Americas: High income** | 401.1 | Nov 2020 | 14 | 0.0266 | [0.0154-0.0458] | 0.9942 |
| **Americas: High income** | 401.1 | Dec 2020 | 12 | 0.0362 | [0.0198-0.0652] | 0.9991 |
| **Americas: High income** | 401.1 | Jan 2021 | 6 | 0.0563 | [0.0202-0.1473] | 0.9997 |
| **Americas: High income** | 401.1 | Feb 2021 | 8 | 0.1562 | [0.0774-0.2901] | 0.9998 |
| **Americas: High income** | 401.1 | Mar 2021 | 8 | 0.3052 | [0.1905-0.4505] | 0.9999 |
| **Americas: High income** | 401.1 | Apr 2021 | 10 | 0.3998 | [0.2485-0.573] | 0.9999 |
| **Americas: High income** | 401.1 | May 2021 | 7 | 0.5983 | [0.3891-0.7769] | 0.9997 |
| **Americas: High income** | 401.1 | May 2021 | 6 | 0.7004 | [0.4709-0.8599] | 0.9998 |
| **Americas: High income** | 401.1 | Jun 2021 | 6 | 0.8119 | [0.6537-0.908] | 0.9992 |
| **Americas: High income** | 401.1 | Jul 2021 | 3 | 0.9305 | [0.903-0.9506] | 0.9919 |
| **Americas: High income** | 401.1 | Aug 2021 | 3 | 0.9489 | [0.9373-0.9585] | 0.9581 |
| **Americas: Low and middle income** | 620.5 | Apr 2020 | 5 | 0.0022 | [4e-04-0.0113] | 0.9864 |
| **Americas: Low and middle income** | 620.5 | May 2020 | 11 | 0.0130 | [0.0033-0.0494] | 0.9983 |
| **Americas: Low and middle income** | 620.5 | Jun 2020 | 13 | 0.0238 | [0.0085-0.0649] | 0.9980 |
| **Americas: Low and middle income** | 620.5 | Jul 2020 | 14 | 0.0404 | [0.0187-0.085] | 0.9980 |
| **Americas: Low and middle income** | 620.5 | Aug 2020 | 14 | 0.0732 | [0.0344-0.1492] | 0.9970 |
| **Americas: Low and middle income** | 620.5 | Aug 2020 | 14 | 0.0852 | [0.0448-0.1562] | 0.9960 |
| **Americas: Low and middle income** | 620.5 | Sep 2020 | 10 | 0.1522 | [0.0804-0.2695] | 0.9956 |
| **Americas: Low and middle income** | 620.5 | Oct 2020 | 7 | 0.2119 | [0.117-0.353] | 0.9922 |
| **Americas: Low and middle income** | 620.5 | Nov 2020 | 2 | 0.2415 | [0.1129-0.4435] | 0.9970 |
| **Americas: Low and middle income** | 620.5 | Dec 2020 | 4 | 0.1328 | [0.1114-0.1576] | 0.9433 |
| **Americas: Low and middle income** | 620.5 | Jan 2021 | 4 | 0.1328 | [0.1114-0.1576] | 0.9433 |
| **Americas: Low and middle income** | 620.5 | Feb 2021 | 4 | 0.1328 | [0.1114-0.1576] | 0.9433 |
| **Americas: Low and middle income** | 620.5 | Mar 2021 | 4 | 0.1695 | [0.1175-0.2384] | 0.9830 |
| **Americas: Low and middle income** | 620.5 | Apr 2021 | 2 | 0.2222 | [0.164-0.2938] | 0.9576 |
| **Eastern Mediterranean** | 730.8 | Apr 2020 | 3 | 0.1692 | [0.1311-0.2156] | 0.9495 |
| **Eastern Mediterranean** | 730.8 | May 2020 | 3 | 0.1692 | [0.1311-0.2156] | 0.9495 |
| **Eastern Mediterranean** | 730.8 | Jun 2020 | 4 | 0.1502 | [0.0675-0.3016] | 0.9996 |
| **Eastern Mediterranean** | 730.8 | Jul 2020 | 6 | 0.0749 | [0.0211-0.233] | 0.9994 |
| **Eastern Mediterranean** | 730.8 | Aug 2020 | 8 | 0.0881 | [0.034-0.2097] | 0.9992 |
| **Eastern Mediterranean** | 730.8 | Aug 2020 | 7 | 0.0856 | [0.029-0.227] | 0.9990 |
| **Eastern Mediterranean** | 730.8 | Sep 2020 | 6 | 0.0705 | [0.0226-0.1994] | 0.9935 |
| **Eastern Mediterranean** | 730.8 | Oct 2020 | 5 | 0.1506 | [0.1008-0.219] | 0.9932 |
| **Eastern Mediterranean** | 730.8 | Nov 2020 | 5 | 0.2289 | [0.1329-0.3649] | 0.9974 |
| **Eastern Mediterranean** | 730.8 | Dec 2020 | 4 | 0.2952 | [0.2292-0.3711] | 0.9923 |
| **Eastern Mediterranean** | 730.8 | Jan 2021 | 4 | 0.3964 | [0.355-0.4394] | 0.9522 |
| **Eastern Mediterranean** | 730.8 | Feb 2021 | 2 | 0.4271 | [0.3767-0.4791] | 0.9055 |
| **Europe: High income** | 529.3 | Mar 2020 | 14 | 0.0351 | [0.0242-0.0505] | 0.9621 |
| **Europe: High income** | 529.3 | Mar 2020 | 37 | 0.0313 | [0.0227-0.043] | 0.9929 |
| **Europe: High income** | 529.3 | Apr 2020 | 46 | 0.0358 | [0.0275-0.0466] | 0.9917 |
| **Europe: High income** | 529.3 | May 2020 | 58 | 0.0375 | [0.0304-0.0462] | 0.9930 |
| **Europe: High income** | 529.3 | Jun 2020 | 47 | 0.0451 | [0.0372-0.0545] | 0.9936 |
| **Europe: High income** | 529.3 | Jul 2020 | 36 | 0.0449 | [0.0392-0.0514] | 0.9790 |
| **Europe: High income** | 529.3 | Aug 2020 | 25 | 0.0462 | [0.0379-0.0563] | 0.9850 |
| **Europe: High income** | 529.3 | Sep 2020 | 31 | 0.0376 | [0.0298-0.0475] | 0.9967 |
| **Europe: High income** | 529.3 | Oct 2020 | 37 | 0.0390 | [0.0309-0.0493] | 0.9964 |
| **Europe: High income** | 529.3 | Nov 2020 | 44 | 0.0406 | [0.0324-0.0507] | 0.9960 |
| **Europe: High income** | 529.3 | Dec 2020 | 47 | 0.0560 | [0.0456-0.0686] | 0.9854 |
| **Europe: High income** | 529.3 | Jan 2021 | 43 | 0.0738 | [0.0563-0.0962] | 0.9965 |
| **Europe: High income** | 529.3 | Jan 2021 | 36 | 0.0944 | [0.0687-0.1284] | 0.9971 |
| **Europe: High income** | 529.3 | Feb 2021 | 33 | 0.1177 | [0.0853-0.1603] | 0.9971 |
| **Europe: High income** | 529.3 | Mar 2021 | 32 | 0.1901 | [0.142-0.2496] | 0.9956 |
| **Europe: High income** | 529.3 | Apr 2021 | 29 | 0.2799 | [0.2083-0.3649] | 0.9969 |
| **Europe: High income** | 529.3 | May 2021 | 24 | 0.4160 | [0.3299-0.5075] | 0.9941 |
| **Europe: High income** | 529.3 | Jun 2021 | 22 | 0.5775 | [0.4415-0.7027] | 0.9960 |
| **Europe: High income** | 529.3 | Jul 2021 | 20 | 0.6693 | [0.5141-0.7947] | 0.9961 |
| **Europe: High income** | 529.3 | Aug 2021 | 18 | 0.7202 | [0.5472-0.8457] | 0.9971 |
| **Europe: Low and middle income** | 397.4 | Jul 2020 | 3 | 0.0830 | [0.0087-0.4834] | 0.9935 |
| **Europe: Low and middle income** | 397.4 | Aug 2020 | 3 | 0.0830 | [0.0087-0.4834] | 0.9935 |
| **Europe: Low and middle income** | 397.4 | Sep 2020 | 2 | 0.0372 | [0.0021-0.412] | 0.9901 |
| **Europe: Low and middle income** | 397.4 | Oct 2020 | 3 | 0.2666 | [0.1797-0.3764] | 0.9932 |
| **Europe: Low and middle income** | 397.4 | Nov 2020 | 5 | 0.4089 | [0.2941-0.5345] | 0.9927 |
| **Europe: Low and middle income** | 397.4 | Dec 2020 | 5 | 0.4089 | [0.2941-0.5345] | 0.9927 |
| **Europe: Low and middle income** | 397.4 | Jan 2021 | 4 | 0.4749 | [0.4138-0.5368] | 0.9864 |
| **Europe: Low and middle income** | 397.4 | Apr 2021 | 1 | 0.3840 | [0.3757-0.3925] | NA |
| **Europe: Low and middle income** | 397.4 | May 2021 | 2 | 0.4347 | [0.365-0.5072] | 0.9958 |
| **Europe: Low and middle income** | 397.4 | Jun 2021 | 2 | 0.4347 | [0.365-0.5072] | 0.9958 |
| **South-East Asia** | 2021.4 | Jun 2020 | 5 | 0.0922 | [0.0391-0.202] | 0.9952 |
| **South-East Asia** | 2021.4 | Jul 2020 | 8 | 0.1144 | [0.0622-0.2012] | 0.9984 |
| **South-East Asia** | 2021.4 | Aug 2020 | 8 | 0.1291 | [0.0774-0.2076] | 0.9982 |
| **South-East Asia** | 2021.4 | Sep 2020 | 10 | 0.1776 | [0.1193-0.256] | 0.9980 |
| **South-East Asia** | 2021.4 | Oct 2020 | 7 | 0.2240 | [0.1649-0.2966] | 0.9935 |
| **South-East Asia** | 2021.4 | Nov 2020 | 5 | 0.2622 | [0.1948-0.343] | 0.9938 |
| **South-East Asia** | 2021.4 | Dec 2020 | 4 | 0.1228 | [0.0179-0.5175] | 0.9994 |
| **South-East Asia** | 2021.4 | Jan 2021 | 4 | 0.1228 | [0.0179-0.5175] | 0.9994 |
| **South-East Asia** | 2021.4 | Feb 2021 | 4 | 0.1228 | [0.0179-0.5175] | 0.9994 |
| **South-East Asia** | 2021.4 | Apr 2021 | 2 | 0.6431 | [0.6321-0.6539] | 0.0000 |
| **South-East Asia** | 2021.4 | May 2021 | 2 | 0.6431 | [0.6321-0.6539] | 0.0000 |
| **South-East Asia** | 2021.4 | May 2021 | 2 | 0.6431 | [0.6321-0.6539] | 0.0000 |
| **South-East Asia** | 2021.4 | Jul 2021 | 1 | 0.6539 | [0.6341-0.6732] | NA |
| **South-East Asia** | 2021.4 | Aug 2021 | 7 | 0.7465 | [0.6273-0.8374] | 0.9952 |
| **Western Pacific** | 1932.3 | Apr 2020 | 2 | 0.0295 | [0.0087-0.0949] | 0.9987 |
| **Western Pacific** | 1932.3 | May 2020 | 4 | 0.0145 | [0.0038-0.0537] | 0.9965 |
| **Western Pacific** | 1932.3 | Jun 2020 | 2 | 0.0068 | [9e-04-0.0476] | 0.9737 |
| **Western Pacific** | 1932.3 | Jul 2020 | 2 | 0.0068 | [9e-04-0.0476] | 0.9737 |
| **Western Pacific** | 1932.3 | Aug 2020 | 2 | 0.0034 | [0.0014-0.0085] | 0.8599 |
| **Western Pacific** | 1932.3 | Aug 2020 | 1 | 0.0060 | [0.0043-0.0086] | NA |
| **Western Pacific** | 1932.3 | Sep 2020 | 4 | 0.0056 | [0.0029-0.0108] | 0.9287 |
| **Western Pacific** | 1932.3 | Oct 2020 | 3 | 0.0054 | [0.0022-0.013] | 0.9435 |
| **Western Pacific** | 1932.3 | Nov 2020 | 3 | 0.0054 | [0.0022-0.013] | 0.9435 |
| **Western Pacific** | 1932.3 | Dec 2020 | 1 | 0.0144 | [0.0114-0.0181] | NA |
| **Western Pacific** | 1932.3 | Jan 2021 | 2 | 0.0251 | [0.0132-0.0473] | 0.9425 |
| **Western Pacific** | 1932.3 | Feb 2021 | 2 | 0.0251 | [0.0132-0.0473] | 0.9425 |

**Table S10. Estimated seroprevalence over time globally (population-weighted)**

| **Global** | **Month** | **Effect size** | **95% CI** |
| --- | --- | --- | --- |
| **Global (combined seroprevalence)** | Jan 2020 | 0.0024 | [3e-04-0.0173] |
| **Global (combined seroprevalence)** | Feb 2020 | 0.0032 | [8e-04-0.0132] |
| **Global (combined seroprevalence)** | Mar 2020 | 0.0181 | [0.0104-0.0314] |
| **Global (combined seroprevalence)** | Apr 2020 | 0.0404 | [0.0238-0.0678] |
| **Global (combined seroprevalence)** | May 2020 | 0.0367 | [0.0236-0.0567] |
| **Global (combined seroprevalence)** | Jun 2020 | 0.0548 | [0.0305-0.0964] |
| **Global (combined seroprevalence)** | Jul 2020 | 0.0593 | [0.0342-0.1008] |
| **Global (combined seroprevalence)** | Aug 2020 | 0.0636 | [0.0499-0.0807] |
| **Global (combined seroprevalence)** | Sep 2020 | 0.0964 | [0.0736-0.1252] |
| **Global (combined seroprevalence)** | Oct 2020 | 0.1306 | [0.1033-0.1638] |
| **Global (combined seroprevalence)** | Nov 2020 | 0.1599 | [0.1264-0.2001] |
| **Global (combined seroprevalence)** | Dec 2020 | 0.1264 | [0.0769-0.2009] |
| **Global (combined seroprevalence)** | Jan 2021 | 0.1719 | [0.1105-0.2577] |
| **Global (combined seroprevalence)** | Feb 2021 | 0.1823 | [0.1112-0.2842] |
| **Global (combined seroprevalence)** | Mar 2021 | 0.2023 | [0.1246-0.3113] |
| **Global (combined seroprevalence)** | Apr 2021 | 0.3503 | [0.3023-0.4015] |
| **Global (combined seroprevalence)** | May 2021 | 0.4723 | [0.4362-0.5087] |
| **Global (combined seroprevalence)** | Jun 2021 | 0.4344 | [0.3897-0.4803] |
| **Global (combined seroprevalence)** | Jul 2021 | 0.4521 | [0.4066-0.4984] |

| **Global** | **Month** | **Effect size** | **95% CI** |
| --- | --- | --- | --- |
| **Global (seroprevalence from infection)** | Jan 2020 | 0.0024 | [3e-04-0.0173] |
| **Global (seroprevalence from infection)** | Feb 2020 | 0.0032 | [8e-04-0.0132] |
| **Global (seroprevalence from infection)** | Mar 2020 | 0.0157 | [0.0084-0.0289] |
| **Global (seroprevalence from infection)** | Apr 2020 | 0.0140 | [0.0102-0.0192] |
| **Global (seroprevalence from infection)** | May 2020 | 0.0344 | [0.0214-0.0547] |
| **Global (seroprevalence from infection)** | Jun 2020 | 0.0427 | [0.0203-0.0877] |
| **Global (seroprevalence from infection)** | Jul 2020 | 0.0496 | [0.0245-0.0978] |
| **Global (seroprevalence from infection)** | Aug 2020 | 0.0673 | [0.0534-0.0844] |
| **Global (seroprevalence from infection)** | Sep 2020 | 0.0864 | [0.068-0.1091] |
| **Global (seroprevalence from infection)** | Oct 2020 | 0.1086 | [0.0864-0.1356] |
| **Global (seroprevalence from infection)** | Nov 2020 | 0.1352 | [0.1061-0.1708] |
| **Global (seroprevalence from infection)** | Dec 2020 | 0.1236 | [0.0708-0.2071] |
| **Global (seroprevalence from infection)** | Jan 2021 | 0.1631 | [0.1009-0.2528] |
| **Global (seroprevalence from infection)** | Feb 2021 | 0.1540 | [0.0764-0.2858] |
| **Global (seroprevalence from infection)** | Mar 2021 | 0.1629 | [0.0813-0.2998] |
| **Global (seroprevalence from infection)** | Apr 2021 | 0.3125 | [0.2788-0.3483] |
| **Global (seroprevalence from infection)** | May 2021 | 0.3742 | [0.3428-0.4067] |
| **Global (seroprevalence from infection)** | Jun 2021 | 0.3575 | [0.3351-0.3804] |
| **Global (seroprevalence from infection)** | Jul 2021 | 0.3517 | [0.3332-0.3707] |

### Table S11: Meta-regression results and model comparison.

|  |  | ***(1) Full model (Poisson)*** | | ***(1) Full model minus sample frame (Poisson)*** | | ***(1) Full model minus sample frame (Logistic)*** | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study characteristics** | | **Prevalence ratio  [95% CI]** | **p-value** | **Prevalence ratio  [95% CI]** | **p-value** | **Odds ratio**  **[95% CI]** | **p-value** |
| **Sample frame** | |  |  |  |  |  |  |
|  | Households | Reference | - | - | - | - | - |
|  | Blood donors | 1.64 [1.21-2.22] | <0.0001 |  |  |  |  |
|  | Residual sera | 0.90 [0.70-1.17] | 0.440 |  |  |  |  |
|  | Pregnant or parturient women | 2.00 [0.89-4.51] | 0.095 |  |  |  |  |
|  | Multiple general populations | 0.59 [0.18-1.97] | 0.39 |  |  |  |  |
| **PHSM index (0-10)** | |  |  |  |  |  |  |
|  | Average PHSM index up to study | 0.90 [0.80-1.01] | 0.083 | 0.88 [0.78- 0.99] | 0.034 | 0.87 [0.76-0.99] | 0.040 |
| **Cases per 100 pop.** | |  |  |  |  |  |  |
|  | Cases per 100 | 1.24 [1.12-1.37] | <0.0001 | 1.28 [1.16- 1.42] | <0.0001 | 1.27 [1.13-1.43] | <0.0001 |
| **Transmission phase** | |  |  |  |  |  |  |
|  | Before peak of 1st wave | Reference | - | Reference | - | Reference | - |
|  | After peak of 1st wave | 1.77 [1.33-2.35] | <0.0001 | 1.70 [1.28- 2.26] | 0.000 | 1.91 [1.38-2.64] | <0.0001 |
|  | After peak of 2nd wave | 2.79 [1.92-4.05] | <0.0001 | 2.68 [1.84- 3.91] | <0.0001 | 3.66 [2.39-5.62] | <0.0001 |
| **Geographic scope** | |  |  |  |  |  |  |
|  | National | Reference | - | Reference | - | Reference | - |
|  | Subnational | 1.46 [1.17-1.81] | 0.007 | 1.36 [1.10- 1.68] | 0.005 | 1.37 [1.07-1.74] | <0.0001 |
| **WHO region** | |  |  |  |  |  |  |
|  | Americas | Reference | - | Reference | - | Reference | - |
|  | Europe | 1.89 [1.45-2.47] | <0.0001 | 1.86 [1.44-2.41] | <0.0001 | 1.97 [1.47-2.63] | <0.0001 |
|  | Africa | 1.69 [0.98-2.98] | 0.061 | 1.80 [1.03-3.13] | 0.038 | 1.95 [1.04-3.67] | 0.039 |
|  | Eastern Mediterranean | 2.57 [1.66-3.99] | <0.0001 | 2.41 [1.55-3.74] | <0.0001 | 2.63 [1.59-4.35] | <0.0001 |
|  | South-East Asia | 1.72 [0.99-2.98] | 0.054 | 1.77 [1.01-3.09] | 0.045 | 1.83 [0.97-3.45] | 0.062 |
|  | Western Pacific | 0.20 [0.11-0.37] | <0.0001 | 0.19 [0.11-0.35] | <0.0001 | 0.16 [0.08-0.31] | <0.0001 |
| **Income class** | |  |  |  |  |  |  |
|  | High income country | Reference | - | Reference | - | Reference | - |
|  | Upper middle income country | 4.73 [3.31- 6.74] | <0.0001 | 4.47 [3.21- 6.23] | <0.0001 | 5.06 [3.504- 7.32] | <0.0001 |
|  | Lower middle income country | 8.83 [5.31- 14.69] | <0.0001 | 8.47 [5.17- 13.89] | <0.0001 | 13.35 [5.618- 31.73] | <0.0001 |
|  | Low income country | 6.43 [3.07- 13.47] | <0.0001 | 7.44 [3.67- 15.09] | <0.0001 | 12.41 [6.720- 22.92] | <0.0001 |
| **Age** | |  |  |  |  |  |  |
|  | Adults (18-64 years) | Reference | - | Reference | - | Reference | - |
|  | Multiple groups | 1.93 [1.32-2.83] | 0.001 | 1.46 [1.05-2.04] | 0.024 |  |  |
|  | Seniors (65+ years) | 1.65 [0.62-4.34] | 0.31 | 1.31 [0.50-3.44] | 0.58 |  |  |
|  | Children and youth (0-17 years) | 5.25 [2.93-9.41] | <0.0001 | 3.40 [2.04-5.68] | <0.0001 |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  | Number of studies | 305 |  | 305 |  | 305 |  |
|  | τ2 (SE) | 0.78 (0.88) |  | 0.79 (0.89) |  | 0.90 (0.95) |  |
|  | Marginal R2 | 63.02% |  | 60.90% |  | 61.80% |  |
|  | AIC | 1693.47 |  | 1699.54 |  | 1726.01 |  |

# S5 References for all included studies

1. Sachathep K, Kainne E, Cecile BA, et al. Seroprevalence of SARS-CoV-2 in 10 Regional Capitals of Cameroon. Published online November 2021. doi:[*10.5281/ZENODO.5680032*](https://doi.org/10.5281/ZENODO.5680032)

2. Tadesse EB, Endris AA, Solomon H, et al. Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: A cross-sectional evaluation during July 2020. *International Journal of Infectious Diseases*. 2021;111:179-185. doi:[*10.1016/j.ijid.2021.08.028*](https://doi.org/10.1016/j.ijid.2021.08.028)

3. Uyoga S, Adetifa IMO, Otiende M, et al. Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021. *JAMA*. Published online September 2021. doi:[*10.1001/jama.2021.15265*](https://doi.org/10.1001/jama.2021.15265)

4. Adetifa IMO, Uyoga S, Gitonga JN, et al. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. *Nature Communications*. 2021;12(1):3966. doi:[*10.1038/s41467-021-24062-3*](https://doi.org/10.1038/s41467-021-24062-3)

5. Mandolo J, Msefula J, Henrion M, et al. Data from: SARS-CoV-2 exposure in Malawian blood donors: An analysis of seroprevalence and variant dynamics between January 2020 and July 2021. Published online November 2021. doi:[*10.5281/ZENODO.5644207*](https://doi.org/10.5281/ZENODO.5644207)

6. Kagoli MM, Banda EC, Mwale A, et al. Community and Facility-based COVID-19 Surveillance in Selected Districts of Malawi. Published online November 2021. doi:[*10.5281/ZENODO.5711715*](https://doi.org/10.5281/ZENODO.5711715)

7. Talla C, Loucoubar C, Roka JL, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Senegal: A National Population-Based Cross-Sectional Survey, between October and November 2020. *SSRN Electronic Journal*. Published online 2021. doi:[*10.2139/ssrn.3925475*](https://doi.org/10.2139/ssrn.3925475)

8. Barrie MB, Lakoh S, Kelly JD, et al. SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: A cross-sectional, nationally representative, age-stratified serosurvey. *medRxiv*. Published online May 2021. doi:[*10.1101/2021.06.27.21259271*](https://doi.org/10.1101/2021.06.27.21259271)

9. Wolter N, Tempia S, Von Gottberg A, et al. *Seroprevalence of SARS-CoV-2 After the Second Wave in South Africa in HIV-Infected and Uninfected Persons: A Cross-Sectional Household Survey, November 2020 April 2021*. Social Science Research Network; 2021. doi:[*10.2139/ssrn.3957112*](https://doi.org/10.2139/ssrn.3957112)

10. Vermeulen M. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021 | Research Square. Published online July 2021.

11. Bosa, Henry Kyobe, Ario, Alex R., Wamala, Robert, et al. Population-based, Age- and Gender- Stratified Sero-Survey Study for SARS-CoV-2 in Uganda. Published online February 2022. doi:[*10.5281/ZENODO.5961443*](https://doi.org/10.5281/ZENODO.5961443)

12. Mulenga LB, Hines JZ, Fwoloshi S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: A cross-sectional cluster sample survey. *The Lancet Global Health*. 2021;0(0). doi:[*10.1016/S2214-109X(21)00053-X*](https://doi.org/10.1016/S2214-109X(21)00053-X)

13. Hines JZ, Fwoloshi S, Kampamba D, et al. SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020. *Emerging Infectious Diseases*. 2021;27(8):2166-2168. doi:[*10.3201/eid2708.210502*](https://doi.org/10.3201/eid2708.210502)

14. Barros FC, Hartwig FP, Barros AJD, et al. COVID-19 and social distancing among children and adolescents in Brazil. *Revista De Saude Publica*. 2021;55:42. doi:[*10.11606/s1518-8787.2021055003832*](https://doi.org/10.11606/s1518-8787.2021055003832)

15. Paulino-Ramirez R, Báez AA, Degaudenzi AV, Tapia L. Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic. *The American Journal of Tropical Medicine and Hygiene*. 2020;103(6):2343-2346. doi:[*10.4269/ajtmh.20-0907*](https://doi.org/10.4269/ajtmh.20-0907)

16. Rene Mejía Nùñez M, Lara J Ángel, Araujo Pleitez S, Ariel Ramírez G. Vista de Vigilancia seroepidemiológica de la circulación del SARS-CoV-2 en 41 municipios de Honduras sin reporte de casos activos, COVID-19, del 16- 23 junio 2020. | Población y Salud en Mesoamérica. *Revista Población y Salud en Mesoamérica*. 2020;18(2). doi:[*10.15517/psm.v18i2.43261*](https://doi.org/10.15517/psm.v18i2.43261)

17. Canto-Osorio F, Stern D, Pérez-Ferrer C, et al. Seroprevalencia de SARS-CoV-2 en niños y adolescentes mexicanos en edad escolar. *Salud Pública de México*. 2021;63(6, Nov-Dic):803-806. doi:[*10.21149/12847*](https://doi.org/10.21149/12847)

18. Canadian Blood Services. *COVID-19 Seroprevalence Report November 30th, 2021 Report #14: September 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

19. Canadian Blood Services. *COVID-19 Seroprevalence Report October 13, 2021 Report #13: August 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

20. Canadian Blood Services. *COVID-19 Seroprevalence Report October 13, 2021 Report #12: July 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

21. Canadian Blood Services. *COVID-19 Seroprevalence Report August 30, 2021 Report #11: June 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

22. Canadian Blood Services. *COVID-19 Seroprevalence Report July 27, 2021 Report #10: May 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

23. Canadian Blood Services. *COVID-19 Seroprevalence Report June 30, 2021 Report #9: April 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

24. Canadian Blood Services. *COVID-19 Seroprevalence Report June 9, 2021 Report #8: March 2021 Survey Tracking Seroprevalence in the Vaccine Era*.; 2021.

25. Canadian Blood Services. *COVID-19 Seroprevalence Report May 10, 2021 Report #7: January 2021 Survey Monitoring Immunity in the Vaccine Era*.; 2021.

26. Canadian Blood Services CBS. *COVID-19 Seroprevalence Report 4 January 12, 2021*.; 2021.

27. Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O’Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. *Transfusion*. 2021;61(3):862-872. doi:[*10.1111/trf.16296*](https://doi.org/10.1111/trf.16296)

28. Vial PA, González C, Icaza G, et al. Seroprevalence, Spatial Distribution, and Social Determinants of SARS-CoV-2 in Three Urban Centers of Chile. *SSRN Electronic Journal*. Published online 2021. doi:[*10.2139/ssrn.3933650*](https://doi.org/10.2139/ssrn.3933650)

29. Jones JM, Stone M, Sulaeman H, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. *JAMA*. Published online September 2021. doi:[*10.1001/jama.2021.15161*](https://doi.org/10.1001/jama.2021.15161)

30. Sullivan PS, Siegler AJ, Shioda K, et al. SARS-CoV-2 cumulative incidence, United States, August-December 2020. *Clinical Infectious Diseases*. 2021;(ciab626). doi:[*10.1093/cid/ciab626*](https://doi.org/10.1093/cid/ciab626)

31. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: A cross-sectional study. *The Lancet*. 2020;396(10259):1335-1344. doi:[*10.1016/S0140-6736(20)32009-2*](https://doi.org/10.1016/S0140-6736(20)32009-2)

32. Khalagi K, Gharibzadeh S, Khalili D, et al. Prevalence of COVID-19 in Iran: Results of the first survey of the Iranian COVID-19 Serological Surveillance programme. *Clinical Microbiology and Infection*. 2021;0(0). doi:[*10.1016/j.cmi.2021.06.002*](https://doi.org/10.1016/j.cmi.2021.06.002)

33. Poustchi H, Darvishian M, Mohammadi Z, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study. *The Lancet Infectious Diseases*. 2020;0(0). doi:[*10.1016/S1473-3099(20)30858-6*](https://doi.org/10.1016/S1473-3099(20)30858-6)

34. Bellizzi S, Alsawalha L, Sheikh Ali S, et al. A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan. *One Health*. 2021;13:100292. doi:[*10.1016/j.onehlt.2021.100292*](https://doi.org/10.1016/j.onehlt.2021.100292)

35. Al-Abri SS, Al-Wahaibi A, Al-Kindi H, et al. SARS-COV-2 antibody seroprevalence in the general population of Oman: Results from four successive nationwide seroepidemiological surveys. *International Journal of Infectious Diseases*. 2021;112:269-277. doi:[*10.1016/j.ijid.2021.09.062*](https://doi.org/10.1016/j.ijid.2021.09.062)

36. Haq M, Rehman A, Ahmad J, et al. SARS-CoV-2: Big seroprevalence data from Pakistanis herd immunity at hand? *Infection*. Published online May 2021. doi:[*10.1007/s15010-021-01629-2*](https://doi.org/10.1007/s15010-021-01629-2)

37. Coyle PV, Chemaitelly H, Ben Hadj Kacem MA, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. *iScience*. 2021;24(6):102646. doi:[*10.1016/j.isci.2021.102646*](https://doi.org/10.1016/j.isci.2021.102646)

38. Popova AYu, Tarasenko AA, Smolensky VYu, et al. Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic. *Russian Journal of Infection and Immunity*. 2021;11(5):887-904. doi:[*10.15789/2220-7619-HIT-1798*](https://doi.org/10.15789/2220-7619-HIT-1798)

39. Bokonjic D. A NATIONAL STUDY OF SEROPREVALENCE OF COVID-19 INFECTION IN THE POPULATION OF THE REPUBLIKA SRPSKA. Published online November 2021. doi:[*10.5281/ZENODO.5645793*](https://doi.org/10.5281/ZENODO.5645793)

40. Zhussupov B, Kaidar E, Suleimenova Z, et al. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, Republic of Kazakhstan. Published online November 2021. doi:[*10.5281/ZENODO.5646794*](https://doi.org/10.5281/ZENODO.5646794)

41. Popova AY, Kasymov OT, Smolenski VY, et al. SARS-CoV-2 Herd Immunity of the Kyrgyz Population in 2021. Published online December 2021. doi:[*10.21203/rs.3.rs-1138128/v1*](https://doi.org/10.21203/rs.3.rs-1138128/v1)

42. Kuchuk T, Nurmatov Z, Kasymbekova K. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection in Kyrgyz Republic. Published online November 2021. doi:[*10.5281/ZENODO.5645779*](https://doi.org/10.5281/ZENODO.5645779)

43. Ceban A, Gheorghita S. Serological surveillance of COVID-19 in the general population of Moldova. Published online November 2021. doi:[*10.5281/ZENODO.5645781*](https://doi.org/10.5281/ZENODO.5645781)

44. R. A. R, N. S. I, A. S. K, et al. FORMATION OF HERD IMMUNITY TO SARS-CoV-2 IN THE REGIONS OF UZBEKISTAN. *European Journal of Molecular & Clinical Medicine*. 2021;8(3):574-581.

45. Royo-Cebrecos C, Vilanova D, López J, et al. Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra. *The Lancet Regional Health - Europe*. 2021;5:100119. doi:[*10.1016/j.lanepe.2021.100119*](https://doi.org/10.1016/j.lanepe.2021.100119)

46. Herzog SA, Bie JD, Abrams S, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium - a serial prospective cross-sectional nationwide study of residual samples. *medRxiv*. Published online April 2021:2020.06.08.20125179. doi:[*10.1101/2020.06.08.20125179*](https://doi.org/10.1101/2020.06.08.20125179)

47. Fogh K, Eriksen AR, Hasselbalch RB, et al. *Seroprevalence of SARS-CoV-2 Antibodies in Social Housing Areas in Denmark*. Epidemiology; 2021. doi:[*10.1101/2021.05.07.21256725*](https://doi.org/10.1101/2021.05.07.21256725)

48. Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: Nationwide, population-based seroepidemiological study. *European Journal of Epidemiology*. 2021;36(7):715-725. doi:[*10.1007/s10654-021-00796-8*](https://doi.org/10.1007/s10654-021-00796-8)

49. Fogh K, Strange JE, Scharff BF, et al. Testing Denmark: A Danish nationwide surveillance study of COVID-19. *medRxiv*. Published online August 2021. doi:[*10.1101/2021.08.10.21261777*](https://doi.org/10.1101/2021.08.10.21261777)

50. Pedersen OB, Nissen J, Dinh KM, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Fatality Rate Among Elderly Danes: A Cross-sectional Study on Retired Blood Donors. *Clinical Infectious Diseases*. 2020;(ciaa1627). doi:[*10.1093/cid/ciaa1627*](https://doi.org/10.1093/cid/ciaa1627)

51. Erikstrup C, Hother CE, Pedersen OBV, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *medRxiv*. Published online April 2020:2020.04.24.20075291. doi:[*10.1101/2020.04.24.20075291*](https://doi.org/10.1101/2020.04.24.20075291)

52. Merit Melin, Arto Palmu. Report of THL serological population study of the coronavirus epidemic. *thl*. Published online August 2021.

53. Le Vu S, Jones G, Anna F, et al. Prevalence of SARS-CoV-2 antibodies in France: Results from nationwide serological surveillance. *Nature Communications*. 2021;12(1):3025. doi:[*10.1038/s41467-021-23233-6*](https://doi.org/10.1038/s41467-021-23233-6)

54. Fuest C, Neumeier F, Peichl A, Charité - Universitätsmedizin Berlin, Forsa Gesellschaft für Sozialforschung und statistische Analysen mbH, GmbH PHS. *Die Deutschen und Corona*. ifo Institut; 2020.

55. Gornyk D, Harries M, Glöckner S, et al. SARS-CoV-2 Seroprevalence in Germany - A Population Based Sequential Study in Five Regions. *SSRN*. Published online April 2021.

56. Merkely B, Szabó AJ, Kosztin A, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *GeroScience*. 2020;42(4):1063-1074. doi:[*10.1007/s11357-020-00226-9*](https://doi.org/10.1007/s11357-020-00226-9)

57. Indenbaum V, Lustig Y, Mendelson E, et al. Under-diagnosis of SARS-CoV-2 infections among children aged 0 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021. *Eurosurveillance*. 2021;26(48):2101040. doi:[*10.2807/1560-7917.ES.2021.26.48.2101040*](https://doi.org/10.2807/1560-7917.ES.2021.26.48.2101040)

58. Reicher S, Ratzon R, Ben-Sahar S, et al. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. *European Journal of Epidemiology*. Published online April 2021. doi:[*10.1007/s10654-021-00749-1*](https://doi.org/10.1007/s10654-021-00749-1)

59. Instituto Nazionale di Statistica. *PRIMI RISULTATI DELL’INDAGINE DI SIEROPREVALENZA SUL SARS-CoV-2*. Instituto Nazionale di Statistica; 2020.

60. Jersey S. *SARS-CoV-2: Prevalence of Antibodies in Jersey Community Survey Round 3*. Statistics Jersey; 2020.

61. Šmigelskas K, Petrikonis K, Kasiulevičius V, et al. SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey. *Acta medica Lituanica*. 2021;28(1):2. doi:[*10.15388/Amed.2020.28.1.2*](https://doi.org/10.15388/Amed.2020.28.1.2)

62. Snoeck C. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: The CON-VINCE study. *Pre-print*.

63. Tunheim G, Rø GØI, Tran T, et al. Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic. *Influenza and Other Respiratory Viruses*. Published online November 2021:irv.12932. doi:[*10.1111/irv.12932*](https://doi.org/10.1111/irv.12932)

64. Kislaya I, Gonçalves P, Barreto M, et al. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). *Acta Médica Portuguesa*. 2021;34(2):87-94. doi:[*10.20344/amp.15122*](https://doi.org/10.20344/amp.15122)

65. Poljak M, Oštrbenk Valenčak A, Štrumbelj E, et al. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: Results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned. *Clinical Microbiology and Infection*. Published online April 2021:S1198743X21001440. doi:[*10.1016/j.cmi.2021.03.009*](https://doi.org/10.1016/j.cmi.2021.03.009)

66. Pérez-Olmeda M, Saugar JM, Fernández-García A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the Nationwide Seroprevalence ENE-COVID Study in Spain. *medRxiv*. Published online March 2021. doi:[*10.1101/2021.03.11.21253142*](https://doi.org/10.1101/2021.03.11.21253142)

67. Prados N, González-Ravina C, Vergara V, Herrero J, Cruz M, Requena A. RISK FACTOR ANALYSIS FOR SARS-COV-2 SEROPOSITIVITY WITHIN ASSISTED REPRODUCTIVE. *Fertility and Sterility*. 2020;114(3):e547. doi:[*10.1016/j.fertnstert.2020.09.077*](https://doi.org/10.1016/j.fertnstert.2020.09.077)

68. Agency SPH. Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården.

69. Agency SPH. Påvisning av antikroppar mot SARS-CoV-2 i blodprov från öppenvården. *2021-07-19*.

70. Agency SPH. *Påvisning Av Antikroppar Efter Genomgången Covid-19 Hos Blodgivare (Delrapport 2)*. Swedish Public Health Agency; 2021.

71. Oeser C, Whitaker H, Linley E, et al. Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the delta wave and vaccination. *Journal of Infection*. 2021;0(0). doi:[*10.1016/j.jinf.2021.11.019*](https://doi.org/10.1016/j.jinf.2021.11.019)

72. Scotland PH. *Enhanced Surveillance of COVID-19 in Scotland - Population-based Seroprevalence Surveillance 3 November 2021*. Public Health Scotland; 2021.

73. Scotland PH. *Enhanced Surveillance of COVID-19 in Scotland - Population-based Seroprevalence Surveillance 25 August 2021*. Public Health Scotland; 2021.

74. Scotland PH. *Enhanced Surveillance of COVID-19 in Scotland - Population-based Seroprevalence Surveillance 21 July 2021*. Public Health Scotland; 2021.

75. Public health Scotland. *Enhanced Surveillance of COVID-19 in Scotland 16 June 2021*. Public Health Scotland; 2021.

76. Public health Scotland. *Enhanced Surveillance of COVID-19 in Scotland 12 May 2021*. Public Health Scotland; 2021.

77. Aldridge RW, Pineo H, Fragaszy E, et al. Household overcrowding and risk of SARS-CoV-2: Analysis of the Virus Watch prospective community cohort study in England and Wales. *medRxiv*. Published online May 2021:2021.05.10.21256912. doi:[*10.1101/2021.05.10.21256912*](https://doi.org/10.1101/2021.05.10.21256912)

78. Beale S, Patel P, Rodger A, et al. Occupation, Work-Related Contact, and SARS-CoV-2 Anti-Nucleocapsid Serological Status: Findings from the Virus Watch prospective cohort study. *medRxiv*. Published online May 2021:2021.05.13.21257161. doi:[*10.1101/2021.05.13.21257161*](https://doi.org/10.1101/2021.05.13.21257161)

79. Whitaker HJ, Elgohari S, Rowe C, et al. Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021. *Journal of Infection*. 2021;0(0). doi:[*10.1016/j.jinf.2021.04.037*](https://doi.org/10.1016/j.jinf.2021.04.037)

80. Public health Scotland. *Enhanced Surveillance of COVID-19 in Scotland 7 April 2021*. Public Health Scotland; 2021.

81. Public health Scotland. *Enhanced Surveillance of COVID-19 in Scotland 3 March 2021*. Public Health Scotland; 2021.

82. Public health Scotland. *Enhanced Surveillance of COVID-19 in Scotland 27 January 2021*. Public Health Scotland; 2021.

83. Ladhani S. *Prospective Active National Surveillance of Preschools and Primary Schools for SARS-CoV-2 Infection and Transmission in England, June 2020*. Social Science Research Network; 2021.

84. Public health Scotland. *Enhanced Surveillance of COVID-19 in Scotland 23 December 2020*.; 2020.

85. England PH. *National COVID-19 Surveillance Report: 28 May 2020 (Week 22)*. Public Health England; 2020.

86. Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 2021;108:145-155. doi:[*10.1016/j.ijid.2021.05.040*](https://doi.org/10.1016/j.ijid.2021.05.040)

87. Wahyono TYM, Mahkota R, Ansariadi H, et al. Population-based Age-Stratified Seroepidemiological Investigation for Coronavirus 2019 (COVID-19) Infection in Indonesia. Published online November 2021. doi:[*10.5281/ZENODO.5665348*](https://doi.org/10.5281/ZENODO.5665348)

88. Government of Nepal. *Enhanced Surveillance on Sero-Prevalence of SARS-CoV-2 In General Population*. Government of Nepal; 2021.

89. Nakphook S, Iamsirithavorn S, Puthavathana P Pilaipan, et al. Age-stratified sero-surveillance for SARS-CoV-2 infections in four cities in Thailand. Published online November 2021. doi:[*10.5281/ZENODO.5703307*](https://doi.org/10.5281/ZENODO.5703307)

90. Coatsworth N, Myles PS, Mann GJ, et al. Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: A prospective surveillance study. *ANZ Journal of Surgery*. 2021;91(1-2):27-32. doi:[*10.1111/ans.16564*](https://doi.org/10.1111/ans.16564)

91. Li Z, Guan X, Mao N, et al. Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China. *The Lancet Regional Health Western Pacific*. 2021;8. doi:[*10.1016/j.lanwpc.2021.100094*](https://doi.org/10.1016/j.lanwpc.2021.100094)

92. Zhuo Lin C, Hatta Bin Abdul Mutalip M, Ani binti Ahmad N. POPULATION-BASED SEROPREVALENCE SURVEY OF COVID-19 VIRUS INFECTION IN MALAYSIA. Published online November 2021. doi:[*10.5281/ZENODO.5645887*](https://doi.org/10.5281/ZENODO.5645887)

93. Chimeddorj B, Nyamadawa P, Davaalkham D, et al. Novel Coronavirus (COVID-19) Population-Based Age-Stratified Sero-Epidemiological Study in Mongolia (A Prospective, Nationwide Study). Published online November 2021. doi:[*10.5281/ZENODO.5646781*](https://doi.org/10.5281/ZENODO.5646781)

94. Lavu E, Mapira P, Ila R, et al. Seroprevalence of COVID-19 in Papua New Guinea. Published online November 2021. doi:[*10.5281/ZENODO.5703345*](https://doi.org/10.5281/ZENODO.5703345)

95. Nah EH, Cho S, Park H, Hwang I, Cho HI. Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea: A cross-sectional study. *BMJ Open*. 2021;11(4):e049837. doi:[*10.1136/bmjopen-2021-049837*](https://doi.org/10.1136/bmjopen-2021-049837)

96. Makiala-Mandanda, Sheila, Folefack, Gervais Léon, Ahuka, Steve, et al. Seroprevalence survey on infection with the SARS-CoV-2 virus after the second wave in Kinshasa, Democratic Republic of the Congo. 2021. Published online November 2021. doi:[*10.5281/ZENODO.5644148*](https://doi.org/10.5281/ZENODO.5644148)

97. Assefa N, Regassa LD, Teklemariam Z, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: A facility-based surveillance. *BMJ Open*. 2021;11(11):e055834. doi:[*10.1136/bmjopen-2021-055834*](https://doi.org/10.1136/bmjopen-2021-055834)

98. Donkor IO, Akorli J, Abuaku B, et al. SARS CoV-2 Seroprevalence in Rural and Urban Populations In Ghana. Published online December 2021. doi:[*10.5281/ZENODO.5771207*](https://doi.org/10.5281/ZENODO.5771207)

99. Kolawole O, Tomori O, Agbonlahor D, et al. Population-based Age-stratified Seroprevalence Investigation on SARS-CoV-2 Virus in Selected States of High and Low Burden of Disease in Nigeria. Published online November 2021. doi:[*10.5281/ZENODO.5644223*](https://doi.org/10.5281/ZENODO.5644223)

100. Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria. *International Journal of Infectious Diseases*. Published online July 2021. doi:[*10.1016/j.ijid.2021.07.040*](https://doi.org/10.1016/j.ijid.2021.07.040)

101. Ilori E, Stafford K, Steinhardt L, et al. Nigeria COVID-19 Household Seroprevalence Survey. Published online November 2021. doi:[*10.5281/ZENODO.5644231*](https://doi.org/10.5281/ZENODO.5644231)

102. Majiya H, Aliyu-Paiko M, Balogu VT, et al. Seroprevalence of COVID-19 in Niger State. *medRxiv*. Published online August 2020. doi:[*10.1101/2020.08.04.20168112*](https://doi.org/10.1101/2020.08.04.20168112)

103. George JA, Khoza S, Mayne E, et al. Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August - October 2020. *South African Medical Journal*. 2021;111(11):1078-1083. doi:[*10.7196/SAMJ.2021.v111i11.15669*](https://doi.org/10.7196/SAMJ.2021.v111i11.15669)

104. Barros AJD, Victora CG, Menezes AMB, et al. Population-level seropositivity trend for SARS-Cov-2 in Rio Grande do Sul, Brazil. *Revista de Saúde Pública*. 2021;55:78. doi:[*10.11606/s1518-8787.2021055004075*](https://doi.org/10.11606/s1518-8787.2021055004075)

105. Albuquerque JOM de, Kamioka GA. Prevalence evolution of SARS-CoV-2 infection in the city of São Paulo, 2020. *Revista de Saúde Pública*. 2021;55:62-62. doi:[*10.11606/s1518-8787.2021055003970*](https://doi.org/10.11606/s1518-8787.2021055003970)

106. da Silva AAM. *Prevalência Da Infecção Pelo Vírus SARS-Cov-2 No Maranhão, Brasil - Fase 2*. Universidade Federal do Maranhão; 2020.

107. Schneider APH, Gaedke MÂ, Koepp J, et al. [Social distancing as protection factor against COVID-19 in a non-metropolitan area in the State of Rio Grande do Sul, BrazilLas medidas de distanciamiento social como factor de protección contra la COVID-19 en el interior de Rio Grande do Sul, Brasil]. *Revista Panamericana De Salud Publica = Pan American Journal of Public Health*. 2021;45:e145. doi:[*10.26633/RPSP.2021.145*](https://doi.org/10.26633/RPSP.2021.145)

108. Hallal PC, Silveira MF, Menezes AMB, et al. Slow Spread of SARS-CoV-2 in Southern Brazil Over a 6-Month Period: Report on 8 Sequential Statewide Serological Surveys Including 35611 Participants. *American Journal of Public Health*. Published online June 2021:e1-e9. doi:[*10.2105/AJPH.2021.306351*](https://doi.org/10.2105/AJPH.2021.306351)

109. Maciel ELN, Gomes CC, Almada GL, et al. COVID-19 em crianças, adolescentes e jovens: Estudo transversal no Espírito Santo, 2020. *Epidemiologia e Serviços de Saúde*. 2021;30(4):e20201029. doi:[*10.1590/s1679-49742021000400001*](https://doi.org/10.1590/s1679-49742021000400001)

110. Concha G, Frickmann H, Oey A, Strengert M, Kreienbrock L, Kann S. Direct and Indirect Proof of SARS-CoV-2 Infections in Indigenous Wiwa Communities in North-Eastern Colombia. *Vaccines*. 2021;9(10):1120. doi:[*10.3390/vaccines9101120*](https://doi.org/10.3390/vaccines9101120)

111. Garay E, Serrano-Coll H, Rivero R, et al. SARS-CoV-2 in eight municipalities of the Colombian tropics: High immunity, clinical and sociodemographic outcomes. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. Published online June 2021. doi:[*10.1093/trstmh/trab094*](https://doi.org/10.1093/trstmh/trab094)

112. Guzman NA, De la Hoz Restrepo F, Serrano-Coll H, Gastelbondo B, Mattar S. Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department. *International Journal of Infectious Diseases*. Published online June 2021:S1201971221005075. doi:[*10.1016/j.ijid.2021.06.018*](https://doi.org/10.1016/j.ijid.2021.06.018)

113. Huamaní C, Velásquez L, Montes S, Mayanga-Herrera A, Bernabé-Ortiz A. SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study. *PeerJ*. 2021;9:e12149. doi:[*10.7717/peerj.12149*](https://doi.org/10.7717/peerj.12149)

114. Héma-Québec. *Phase 2 de l’étude Sur La Séroprévalence Des Anticorps Dirigés Contre Le SRAS-CoV-2 Au Québec*. Héma-Québec; 2021.

115. Charlton CL, Nguyen LT, Bailey A, et al. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic. Bard JD, ed. *Microbiology Spectrum*. Published online August 2021. doi:[*10.1128/Spectrum.00291-21*](https://doi.org/10.1128/Spectrum.00291-21)

116. Bolotin S, Tran V. COVID-19 Seroprevalence in Ontario; March 27 - October 30, 2020. Published online November 2021. doi:[*10.5281/ZENODO.5703273*](https://doi.org/10.5281/ZENODO.5703273)

117. Skowronski DM, Sekirov I, Sabaiduc S, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. *medRxiv*. Published online July 2020:2020.07.13.20153148. doi:[*10.1101/2020.07.13.20153148*](https://doi.org/10.1101/2020.07.13.20153148)

118. Vial, Pablo, González, Claudia, Icaza, Gloria, et al. Serial seroprevalence study: Follow-up of immunity to SARS-Cov-2 infection and monitoring of effective vaccination coverage, in three Chilean cities. Published online February 2022. doi:[*10.5281/ZENODO.5998971*](https://doi.org/10.5281/ZENODO.5998971)

119. Mehrotra ML, Lim E, Lamba K, et al. *CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021 July 2021*. Epidemiology; 2021. doi:[*10.1101/2021.12.09.21267565*](https://doi.org/10.1101/2021.12.09.21267565)

120. Boehme KW, Kennedy JL, Snowden J, et al. *Pediatric SARS-CoV-2 Seroprevalence in Arkansas over the First Year of the COVID-19 Pandemic*. Epidemiology; 2021. doi:[*10.1101/2021.08.04.21261592*](https://doi.org/10.1101/2021.08.04.21261592)

121. Wong MP, Meas MA, Adams C, et al. Development and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for Epidemiologic Studies. Published online November 2021:2021.11.25.21266786. doi:[*10.1101/2021.11.25.21266786*](https://doi.org/10.1101/2021.11.25.21266786)

122. Kennedy JL, Forrest JC, Young SG, et al. Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas. *medRxiv*. Published online July 2021:2021.07.15.21260213. doi:[*10.1101/2021.07.15.21260213*](https://doi.org/10.1101/2021.07.15.21260213)

123. Pressman A, Lockhart SH, Wilcox J, et al. COVID-19 in pregnancy by race and ethnicity: Implications for development of a vaccination strategy. *Women’s Health*. 2021;17:174550652110633. doi:[*10.1177/17455065211063300*](https://doi.org/10.1177/17455065211063300)

124. Levorson RE, Christian E, Hunter B, et al. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States. *PLOS ONE*. 2021;16(11):e0259823. doi:[*10.1371/journal.pone.0259823*](https://doi.org/10.1371/journal.pone.0259823)

125. Lopez CA, Cunningham CH, Pugh S, et al. Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period. *medRxiv*. Published online March 2021:2021.03.25.21254320. doi:[*10.1101/2021.03.25.21254320*](https://doi.org/10.1101/2021.03.25.21254320)

126. Adams C, Horton M, Solomon O, et al. *Impact of Individual-Level Characteristics and Transmission Mitigation Behaviors on SARS-CoV-2 Infection and Seroprevalence in a Large Northern California Bay Area Cohort*. Epidemiology; 2021. doi:[*10.1101/2021.12.02.21266871*](https://doi.org/10.1101/2021.12.02.21266871)

127. Kugeler KJ, Podewils LJ, Alden NB, et al. Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July 2020. *Public Health Reports*. Published online November 2021:003335492110551. doi:[*10.1177/00333549211055137*](https://doi.org/10.1177/00333549211055137)

128. Rogawski McQuade ET, Guertin KA, Becker L, et al. Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia. *JAMA Network Open*. 2021;4(2):e2035234. doi:[*10.1001/jamanetworkopen.2020.35234*](https://doi.org/10.1001/jamanetworkopen.2020.35234)

129. Mahajan S, Srinivasan R, Redlich CA, et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. *The American Journal of Medicine*. Published online October 2020. doi:[*10.1016/j.amjmed.2020.09.024*](https://doi.org/10.1016/j.amjmed.2020.09.024)

130. Haizler-Cohen L, Davidov A, Blitz MJ, Fruhman G. Severe acute respiratory syndrome coronavirus 2 antibodies in pregnant women admitted to labor and delivery units. *American Journal of Obstetrics & Gynecology*. 2020;0(0). doi:[*10.1016/j.ajog.2020.09.022*](https://doi.org/10.1016/j.ajog.2020.09.022)

131. Lim T, Delorey M, Bestul N, et al. Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March August, 2020. *Clinical Infectious Diseases*. 2021;(ciab185). doi:[*10.1093/cid/ciab185*](https://doi.org/10.1093/cid/ciab185)

132. Samore MH, Looney A, Orleans B, et al. Early Release - Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA - Volume 27, Number 11 2021 - Emerging Infectious Diseases journal - CDC. Published online September 2021. doi:[*10.3201/eid2711.204435*](https://doi.org/10.3201/eid2711.204435)

133. Sutton M. Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample Oregon, May 11 15, 2020. *MMWR Morbidity and Mortality Weekly Report*. 2020;69. doi:[*10.15585/mmwr.mm6932a4*](https://doi.org/10.15585/mmwr.mm6932a4)

134. Chan PA, King E, Xu Y, et al. Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample. *American Journal of Public Health*. 2021;111(4):700-703. doi:[*10.2105/AJPH.2020.306115*](https://doi.org/10.2105/AJPH.2020.306115)

135. Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample Indiana, April 25, 2020. *MMWR Morbidity and Mortality Weekly Report*. 2020;69(29):960-964. doi:[*10.15585/mmwr.mm6929e1*](https://doi.org/10.15585/mmwr.mm6929e1)

136. Shakiba M, Nazemipour M, Salari A, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. *Emerging Infectious Disease journal*. 2021;27(2). doi:[*10.3201/eid2702.201960*](https://doi.org/10.3201/eid2702.201960)

137. Mousavi SA, Rouhanizadeh H, Saeedi M, et al. Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran. *Asian Pacific Journal of Tropical Medicine*. 2021;14(1):10. doi:[*10.4103/1995-7645.304296*](https://doi.org/10.4103/1995-7645.304296)

138. Maraqa B, Basha W, Khayyat R, et al. Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study. *PLOS ONE*. 2021;16(10):e0258255. doi:[*10.1371/journal.pone.0258255*](https://doi.org/10.1371/journal.pone.0258255)

139. Alsuwaidi AR, Al Hosani FI, Al Memari S, et al. Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: A population-based cross-sectional study. *International Journal of Epidemiology*. 2021;(dyab077). doi:[*10.1093/ije/dyab077*](https://doi.org/10.1093/ije/dyab077)

140. Musa S. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection in the Federation of Bosnia and Herzegovina. Published online November 2021. doi:[*10.5281/ZENODO.5645820*](https://doi.org/10.5281/ZENODO.5645820)

141. Mouravi-Tarkhan O, Chitadze N. Sero-epidemiological Cross-sectional investigation on COVID-19 virus infection in Georgia. Published online November 2021. doi:[*10.5281/ZENODO.5703254*](https://doi.org/10.5281/ZENODO.5703254)

142. Rytter MJH, Nygaard U, Mandic IN, et al. Prevalence of SARS-CoV-2-Antibodies in Danish Children and Adults. *Pediatric Infectious Disease Journal*. 2021;40(4):e157-e159. doi:[*10.1097/INF.0000000000003048*](https://doi.org/10.1097/INF.0000000000003048)

143. Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. *The Lancet Infectious diseases*. Published online August 2020. doi:[*10.1016/S1473-3099(20)30589-2*](https://doi.org/10.1016/S1473-3099(20)30589-2)

144. Petersen MS, Strøm M, Christiansen DH, et al. Seroprevalence of SARS-CoV-2, Faroe Islands. *Emerging Infectious Diseases*. 2020;26(11):2760-2762. doi:[*10.3201/eid2611.202736*](https://doi.org/10.3201/eid2611.202736)

145. Capai L, Masse S, Fourié T, et al. Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People. *Frontiers in Public Health*. 2021;9:1078. doi:[*10.3389/fpubh.2021.715192*](https://doi.org/10.3389/fpubh.2021.715192)

146. Laub O, Leipold G, Toncheva AA, et al. Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children. *Frontiers in Pediatrics*. 2021;9:678937. doi:[*10.3389/fped.2021.678937*](https://doi.org/10.3389/fped.2021.678937)

147. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Eurosurveillance*. 2020;25(28). doi:[*10.2807/1560-7917.ES.2020.25.28.2001285*](https://doi.org/10.2807/1560-7917.ES.2020.25.28.2001285)

148. Ralli M, Arcangeli A, Soave PM, Voglino MC, De-Giorgio F. SARS-CoV-2 seroprevalence in the Vatican City State. *European Journal of Internal Medicine*. 2021;0(0). doi:[*10.1016/j.ejim.2021.01.029*](https://doi.org/10.1016/j.ejim.2021.01.029)

149. Calò F, Di Fraia A, Russo A, Di Biase A, Misso S, Coppola N. Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic. *Blood Transfusion*. Published online 2021. doi:[*10.2450/2021.0196-21*](https://doi.org/10.2450/2021.0196-21)

150. Stefanelli P, Bella A, Fedele G, et al. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: A population-based study. *Clinical Microbiology and Infection*. 2020;0(0). doi:[*10.1016/j.cmi.2020.11.013*](https://doi.org/10.1016/j.cmi.2020.11.013)

151. Castro LC e, Gomes A, Serrano M, et al. Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemic. Published online June 2021. doi:[*10.21203/rs.3.rs-603060/v1*](https://doi.org/10.21203/rs.3.rs-603060/v1)

152. Karachaliou M, Moncunill G, Espinosa A, et al. Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain. *Scientific Reports*. 2021;11(1):21571. doi:[*10.1038/s41598-021-00807-4*](https://doi.org/10.1038/s41598-021-00807-4)

153. Iruzubieta P, Fernández-Lanas T, Rasines L, et al. Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. *Scientific Reports*. 2021;11(1):9819. doi:[*10.1038/s41598-021-89236-x*](https://doi.org/10.1038/s41598-021-89236-x)

154. El May E, Anker D, Epure A, et al. *Corona Immunitas Fribourg Immunité de la population Episode 2/2021*. Université de Fribourg; 2021.

155. Anker D, Chiorelo A, Epure A, et al. *Corona Immunitas Fribourg Immunté de la population Episode 1/2020*. Corona Immunitas; 2020.

156. Richard A, Wisniak A, Perez-Saez J, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: A population-based study. *Scandinavian Journal of Public Health*. Published online October 2021:140349482110480. doi:[*10.1177/14034948211048050*](https://doi.org/10.1177/14034948211048050)

157. Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Subbarao K, ed. *Journal of Virology*. 2020;95(3):e01828-20, /jvi/95/3/JVI.01828-20.atom. doi:[*10.1128/JVI.01828-20*](https://doi.org/10.1128/JVI.01828-20)

158. Bi Q, Lessler J, Eckerle I, et al. *Household Transmission of SARS-CoV-2: Insights from a Population-based Serological Survey*. Epidemiology; 2020. doi:[*10.1101/2020.11.04.20225573*](https://doi.org/10.1101/2020.11.04.20225573)

159. Scotland PH. *Enhanced Surveillance of COVID-19 in Scotland - Population-based Seroprevalence Surveillance 8 December 2021*. Public Health Scotland; 2021.

160. Office for National Statistics. *Coronavirus (COVID-19) Antibody and Vaccination Data for the UK*. Office for National Statistics; 2021.

161. Steel K, Davies B. *Coronavirus (COVID-19) Infection Survey: Characteristics of People Testing Positive for COVID-19 in England and Antibody Data for the UK - Office for National Statistics*. Office for National Statistics; 2020:12.

162. Thompson CP, Grayson NE, Paton RS, et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. *Eurosurveillance*. 2020;25(42):2000685. doi:[*10.2807/1560-7917.ES.2020.25.42.2000685*](https://doi.org/10.2807/1560-7917.ES.2020.25.42.2000685)

163. Department of Health & Family Welfare, Government of Kerala. *COVID 19 SERO SURVEILLANCE REPORT August - September 2021*. Government of Kerala; :84.

164. Misra P, Kant S, Rai S, et al. A Multi-Centric Novel Coronavirus (COVID-19) Population-Based Age-Stratified Sero-Epidemiological Study (In Urban, Rural and Tribal Communities at Selected Centers in India: A Prospective Study). Published online November 2021. doi:[*10.5281/ZENODO.5703289*](https://doi.org/10.5281/ZENODO.5703289)

165. Sharma N, Sharma P, Basu S, et al. Second wave of the Covid-19 pandemic in Delhi, India: High seroprevalence not a deterrent? *medRxiv : the preprint server for health sciences*. Published online 2021. doi:[*10.1101/2021.09.09.21263331*](https://doi.org/10.1101/2021.09.09.21263331)

166. Khan SMS, Qurieshi MA, Haq I, et al. Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: Results of a population-based seroprevalence survey from October to November 2020. *BMJ Open*. 2021;11(9):e053791. doi:[*10.1136/bmjopen-2021-053791*](https://doi.org/10.1136/bmjopen-2021-053791)

167. Sharma N, Sharma P, Basu S, et al. The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: A repeated population-based seroepidemiological study. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. Published online August 2021:trab109. doi:[*10.1093/trstmh/trab109*](https://doi.org/10.1093/trstmh/trab109)

168. Kar SS, Sarkar S, Murali S, Dhodapkar R, Joseph NM, Aggarwal R. Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August 2020. *Emerging Infectious Diseases*. 2021;27(2):666-669. doi:[*10.3201/eid2702.204480*](https://doi.org/10.3201/eid2702.204480)

169. Namasivayam V, Jain A, Agrawal V, et al. Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India. *Journal of Epidemiology and Global Health*. Published online October 2021. doi:[*10.1007/s44197-021-00012-6*](https://doi.org/10.1007/s44197-021-00012-6)

170. Satpati P, Sarangi S, Gantait K, et al. *Sero-Surveillance (IgG) of SARS-CoV-2 Among Asymptomatic General Population of Paschim Medinipur, West Bengal, India*. Infectious Diseases (except HIV/AIDS); 2020. doi:[*10.1101/2020.09.12.20193219*](https://doi.org/10.1101/2020.09.12.20193219)

171. Khan SMS, Qurieshi MA, Haq I, et al. Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India A cross-sectional study. *PLOS ONE*. 2020;15(11):e0239303. doi:[*10.1371/journal.pone.0239303*](https://doi.org/10.1371/journal.pone.0239303)

172. Delhi P. *Sero-Prevalence Study Conducted by National Center for Disease Control NCDC, MoHFW, in Delhi, June 2020*. Indian Ministry of Health and Family Welfare; 2020.

173. Megasari NLA, Utsumi T, Yamani LN, et al. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. *PLOS ONE*. 2021;16(5):e0251234. doi:[*10.1371/journal.pone.0251234*](https://doi.org/10.1371/journal.pone.0251234)

174. He Z, Ren L, Yang J, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: A longitudinal, population-level, cross-sectional study. *The Lancet*. 2021;397(10279):1075-1084. doi:[*10.1016/S0140-6736(21)00238-5*](https://doi.org/10.1016/S0140-6736(21)00238-5)

175. Prefecture of Hiroshima. *About the result of the 2nd new coronavirus antibody prevalence survey*. Prefecture of Hiroshima; 2021.

176. Sam IC, Chong YM, Abdullah A, et al. Changing predominant SARS-CoV-2 lineages drives successive COVID-19 waves in Malaysia, February 2020 to March 2021. *Journal of Medical Virology*. 2021;n/a(n/a). doi:[*10.1002/jmv.27441*](https://doi.org/10.1002/jmv.27441)

177. Sebastião CS, Galangue M, Gaston C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola. *BMC Infectious Diseases*. 2021;21(1):1131. doi:[*10.1186/s12879-021-06814-0*](https://doi.org/10.1186/s12879-021-06814-0)

178. Dabakuyo Yonli S, Traoré I, Tinto H, Ouédraogo S. ÉMuL-COVID-19: A Multidisciplinary study against COVID-19 in Burkina Faso. Published online November 2021. doi:[*10.5281/ZENODO.5644217*](https://doi.org/10.5281/ZENODO.5644217)

179. Nwosu K, Fokam J, Wanda F, et al. SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. *Nature Communications*. 2021;12(1):5851. doi:[*10.1038/s41467-021-25946-0*](https://doi.org/10.1038/s41467-021-25946-0)

180. Manirakiza A, Malaka C, Yambiyo BM, Marie-Astrid Vernet, Vernet G, Nakoune E. Seroprevalence of anti-SARS-CoV-2 antibodies among communities in Bangui, Central African Republic. Published online December 2021. doi:[*10.5281/ZENODO.5794867*](https://doi.org/10.5281/ZENODO.5794867)

181. Nkuba AN, Makiala SM, Guichet E, et al. High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: Results of a cross-sectional household-based survey. *Clinical Infectious Diseases*. Published online June 2021:ciab515. doi:[*10.1093/cid/ciab515*](https://doi.org/10.1093/cid/ciab515)

182. Gudina EK, Ali S, Girma E, et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: Longitudinal cohort study among front-line hospital workers and communities. *The Lancet Global Health*. 2021;9(11):e1517-e1527. doi:[*10.1016/S2214-109X(21)00386-7*](https://doi.org/10.1016/S2214-109X(21)00386-7)

183. Abdella S, Riou S, Tessema M, et al. Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic. *EClinicalMedicine*. 2021;35:100880. doi:[*10.1016/j.eclinm.2021.100880*](https://doi.org/10.1016/j.eclinm.2021.100880)

184. Shaweno T, Abdulhamid I, Bezabih L, et al. *Sero-Prevalence of SARS-CoV-2 Antibody Among Adults in the General Population in Diredawa, Ethiopia*. In Review; 2021. doi:[*10.21203/rs.3.rs-266413/v1*](https://doi.org/10.21203/rs.3.rs-266413/v1)

185. Kempen JH, Abashawl A, Suga HK, et al. SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia. *The American Journal of Tropical Medicine and Hygiene*. 2020;103(5):2022-2023. doi:[*10.4269/ajtmh.20-0816*](https://doi.org/10.4269/ajtmh.20-0816)

186. Mveang Nzoghe A, Leboueny M, Kuissi Kamgaing E, et al. Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: Herd immunity, not there yet! *BMC Research Notes*. 2021;14(1):152. doi:[*10.1186/s13104-021-05570-3*](https://doi.org/10.1186/s13104-021-05570-3)

187. Nyagwange J, Kutima B, Mwai K, et al. Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations. *Journal of Clinical Virology*. 2022;146:105061. doi:[*10.1016/j.jcv.2021.105061*](https://doi.org/10.1016/j.jcv.2021.105061)

188. Munywoki PK, Nasimiyu C, Alando MD, et al. Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020. Published online August 2021. doi:[*10.12688/f1000research.72914.1*](https://doi.org/10.12688/f1000research.72914.1)

189. Lucinde R, Mugo D, Bottomley C, et al. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals. *medRxiv*. Published online February 2021:2021.02.05.21250735. doi:[*10.1101/2021.02.05.21250735*](https://doi.org/10.1101/2021.02.05.21250735)

190. Ngere I, Dawa J, Hunsperger E, et al. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya. *International Journal of Infectious Diseases*. 2021;0(0). doi:[*10.1016/j.ijid.2021.08.062*](https://doi.org/10.1016/j.ijid.2021.08.062)

191. Crowell TA, Daud II, Maswai J, et al. SARS-CoV-2 antibody prevalence in people with and without HIV in rural western Kenya, January to March 2020. *AIDS*. Published online September 2021. doi:[*10.1097/QAD.0000000000003054*](https://doi.org/10.1097/QAD.0000000000003054)

192. Razafimahatratra SL, Ndiaye MDB, Rasoloharimanana LT, et al. Seroprevalence of ancestral and Beta SARS-CoV-2 antibodies in Malagasy blood donors. *The Lancet Global Health*. 2021;9(10):e1363-e1364. doi:[*10.1016/S2214-109X(21)00361-2*](https://doi.org/10.1016/S2214-109X(21)00361-2)

193. Schoenhals M, Rabenindrina N, Rakotondramanga JM, et al. SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic. *EBioMedicine*. 2021;68:103419. doi:[*10.1016/j.ebiom.2021.103419*](https://doi.org/10.1016/j.ebiom.2021.103419)

194. Sagara I, Woodford J, Kone M, et al. Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: A prospective cohort study. *medRxiv*. Published online April 2021:2021.04.26.21256016. doi:[*10.1101/2021.04.26.21256016*](https://doi.org/10.1101/2021.04.26.21256016)

195. Mussagy Mahomed. *Inquérito Sero-epidemiológico de SARS-CoV-2 Na Cidade de Maxixe e Vila de Massinga (InCOVID 2020)*. República de Moçambique Ministério da Saúde; 2020.

196. Arlete Mahumane. *Inquérito Sero-epidemiológico de SARS-CoV-2 Na Cidade de Chimoio (InCOVID 2020)*. República de Moçambique Ministério da Saúde; 2020.

197. Jerónimo Langa. *Inquérito Sero-epidemiológico de SARS-CoV-2 Na Cidade de Lichinga (InCOVID 2020)*. República de Moçambique Ministério da Saúde; 2020.

198. Mussagy Mahomed. *Inquérito Sero-epidemiológico de SARS-CoV-2 Na Cidade de Tete (InCOVID 2020)*. República de Moçambique Ministério da Saúde; 2020.

199. Paulo Arnaldo. *Inquérito Sero-epidemiológico de SARS-CoV-2 Na Cidade de Pemba (InCOVID 2020)*. República de Moçambique Ministério da Saúde; 2020.

200. Eduardo Samo Gudo. *Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula*. República de Moçambique Ministério da Saúde; 2020:19.

201. Sero-pravelence of SARS CoV-2 IgM and IgG Antibodies Amongst Blood Donors in Nigeria. Published online January 2021. doi:[*10.21203/rs.3.rs-151037/v1*](https://doi.org/10.21203/rs.3.rs-151037/v1)

202. Cohen C, Kleynhans J, von Gottberg, Anne, et al. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort, South Africa, July 2020 2021. Published online January 2022. doi:[*10.5281/ZENODO.5898414*](https://doi.org/10.5281/ZENODO.5898414)

203. Sawry S, le Roux JG, Mbatha P, et al. High prevalence of SARS-CoV-2 antibodies in pregnant women in the inner city of Johannesburg, Gauteng Province, South Africa. Published online November 2021. doi:[*10.5281/ZENODO.5643228*](https://doi.org/10.5281/ZENODO.5643228)

204. Hsiao M, Davies MA, Kalk E, et al. SARS-CoV-2 seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infections. *NICD COVID-19 Special Public Health Surveillance Bulletin*. 2020;18(Supplementary issue 5):9.

205. Wiens KE, Mawien PN, Rumunu J, et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020. *Emerging Infectious Diseases*. 2021;27(6). doi:[*10.3201/eid2706.210568*](https://doi.org/10.3201/eid2706.210568)

206. Fryatt A, Simms V, Bandason T, et al. Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe. *EClinicalMedicine*. 2021;41:101172. doi:[*10.1016/j.eclinm.2021.101172*](https://doi.org/10.1016/j.eclinm.2021.101172)

207. Muñoz L, Pífano M, Bolzán A, et al. *Surveillance and Seroprevalence: Evaluation of IgG Antibodies for SARS-Cov2 by ELISA in the Popular Neighborhood Villa Azul, Quilmes, Province of Buenos Aires, Argentina*.; 2020. doi:[*10.1590/SciELOPreprints.1147*](https://doi.org/10.1590/SciELOPreprints.1147)

208. Figar S, Pagotto V, Luna L, et al. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM. *Medicina Buenos Aires*. 2021;81(21):2020.07.14.20153858.

209. Tess BH, Alves MCGP, Reinach FC, et al. *SoroEpi MSP Inquéritos soroepidemiológicos seriados para monitorar a prevalência da infecção por SARS-CoV-2 no Município de São Paulo, SP, Brasil: Fase 6*. SoroEpi MSP; 2020.

210. Cidade de São Paulo. *Inquérito sorológico adultos (18)para sars-cov-2 - resultado da fase 4 de 2021*. Cidade de São Paulo; 2021.

211. da Silva HP, Abreu IN, Lima CNC, et al. Migration in times of pandemic: SARS-CoV-2 infection among the Warao indigenous refugees in Belém, Pará, Amazonia, Brazil. *BMC Public Health*. 2021;21(1):1659. doi:[*10.1186/s12889-021-11696-7*](https://doi.org/10.1186/s12889-021-11696-7)

212. Miraglia JL, Nascimento Monteiro C, Giannecchini Romagnolo A, et al. A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil. *PLOS ONE*. 2021;16(7):1-9. doi:[*10.1371/journal.pone.0255412*](https://doi.org/10.1371/journal.pone.0255412)

213. Pontes GS, de Melo Silva J, Pinheiro-Silva R, et al. Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus. *Scientific Reports*. 2021;11(1):17534. doi:[*10.1038/s41598-021-96843-1*](https://doi.org/10.1038/s41598-021-96843-1)

214. Buss LF, Prete CA, Abrahim CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*. 2021;371(6526):288-292. doi:[*10.1126/science.abe9728*](https://doi.org/10.1126/science.abe9728)

215. Lugon P, Fuller T, Damasceno L, et al. SARS-CoV-2 Infection Dynamics in Children and Household Contacts in a Slum in Rio de Janeiro. *Pediatrics*. 2021;148(1):e2021050182. doi:[*10.1542/peds.2021-050182*](https://doi.org/10.1542/peds.2021-050182)

216. Oliveira LM da S, Tiyo BT, Silva LT da, et al. Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil. *Revista do Instituto de Medicina Tropical de São Paulo*. 2020;62. doi:[*10.1590/s1678-9946202062091*](https://doi.org/10.1590/s1678-9946202062091)

217. Gilson Silva AVF, Menezes D, Moreira FRR, et al. *Seroprevalence, Prevalence, and Genomic Surveillance: Monitoring the Initial Phases of the SARS-CoV-2 Pandemic in Betim, Brazil*. Epidemiology; 2021. doi:[*10.1101/2021.10.21.21265140*](https://doi.org/10.1101/2021.10.21.21265140)

218. Diegoli H, Conzatti VS, Mazin SC, et al. *Population-Based Study of Anti-SARS-CoV-2, Social Distancing and Government Responses in Joinville, Brazil*. Public and Global Health; 2021. doi:[*10.1101/2021.02.08.21251009*](https://doi.org/10.1101/2021.02.08.21251009)

219. Calheiros Santos A, Salete de Paula V, Custódio Miguel J, et al. P-87 HIGH PREVALENCE OF SARS-COV-2 ANTIBODIES IN PREGNANT WOMEN INFECTED WITH VIRAL HEPATITIS IN BRAZIL. *Annals of Hepatology*. 2021;24:100450. doi:[*10.1016/j.aohep.2021.100450*](https://doi.org/10.1016/j.aohep.2021.100450)

220. Bernardes-Souza B, Júnior SRC, Santos CA, et al. Logistics workers are a key factor for SARS-CoV-2 spread in Brazilian small towns: Case-control study (Preprint). *JMIR Public Health and Surveillance*. Published online May 2021. doi:[*10.2196/30406*](https://doi.org/10.2196/30406)

221. Martinez EZ, Passos ADC, Fabbro ALD, et al. Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirão Preto, Southeast Brazil: An epidemiological survey. *Revista da Sociedade Brasileira de Medicina Tropical*. 2021;54:e0210-2021. doi:[*10.1590/0037-8682-0210-2021*](https://doi.org/10.1590/0037-8682-0210-2021)

222. Tess BH, Granato CFH, Alves MCGP, et al. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil. *The Brazilian Journal of Infectious Diseases*. 2021;25(4):101604. doi:[*10.1016/j.bjid.2021.101604*](https://doi.org/10.1016/j.bjid.2021.101604)

223. Serrano-Coll H, Miller H, Rodríguez-Van Der Hamen C, et al. High Prevalence of SARS-CoV-2 in an Indigenous Community of the Colombian Amazon Region. *Tropical Medicine and Infectious Disease*. 2021;6(4):191. doi:[*10.3390/tropicalmed6040191*](https://doi.org/10.3390/tropicalmed6040191)

224. Mattar S, Alvis-Guzman N, Garay E, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? *Open Forum Infectious Diseases*. 2020;7(ofaa550). doi:[*10.1093/ofid/ofaa550*](https://doi.org/10.1093/ofid/ofaa550)

225. Del Brutto OH, Costa AF, Recalde BY, Mera RM. Factors Associated With a Persistent Seronegative Status 1 Year After a SARS-CoV-2 Massive Infection Outbreak in Community Dwellers Living in Rural Ecuador: A Prospective Population-based Study. *Journal of Primary Care & Community Health*. 2021;12:21501327211054989. doi:[*10.1177/21501327211054989*](https://doi.org/10.1177/21501327211054989)

226. Acurio-Páez D, Vega B, Orellana D, et al. Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study. *International Journal of Environmental Research and Public Health*. 2021;18(9):4657. doi:[*10.3390/ijerph18094657*](https://doi.org/10.3390/ijerph18094657)

227. Flamand C, Enfissi A, Bailly S, et al. Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. *medRxiv*. Published online September 2020:2020.09.27.20202465. doi:[*10.1101/2020.09.27.20202465*](https://doi.org/10.1101/2020.09.27.20202465)

228. Chisolm T, Walker JP, Leys Y, et al. SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020. Published online February 2021. doi:[*10.1101/2021.02.08.21251367*](https://doi.org/10.1101/2021.02.08.21251367)

229. Muñoz-Medina JE, Grajales-Muñiz C, Salas-Lais AG, et al. SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020. *Microorganisms*. 2021;9(4):850. doi:[*10.3390/microorganisms9040850*](https://doi.org/10.3390/microorganisms9040850)

230. Remes-Troche JM, Ramos-De-la-Medina A, Manríquez-Reyes M, et al. Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico). *medRxiv*. Published online October 2020. doi:[*10.1101/2020.10.19.20215558*](https://doi.org/10.1101/2020.10.19.20215558)

231. Martinez-Acuña N, Avalos-Nolazco DM, Rodriguez-Rodriguez DR, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation. *Viruses*. 2021;13(7):1225. doi:[*10.3390/v13071225*](https://doi.org/10.3390/v13071225)

232. Champigneulle B, Hancco I, Renan R, et al. High-Altitude Environment and COVID-19: SARS-CoV-2 Seropositivity in the Highest City in the World. *High Altitude Medicine & Biology*. Published online July 2021:ham.2021.0020. doi:[*10.1089/ham.2021.0020*](https://doi.org/10.1089/ham.2021.0020)

233. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru. *medRxiv*. Published online January 2021:2021.01.17.21249913. doi:[*10.1101/2021.01.17.21249913*](https://doi.org/10.1101/2021.01.17.21249913)

234. Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, et al. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru. *EClinicalMedicine*. 2021;34. doi:[*10.1016/j.eclinm.2021.100801*](https://doi.org/10.1016/j.eclinm.2021.100801)

235. Guevara-Ríos E, Espinola-Sánchez M, Carranza-Asmat C, et al. SARS-COVID-19 antibodies in pregnant women at a level III hospital in PeruSARS-COVID-19 antibodies in pregnant women at a level III hospital in Peru. *Revista Peruana de Ginecología y Obstetricia*. 2020;66(3). doi:[*10.31403/rpgo.v66i2259*](https://doi.org/10.31403/rpgo.v66i2259)

236. Manny E, Carroll A, Charlton C, et al. Increased Mask Use and Fewer Gatherings Associated with Lower SARS-CoV-2 Seropositivity Among Young School-Age Children. *SSRN Electronic Journal*. Published online 2020. doi:[*10.2139/ssrn.3728570*](https://doi.org/10.2139/ssrn.3728570)

237. Lewin A, Therrien R, De Serres G, et al. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: A nested case-control study. *Canadian Journal of Public Health*. Published online May 2021. doi:[*10.17269/s41997-021-00531-6*](https://doi.org/10.17269/s41997-021-00531-6)

238. Villarreal A, Rangel G, Zhang X, et al. Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. *Frontiers in Medicine*. 2021;8. doi:[*10.3389/fmed.2021.616106*](https://doi.org/10.3389/fmed.2021.616106)

239. Messiah S, Valerio-Shewmaker MA, DeSantis SM, et al. Estimated Prevalence of SARS-CoV-2 Antibodies in the Texas Pediatric Population, 2021. *SSRN Electronic Journal*. Published online 2021. doi:[*10.2139/ssrn.3868061*](https://doi.org/10.2139/ssrn.3868061)

240. Xu L, Doyle J, Barbeau DJ, et al. A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. *Pathogens*. 2021;10(6):710. doi:[*10.3390/pathogens10060710*](https://doi.org/10.3390/pathogens10060710)

241. Smith BK, Janowski AB, Fremont AC, et al. Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021. *mSphere*. 0(0):e00450-21. doi:[*10.1128/mSphere.00450-21*](https://doi.org/10.1128/mSphere.00450-21)

242. Dodd RY, Notari EP, Brodsky JP, et al. Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 June 2021. *The Journal of Infectious Diseases*. 2021;(jiab514). doi:[*10.1093/infdis/jiab514*](https://doi.org/10.1093/infdis/jiab514)

243. Stout RL, Rigatti SJ. The Silent Pandemic COVID-19 in the Asymptomatic Population. *medRxiv*. Published online January 2021. doi:[*doi.org/10.1101/2020.11.10.20215145*](https://doi.org/doi.org/10.1101/2020.11.10.20215145)

244. Dodd RY, Spencer BR, Xu M, et al. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines. *Transfusion Medicine Reviews*. Published online July 2021. doi:[*10.1016/j.tmrv.2021.07.001*](https://doi.org/10.1016/j.tmrv.2021.07.001)

245. Staszewski C, Rochelson B, Krantz DA, et al. Persistence of infection-induced SARS-CoV-2 seropositivity throughout gestation. *American Journal of Obstetrics and Gynecology*. Published online October 2021:S0002-9378(21)01087-5. doi:[*10.1016/j.ajog.2021.09.037*](https://doi.org/10.1016/j.ajog.2021.09.037)

246. Arnold CRK, Srinivasan S, Herzog CM, et al. SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members. *medRxiv*. Published online February 2021:2021.02.17.21251942. doi:[*10.1101/2021.02.17.21251942*](https://doi.org/10.1101/2021.02.17.21251942)

247. Bonelli F, Blocki FA, Bunnell T, et al. Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. *Clinical Chemistry and Laboratory Medicine (CCLM)*. Published online March 2021. doi:[*10.1515/cclm-2021-0023*](https://doi.org/10.1515/cclm-2021-0023)

248. Stout RL, Rigatti SJ. Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020. *JAMA Network Open*. 2021;4(3):e211552. doi:[*10.1001/jamanetworkopen.2021.1552*](https://doi.org/10.1001/jamanetworkopen.2021.1552)

249. Symanski E, Ensor KB, Piedra PA, et al. Population-Based Estimates of SARS-CoV-2 Seroprevalence in Houston, TX as of September 2020. *The Journal of Infectious Diseases*. 2021;(jiab203). doi:[*10.1093/infdis/jiab203*](https://doi.org/10.1093/infdis/jiab203)

250. Bahar B, Simpson JN, Biddle C, et al. Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in The Washington Metropolitan Area as of October 2020. *medRxiv*. Published online February 2021:2021.01.30.21250830. doi:[*10.1101/2021.01.30.21250830*](https://doi.org/10.1101/2021.01.30.21250830)

251. Jia X, Gesualdo P, Geno Rasmussen C, et al. Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes. *Diabetes Technology & Therapeutics*. Published online February 2021. doi:[*10.1089/dia.2020.0609*](https://doi.org/10.1089/dia.2020.0609)

252. Sherman A, Reuben J, David N, et al. SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites Washington, DC, July, 2020. *medRxiv*. Published online February 2021:2021.02.15.21251764. doi:[*10.1101/2021.02.15.21251764*](https://doi.org/10.1101/2021.02.15.21251764)

253. Parrott JC, Maleki AN, Vassor VE, et al. Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June 2020: A Population-Based Survey. *The Journal of Infectious Diseases*. 2021;224(2):188-195. doi:[*10.1093/infdis/jiab296*](https://doi.org/10.1093/infdis/jiab296)

254. Bruckner TA, Parker DM, Bartell SM, et al. Estimated Seroprevalence of SARS-CoV-2 Antibodies Among Adults in Orange County, California. *medRxiv*. Published online October 2020:2020.10.07.20208660. doi:[*10.1101/2020.10.07.20208660*](https://doi.org/10.1101/2020.10.07.20208660)

255. Feehan AK, Velasco C, Fort D, et al. Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. *Emerging Infectious Diseases*. 2021;27(1):314-317. doi:[*10.3201/eid2701.203808*](https://doi.org/10.3201/eid2701.203808)

256. Yamaki J, Peled H, Mathews S, et al. Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California. *Journal of Racial and Ethnic Health Disparities*. Published online November 2020. doi:[*10.1007/s40615-020-00918-0*](https://doi.org/10.1007/s40615-020-00918-0)

257. Gonik CO, Alonso AM, Gonik B. SARS-CoV-2 Seroprevalence in Florida Department of Health in Palm Beach County Obstetric Clinics: A Cross-Sectional Study during the First Pandemic Surge. *American Journal of Perinatology*. Published online November 2021. doi:[*10.1055/s-0041-1739353*](https://doi.org/10.1055/s-0041-1739353)

258. Molenaar NM, Rommel AS, de Witte L, et al. SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort. *Paediatric and Perinatal Epidemiology*. 2021;n/a(n/a). doi:[*10.1111/ppe.12812*](https://doi.org/10.1111/ppe.12812)

259. Stadlbauer D, Tan J, Jiang K, et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. *Nature*. Published online November 2020. doi:[*10.1038/s41586-020-2912-6*](https://doi.org/10.1038/s41586-020-2912-6)

260. Robertson MM, Kulkarni SG, Rane M, et al. Cohort profile: A national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USAthe CHASING COVID Cohort study. *BMJ Open*. 2021;11(9):e048778. doi:[*10.1136/bmjopen-2021-048778*](https://doi.org/10.1136/bmjopen-2021-048778)

261. Kamath K, Baum-Jones E, Jordan G, et al. Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York. *medRxiv*. Published online October 2020:2020.10.19.20215368. doi:[*10.1101/2020.10.19.20215368*](https://doi.org/10.1101/2020.10.19.20215368)

262. Morozova O, Clouston SAP, Valentine J, Newman A, Carr M, Luft BJ. COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January 2020: A cohort of World Trade Center responders. Yon DK, ed. *PLOS ONE*. 2021;16(7):e0254713. doi:[*10.1371/journal.pone.0254713*](https://doi.org/10.1371/journal.pone.0254713)

263. Molenaar NM, Rommel AS, Witte L de, et al. Seroprevalence of SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort study, New York City. *medRxiv*. Published online February 2021:2021.02.01.21250943. doi:[*10.1101/2021.02.01.21250943*](https://doi.org/10.1101/2021.02.01.21250943)

264. Barzin A, Schmitz JL, Rosin S, et al. SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures. Schultz-Cherry S, ed. *mBio*. 2020;11(5):e02426-20, /mbio/11/5/mBio.02426-20.atom. doi:[*10.1128/mBio.02426-20*](https://doi.org/10.1128/mBio.02426-20)

265. Reifer J, Hayum N, Heszkel B, Klagsbald I, Streva VA. SARS-CoV-2 IgG antibody responses in New York City. *Diagnostic Microbiology and Infectious Disease*. 2020;98(3):115128. doi:[*10.1016/j.diagmicrobio.2020.115128*](https://doi.org/10.1016/j.diagmicrobio.2020.115128)

266. Feehan AK, Fort D, Garcia-Diaz J, et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerging Infectious Diseases*. 2020;26(11):2765-2768. doi:[*10.3201/eid2611.203029*](https://doi.org/10.3201/eid2611.203029)

267. Routledge I, Epstein A, Takahashi S, et al. Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records. *Nature Communications*. 2021;12(1):3566. doi:[*10.1038/s41467-021-23651-6*](https://doi.org/10.1038/s41467-021-23651-6)

268. Flannery DD, Gouma S, Dhudasia MB, et al. SARS-CoV-2 Seroprevalence Among Parturient Women. *medRxiv*. Published online May 2020. doi:[*10.21203/rs.3.rs-27402/v1*](https://doi.org/10.21203/rs.3.rs-27402/v1)

269. Smith BK, Janowski AB, Danis JE, et al. Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA. *mSphere*. 2021;6(1). doi:[*10.1128/mSphere.01207-20*](https://doi.org/10.1128/mSphere.01207-20)

270. Nesbitt DJ, Jin DP, Hogan JW, et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats. *BMC Infectious Diseases*. 2021;21(1):871. doi:[*10.1186/s12879-021-06438-4*](https://doi.org/10.1186/s12879-021-06438-4)

271. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies Two Georgia Counties, April 28 3, 2020. *MMWR Morbidity and Mortality Weekly Report*. 2020;69(29):965-970. doi:[*10.15585/mmwr.mm6929e2*](https://doi.org/10.15585/mmwr.mm6929e2)

272. Bajema KL, Dahlgren FS, Lim TW, et al. Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey. *Clinical Infectious Diseases*. 2020;(ciaa1804). doi:[*10.1093/cid/ciaa1804*](https://doi.org/10.1093/cid/ciaa1804)

273. Chamie G, Marquez C, Crawford E, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. *Clinical Infectious Diseases*. Published online August 2020. doi:[*10.1093/cid/ciaa1234*](https://doi.org/10.1093/cid/ciaa1234)

274. Laeyendecker O, Hsieh YH, Rothman RE, et al. Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. Emergency department. *The American Journal of Emergency Medicine*. 2021;48:261-268. doi:[*10.1016/j.ajem.2021.04.081*](https://doi.org/10.1016/j.ajem.2021.04.081)

275. Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2 in Los Angeles County, California, on April 10-11, 2020. *The Journal of the American Medical Association*. 2020;Published Online. doi:[*doi:10.1001/jama.2020.8279*](https://doi.org/doi:10.1001/jama.2020.8279)

276. Rathe JA, Hemann EA, Eggenberger J, et al. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing. *The Journal of Infectious Diseases*. 2021;223(7):1120-1131. doi:[*10.1093/infdis/jiaa797*](https://doi.org/10.1093/infdis/jiaa797)

277. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. *medRxiv*. Published online April 2020. doi:[*10.1101/2020.04.14.20062463*](https://doi.org/10.1101/2020.04.14.20062463)

278. Dingens AS, Crawford KH, Adler A, et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. *medRxiv*. Published online June 2020:2020.05.26.20114124. doi:[*10.1101/2020.05.26.20114124*](https://doi.org/10.1101/2020.05.26.20114124)

279. Ng DL, Goldgof GM, Shy BR, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. *medRxiv*. Published online May 2020. doi:[*10.1101/2020.05.19.20107482*](https://doi.org/10.1101/2020.05.19.20107482)

280. Abdelmaksoud S. Seropositive coronavirus disease 2019 detection among apparently healthy voluntary blood donors: A preliminary step to catch asymptomatic cases as a potential viral spread route. 2021;46(2):65-69. doi:[*10.4103/ejh.ejh\_59\_20*](https://doi.org/10.4103/ejh.ejh_59_20)

281. Girgis SA, Hafez HM, Elarab HE, et al. SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital. Blackard JT, ed. *PLOS ONE*. 2021;16(7):e0254581. doi:[*10.1371/journal.pone.0254581*](https://doi.org/10.1371/journal.pone.0254581)

282. Mohammadi Z, Eghtesad S, Hashemi-Shahri SM, Tabatabaei SM, Sharafkhah M, Poustchi H. The seroprevalence of COVID-19 in intravenous drug users in comparison to non-drug users. *Middle East Journal of Digestive Diseases*. 2021;13(1). doi:[*10.34172/mejdd.2021.206*](https://doi.org/10.34172/mejdd.2021.206)

283. Hussein NR, Balatay AA, Naqid IA, et al. COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-based study. *medRxiv*. Published online March 2021:2021.03.23.21254169. doi:[*10.1101/2021.03.23.21254169*](https://doi.org/10.1101/2021.03.23.21254169)

284. Sughayer MA, Mansour A, Nuirat AA, Souan L, Abdel-Razeq R, Siag M. A second dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among adult healthy blood donors in Jordan; have we achieved herd immunity? *medRxiv*. Published online August 2021. doi:[*10.1101/2021.08.15.21261584*](https://doi.org/10.1101/2021.08.15.21261584)

285. Sughayer MA, Mansour A, Al Nuirat A, Souan L, Ghanem M, Siag M. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic. *International Journal of Infectious Diseases*. 2021;107:116-120. doi:[*10.1016/j.ijid.2021.04.059*](https://doi.org/10.1016/j.ijid.2021.04.059)

286. Qutob N, Awartani F, Salah Z, et al. Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: A cross-sectional seroepidemiological study. *BMJ Open*. 2021;11(2):e044552. doi:[*10.1136/bmjopen-2020-044552*](https://doi.org/10.1136/bmjopen-2020-044552)

287. Nisar MI, Ansari N, Khalid F, et al. Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan. *International Journal of Infectious Diseases*. 2021;106:176-182. doi:[*10.1016/j.ijid.2021.03.040*](https://doi.org/10.1016/j.ijid.2021.03.040)

288. Ansari S, Memon M, Kumar R, Memon S, Memon MK. Do COVID-19 Antibodies Provide Long-Term Protection? *Cureus*. 2021;13(1):e12441. doi:[*10.7759/cureus.12441*](https://doi.org/10.7759/cureus.12441)

289. Alosaimi MF, Alhetheel A, Aleisa KA, et al. Risk factors and predictors that influence SARS-Cov-2 IgG positivity: A cross-sectional study of blood donors in Riyadh, Saudi Arabia. *Saudi Medical Journal*. 2021;42(8):853-861. doi:[*10.15537/smj.2021.42.8.20210238*](https://doi.org/10.15537/smj.2021.42.8.20210238)

290. Almudarra S, Kamel S, Saleh E, et al. High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia. *Infection*. Published online December 2021. doi:[*10.1007/s15010-021-01726-2*](https://doi.org/10.1007/s15010-021-01726-2)

291. Raouf M, Rabeh M, Kaur S, Sharma R, Thottumkal N, Mohammed R. Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors. *Dubai Medical Journal*. Published online July 2021:1-8. doi:[*10.1159/000517456*](https://doi.org/10.1159/000517456)

292. Sulcebe G, Ylli A, Cenko F, Kurti-Prifti M. Rapid increase of SARS-CoV-2 seroprevalence during the 2020 pandemic year in the population of the city of Tirana, Albania. Published online February 2021. doi:[*10.1101/2021.02.18.21251776*](https://doi.org/10.1101/2021.02.18.21251776)

293. Ašić A, Prguda-Mujić J, Salihefendić L, et al. Serological testing for SARS-CoV-2 in Bosnia and Herzegovina: First report. *Archives of Medical Science*. 2021;17(3):823-826. doi:[*10.5114/aoms/134143*](https://doi.org/10.5114/aoms/134143)

294. Tsaneva-Damyanova D. SARS-CoV-2: Seroepidemiological pattern in northeastern Bulgaria. *Biotechnology & Biotechnological Equipment*. 2020;34(1):441-446. doi:[*10.1080/13102818.2020.1772105*](https://doi.org/10.1080/13102818.2020.1772105)

295. T. Makarovska Bojadjieva, S. Useini, J. Nikolova, et al. Seroprevalence of SARS-CoV-2 among blood donors. *Vox Sanguinis*. 2021;116(S1):5-188. doi:[*10.1111/vox.13117*](https://doi.org/10.1111/vox.13117)

296. Barchuk A, Skougarevskiy D, Kouprianov A, et al. *COVID-19 Pandemic in Saint Petersburg, Russia: Combining Surveillance and Population-Based Serological Study Data in May, 2020, 2021*. Epidemiology; 2021. doi:[*10.1101/2021.07.31.21261428*](https://doi.org/10.1101/2021.07.31.21261428)

297. Barchuk A, Skougarevskiy D, Titaev K, et al. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: A population-based study. *Scientific Reports*. 2021;11(1):12930. doi:[*10.1038/s41598-021-92206-y*](https://doi.org/10.1038/s41598-021-92206-y)

298. Celik OY, Çelen Ş, Üstün YE. Did the SARS-CoV-2 effect pregnancy complications? *Ginekologia Polska*. 2021;0(0). doi:[*10.5603/GP.a2021.0134*](https://doi.org/10.5603/GP.a2021.0134)

299. Riesenhuber M, Nitsche C, Binder CJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers and an unselected all comer patient population. In: *Wiener Klinische Wochenschrift*. Vol 133.; 2021:33-154. doi:[*10.1007/s00508-021-01884-1*](https://doi.org/10.1007/s00508-021-01884-1)

300. Rebholz H, Braun RJ, Saha T, Harzer O, Schneider M, Ladage D. Longitudinal monitoring of SARS-CoV-2-specific immune responses. Published online August 2021:2021.08.14.21262042. doi:[*10.1101/2021.08.14.21262042*](https://doi.org/10.1101/2021.08.14.21262042)

301. Weidner L, Nunhofer V, Jungbauer C, et al. Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors. *Infection*. Published online June 2021. doi:[*10.1007/s15010-021-01639-0*](https://doi.org/10.1007/s15010-021-01639-0)

302. Lehmann J, Giesinger JM, Rumpold G, et al. Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: Development of a prediction model based on data from Ischgl, Austria. *Epidemiology and Infection*. 2021;149:e52. doi:[*10.1017/S0950268821000418*](https://doi.org/10.1017/S0950268821000418)

303. Heireman L, Baetens M, Menten B, Dehaene I, Padalko E. Comparison of the positivity rate of anti-spike and anti-nucleocapsid SARS-CoV-2 IgG in asymptomatic pregnant women. *Journal of Obstetrics and Gynaecology*. Published online December 2021:1-2. doi:[*10.1080/01443615.2021.1997960*](https://doi.org/10.1080/01443615.2021.1997960)

304. van Dam P, Huizing M, Roelant E, et al. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. *European Journal of Cancer (Oxford, England: 1990)*. 2021;148:328-339. doi:[*10.1016/j.ejca.2021.02.024*](https://doi.org/10.1016/j.ejca.2021.02.024)

305. Vilibic-Cavlek T, Stevanovic V, Ilic M, et al. SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia. *Pathogens*. 2021;10(6):774. doi:[*10.3390/pathogens10060774*](https://doi.org/10.3390/pathogens10060774)

306. Lenicek Krleza J, Zrinski Topic R, Stevanovic V, et al. Seroprevalence of SARS-CoV-2 infection among children in Children’s Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia. *Biochemia Medica*. 2021;31(2):020706. doi:[*10.11613/BM.2021.020706*](https://doi.org/10.11613/BM.2021.020706)

307. Bloomfield M, Pospisilova I, Cabelova T, et al. Searching for COVID-19 Antibodies in Czech Children in the Haystack. *Frontiers in Pediatrics*. 2020;8. doi:[*10.3389/fped.2020.597736*](https://doi.org/10.3389/fped.2020.597736)

308. Jespersen S, Mikkelsen S, Greve T, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region. *Clinical Infectious Diseases*. Published online October 2020:ciaa1471. doi:[*10.1093/cid/ciaa1471*](https://doi.org/10.1093/cid/ciaa1471)

309. Egerup P, Fich Olsen L, Christiansen AMH, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns. *Obstetrics & Gynecology*. 2021;137(1):49-55. doi:[*10.1097/AOG.0000000000004199*](https://doi.org/10.1097/AOG.0000000000004199)

310. Soeorg H, Jõgi P, Naaber P, Ottas A, Toompere K, Lutsar I. Anti-spike protein receptor-binding domain IgG levels after COVID-19 infection or vaccination against SARS-CoV-2 in a seroprevalence study. *medRxiv*. Published online June 2021:2021.06.06.21258406. doi:[*10.1101/2021.06.06.21258406*](https://doi.org/10.1101/2021.06.06.21258406)

311. Veerus P, Salumets A, Naaber P, et al. Seroprevalence of SARS-CoV-2 antibodies among pregnant women in Estonia: A call for epidemiological studies. *Acta Obstetricia Et Gynecologica Scandinavica*. 2020;99(12):1736-1737. doi:[*10.1111/aogs.13995*](https://doi.org/10.1111/aogs.13995)

312. Carrat F, Lapidus N, Ninove L, et al. Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. *Infection*. Published online November 2021. doi:[*10.1007/s15010-021-01731-5*](https://doi.org/10.1007/s15010-021-01731-5)

313. Beaumont A, Durand C, Ledrans M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: A cross-sectional study. *BMJ Open*. 2021;11(11):e053201. doi:[*10.1136/bmjopen-2021-053201*](https://doi.org/10.1136/bmjopen-2021-053201)

314. Gégout Petit A, Jeulin H, Legrand K, et al. Seroprevalence of SARS-CoV-2, symptom profiles and sero-neutralization in a suburban area, france. *Viruses*. 2021;13(6). doi:[*10.3390/v13061076*](https://doi.org/10.3390/v13061076)

315. Woudenberg T, Pelleau S, Anna F, et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. *EBioMedicine*. 2021;70:103495. doi:[*10.1016/j.ebiom.2021.103495*](https://doi.org/10.1016/j.ebiom.2021.103495)

316. Tsatsaris V, Mariaggi AA, Launay O, et al. SARS-COV-2 IgG antibody response in pregnant women at delivery. *Journal of Gynecology Obstetrics and Human Reproduction*. 2020;50(7):102041. doi:[*10.1016/j.jogoh.2020.102041*](https://doi.org/10.1016/j.jogoh.2020.102041)

317. Mattern J, Vauloup-Fellous C, Zakaria H, et al. Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France. *PLOS ONE*. 2020;15(10):e0240782. doi:[*10.1371/journal.pone.0240782*](https://doi.org/10.1371/journal.pone.0240782)

318. Capai L, Ayhan N, Masse S, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020. *Journal of Clinical Medicine*. 2020;9(11):3569. doi:[*10.3390/jcm9113569*](https://doi.org/10.3390/jcm9113569)

319. Cohen R, Jung C, Ouldali N, et al. Assessment of SARS-CoV-2 infection by Reverse transcription-PCR and serology in the Paris area: A cross-sectional study. *BMJ Paediatrics Open*. 2020;4(1):e000887. doi:[*10.1136/bmjpo-2020-000887*](https://doi.org/10.1136/bmjpo-2020-000887)

320. Radon K, Bakuli A, Pütz P, et al. From first to second wave: Follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany). *medRxiv*. Published online April 2021:2021.04.27.21256133. doi:[*10.1101/2021.04.27.21256133*](https://doi.org/10.1101/2021.04.27.21256133)

321. Robert Koch Institut. RKI - CORONA MONITORING local - Corona monitoring local. *Robert Koch Institut*. Published online February 2021.

322. Brinkmann F, Diebner HH, Matenar C, et al. Longitudinal Rise in Seroprevalence of SARS-CoV-2 Infections in Children in Western Germany in Epidemiology? *Infectious Disease Reports*. 2021;13(4):957-964. doi:[*10.3390/idr13040088*](https://doi.org/10.3390/idr13040088)

323. Robert Koch Institut. RKI - CORONA MONITORING local - Corona monitoring local. *Robert Koch Institut*. Published online December 2020.

324. Eichner FA, Gelbrich G, Weißbrich B, et al. Seroprävalenz von COVID-19 und psychosoziale Auswirkungen in der Allgemeinbevölkerung: Ergebnisse des STAAB-COVID-One Programms. *Das Gesundheitswesen*. Published online October 2021. doi:[*10.1055/a-1630-7601*](https://doi.org/10.1055/a-1630-7601)

325. Hippich M, Holthaus L, Assfalg R, et al. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. *Med*. 2021;2(2):149-163.e4. doi:[*10.1016/j.medj.2020.10.003*](https://doi.org/10.1016/j.medj.2020.10.003)

326. Wagner R, Peterhoff D, Beileke S, et al. Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: The population-based Tirschenreuth study in the hardest-hit German county in spring 2020. *medRxiv*. Published online April 2021. doi:[*10.1101/2021.03.29.21254343*](https://doi.org/10.1101/2021.03.29.21254343)

327. Santos-Hövener C, Neuhauser HK, Rosario AS, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. *Eurosurveillance*. 2020;25(47):2001752. doi:[*10.2807/1560-7917.ES.2020.25.47.2001752*](https://doi.org/10.2807/1560-7917.ES.2020.25.47.2001752)

328. Aziz NA, Corman VM, Echterhoff AKC, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. *Nature Communications*. 2021;12(1):2117. doi:[*10.1038/s41467-021-22351-5*](https://doi.org/10.1038/s41467-021-22351-5)

329. Pritsch M, Radon K, Bakuli A, et al. *Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich*. Social Science Research Network; 2021. doi:[*10.2139/ssrn.3745128*](https://doi.org/10.2139/ssrn.3745128)

330. Runkel S, Kowalzik F, Gehring S, et al. Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic. *Clinical laboratory*. 2020;66(10). doi:[*10.7754/Clin.Lab.2020.200915*](https://doi.org/10.7754/Clin.Lab.2020.200915)

331. Zöllkau J, Baier M, Scherag A, Schleußner E, Groten T. Periodenprävalenz von SARS-CoV-2 in einer unselektierten Stichprobe schwangerer Frauen in Jena, Thüringen. *Zeitschrift für Geburtshilfe und Neonatologie*. 2020;224(04):194-198. doi:[*10.1055/a-1206-1033*](https://doi.org/10.1055/a-1206-1033)

332. Häusler S, Weigl M, Ambrosch A, Gruber R, Seelbach-Göbel B, Malfertheiner SF. Peripartal anti-SARS-CoV-2-IgA/IgG in asymptomatic pregnant women during regional SARS-CoV-2-outbreak. *Journal of Perinatal Medicine*. Published online February 2021. doi:[*10.1515/jpm-2021-0001*](https://doi.org/10.1515/jpm-2021-0001)

333. Streeck H, Schulte B, Kümmerer BM, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. *Nature Communications*. 2020;11(1):5829. doi:[*10.1038/s41467-020-19509-y*](https://doi.org/10.1038/s41467-020-19509-y)

334. Maltezou HC, Krumbholz B, Mavrouli M, et al. A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021. *Journal of Medical Virology*. 2021;n/a(n/a). doi:[*10.1002/jmv.27465*](https://doi.org/10.1002/jmv.27465)

335. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Eurosurveillance*. 2020;25(31):2001369. doi:[*10.2807/1560-7917.ES.2020.25.31.2001369*](https://doi.org/10.2807/1560-7917.ES.2020.25.31.2001369)

336. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *New England Journal of Medicine*. 2020;383(18):1724-1734. doi:[*10.1056/NEJMoa2026116*](https://doi.org/10.1056/NEJMoa2026116)

337. Heavey L, Garvey P, Colgan AM, et al. The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020. *Eurosurveillance*. 2021;26(48):2001741. doi:[*10.2807/1560-7917.ES.2021.26.48.2001741*](https://doi.org/10.2807/1560-7917.ES.2021.26.48.2001741)

338. Breuer A, Raphael A, Stern H, et al. SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population. *Acta Paediatrica*. n/a(n/a). doi:[*10.1111/apa.16031*](https://doi.org/10.1111/apa.16031)

339. Gozlan Y, Reingold S, Koren R, et al. SARS-CoV-2 outbreak in a synagogue community: Longevity and strength of anti-SARS-CoV-2 IgG responses. *Epidemiology and Infection*. Published online June 2021:1-14. doi:[*10.1017/S0950268821001369*](https://doi.org/10.1017/S0950268821001369)

340. Antonucci F, Fiore JR, De Feo L, et al. Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: Evidence for asymptomatic young donors as potential virus spreaders. *Infectious Diseases*. Published online November 2021:1-6. doi:[*10.1080/23744235.2021.2003856*](https://doi.org/10.1080/23744235.2021.2003856)

341. Polvere I, Parrella A, Casamassa G, et al. Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy. *Diagnostics*. 2021;11(3):483. doi:[*10.3390/diagnostics11030483*](https://doi.org/10.3390/diagnostics11030483)

342. Melotti R, Scaggiante F, Falciani M, et al. Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley. *medRxiv*. Published online March 2021:2021.03.19.21253883. doi:[*10.1101/2021.03.19.21253883*](https://doi.org/10.1101/2021.03.19.21253883)

343. Pagani G, Giacomelli A, Conti F, et al. Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d’Adda, Italy. Hozbor DF, ed. *PLOS ONE*. 2021;16(2):e0246513. doi:[*10.1371/journal.pone.0246513*](https://doi.org/10.1371/journal.pone.0246513)

344. Cerino P, Coppola A, Volzone P, et al. Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): A population-based study. *Future Science OA*. Published online January 2021:FSO673. doi:[*10.2144/fsoa-2020-0203*](https://doi.org/10.2144/fsoa-2020-0203)

345. Fiore JR, Centra M, De Carlo A, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *Journal of Medical Virology*. Published online August 2020:jmv.26425. doi:[*10.1002/jmv.26425*](https://doi.org/10.1002/jmv.26425)

346. Dorigatti I, Lavezzo E, Manuto L, et al. SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’. *Nature Communications*. 2021;12(1):4383. doi:[*10.1038/s41467-021-24622-7*](https://doi.org/10.1038/s41467-021-24622-7)

347. Cassaniti I, Percivalle E, Sarasini A, et al. Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area. *Clinical Microbiology and Infection*. 2021;0(0). doi:[*10.1016/j.cmi.2021.01.030*](https://doi.org/10.1016/j.cmi.2021.01.030)

348. Guerriero M, Bisoffi Z, Poli A, Micheletto C, Conti A, Pomari C. Prevalence of SARS-CoV-2, Verona, Italy, April 2020 - Volume 27, Number 1 2021 - Emerging Infectious Diseases journal - CDC. *Emerging Infectious Diseases*. Published online December 2020. doi:[*10.3201/eid2701.202740*](https://doi.org/10.3201/eid2701.202740)

349. Baracco A, Perotti G, Filippin A, et al. *SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre*. Social Science Research Network; 2020.

350. Cavaliere AF, Carabaneanu AI, Perelli F, et al. Universal screening for SARS-CoV-2 in pregnant women admitted for delivery: How to manage antibody testing? *The Journal of Maternal-Fetal & Neonatal Medicine*. Published online July 2020:1-2. doi:[*10.1080/14767058.2020.1793317*](https://doi.org/10.1080/14767058.2020.1793317)

351. Cito F, Amato L, Di Giuseppe A, et al. A COVID-19 Hotspot Area: Activities and Epidemiological Findings. *Microorganisms*. 2020;8(11):1711. doi:[*10.3390/microorganisms8111711*](https://doi.org/10.3390/microorganisms8111711)

352. Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. *Blood Transfusion*. Published online 2021. doi:[*10.2450/2021.0324-20*](https://doi.org/10.2450/2021.0324-20)

353. Pancrazzi A, Magliocca P, Lorubbio M, et al. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity. *Clinical Biochemistry*. 2020;84:87-92. doi:[*10.1016/j.clinbiochem.2020.07.002*](https://doi.org/10.1016/j.clinbiochem.2020.07.002)

354. Coyer L, Boyd A, Schinkel J, et al. SARS-CoV-2 antibody prevalence and determinants of six ethnic groups living in Amsterdam, the Netherlands: A population-based cross-sectional study, June-October 2020. *medRxiv*. Published online March 2021:2021.03.08.21252788. doi:[*10.1101/2021.03.08.21252788*](https://doi.org/10.1101/2021.03.08.21252788)

355. Keuning MW, Grobben M, de Groen AEC, et al. Saliva SARS-CoV-2 Antibody Prevalence in Children. *Microbiology Spectrum*. 2021;0(0):e00731-21. doi:[*10.1128/Spectrum.00731-21*](https://doi.org/10.1128/Spectrum.00731-21)

356. Slot E, Hogema BM, Reusken CBEM, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. *Nature Communications*. 2020;11(1):5744. doi:[*10.1038/s41467-020-19481-7*](https://doi.org/10.1038/s41467-020-19481-7)

357. Zejda JE, Kowalska M, Brożek GM, Barański K, Kaleta-Pilarska A. Infection Fatality Rate (IFR) during the course of COVID-19 pandemic in Upper Silesia Metropolitan Area (Poland) in 2020. *Medycyna Pracy*. Published online November 2021. doi:[*10.13075/mp.5893.01179*](https://doi.org/10.13075/mp.5893.01179)

358. Olariu TR, Lighezan R, Ursoniu S, Craciun AC, Paduraru AA, Lupu MA. Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021;27(5). doi:[*10.1016/j.cmi.2020.12.027*](https://doi.org/10.1016/j.cmi.2020.12.027)

359. Soriano V, Ganado-Pinilla P, Sanchez-Santos M, et al. Main differences between the first and second waves of COVID-19 in Madrid, Spain. *International Journal of Infectious Diseases*. 2021;105:374-376. doi:[*10.1016/j.ijid.2021.02.115*](https://doi.org/10.1016/j.ijid.2021.02.115)

360. Kogevinas M, Casta ño VG, Karachaliou M, et al. Ambient Air Pollution in Relation to SARS-CoV-2 Infection, Antibody Response, and COVID-19 Disease: A Cohort Study in Catalonia, Spain (COVICAT Study). *Environmental Health Perspectives*. 2021;129(11):117003. doi:[*10.1289/EHP9726*](https://doi.org/10.1289/EHP9726)

361. Viñuela MC, De León-Luis JA, Alonso R, et al. SARS-CoV-2 screening of asymptomatic women admitted for delivery must be performed with a combination of microbiological techniques: An observational study. *Revista Española de Quimioterapia*. 2020;33(6):415-421. doi:[*10.37201/req/088.2020*](https://doi.org/10.37201/req/088.2020)

362. Crovetto F, Crispi F, Llurba E, et al. Impact of SARS-CoV-2 Infection on Pregnancy Outcomes: A Population-Based Study. *Clinical Infectious Diseases*. 2021;(ciab104). doi:[*10.1093/cid/ciab104*](https://doi.org/10.1093/cid/ciab104)

363. Alenda R, Gonzalez-Diez R, Richart A, et al. P-216 Anti SARS-CoV-2 antibodies prevalence in Madrid blood donors prior to first outbreak. *Vox Sanguinis*. 2021;116(S1):5-188.

364. Lundkvist Å, Hanson S, Olsen B. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden. *Infection Ecology & Epidemiology*. 2020;10(1):1806505. doi:[*10.1080/20008686.2020.1806505*](https://doi.org/10.1080/20008686.2020.1806505)

365. Stringhini S, Zaballa ME, Pullen N, et al. *Seroprevalence of Anti-SARS-CoV-2 Antibodies Six Months into the Vaccination Campaign in Geneva, Switzerland*. Epidemiology; 2021.

366. Giuliano E, Gennaro V, Milani GP, et al. Seroprevalence of anti-SARS-CoV-2 IgG among adolescents at military fitness-for-duty evaluation. *BMJ Military Health*. Published online April 2021:bmjmilitary-2021-001828. doi:[*10.1136/bmjmilitary-2021-001828*](https://doi.org/10.1136/bmjmilitary-2021-001828)

367. Emmenegger M, De Cecco E, Lamparter D, et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region. *medRxiv*. Published online August 2020. doi:[*10.1101/2020.05.31.20118554*](https://doi.org/10.1101/2020.05.31.20118554)

368. Ulyte A, Radtke T, Abela IA, et al. Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: Baseline measurements from a cohort of primary and secondary school children in Switzerland. *BMJ Open*. 2021;11(7):e047483. doi:[*10.1136/bmjopen-2020-047483*](https://doi.org/10.1136/bmjopen-2020-047483)

369. Baggio S, Vernaz N, Spechbach H, et al. Vulnerable patients forgo health care during the first wave of the Covid-19 pandemic. *Preventive Medicine*. 2021;150:106696. doi:[*10.1016/j.ypmed.2021.106696*](https://doi.org/10.1016/j.ypmed.2021.106696)

370. Milani GP, Bianchetti MG, Togni G, Schoenenberger AW, Muggli F. SARS-CoV-2 Ig G among Healthcare Workers and the General Population. *Pathogens*. 2021;10(4):465. doi:[*10.3390/pathogens10040465*](https://doi.org/10.3390/pathogens10040465)

371. Major-Smith D, Matthews S, Breeze T, et al. The Avon Longitudinal Study of Parents and Children - A resource for COVID-19 research: Antibody testing results, April June 2021. Published online October 2021. doi:[*10.12688/wellcomeopenres.17294.1*](https://doi.org/10.12688/wellcomeopenres.17294.1)

372. Gaskell KM, Johnson M, Gould V, et al. SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK: A retrospective cohort study. *The Lancet Regional Health - Europe*. 2021;6:100127. doi:[*10.1016/j.lanepe.2021.100127*](https://doi.org/10.1016/j.lanepe.2021.100127)

373. Oakey J, Haslam S, Brown AP, Eglin J, Houghton B, Singleton D. EXPRESS: Comparison of four high throughput, automated immunoassays for the detection of SARS-CoV-2 antibodies. *Annals of Clinical Biochemistry: International Journal of Laboratory Medicine*. Published online April 2021:000456322110157. doi:[*10.1177/00045632211015711*](https://doi.org/10.1177/00045632211015711)

374. Abo-Leyah H, Gallant S, Cassidy D, et al. The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. *ERJ Open Research*. 2021;7(2):00080-02021. doi:[*10.1183/23120541.00080-2021*](https://doi.org/10.1183/23120541.00080-2021)

375. Wells PM, Doores KM, Couvreur S, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *medRxiv*. Published online July 2020:2020.07.29.20162701. doi:[*10.1101/2020.07.29.20162701*](https://doi.org/10.1101/2020.07.29.20162701)

376. Lumley SF, Eyre DW, McNaughton AL, et al. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. *Eurosurveillance*. 2020;25(42):2001721. doi:[*10.2807/1560-7917.ES.2020.25.41.2001721*](https://doi.org/10.2807/1560-7917.ES.2020.25.41.2001721)

377. Glennon K, Donnelly J, Knowles S, et al. Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study. *PLOS ONE*. 2021;16(9):e0253090. doi:[*10.1371/journal.pone.0253090*](https://doi.org/10.1371/journal.pone.0253090)

378. Amirthalingam G, Whitaker H, Brooks T, et al. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK. *Emerging Infectious Diseases*. 2021;27(7):1795-1801. doi:[*10.3201/eid2707.203167*](https://doi.org/10.3201/eid2707.203167)

379. Bird PW, Sandhu K, Fletcher O, Ames B, Toovey O, Tang JWT. Retrospective SARS-CoV-2 IgG screening during the first wave (March 2020) of the COVID-19 pandemic in the United Kingdom. *Journal of Medical Virology*. 2021;n/a(n/a). doi:[*10.1002/jmv.27162*](https://doi.org/10.1002/jmv.27162)

380. Hughes EC, Amat JAR, Haney J, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. *The Journal of Infectious Diseases*. 2021;223(6):971-980. doi:[*10.1093/infdis/jiaa788*](https://doi.org/10.1093/infdis/jiaa788)

381. Bhuiyan TR, Hulse JD, Hegde ST, et al. SARS-CoV-2 seroprevalence in Chattogram, Bangladesh before a National Lockdown, March-April 2021. Published online July 2021. doi:[*10.1101/2021.07.16.21260611*](https://doi.org/10.1101/2021.07.16.21260611)

382. Shirin T, Flora MS, Salimuzzaman M, et al. Population-based seroepidemiological investigation for coronavirus 2019 (COVID-19) infection in Cox’s Bazar Rohingya camps. Published online November 2021. doi:[*10.5281/ZENODO.5646776*](https://doi.org/10.5281/ZENODO.5646776)

383. Laxmaiah A, Rao NM, Arlappa N, et al. SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021. *medRxiv*. Published online July 2021. doi:[*10.1101/2021.07.18.21260555*](https://doi.org/10.1101/2021.07.18.21260555)

384. Kumar D, Burma A, Mandal AK. A seroprevalence study of Covid 19 antibody after 1st wave of the pandemic in South Andaman district, India. *Clinical Epidemiology and Global Health*. 2021;12. doi:[*10.1016/j.cegh.2021.100901*](https://doi.org/10.1016/j.cegh.2021.100901)

385. Cross-sectional Study on Sero-Prevalence of SARS-CoV-2 Infection in Jabalpur, Madhya Pradesh, India | Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138). Published online April 2021.

386. Mahapatra S. SARS COV-2- IgG antibodies in blood donors in pandemic a game changer for policy makers. *Transfusion Clinique et Biologique*. Published online October 2021:S1246782021004808. doi:[*10.1016/j.tracli.2021.10.004*](https://doi.org/10.1016/j.tracli.2021.10.004)

387. Isaac R, Paul B, Finkel M, et al. The Burden of COVID-19 Infection in a Rural Tamil Nadu Community. Published online March 2021. doi:[*10.21203/rs.3.rs-289385/v1*](https://doi.org/10.21203/rs.3.rs-289385/v1)

388. Prakash O, Solanki B, Sheth J, et al. Reassessing the population based Seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad. *Asian Journal of Medical Sciences*. 2021;12(5):1-6. doi:[*10.3126/ajms.v12i5.35099*](https://doi.org/10.3126/ajms.v12i5.35099)

389. Ayub T, Raja MW, Khan SMS, et al. Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: A population based study. *International Journal Of Community Medicine And Public Health*. 2021;8(4):1792. doi:[*10.18203/2394-6040.ijcmph20211236*](https://doi.org/10.18203/2394-6040.ijcmph20211236)

390. Banerjee A, Gaikwad B, Desale A, Jadhav SL, Rathod H, Srivastava K. Severe acute respiratory syndrome-coronavirus-2 seroprevalence study in Pimpri-Chinchwad, Maharashtra, India coinciding with falling trend - Do the results suggest imminent herd immunity? *Indian Journal of Public Health*. 2021 Jul-Sep;65(3):256-260. doi:[*10.4103/ijph.IJPH\_122\_21*](https://doi.org/10.4103/ijph.IJPH_122_21)

391. Kumar MS, Thangaraj JWV, Saravanakumar V, et al. Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 2021;115(11):1350-1352. doi:[*10.1093/trstmh/trab136*](https://doi.org/10.1093/trstmh/trab136)

392. Kshatri JS, Bhattacharya D, Praharaj I, et al. Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: Findings from 3 rounds of community surveys. *Epidemiology & Infection*. Published online undefined/ed:1-29. doi:[*10.1017/S0950268821000972*](https://doi.org/10.1017/S0950268821000972)

393. Prakash Om, Solanki Bhavin, Sheth Jay, et al. Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city. Published online February 2021.

394. Kolthur-Seetharam U, Shah D, Shastri J, et al. *SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2*. NITI-BMC-TIFR; 2020.

395. Salil Sakalle, Satish Saroshe, Harish Shukla, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020. *Journal of family medicine and primary care*. Published online April 2021.

396. Jaya Singh Kshatri et al. Serological surveys to inform SARS-CoV-2 epidemic curve: A cross-sectional study from Odisha, India. Published online May 2021.

397. Saple P, Gosavi S, Pawar T, et al. Seroprevalence of anti-SARS-CoV-2 of IgG antibody by ELISA: Community-based, cross-sectional study from urban area of Malegaon, Maharashtra. *Journal of Family Medicine and Primary Care*. 2021;10(3):1453. doi:[*10.4103/jfmpc.jfmpc\_2191\_20*](https://doi.org/10.4103/jfmpc.jfmpc_2191_20)

398. Selvaraju S, Kumar MS, Thangaraj JWV, et al. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India - Volume 27, Number 2 2021 - Emerging Infectious Diseases journal - CDC. 2021;27(2). doi:[*10.3201/eid2702.203938*](https://doi.org/10.3201/eid2702.203938)

399. Malani A, Shah D, Kang G, et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. *The Lancet Global Health*. 2021;9(2):e110-e111. doi:[*10.1016/S2214-109X(20)30467-8*](https://doi.org/10.1016/S2214-109X(20)30467-8)

400. Prakash O, Solanki B, Sheth JK, et al. Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: A cross-sectional study. *BMJ Open*. 2021;11(1):e044101. doi:[*10.1136/bmjopen-2020-044101*](https://doi.org/10.1136/bmjopen-2020-044101)

401. Pandey HC, Dhiman Y, C S C, Coshic P, Jain P. Seroprevalence of SARS-Coronavirus 2 among asymptomatic healthy blood donors from healthcare and non-healthcare settings: Implications for safety of blood donors and blood collection staff during blood donation. *Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis*. Published online March 2021:103118. doi:[*10.1016/j.transci.2021.103118*](https://doi.org/10.1016/j.transci.2021.103118)

402. Chandrasingh S, George CE, Inbaraj LR. Are hospitals epicentres of COVID19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India. *Indian Journal of Medical Microbiology*. Published online November 2021. doi:[*10.1016/j.ijmmb.2021.10.006*](https://doi.org/10.1016/j.ijmmb.2021.10.006)

403. Machalek D, Vette K, Downes M, et al. Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, 2020. Published online November 2021. doi:[*10.5281/ZENODO.5644235*](https://doi.org/10.5281/ZENODO.5644235)

404. Gidding HF, Machalek DA, Hendry AJ, et al. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020. *Medical Journal of Australia*. 2021;214(4):179-185. doi:[*10.5694/mja2.50940*](https://doi.org/10.5694/mja2.50940)

405. Ho HL, Wang FY, Lee HR, et al. Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients. *The Lancet Regional Health - Western Pacific*. 2020;3:100041. doi:[*10.1016/j.lanwpc.2020.100041*](https://doi.org/10.1016/j.lanwpc.2020.100041)

406. He L, Zeng Y, Zeng C, et al. Positive Rate of Serology and RT-PCR for COVID-19 between Community Residents and Healthcare Workers in Wuhan, China. *Japanese Journal of Infectious Diseases*. 2020;advpub. doi:[*10.7883/yoken.JJID.2020.691*](https://doi.org/10.7883/yoken.JJID.2020.691)

407. Zhang Z, Bi Q, Fang S, et al. Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: A cohort study. *The Lancet Microbe*. 2021;2(2):e79-e87. doi:[*10.1016/S2666-5247(20)30200-7*](https://doi.org/10.1016/S2666-5247(20)30200-7)

408. Xu R, Huang J, Duan C, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China. *Journal of Medical Virology*. n/a(n/a). doi:[*10.1002/jmv.26445*](https://doi.org/10.1002/jmv.26445)

409. Zhang J, Liu J, Li N, et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. *medRxiv*. Published online March 2020:2020.03.04.20030916. doi:[*10.1101/2020.03.04.20030916*](https://doi.org/10.1101/2020.03.04.20030916)

410. Morikane K, Satoh N, Hatano K, et al. Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020. *Western Pacific Surveillance and Response Journal : WPSAR*. 2021;12(1):69-71. doi:[*10.5365/wpsar.2020.11.3.012*](https://doi.org/10.5365/wpsar.2020.11.3.012)

411. Lee K, Jo S, Lee J. Seroprevalence of SARS-CoV-2 antibodies in South Korea. *Journal of the Korean Statistical Society*. Published online May 2021. doi:[*10.1007/s42952-021-00131-7*](https://doi.org/10.1007/s42952-021-00131-7)

412. Jeong HW, Chang HH, Kim EJ, et al. Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea. *Journal of Microbiology*. 2021;59(5):530-533. doi:[*10.1007/s12275-021-1095-7*](https://doi.org/10.1007/s12275-021-1095-7)

413. Clapham HE, Chia WN, Tan LWL, et al. *Contrasting SARS-CoV-2 Epidemics in Singapore: Cohort Studies in Migrant Workers and the General Population*. In Review; 2021. doi:[*10.21203/rs.3.rs-441527/v1*](https://doi.org/10.21203/rs.3.rs-441527/v1)

# S6 References cited in supplementary file

[1. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. Published online March 29, 2021:n71. doi:10.1136/bmj.n71](https://www.zotero.org/google-docs/?vDe9BQ)

[2. Bobrovitz N, Arora RK, Cao C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. Khudyakov YE, ed. *PLOS ONE*. 2021;16(6):e0252617. doi:10.1371/journal.pone.0252617](https://www.zotero.org/google-docs/?vDe9BQ)

[3. Arora RK, Joseph A, Van Wyk J, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. *Lancet Infect Dis*. 2021;21(4):e75-e76. doi:10.1016/S1473-3099(20)30631-9](https://www.zotero.org/google-docs/?vDe9BQ)

[4. Yazdani S, Asli A, Asli A, Sarbakhsh P, Salemi S. Final Sensitivity and Specificity of Different Test Combinations in Screening. *JMED Res*. Published online April 23, 2014:1-10. doi:10.5171/2014.558523](https://www.zotero.org/google-docs/?vDe9BQ)

[5. NRL. WHO COVID Evaluations Summary of Results. nrlquality. Published November 22, 2021. Accessed November 22, 2021. https://www.nrlquality.org.au/who-covid-evaluations-summary-of-results](https://www.zotero.org/google-docs/?vDe9BQ)

[6. Aus AGD of HTG. Post market review of COVID-19 point-of-care tests. Therapeutic Goods Administration (TGA). Published March 24, 2021. Accessed November 22, 2021. https://www.tga.gov.au/post-market-review-covid-19-point-care-tests](https://www.zotero.org/google-docs/?vDe9BQ)

[7. FIND. FIND evaluation of SARS-CoV-2 antibody (Ab) detection tests. FIND: Diagnosis for All. Published April 30, 2021. Accessed November 22, 2021. https://www.finddx.org/sarscov2-eval-antibody/](https://www.zotero.org/google-docs/?vDe9BQ)

[8. Bewley KR, Coombes NS, Gagnon L, et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. *Nat Protoc*. 2021;16(6):3114-3140. doi:10.1038/s41596-021-00536-y](https://www.zotero.org/google-docs/?vDe9BQ)

[9. Mohit E, Rostami Z, Vahidi H. A comparative review of immunoassays for COVID-19 detection. *Expert Rev Clin Immunol*. 2021;17(6):573-599. doi:10.1080/1744666X.2021.1908886](https://www.zotero.org/google-docs/?vDe9BQ)

[10. WHO Unity Global SARS-CoV-2 Seroepidemiological Investigations. Zenodo Community. Published October 26, 2021. Accessed November 5, 2021. https://zenodo.org/communities/unity-sero-2021?page=1&size=20](https://www.zotero.org/google-docs/?vDe9BQ)

[11. Ware H, Whelan M, Li Z, et al. WHO Unity Sero-Epidemiological Studies Early Results Submission Template - Blank. Published online November 23, 2021. doi:10.5281/ZENODO.5719533](https://www.zotero.org/google-docs/?vDe9BQ)

[12. World Health Organization. Guidelines on the Use of Serosurveys in Support of Measles and Rubella Elimination. Published 2013. Accessed November 21, 2021. https://www.who.int/immunization/monitoring\_surveillance/burden/laboratory/Serosurvey\_Manual\_chapter\_1.pdf](https://www.zotero.org/google-docs/?vDe9BQ)

[13. Clapham H, Hay J, Routledge I, et al. Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. *Emerg Infect Dis J*. 2020;26(9):1978. doi:10.3201/eid2609.201840](https://www.zotero.org/google-docs/?vDe9BQ)

[14. Bergeri I, Lewis HC, Subissi L, et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. *Influenza Other Respir Viruses*. 2021;n/a(n/a). doi:10.1111/irv.12915](https://www.zotero.org/google-docs/?vDe9BQ)

[15. Jackson JL, Kuriyama A, Anton A, et al. The Accuracy of Google Translate for Abstracting Data From Non-English-Language  Trials for Systematic Reviews. *Ann Intern Med*. 2019;171(9):677-679. doi:10.7326/M19-0891](https://www.zotero.org/google-docs/?vDe9BQ)

[16. Bobrovitz N, Noel KC, Li Z, et al. *SeroTracker-ROB: Reproducible Decision Rules for Risk of Bias Assessment of Seroprevalence Studies*. Epidemiology; 2021. doi:10.1101/2021.11.17.21266471](https://www.zotero.org/google-docs/?vDe9BQ)

[17. Migliavaca CB, Stein C, Colpani V, Munn Z, Falavigna M. Quality assessment of prevalence studies: a systematic review. *J Clin Epidemiol*. 2020;127:59-68. doi:10.1016/j.jclinepi.2020.06.039](https://www.zotero.org/google-docs/?vDe9BQ)

[18. Borges Migliavaca C, Stein C, Colpani V, et al. How are systematic reviews of prevalence conducted? A methodological study. *BMC Med Res Methodol*. 2020;20(1):96. doi:10.1186/s12874-020-00975-3](https://www.zotero.org/google-docs/?vDe9BQ)

[19. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Our World in Data. Published 2020. Accessed November 4, 2021. https://ourworldindata.org/coronavirus](https://www.zotero.org/google-docs/?vDe9BQ)

[20. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Published June 11, 2021. Accessed June 11, 2021. https://covid19.who.int/](https://www.zotero.org/google-docs/?vDe9BQ)

[21. WHO Headquarters (HQ). WHO COVID-19 Case definition. Published online December 16, 2020. Accessed November 5, 2021. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance\_Case\_Definition-2020.2](https://www.zotero.org/google-docs/?vDe9BQ)

[22. Institute for Health metrics and Evaluation (IHME). *COVID-19: Estimating the Historical Time Series of Infections*. IHME, University of Washington; 2021. http://www.healthdata.org/special-analysis/covid-19-estimating-historical-infections-time-series](https://www.zotero.org/google-docs/?vDe9BQ)

[23. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using **lme4**. *J Stat Softw*. 2015;67(1). doi:10.18637/jss.v067.i01](https://www.zotero.org/google-docs/?vDe9BQ)